WO2024068768A9 - Glycoengineering using leishmania cells - Google Patents
Glycoengineering using leishmania cells Download PDFInfo
- Publication number
- WO2024068768A9 WO2024068768A9 PCT/EP2023/076767 EP2023076767W WO2024068768A9 WO 2024068768 A9 WO2024068768 A9 WO 2024068768A9 EP 2023076767 W EP2023076767 W EP 2023076767W WO 2024068768 A9 WO2024068768 A9 WO 2024068768A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- galnac
- host cell
- udp
- certain embodiments
- heterologous
- Prior art date
Links
- 241000222722 Leishmania <genus> Species 0.000 title claims abstract description 212
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 186
- 229920001184 polypeptide Polymers 0.000 claims abstract description 181
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 181
- 238000012258 culturing Methods 0.000 claims abstract description 13
- 101000887519 Homo sapiens Globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 Proteins 0.000 claims description 441
- 108010066816 Polypeptide N-acetylgalactosaminyltransferase Proteins 0.000 claims description 335
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 claims description 278
- 102100039847 Globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 Human genes 0.000 claims description 250
- LFTYTUAZOPRMMI-NESSUJCYSA-N UDP-N-acetyl-alpha-D-galactosamine Chemical compound O1[C@H](CO)[C@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1O[P@](O)(=O)O[P@](O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-NESSUJCYSA-N 0.000 claims description 250
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 194
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 194
- 108090000623 proteins and genes Proteins 0.000 claims description 192
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 155
- 102000004169 proteins and genes Human genes 0.000 claims description 132
- 241000282414 Homo sapiens Species 0.000 claims description 128
- 230000037361 pathway Effects 0.000 claims description 128
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 127
- 230000003248 secreting effect Effects 0.000 claims description 121
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 118
- 108010078791 Carrier Proteins Proteins 0.000 claims description 114
- 108700026244 Open Reading Frames Proteins 0.000 claims description 110
- 102000004357 Transferases Human genes 0.000 claims description 110
- 108090000992 Transferases Proteins 0.000 claims description 110
- 230000006696 biosynthetic metabolic pathway Effects 0.000 claims description 105
- 150000007523 nucleic acids Chemical class 0.000 claims description 105
- 108020004707 nucleic acids Proteins 0.000 claims description 104
- 102000039446 nucleic acids Human genes 0.000 claims description 104
- 230000014759 maintenance of location Effects 0.000 claims description 92
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims description 79
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 claims description 71
- 101710186714 2-acylglycerol O-acyltransferase 1 Proteins 0.000 claims description 70
- 108700023372 Glycosyltransferases Proteins 0.000 claims description 63
- 230000015572 biosynthetic process Effects 0.000 claims description 60
- 241000222702 Leishmania tarentolae Species 0.000 claims description 59
- 102000051366 Glycosyltransferases Human genes 0.000 claims description 57
- 150000001413 amino acids Chemical class 0.000 claims description 55
- 108010090473 UDP-N-acetylglucosamine-peptide beta-N-acetylglucosaminyltransferase Proteins 0.000 claims description 53
- 102000004190 Enzymes Human genes 0.000 claims description 52
- 108090000790 Enzymes Proteins 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 49
- 102100037921 UDP-N-acetylglucosamine pyrophosphorylase Human genes 0.000 claims description 37
- 101710176474 UDP-N-acetylglucosamine pyrophosphorylase Proteins 0.000 claims description 35
- 230000002068 genetic effect Effects 0.000 claims description 34
- 102100024296 Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 claims description 33
- 101710186725 2-acylglycerol O-acyltransferase 2 Proteins 0.000 claims description 32
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 31
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 claims description 29
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 24
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 24
- 230000002829 reductive effect Effects 0.000 claims description 19
- 102100037774 N-acetylgalactosamine kinase Human genes 0.000 claims description 14
- 108030003719 N-acetylgalactosamine kinases Proteins 0.000 claims description 14
- 150000004676 glycans Chemical class 0.000 claims description 14
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims description 12
- 102000002493 N-Acetylglucosaminyltransferases Human genes 0.000 claims description 11
- 108010093077 N-Acetylglucosaminyltransferases Proteins 0.000 claims description 11
- 241000244206 Nematoda Species 0.000 claims description 11
- 238000010353 genetic engineering Methods 0.000 claims description 11
- 125000000539 amino acid group Chemical group 0.000 claims description 10
- 239000001573 invertase Substances 0.000 claims description 10
- 235000011073 invertase Nutrition 0.000 claims description 10
- 230000004988 N-glycosylation Effects 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 241000258971 Brachiopoda Species 0.000 claims description 6
- 241000589875 Campylobacter jejuni Species 0.000 claims description 6
- 241001134734 Choanoflagellida Species 0.000 claims description 6
- 241000251556 Chordata Species 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 6
- 241000237852 Mollusca Species 0.000 claims description 6
- 241000700683 Placozoa Species 0.000 claims description 6
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 claims description 6
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 claims description 6
- 102100032284 UDP-glucuronic acid/UDP-N-acetylgalactosamine transporter Human genes 0.000 claims description 5
- 230000037362 glycan biosynthesis Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 241001209257 Dentipellis fragilis Species 0.000 claims description 4
- 241001105021 Fragilariopsis cylindrus Species 0.000 claims description 4
- 241000035303 Geotrypetes seraphini Species 0.000 claims description 4
- 241000258953 Lingula anatina Species 0.000 claims description 4
- 125000003047 N-acetyl group Chemical group 0.000 claims description 4
- 241001522227 Octopus bimaculoides Species 0.000 claims description 4
- 241001534827 Parambassis ranga Species 0.000 claims description 4
- 241000662257 Salpingoeca rosetta Species 0.000 claims description 4
- 241000512310 Scophthalmus maximus Species 0.000 claims description 4
- 241001126920 Trichoplax sp. Species 0.000 claims description 4
- 108091035707 Consensus sequence Proteins 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 10
- 101000869390 Homo sapiens UDP-glucuronic acid/UDP-N-acetylgalactosamine transporter Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 91
- 210000004027 cell Anatomy 0.000 description 298
- 235000018102 proteins Nutrition 0.000 description 105
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 69
- 239000003814 drug Substances 0.000 description 56
- 229940088598 enzyme Drugs 0.000 description 51
- 201000010099 disease Diseases 0.000 description 35
- 208000035475 disorder Diseases 0.000 description 34
- -1 Man3GlcNAc2 glycan Chemical class 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 23
- 238000001890 transfection Methods 0.000 description 21
- 229960002964 adalimumab Drugs 0.000 description 19
- 239000003550 marker Substances 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 17
- 239000001963 growth medium Substances 0.000 description 16
- 102220005405 rs33915947 Human genes 0.000 description 16
- 230000010354 integration Effects 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 13
- 101000819146 Homo sapiens UDP-glucose 4-epimerase Proteins 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 230000004807 localization Effects 0.000 description 12
- 239000008188 pellet Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 241000244203 Caenorhabditis elegans Species 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 102220062005 rs786202890 Human genes 0.000 description 11
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 11
- 229910001868 water Inorganic materials 0.000 description 11
- 108091033409 CRISPR Proteins 0.000 description 10
- 241000252212 Danio rerio Species 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 10
- 230000013595 glycosylation Effects 0.000 description 10
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 9
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 108010029485 Protein Isoforms Proteins 0.000 description 9
- 102000001708 Protein Isoforms Human genes 0.000 description 9
- 241000700157 Rattus norvegicus Species 0.000 description 9
- 108010081734 Ribonucleoproteins Proteins 0.000 description 9
- 102000004389 Ribonucleoproteins Human genes 0.000 description 9
- 241000256251 Spodoptera frugiperda Species 0.000 description 9
- 241000223105 Trypanosoma brucei Species 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 9
- 229960000244 procainamide Drugs 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 108020005004 Guide RNA Proteins 0.000 description 8
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 8
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 238000006206 glycosylation reaction Methods 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 102100031929 UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase 110 kDa subunit Human genes 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 6
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 6
- 241000282577 Pan troglodytes Species 0.000 description 6
- 239000012737 fresh medium Substances 0.000 description 6
- 238000012239 gene modification Methods 0.000 description 6
- 230000005017 genetic modification Effects 0.000 description 6
- 235000013617 genetically modified food Nutrition 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000017854 proteolysis Effects 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 229960000187 tissue plasminogen activator Drugs 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 5
- 241000219195 Arabidopsis thaliana Species 0.000 description 5
- 241000282461 Canis lupus Species 0.000 description 5
- 241001312740 Gekko japonicus Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 108010051696 Growth Hormone Proteins 0.000 description 5
- 241000876435 Hucho hucho Species 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 240000008467 Oryza sativa Japonica Group Species 0.000 description 5
- 235000005043 Oryza sativa Japonica Group Nutrition 0.000 description 5
- 241000188667 Parasteatoda tepidariorum Species 0.000 description 5
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 5
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 5
- 102100038803 Somatotropin Human genes 0.000 description 5
- 241000269457 Xenopus tropicalis Species 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 210000002288 golgi apparatus Anatomy 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000000415 inactivating effect Effects 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 229960004641 rituximab Drugs 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 4
- 102000004411 Antithrombin III Human genes 0.000 description 4
- 108090000935 Antithrombin III Proteins 0.000 description 4
- 108010024976 Asparaginase Proteins 0.000 description 4
- 238000010354 CRISPR gene editing Methods 0.000 description 4
- 108700010070 Codon Usage Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 4
- 108090000394 Erythropoietin Proteins 0.000 description 4
- 102000003951 Erythropoietin Human genes 0.000 description 4
- 108010076282 Factor IX Proteins 0.000 description 4
- 102000012558 Fibroblast growth factor 20 Human genes 0.000 description 4
- 108050002085 Fibroblast growth factor 20 Proteins 0.000 description 4
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 4
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 4
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 4
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 4
- 102000006395 Globulins Human genes 0.000 description 4
- 108010044091 Globulins Proteins 0.000 description 4
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 4
- 108010003272 Hyaluronate lyase Proteins 0.000 description 4
- 102000001974 Hyaluronidases Human genes 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000014429 Insulin-like growth factor Human genes 0.000 description 4
- 108010078049 Interferon alpha-2 Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 4
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102100020873 Interleukin-2 Human genes 0.000 description 4
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 4
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010077991 O-GlcNAc transferase Proteins 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 102100022831 Somatoliberin Human genes 0.000 description 4
- 101710142969 Somatoliberin Proteins 0.000 description 4
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 4
- 108010023197 Streptokinase Proteins 0.000 description 4
- 108010061174 Thyrotropin Proteins 0.000 description 4
- 102000011923 Thyrotropin Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 108010092464 Urate Oxidase Proteins 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 238000005571 anion exchange chromatography Methods 0.000 description 4
- 230000001494 anti-thymocyte effect Effects 0.000 description 4
- 229960005348 antithrombin iii Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 229960000455 brentuximab vedotin Drugs 0.000 description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 4
- 108010017271 denileukin diftitox Proteins 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000006345 epimerization reaction Methods 0.000 description 4
- 229940105423 erythropoietin Drugs 0.000 description 4
- 229940098448 fibroblast growth factor 7 Drugs 0.000 description 4
- 229940028334 follicle stimulating hormone Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 4
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 4
- 108010049491 glucarpidase Proteins 0.000 description 4
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 4
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 229940025294 hemin Drugs 0.000 description 4
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 4
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 4
- 229960002773 hyaluronidase Drugs 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000000921 morphogenic effect Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 229960003347 obinutuzumab Drugs 0.000 description 4
- 229960002450 ofatumumab Drugs 0.000 description 4
- 229960001972 panitumumab Drugs 0.000 description 4
- 229960002087 pertuzumab Drugs 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
- 108010029667 pramlintide Proteins 0.000 description 4
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 102000008467 protein O-GlcNAc transferase activity proteins Human genes 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 3
- 108010022379 (N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferase Proteins 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102100022641 Coagulation factor IX Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 3
- 108010014173 Factor X Proteins 0.000 description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 3
- 101000920640 Homo sapiens EGF domain-specific O-linked N-acetylglucosamine transferase Proteins 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 3
- 241000277288 Salmo trutta Species 0.000 description 3
- 108010086019 Secretin Proteins 0.000 description 3
- 102100037505 Secretin Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108091028113 Trans-activating crRNA Proteins 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 108010075202 UDP-glucose 4-epimerase Proteins 0.000 description 3
- 102100021436 UDP-glucose 4-epimerase Human genes 0.000 description 3
- 102000000102 UDP-sugar pyrophosphorylases Human genes 0.000 description 3
- 108050008412 UDP-sugar pyrophosphorylases Proteins 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 229960004238 anakinra Drugs 0.000 description 3
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 238000001818 capillary gel electrophoresis Methods 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 229960002923 denileukin diftitox Drugs 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- 229960004859 glucarpidase Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 102000047917 human EOGT Human genes 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000004020 intracellular membrane Anatomy 0.000 description 3
- 229960002486 laronidase Drugs 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 229960003611 pramlintide Drugs 0.000 description 3
- 229960004910 raxibacumab Drugs 0.000 description 3
- 229960002101 secretin Drugs 0.000 description 3
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 229960005202 streptokinase Drugs 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960005267 tositumomab Drugs 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- 229960005356 urokinase Drugs 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- XNGDIOBPVDBNQH-QMMMGPOBSA-N (2S)-2-amino-6-(2-methoxyethoxycarbonylamino)hexanoic acid Chemical compound COCCOC(=O)NCCCC[C@H](N)C(O)=O XNGDIOBPVDBNQH-QMMMGPOBSA-N 0.000 description 2
- ZDRRIRUAESZNIH-BZGUUIOASA-N (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-13-[(2s)-butan-2-yl]-10-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]- Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZDRRIRUAESZNIH-BZGUUIOASA-N 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 2
- 102000055025 Adenosine deaminases Human genes 0.000 description 2
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010058207 Anistreplase Proteins 0.000 description 2
- 101710081722 Antitrypsin Proteins 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 2
- 108010037003 Buserelin Proteins 0.000 description 2
- WEDIKSVWBUKTRA-WTKGVUNUSA-N CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC WEDIKSVWBUKTRA-WTKGVUNUSA-N 0.000 description 2
- 101001120790 Caenorhabditis elegans UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase Proteins 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 241000008374 Capirona Species 0.000 description 2
- 102100023804 Coagulation factor VII Human genes 0.000 description 2
- 102100036486 Cobalamin binding intrinsic factor Human genes 0.000 description 2
- 101710123904 Cobalamin binding intrinsic factor Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010091893 Cosyntropin Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 108010019673 Darbepoetin alfa Proteins 0.000 description 2
- 108010032976 Enfuvirtide Proteins 0.000 description 2
- 108010074604 Epoetin Alfa Proteins 0.000 description 2
- 108010056764 Eptifibatide Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 229940122601 Esterase inhibitor Drugs 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 108010071289 Factor XIII Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- 102000048120 Galactokinases Human genes 0.000 description 2
- 108700023157 Galactokinases Proteins 0.000 description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 108010017544 Glucosylceramidase Proteins 0.000 description 2
- 108010048963 Glutamate carboxypeptidase Proteins 0.000 description 2
- 102000005548 Hexokinase Human genes 0.000 description 2
- 108700040460 Hexokinases Proteins 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000863721 Homo sapiens Deoxyribonuclease-1 Proteins 0.000 description 2
- 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 description 2
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 2
- 101001066305 Homo sapiens N-acetylgalactosamine-6-sulfatase Proteins 0.000 description 2
- 101000634196 Homo sapiens Neurotrophin-3 Proteins 0.000 description 2
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 2
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 2
- 101000662009 Homo sapiens UDP-N-acetylglucosamine pyrophosphorylase Proteins 0.000 description 2
- 241001135301 Hypleurochilus fissicornis Species 0.000 description 2
- 108010073961 Insulin Aspart Proteins 0.000 description 2
- 108010089308 Insulin Detemir Proteins 0.000 description 2
- 108010057186 Insulin Glargine Proteins 0.000 description 2
- 108010065920 Insulin Lispro Proteins 0.000 description 2
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 description 2
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 2
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102100030704 Interleukin-21 Human genes 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 102100039064 Interleukin-3 Human genes 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010059881 Lactase Proteins 0.000 description 2
- 241000222732 Leishmania major Species 0.000 description 2
- 108010062867 Lenograstim Proteins 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108010019598 Liraglutide Proteins 0.000 description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010057021 Menotropins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102100035286 N-acetyl-D-glucosamine kinase Human genes 0.000 description 2
- 108010032040 N-acetylglucosamine kinase Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102220575917 Olfactory receptor 7D4_S84N_mutation Human genes 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 101800000989 Oxytocin Proteins 0.000 description 2
- 108010067035 Pancrelipase Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010068701 Pegloticase Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 102000009569 Phosphoglucomutase Human genes 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 101710167959 Putative UTP-glucose-1-phosphate uridylyltransferase Proteins 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 108090001066 Racemases and epimerases Proteins 0.000 description 2
- 241000277263 Salmo Species 0.000 description 2
- 108010082455 Sebelipase alfa Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- 108010039185 Tenecteplase Proteins 0.000 description 2
- 108010049264 Teriparatide Proteins 0.000 description 2
- 108010078233 Thymalfasin Proteins 0.000 description 2
- 108010066702 Thyrotropin Alfa Proteins 0.000 description 2
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 2
- 108010086873 UDP-N-acetylglucosamine transporter Proteins 0.000 description 2
- 102100033778 UDP-N-acetylglucosamine transporter Human genes 0.000 description 2
- 102000048175 UTP-glucose-1-phosphate uridylyltransferases Human genes 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 108010047196 Urofollitropin Proteins 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 229960000446 abciximab Drugs 0.000 description 2
- 229940119059 actemra Drugs 0.000 description 2
- 108010081667 aflibercept Proteins 0.000 description 2
- 108010056760 agalsidase beta Proteins 0.000 description 2
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 2
- 108700025316 aldesleukin Proteins 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 108010060162 alglucerase Proteins 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001475 anti-trypsic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 229960004669 basiliximab Drugs 0.000 description 2
- 229960003270 belimumab Drugs 0.000 description 2
- 229940022836 benlysta Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 108010055460 bivalirudin Proteins 0.000 description 2
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 2
- 229940053031 botulinum toxin Drugs 0.000 description 2
- 229960003735 brodalumab Drugs 0.000 description 2
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 108010033937 calaspargase pegol Proteins 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 2
- 229940112129 campath Drugs 0.000 description 2
- 101150039352 can gene Proteins 0.000 description 2
- 229960001838 canakinumab Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 108010023376 caplacizumab Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 108010072936 cerliponase alfa Proteins 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 229960004681 choriogonadotropin alfa Drugs 0.000 description 2
- 229940015047 chorionic gonadotropin Drugs 0.000 description 2
- 229940090100 cimzia Drugs 0.000 description 2
- 108700005721 conestat alfa Proteins 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- ZOEFCCMDUURGSE-SQKVDDBVSA-N cosyntropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 ZOEFCCMDUURGSE-SQKVDDBVSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229960001251 denosumab Drugs 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 108010034479 digoxin antibodies Fab fragments Proteins 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 108010005794 dulaglutide Proteins 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 108010011867 ecallantide Proteins 0.000 description 2
- 229960002224 eculizumab Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- QBEPNUQJQWDYKU-BMGKTWPMSA-N egrifta Chemical compound C([C@H](NC(=O)C/C=C/CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O)C1=CC=C(O)C=C1 QBEPNUQJQWDYKU-BMGKTWPMSA-N 0.000 description 2
- 108091011464 elapegademase Proteins 0.000 description 2
- 230000002121 endocytic effect Effects 0.000 description 2
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 2
- CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 description 2
- 229940082789 erbitux Drugs 0.000 description 2
- 239000002329 esterase inhibitor Substances 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 229940012413 factor vii Drugs 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 229940012426 factor x Drugs 0.000 description 2
- 229940012444 factor xiii Drugs 0.000 description 2
- 229940094684 feiba Drugs 0.000 description 2
- 108010081934 follitropin beta Proteins 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000002256 galaktoses Chemical class 0.000 description 2
- 108010089296 galsulfase Proteins 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 102000035122 glycosylated proteins Human genes 0.000 description 2
- 108091005608 glycosylated proteins Proteins 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229950010864 guselkumab Drugs 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 2
- 102000043321 human CTLA4 Human genes 0.000 description 2
- 102000049489 human GALNS Human genes 0.000 description 2
- 102000057714 human NTF3 Human genes 0.000 description 2
- 102000058004 human PTH Human genes 0.000 description 2
- 229940048921 humira Drugs 0.000 description 2
- 108010072166 idursulfase Proteins 0.000 description 2
- 108010039650 imiglucerase Proteins 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108700039926 insulin glulisine Proteins 0.000 description 2
- 108010010648 interferon alfacon-1 Proteins 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- VBGWSQKGUZHFPS-VGMMZINCSA-N kalbitor Chemical compound C([C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)NCC(=O)NCC(=O)N[C@H]3CSSC[C@H](NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CO)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)CSSC[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC3=O)CSSC2)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)[C@@H](C)CC)[C@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 VBGWSQKGUZHFPS-VGMMZINCSA-N 0.000 description 2
- 229940116108 lactase Drugs 0.000 description 2
- FIBJDTSHOUXTKV-BRHMIFOHSA-N lepirudin Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)CNC2=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O FIBJDTSHOUXTKV-BRHMIFOHSA-N 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 229940076783 lucentis Drugs 0.000 description 2
- 229950003135 margetuximab Drugs 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108700008455 metreleptin Proteins 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229960005027 natalizumab Drugs 0.000 description 2
- 229960000513 necitumumab Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 229960000470 omalizumab Drugs 0.000 description 2
- 108010046821 oprelvekin Proteins 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 229960000402 palivizumab Drugs 0.000 description 2
- 108010001564 pegaspargase Proteins 0.000 description 2
- 108010044644 pegfilgrastim Proteins 0.000 description 2
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 2
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 2
- 108700037519 pegvisomant Proteins 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 108091000115 phosphomannomutase Proteins 0.000 description 2
- 108010005636 polypeptide C Proteins 0.000 description 2
- 229940092597 prolia Drugs 0.000 description 2
- 229950008679 protamine sulfate Drugs 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 229940024790 prothrombin complex concentrate Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108700027806 rGLP-1 Proteins 0.000 description 2
- 229960002633 ramucirumab Drugs 0.000 description 2
- 229960003876 ranibizumab Drugs 0.000 description 2
- 108010084837 rasburicase Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229940116176 remicade Drugs 0.000 description 2
- 229940107685 reopro Drugs 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 108010051412 reteplase Proteins 0.000 description 2
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 2
- 229950007943 risankizumab Drugs 0.000 description 2
- 108010017584 romiplostim Proteins 0.000 description 2
- 108010068072 salmon calcitonin Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 229940068638 simponi Drugs 0.000 description 2
- 229940115586 simulect Drugs 0.000 description 2
- 229940055944 soliris Drugs 0.000 description 2
- 229940071598 stelara Drugs 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229940036185 synagis Drugs 0.000 description 2
- 108010072309 taliglucerase alfa Proteins 0.000 description 2
- CILIXQOJUNDIDU-ASQIGDHWSA-N teduglutide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 CILIXQOJUNDIDU-ASQIGDHWSA-N 0.000 description 2
- 229960002444 teduglutide Drugs 0.000 description 2
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 2
- 108700002800 tesamorelin Proteins 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 2
- 229960004231 thymalfasin Drugs 0.000 description 2
- 229950005515 tildrakizumab Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960003989 tocilizumab Drugs 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 229940049679 trastuzumab deruxtecan Drugs 0.000 description 2
- 229960001612 trastuzumab emtansine Drugs 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 229940079023 tysabri Drugs 0.000 description 2
- 229940005267 urate oxidase Drugs 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 229960003824 ustekinumab Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 229940014556 xgeva Drugs 0.000 description 2
- 229940099073 xolair Drugs 0.000 description 2
- 229940055760 yervoy Drugs 0.000 description 2
- RNEACARJKXYVND-KQGZCTBQSA-N (2r)-2-[[(5z)-5-[(5-ethylfuran-2-yl)methylidene]-4-oxo-1,3-thiazol-2-yl]amino]-2-(4-fluorophenyl)acetic acid Chemical compound O1C(CC)=CC=C1\C=C/1C(=O)N=C(N[C@@H](C(O)=O)C=2C=CC(F)=CC=2)S\1 RNEACARJKXYVND-KQGZCTBQSA-N 0.000 description 1
- ZMEWRPBAQVSBBB-GOTSBHOMSA-N (2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[[2-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetyl]amino]hexanoic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 ZMEWRPBAQVSBBB-GOTSBHOMSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- MVMSCBBUIHUTGJ-UHFFFAOYSA-N 10108-97-1 Natural products C1=2NC(N)=NC(=O)C=2N=CN1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OC1OC(CO)C(O)C(O)C1O MVMSCBBUIHUTGJ-UHFFFAOYSA-N 0.000 description 1
- JWQZOTGHUDZFMU-WIDFLDSMSA-N 17034-35-4 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 JWQZOTGHUDZFMU-WIDFLDSMSA-N 0.000 description 1
- UQBIAGWOJDEOMN-UHFFFAOYSA-N 2-O-(2-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranosyl)-D-mannopyranose Natural products OC1C(O)C(CO)OC(O)C1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 UQBIAGWOJDEOMN-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- HPNRHPKXQZSDFX-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[6-amino-2-[[52-[[2-[[2-[[2-[[5-amino-2-[[2-[[2-[[6-amino-2-[[1-(2-amino-3-hydroxypropanoyl)pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-butan-2-yl-31,43-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,19,22,25-tetrakis(hydroxymethyl)-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound N1C(=O)C(NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C2N(CCC2)C(=O)C(N)CO)C(C)C)CSSCC(C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=2N=CNC=2)C(O)=O)NC(=O)CNC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)CC)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C1CC1=CC=CC=C1 HPNRHPKXQZSDFX-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical compound N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010056388 Albunex Proteins 0.000 description 1
- 108010002020 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 108030001769 Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000256182 Anopheles gambiae Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100026349 Beta-1,4-galactosyltransferase 1 Human genes 0.000 description 1
- 101710120061 Beta-1,4-galactosyltransferase 1 Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 102100029117 Coagulation factor X Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- LHQIJBMDNUYRAM-AWFVSMACSA-N D-erythro-biopterin Chemical compound N1=C(N)NC(=O)C2=NC([C@H](O)[C@H](O)C)=CN=C21 LHQIJBMDNUYRAM-AWFVSMACSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100031947 EGF domain-specific O-linked N-acetylglucosamine transferase Human genes 0.000 description 1
- 102000012545 EGF-like domains Human genes 0.000 description 1
- 108050002150 EGF-like domains Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- XRHVZWWRFMCBAZ-UHFFFAOYSA-L Endothal-disodium Chemical compound [Na+].[Na+].C1CC2C(C([O-])=O)C(C(=O)[O-])C1O2 XRHVZWWRFMCBAZ-UHFFFAOYSA-L 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- MVMSCBBUIHUTGJ-GDJBGNAASA-N GDP-alpha-D-mannose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=C(NC(=O)C=2N=C1)N)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O MVMSCBBUIHUTGJ-GDJBGNAASA-N 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 description 1
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 1
- 102000005561 Human Isophane Insulin Human genes 0.000 description 1
- 108010084048 Human Isophane Insulin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 description 1
- 108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 102100030694 Interleukin-11 Human genes 0.000 description 1
- 108010081368 Isophane Insulin Proteins 0.000 description 1
- 102000005237 Isophane Insulin Human genes 0.000 description 1
- LHQIJBMDNUYRAM-UHFFFAOYSA-N L-erythro-Biopterin Natural products N1=C(N)NC(=O)C2=NC(C(O)C(O)C)=CN=C21 LHQIJBMDNUYRAM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000222738 Leishmania aethiopica Species 0.000 description 1
- 241001519330 Leishmania aethiopica species complex Species 0.000 description 1
- 241001034085 Leishmania aristidesi Species 0.000 description 1
- 241000178949 Leishmania chagasi Species 0.000 description 1
- 241000892935 Leishmania deanei Species 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 241001519427 Leishmania donovani species complex Species 0.000 description 1
- 241000214058 Leishmania hertigi Species 0.000 description 1
- 241000222697 Leishmania infantum Species 0.000 description 1
- 241001519413 Leishmania major species complex Species 0.000 description 1
- 241001320566 Leishmania martiniquensis Species 0.000 description 1
- 241000222734 Leishmania mexicana Species 0.000 description 1
- 241001519407 Leishmania mexicana species complex Species 0.000 description 1
- 241000222705 Leishmania pifanoi Species 0.000 description 1
- 241000222736 Leishmania tropica Species 0.000 description 1
- 241001519397 Leishmania tropica species complex Species 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- ZTOKCBJDEGPICW-UHFFFAOYSA-N Man3GlcNAc2 Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(NC(C)=O)C(O)C(OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(COC3C(C(O)C(O)C(CO)O3)O)O2)O)C(CO)O1 ZTOKCBJDEGPICW-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- FZLJPEPAYPUMMR-KEWYIRBNSA-N N-acetyl-D-galactosamine 1-phosphate Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)OC1OP(O)(O)=O FZLJPEPAYPUMMR-KEWYIRBNSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108700006640 OspA Proteins 0.000 description 1
- 108010072194 Ovidrel Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000488777 Parasteatoda Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 1
- 108010005991 Pork Regular Insulin Proteins 0.000 description 1
- 108030002269 Protein O-GlcNAc transferases Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010053803 Sermorelin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 101710139184 UDP-N-acetylglucosamine/UDP-glucose/GDP-mannose transporter Proteins 0.000 description 1
- 102100032285 UDP-N-acetylglucosamine/UDP-glucose/GDP-mannose transporter Human genes 0.000 description 1
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 1
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 description 1
- 101710202883 UDP-glucuronic acid/UDP-N-acetylgalactosamine transporter Proteins 0.000 description 1
- 101710159648 Uncharacterized protein Proteins 0.000 description 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 description 1
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 229940036707 acthar Drugs 0.000 description 1
- 229940099550 actimmune Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940099983 activase Drugs 0.000 description 1
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
- 229940060205 adagen Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940125490 aducanumab-avwa Drugs 0.000 description 1
- 229940125463 aduhelm Drugs 0.000 description 1
- 229940031675 advate Drugs 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 229960004470 agalsidase beta Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- 229940092233 albuminar Drugs 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229940022705 aldurazyme Drugs 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 229960003122 alglucerase Drugs 0.000 description 1
- 229960004593 alglucosidase alfa Drugs 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 229960004601 aliskiren Drugs 0.000 description 1
- 229940071626 alprolix Drugs 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940003354 angiomax Drugs 0.000 description 1
- 229960000983 anistreplase Drugs 0.000 description 1
- 229940077770 anthim Drugs 0.000 description 1
- 229940105753 anthrasil Drugs 0.000 description 1
- 229940105834 anthrax immune globulin Drugs 0.000 description 1
- 229940070435 anti-inhibitor coagulant complex Drugs 0.000 description 1
- 229960002843 antithrombin alfa Drugs 0.000 description 1
- 229940112930 apidra Drugs 0.000 description 1
- 229940029403 aplisol Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940038528 aralast Drugs 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- 229940094361 arcalyst Drugs 0.000 description 1
- 229950005725 arcitumomab Drugs 0.000 description 1
- 229960003554 asfotase alfa Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- 229940102797 asparaginase erwinia chrysanthemi Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229940092117 atgam Drugs 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- HYNPZTKLUNHGPM-KKERQHFVSA-N becaplermin Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](Cc8c[nH]c9c8cccc9)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)N HYNPZTKLUNHGPM-KKERQHFVSA-N 0.000 description 1
- 229960004787 becaplermin Drugs 0.000 description 1
- 229960005347 belatacept Drugs 0.000 description 1
- 229950000321 benralizumab Drugs 0.000 description 1
- 229940066363 beractant Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 229950008086 bezlotoxumab Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229940125385 biologic drug Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 229940101815 blincyto Drugs 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 229940094657 botulinum toxin type a Drugs 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 229940054242 bravelle Drugs 0.000 description 1
- 229950000025 brolucizumab Drugs 0.000 description 1
- 229950002817 burosumab Drugs 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229940084891 byetta Drugs 0.000 description 1
- 229950005072 calaspargase pegol Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 229950002176 caplacizumab Drugs 0.000 description 1
- 229950001178 capromab Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 229940049197 cerezyme Drugs 0.000 description 1
- 229950009540 cerliponase alfa Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229940088949 cinryze Drugs 0.000 description 1
- 229940046131 coagadex Drugs 0.000 description 1
- 229940105774 coagulation factor ix Drugs 0.000 description 1
- 229940105756 coagulation factor x Drugs 0.000 description 1
- 229940023664 coagulation factor xiii a-subunit (recombinant) Drugs 0.000 description 1
- 229960005020 conestat alfa Drugs 0.000 description 1
- 229940038717 copaxone Drugs 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229940010466 cosentyx Drugs 0.000 description 1
- 229940092125 creon Drugs 0.000 description 1
- 229950004730 crizanlizumab Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940092456 curosurf Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 229940094732 darzalex Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229960004120 defibrotide Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000001064 degrader Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 108010073652 desirudin Proteins 0.000 description 1
- 229960000296 desirudin Drugs 0.000 description 1
- XYWBJDRHGNULKG-OUMQNGNKSA-N desirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 XYWBJDRHGNULKG-OUMQNGNKSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229960004497 dinutuximab Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 229940121432 dostarlimab Drugs 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940056176 drotrecogin alfa Drugs 0.000 description 1
- 108010008250 drotrecogin alfa activated Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960005175 dulaglutide Drugs 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 229960001174 ecallantide Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 229940057042 efgartigimod alfa Drugs 0.000 description 1
- 229960002451 efmoroctocog alfa Drugs 0.000 description 1
- 229940102510 egrifta Drugs 0.000 description 1
- 229950007838 elapegademase Drugs 0.000 description 1
- 229940012882 elaprase Drugs 0.000 description 1
- 229940045065 elelyso Drugs 0.000 description 1
- KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 description 1
- 229940053603 elitek Drugs 0.000 description 1
- 229960002294 elosulfase alfa Drugs 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 229940125183 elranatamab Drugs 0.000 description 1
- 229940073038 elspar Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229950004645 emapalumab Drugs 0.000 description 1
- 229950006925 emicizumab Drugs 0.000 description 1
- 229940038483 empliciti Drugs 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940104788 entyvio Drugs 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 108010030868 epoetin zeta Proteins 0.000 description 1
- 229950005185 epoetin zeta Drugs 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- 229950006063 eptinezumab Drugs 0.000 description 1
- 229950001616 erenumab Drugs 0.000 description 1
- 229940051398 erwinaze Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 229950004341 evinacumab Drugs 0.000 description 1
- 229940125444 evkeeza Drugs 0.000 description 1
- 229960002027 evolocumab Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940051306 eylea Drugs 0.000 description 1
- 229940014516 fabrazyme Drugs 0.000 description 1
- 108700007283 factor IX Fc fusion Proteins 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229960000256 filgrastim-sndz Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 229940001300 follistim Drugs 0.000 description 1
- 108010006578 follitropin alfa Proteins 0.000 description 1
- 229960005210 follitropin alfa Drugs 0.000 description 1
- 229960002907 follitropin beta Drugs 0.000 description 1
- 229940053641 forteo Drugs 0.000 description 1
- 229950011509 fremanezumab Drugs 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229940099052 fuzeon Drugs 0.000 description 1
- 229950000118 galcanezumab Drugs 0.000 description 1
- 229960005390 galsulfase Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- RKGLLHCSSVJTAN-YYICOITRSA-N glucagen Chemical compound Cl.C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 RKGLLHCSSVJTAN-YYICOITRSA-N 0.000 description 1
- 229940095886 glucagen Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 229940060415 hepatitis b immune globulin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940038661 humalog Drugs 0.000 description 1
- 102000045921 human GAA Human genes 0.000 description 1
- 102000044507 human SERPING1 Human genes 0.000 description 1
- 229940045644 human calcitonin Drugs 0.000 description 1
- 229940100181 human rho(d) immune globulin Drugs 0.000 description 1
- 229940084769 humulin r Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229940044700 hylenex Drugs 0.000 description 1
- 229950010245 ibalizumab Drugs 0.000 description 1
- 229960002308 idarucizumab Drugs 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 229960002396 idursulfase Drugs 0.000 description 1
- 229960002127 imiglucerase Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940090438 infergen Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 229960004717 insulin aspart Drugs 0.000 description 1
- 108010050259 insulin degludec Proteins 0.000 description 1
- 229960004225 insulin degludec Drugs 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 229960000696 insulin glulisine Drugs 0.000 description 1
- 229960002068 insulin lispro Drugs 0.000 description 1
- 229940056984 integrilin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 108010006088 interferon alfa-n1 Proteins 0.000 description 1
- 229940109242 interferon alfa-n3 Drugs 0.000 description 1
- 229960003358 interferon alfacon-1 Drugs 0.000 description 1
- 108010042414 interferon gamma-1b Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229950007752 isatuximab Drugs 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229960005435 ixekizumab Drugs 0.000 description 1
- 229940125454 jemperli Drugs 0.000 description 1
- 229940110516 jetrea Drugs 0.000 description 1
- 229940018902 kalbitor Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229940041615 kanuma Drugs 0.000 description 1
- 229940076483 kcentra Drugs 0.000 description 1
- 229940065223 kepivance Drugs 0.000 description 1
- 229940054136 kineret Drugs 0.000 description 1
- 229940094857 kinlytic Drugs 0.000 description 1
- 229940120535 krystexxa Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229950005287 lanadelumab Drugs 0.000 description 1
- 229940060975 lantus Drugs 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 108010002230 lepirudin Proteins 0.000 description 1
- 229960004408 lepirudin Drugs 0.000 description 1
- 229940102988 levemir Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 108010015964 lucinactant Proteins 0.000 description 1
- 229940091827 lumizyme Drugs 0.000 description 1
- 108010078259 luprolide acetate gel depot Proteins 0.000 description 1
- 229960002332 lutropin alfa Drugs 0.000 description 1
- 229940121581 magrolimab Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010000594 mecasermin Proteins 0.000 description 1
- 229960001311 mecasermin Drugs 0.000 description 1
- 229940032750 menopur Drugs 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 description 1
- 229960000668 metreleptin Drugs 0.000 description 1
- 108010068982 microplasmin Proteins 0.000 description 1
- 229940029238 mircera Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229960001521 motavizumab Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940117040 myalept Drugs 0.000 description 1
- 229940112646 myobloc Drugs 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N n-[1-(2-carbamoylpyrrolidin-1-yl)-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- 229940068704 naglazyme Drugs 0.000 description 1
- 229940054205 natrecor Drugs 0.000 description 1
- 229940049337 neosporin Drugs 0.000 description 1
- 229960001267 nesiritide Drugs 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 229940082926 neumega Drugs 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 108010066090 neutral insulin Proteins 0.000 description 1
- 229940098815 novolin n Drugs 0.000 description 1
- 229940112879 novolog Drugs 0.000 description 1
- 229940112216 novoseven Drugs 0.000 description 1
- 229940109690 nucala Drugs 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229940017335 nulojix Drugs 0.000 description 1
- 229940110078 nuwiq Drugs 0.000 description 1
- 229960003419 obiltoxaximab Drugs 0.000 description 1
- 229940035833 obizur Drugs 0.000 description 1
- 229960001905 ocriplasmin Drugs 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 229940099216 oncaspar Drugs 0.000 description 1
- 229940100027 ontak Drugs 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940035567 orencia Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940112876 ovidrel Drugs 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 229960002404 palifermin Drugs 0.000 description 1
- 229940045258 pancrelipase Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229940048111 pegademase bovine Drugs 0.000 description 1
- 108010027841 pegademase bovine Proteins 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 229960003930 peginterferon alfa-2a Drugs 0.000 description 1
- 229960003931 peginterferon alfa-2b Drugs 0.000 description 1
- 108010027737 peginterferon beta-1a Proteins 0.000 description 1
- 229940106366 pegintron Drugs 0.000 description 1
- 229960001376 pegloticase Drugs 0.000 description 1
- 229960002995 pegvisomant Drugs 0.000 description 1
- 229950011098 pendetide Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940030215 pitocin Drugs 0.000 description 1
- 229940072644 pitressin Drugs 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 108010016297 plasmin drug combination deoxyribonuclease Proteins 0.000 description 1
- 229940007060 plegridy Drugs 0.000 description 1
- 229950009416 polatuzumab vedotin Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229940061821 poractant alfa Drugs 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 229940121596 pozelimab Drugs 0.000 description 1
- 229940028952 praluent Drugs 0.000 description 1
- 229940096959 praxbind Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 108010012557 prothrombin complex concentrates Proteins 0.000 description 1
- 229940034080 provenge Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229940107568 pulmozyme Drugs 0.000 description 1
- 229960000424 rasburicase Drugs 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 108010013773 recombinant FVIIa Proteins 0.000 description 1
- 108010033652 recombinant factor VIII N8 Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 229940030915 refludan Drugs 0.000 description 1
- 229940116157 regranex Drugs 0.000 description 1
- 229940017164 repatha Drugs 0.000 description 1
- 229940116243 retavase Drugs 0.000 description 1
- 229960002917 reteplase Drugs 0.000 description 1
- ORNDKVCWLUZAQL-FOWIMTFFSA-N rgrf 43 Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CN=CN1 ORNDKVCWLUZAQL-FOWIMTFFSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 108010046141 rilonacept Proteins 0.000 description 1
- 229960001886 rilonacept Drugs 0.000 description 1
- 229960004262 romiplostim Drugs 0.000 description 1
- 229950005039 rozanolixizumab Drugs 0.000 description 1
- 229940009560 ruconest Drugs 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 229960000532 sacrosidase Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 229950007308 satumomab Drugs 0.000 description 1
- 229940118080 saxenda Drugs 0.000 description 1
- 229960004542 sebelipase alfa Drugs 0.000 description 1
- 229950006794 secretin porcine Drugs 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 229960002758 sermorelin Drugs 0.000 description 1
- WGWPRVFKDLAUQJ-MITYVQBRSA-N sermorelin Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=C(O)C=C1 WGWPRVFKDLAUQJ-MITYVQBRSA-N 0.000 description 1
- BVLCEKWPOSAKSZ-YQMCHIOTSA-N sermorelin acetate Chemical compound CC(O)=O.C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=C(O)C=C1 BVLCEKWPOSAKSZ-YQMCHIOTSA-N 0.000 description 1
- 229960003137 sermorelin acetate Drugs 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 229960003095 simoctocog alfa Drugs 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940099077 somavert Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940108347 strensiq Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940035681 sucraid Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940080796 surfaxin Drugs 0.000 description 1
- 229960002557 susoctocog alfa Drugs 0.000 description 1
- 229940053017 sylvant Drugs 0.000 description 1
- 229940099093 symlin Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001832 taliglucerase alfa Drugs 0.000 description 1
- 229940020037 talquetamab Drugs 0.000 description 1
- 229940060681 taltz Drugs 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 229940121623 teclistamab Drugs 0.000 description 1
- 108010073046 teduglutide Proteins 0.000 description 1
- 229940058889 tekturna Drugs 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- 229960001874 tesamorelin Drugs 0.000 description 1
- 229960001423 tetracosactide Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 229950010888 thrombomodulin alfa Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 229960000902 thyrotropin alfa Drugs 0.000 description 1
- 229940113038 tnkase Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 229940026454 tresiba Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940013051 trulicity Drugs 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229960004568 turoctocog alfa Drugs 0.000 description 1
- 229940022919 unituxin Drugs 0.000 description 1
- 229960004371 urofollitropin Drugs 0.000 description 1
- 229940041230 varicella-zoster immune globulin Drugs 0.000 description 1
- 229940063215 varizig Drugs 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960004406 velaglucerase alfa Drugs 0.000 description 1
- 229940070429 vetsulin Drugs 0.000 description 1
- 229940103766 vimizim Drugs 0.000 description 1
- 229940110059 voraxaze Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 229940110548 vpriv Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01041—Polypeptide N-acetylgalactosaminyltransferase (2.4.1.41)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/90—Protozoa ; Processes using protozoa
Definitions
- the present application relates to Leishmania host cells, methods of engineering Leishmania host cells, methods of culturing Leishmania host cells, methods of making a polypeptide of interest using a Leishmania host cell, and polypeptides of interest produced by the methods.
- the Leishmania host cells provided herein are capable of producing polypeptides comprising a biantennary, GalNAc-terminated N-glycan, specifically A2GalNAc2.
- a glycoprotein is a glycoconjugate in which a protein carries one or more glycans covalently attached to a polypeptide backbone, usually via N- or O-linkages.
- An N-glycan N-linked oligosaccharide, N-[Asn]-linked oligosaccharide
- N-linked oligosaccharide is a sugar chain covalently linked to an asparagine residue of a polypeptide chain, commonly involving a GlcNAc residue in eukaryotes, and the consensus peptide sequence: Asn-X-Ser/Thr (Varki, Ajit (2009): Essentials of glycobiology. 2ed. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press).
- Protein glycosylation is a ubiquitous post-translational modification found in all domains of life. There is a significant complexity in animal systems and glycan structures have crucial biological and physiological roles, from contributions in protein folding and quality, control to involvement in a large number of biological events, like recognition, stability, action, and turnover of these molecules (Moremen et al. 2012).
- Therapeutic Glycoproteins like monoclonal antibodies, enzymes, and hormones are the major products of the biotechnology industry (Lagasse, H A Daniel et al. 2017; Dimitrov 2012) and the impact of glycan heterogeneity has more and more been recognized as “critical quality attribute”.
- glycosylation is regarded as even one of the most important ones: influencing the biological activity, serum half-life and immunogenicity of the protein.
- Glycans are relevant for increased serum circulation times and many of the biologies approved or under development suffer from an insufficient half-life necessitating frequent applications in order to maintain a therapeutic concentration over an extended period of time.
- Half-life extension strategies are key to allow the generation of long-lasting therapeutics with improved pharmacokinetics (Kontermann 2016).
- Glycosylation also appears to improve protein solubility and stability, for example, through a reduced propensity for aggregation and leads to increased circulatory lifetimes due to the prevention of proteolytic degradation.
- N-glycans with different terminating monosaccharides can be recognized by lectins leading to their degradation (Blasko et al., 2013; Varki, 2017). Consequently, monitoring and control of glycosylation is critical in biopharmaceutical manufacturing and a requirement of regulatory agencies (Costa et al. 2014; Eon-Duval et al. 2012; Reusch and Tejada 2015). For these reasons, glycoengineering of expression platforms is increasingly recognized as an important strategy to improve biopharmaceuticals in many aspects (Dicker and Strasser 2015).
- Endocytic lectins are involved in receptor-mediated endocytosis by capturing glycosylated proteins via specific glycan structures to mediate degradation (Cummings et al., Cold Spring Harbor Laboratory Press, (2017). Endocytic lectins are ubiquitous in humans and can recognize various glycan structures.
- Carbohydrate binding receptors are highly diverse and can be exploited by glycoengineering to develop novel therapeutics with unprecedented effectiveness for different diseases, including but not limited to: inflammatory, blood disorders, autoimmune and cancer. This allows development of novel therapeutics based on the concept of glycan- mediated protein degradation. Leveraging natural protein degradation through the glycosylation of monoclonal antibodies can lead to novel therapeutics.
- the present invention shows a novel finding of Leishmania host cells are capable of producing polypeptides comprising a biantennary, GalNAc-terminated N-glycan, specifically A2GalNAc2, which mediates protein degradation.
- compositions and methods provided herein address the unmet medical need of patients suffering from various difficult to treat diseases such as cancer, autoimmune and inflammatory diseases, and infectious diseases, treated with glycosylated proteins, such as monoclonal antibodies, and provide related advantages.
- Leishmania host cells Provided herein are Leishmania host cells, methods of engineering Leishmania host cells, methods of culturing Leishmania host cells, methods of making a polypeptide of interest using a Leishmania host cell, and polypeptides of interest produced by the methods.
- a Leishmania host cell comprising: (a) a recombinant nucleic acid encoding a polypeptide of interest; and (b) a recombinant nucleic acid encoding one or more recombinant N-acetylgalactosamine (GalNAc) transferases, or functionally active variants thereof.
- the GalNAc transferase is heterologous to the host cell.
- the GalNAc transferase is p4-GalNAcT3, or a functionally active variant thereof.
- the P4-GalNAcT3 is human p4-GalNAcT3, or a functionally active variant thereof.
- the GalNAc transferases are P4-GalNAcT3 and P4-GalNAcT4, or functionally active variants thereof.
- the P4-GalNAcT3 and P4-GalNAcT4 are human p4-GalNAcT3 and P4- GalNAcT4, or functionally active variants thereof.
- the host cell further comprises: (a) a recombinant nucleic acid encoding recombinant UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc; and (b) a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway.
- the host cell further comprises: (a) a recombinant nucleic acid encoding a recombinant UDP-GalNAc biosynthetic pathway protein capable of converting UDP-GlcNAc to UDP-GalNAc; and (b) a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway.
- the host cell further comprises: (a) a recombinant nucleic acid encoding recombinant UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc; and (b) a recombinant nucleic acid encoding a recombinant UDP-GalNAc biosynthetic pathway protein capable of converting UDP-GlcNAc to UDP-GalNAc; and (c) a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway.
- a Leishmania host cell comprising (a) a recombinant nucleic acid encoding a polypeptide of interest; (b) a recombinant nucleic acid encoding one or more recombinant N-acetylgalactosamine (GalNAc) transferases, or functionally active variants thereof; and (c) a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway.
- GalNAc N-acetylgalactosamine
- the host cell further comprises one or more recombinant nucleic acids encoding heterologous UDP-GalNAc biosynthetic pathway proteins capable of generating UDP-GalNAc.
- the host cell further comprises (a) a recombinant nucleic acid encoding recombinant UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc; and/or (b) a recombinant nucleic acid encoding a recombinant UDP-GalNAc biosynthetic pathway protein capable of converting UDP-GlcNAc to UDP-GalNAc.
- the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein are co-localized in the secretory pathway.
- the one or more GalNAc transferases and the heterologous UDP- GalNAc transporter protein each independently comprise: (a) a signal peptide localizing the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein in the secretory pathway; and/or (b) a retention sequence retaining the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein in the secretory pathway.
- the one or more GalNAc transferases and the heterologous UDP- GalNAc transporter protein each independently comprise the same signal peptide and/or retention sequence. In certain embodiments, the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein comprise different signal peptides and/or retention sequences. In certain embodiments, the signal peptide of the one or more GalNAc transferases and/or the signal peptide of the heterologous UDP-GalNAc transporter protein are derived from a Leishmania species.
- the retention sequence of the one or more GalNAc transferases and/or the retention sequence of the heterologous UDP- GalNAc transporter protein are derived from a Leishmania species.
- the Leishmania species is Leishmania tarentolae.
- the signal peptide of the one or more GalNAc transferases and/or the signal peptide of the heterologous UDP- GalNAc transporter protein are processed and removed.
- the recombinant UDP-GalNAc biosynthetic pathway proteins and/or recombinant UDP-GalNAc transporter protein are heterologous to the host cell.
- one or more of the recombinant nucleic acids are integrated into the [ssuPolI] locus of the host cell.
- the one or more GalNAc transferases are derived from a mammalian source.
- the GalNAc transferase is derived from a mammalian source.
- the mammalian source is Homo sapiens.
- the one or more GalNAc transferases, or functionally active variants thereof are capable of catalyzing the addition of a GalNAc to a N-acetyl glucosamine- terminated glycan.
- the GalNAc transferase is capable of catalyzing the addition of a GalNAc to a N-acetyl glucosamine- terminated glycan.
- the one or more GalNAc transferases are selected from the group consisting of p4-GalNAcT3, p4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or functionally active variants thereof.
- the GalNAc transferase is selected from the group consisting of p4-GalNAcT3, P4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or functionally active variants thereof.
- the one or more GalNAc transferases are selected from the group consisting of P4-GalNAcT3, p4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto.
- the GalNAc transferase is selected from the group consisting of P4-GalNAcT3, p4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto.
- the one or more GalNAc transferases comprise P4-GalNAcT3, or an N- terminally truncated variant thereof.
- the GalNAc transferase is P4- GalNAcT3, or an N-terminally truncated variant thereof.
- the one or more GalNAc transferases comprise p4-GalNAcT3. In certain embodiments, the GalNAc transferase is p4-GalNAcT3. In certain embodiments, the one or more GalNAc transferases comprise an N-terminally truncated variant of P4-GalNAcT3. In certain embodiments, the GalNAc transferase is an N-terminally truncated variant of P4-GalNAcT3. In certain embodiments, the N-terminally truncated variant comprises an amino acid sequence of SEQ ID NO: 2.
- the one or more GalNAc transferases comprise a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to p4-GalNAcT3.
- the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to P4-GalNAcT3.
- the one or more GalNAc transferases comprise P4-GalNAcT4, or an N-terminally truncated variant thereof.
- the GalNAc transferase is P4-GalNAcT4, or an N-terminally truncated variant thereof.
- the one or more GalNAc transferases comprise P4- GalNAcT4.
- the GalNAc transferase is P4-GalNAcT4.
- the one or more GalNAc transferases comprise an N-terminally truncated variant of P4-GalNAcT4.
- the GalNAc transferase is an N-terminally truncated variant of P4-GalNAcT4.
- the N-terminally truncated variant is comprises an amino acid sequence of SEQ ID NO: 4.
- the one or more GalNAc transferases comprise a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to p4-GalNAcT4.
- the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to p4-GalNAcT4.
- the one or more GalNAc transferases comprise CeP4GalNAcT, or a variant that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto.
- the one or more GalNAc transferases comprise CeP4GalNAcT. In certain embodiments, the one or more GalNAc transferases comprise Ptp4GalNAcT, or a variant that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto. In certain embodiments, the one or more GalNAc transferases comprise Ptp4GalNAcT.
- the recombinant nucleic acid encodes at least two GalNAc transferases.
- the at least two GalNAc transferases are different GalNAc transferases.
- the at least two GalNAc transferases are selected as a combination of GalNAc transferases listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the at least two GalNAc transferases are selected from the group consisting of p4-GalNAcT3, p4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto.
- the at least two GalNAc transferases are human p4-GalNAcT3 and human P4- GalNAcT4; or human p4-GalNAcT3 and CeP4GalNAcT; or human p4-GalNAcT3 and Ptp4GalNAcT; or functionally active variants thereof.
- the recombinant nucleic acid encoding one or more GalNAc transferases comprises a first open reading frame (ORF) encoding a first GalNAc transferase and a second ORF encoding a second GalNAc transferase.
- ORF open reading frame
- the first ORF encoding the first GalNAc transferase and the second ORF encoding the second GalNAc transferase are integrated into the host cell in the same genetic module.
- the first ORF encoding the first GalNAc transferase and the second ORF encoding the second GalNAc transferase are integrated into the host cell in separate genetic modules.
- the first ORF encoding the first GalNAc transferase and the second ORF encoding the second GalNAc transferase are integrated into the [ssuPolI] locus of the host cell.
- the first and the second GalNAc transferases are different GalNAc transferases.
- the first and the second GalNAc transferases are selected as a combination of GalNAc transferases listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the first and the second GalNAc transferases are human p4-GalNAcT3 and human p4-GalNAcT4, respectively; or human p4-GalNAcT3 and CeP4GalNAcT, respectively; or human P4- GalNAcT3 and Ptp4GalNAcT, respectively; or functionally active variants thereof.
- the host cell comprises a recombinant nucleic acid encoding one or more additional recombinant glycosyltransferases.
- the additional recombinant glycosyltransferase is heterologous to the host cell.
- the additional recombinant glycosyltransferase comprises one or more N- acetyl glucosamine transferases.
- the N-acetyl glucosamine transferase is selected from the group consisting of MGAT1 and MGAT2, or functionally active variants thereof.
- the additional recombinant glycosyltransferase comprises MG ATI and MGAT2.
- the host cell is capable of producing polypepetides comprising a biantennary, GalNAc-terminated N-glycan.
- the host cell is capable of producing polypeptides comprising an N-glycan of the following structure: wherein the black square represents an N-acetyl galactosamine (GalNAc), the white square represents an N-acetylglucosamine (GlcNAc) residue and the black circle represents a mannose (Man) residue, and wherein X represents an amino acid residue of the polypeptide of interest.
- the host cell attaches the N-glycan to an N-glycosylation site of the polypeptide.
- the amino acid residue is Asn.
- the N-glycosylation site comprises a consensus sequence of N-X-S/T or N-X- C, wherein X is any amino acid except proline.
- one or more endogenous enzymes from the glycan biosynthesis pathway have been deleted, mutated and/or functionally inactivated.
- the host cell does not have endogenous N-glycan elongation.
- the host cell has been genetically engineered such that the formation of an O- linked GlcNAc on a polypeptide in the host cell is reduced or eliminated.
- the formation of O-linked GlcNAc in the Leishmania cell prior to genetic engineering is catalyzed by at least one N-acetylglucosamine (GlcNAc)-transferase.
- the gene encoding the at least one GlcNAc-transferase is functionally inactivated, downregulated, deleted, or mutated.
- the formation of the O-linked GlcNAc is reduced by at least 5%, 7%, 10%, 12%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% from the formation of the O-linked GlcNAc in a reference Leishmania cell.
- the at least one GlcNAc-transferase is selected from the group consisting of OGNT1, OGNT2 and OGNTL, and homologous GlcNAc-transferases thereof.
- the host cell is a OGNT1, OGNT2 and OGNTL triple knockout.
- the host cell further comprises a recombinant nucleic acid encoding heterologous UDP-GalNAc biosynthetic pathway proteins capable of generating UDP-GalNAc.
- the heterologous UDP-GalNAc biosynthetic pathway proteins are capable of converting GalNAc to UDP-GalNAc.
- the heterologous UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc are derived from a mammalian source.
- the mammalian source is Homo sapiens.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP-N-acetyl hexosamine pyrophosphorylase (UAP1), or a functionally active variant thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP- N-acetyl hexosamine pyrophosphorylase (UAP1), or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP- N-acetyl hexosamine pyrophosphorylase (UAP1).
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise N-acetyl galactosamine kinase (GALK2), or a functionally active variant thereof.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise N-acetyl galactosamine kinase (GALK2), or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the heterologous UDP- GalNAc biosynthetic pathway proteins comprise N-acetyl galactosamine kinase (GALK2). In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins are capable of converting UDP-GlcNAc to UDP-GalNAc. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins capable of converting UDP- GlcNAc to UDP-GalNAc are derived from a mammalian source. In certain embodiments, the mammalian source is Homo sapiens.
- the heterologous UDP- GalNAc biosynthetic pathway proteins comprise hGalE, or a functionally active variant thereof.
- the heterologous UDP-GalNAc biosynthetic pathway protein comprise hGalE, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise hGalE.
- the heterologous UDP-GalNAc biosynthetic pathway proteins capable of converting UDP-GlcNAc to UDP-GalNAc are derived from a bacterial source.
- the bacterial source is Campylobacter jejuni.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise CjGne, or a functionally active variant thereof.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise CjGne, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise CjGne.
- the host cell further comprises a recombinant nucleic acid encoding a heterologous UDP-GalNAc transporter protein capable of transporting UDP- GalNAc to the secretory pathway.
- the heterologous UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is derived from a nematode source, a mammalian source, a brachiopod source, a chordate source, choanoflagellate source, a gyrista source, a fungi source, a mollusk source, or a placozoan source.
- the heterologous UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is derived from a nematode source.
- the nematode source is C.
- the mammalian source is Homo sapiens
- the brachiopod source is Lingula unguis
- the chordate source is Parambassis ranga
- Geotrypetes seraphini or Scophthalmus maximus
- the choanoflagellate source is Salpingoeca rosetta
- the gyrista source is Fragilariopsis cylindrus
- the fungi source is Dentipellis fragilis
- the mollusk source is Octopus bimaculoides
- the placozoan source is trichoplax sp. H2.
- the nematode source is C. elegans.
- the heterologous UDP-GalNAc transporter protein is CeC03H5.2, or a functionally active variant thereof. In certain embodiments, the heterologous UDP-GalNAc transporter protein is CeC03H5.2, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the heterologous UDP- GalNAc transporter protein is CeC03H5.2. In certain embodiments, the heterologous UDP- GalNAc transporter protein is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to CeC03H5.2.
- the heterologous UDP-GalNAc transporter protein is GnF, GnG, GnH, GnI, or GnJ. In certain embodiments, the heterologous UDP-GalNAc transporter protein is UGTREL7, or a functionally active variant thereof. In certain embodiments, the heterologous UDP-GalNAc transporter protein is UGTREL7, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the heterologous UDP-GalNAc transporter protein is UGTREL7.
- the heterologous UDP-GalNAc transporter protein is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to UGTREL7.
- the heterologous UDP-GalNAc transporter protein is GnL, GnM, GnN, or GnO.
- the recombinant nucleic acid encodes at least two heterologous UDP-GalNAc transporter proteins. In certain embodiments, the recombinant nucleic acid encodes two copies of the same heterologous UDP-GalNAc transporter protein. In certain embodiments, the recombinant nucleic acid encodes two different heterologous UDP-GalNAc transporter proteins.
- the heterologous UDP-GalNAc transporter proteins are selected as a combination of heterologous UDP-GalNAc transporters listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2, GnF, GnG, GnH, GnI, GnJ, UGTREL7, GnL, GnM, GnN, or GnO, or functionally active variants thereof.
- the heterologous UDP-GalNAc transporter proteins comprise CeC03H5.2.
- the heterologous UDP- GalNAc transporter protein is CeC03H5.2.
- the heterologous UDP- GalNAc transporter proteins are CeC03H5.2 and GnJ.
- the recombinant nucleic acid encoding a heterologous UDP-GalNAc transporter comprises a first ORF encoding a first heterologous UDP-GalNAc transporter and a second ORF encoding a second heterologous UDP-GalNAc transporter.
- the first ORF encoding the first heterologous UDP-GalNAc transporter and the second ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module.
- the first ORF encoding the first heterologous UDP-GalNAc transporter and the second ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in separate genetic modules. In certain embodiments, the first ORF encoding the first heterologous UDP-GalNAc transporter and the second ORF encoding the second heterologous UDP- GalNAc transporter are integrated into the [ssuPolI] locus of the host cell.
- the first and the second heterologous UDP-GalNAc transporter are selected as a combination of heterologous UDP-GalNAc transporters listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the first and the second heterologous UDP-GalNAc transporter proteins are the same UDP-GalNAc transporter protein.
- the first and the second heterologous UDP-GalNAc transporter proteins are each CeC03H5.2.
- the first and the second heterologous UDP- GalNAc transporter proteins are different UDP-GalNAc transporter proteins. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter proteins are CeC03H5.2 and GnJ, respectively. [0027] In certain embodiments, the recombinant nucleic acids encode at least two GalNAc transferases and at least two heterologous UDP-GalNAc transporter proteins. In certain embodiments, the at least two GalNAc transferases are different. In certain embodiments, the recombinant nucleic acids encode two copies of the same heterologous UDP-GalNAc transporter protein.
- the recombinant nucleic acids encode two different heterologous UDP-GalNAc transporter proteins.
- the at least two GalNAc transferases and at least two heterologous UDP- GalNAc transporter proteins are selected as a combination of GalNAc transferases and heterologous UDP-GalNAc transporter proteins listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof
- the recombinant nucleic acids encode human P4-GalNAcT3, CeP4GalNAcT, CeC03H5.2, and GnJ.
- the recombinant nucleic acids encode human p4-GalNAcT3, Ptp4GalNAcT, and CeC03H5.2.
- the host cell is such that (a) the recombinant nucleic acid encoding one or more GalNAc transferases comprises a first ORF encoding a first GalNAc transferase and a second ORF encoding a second GalNAc transferase; and (b) b.
- the recombinant nucleic acid encoding a heterologous UDP-GalNAc transporter comprises a third ORF encoding a first heterologous UDP-GalNAc transporter and a fourth ORF encoding a second heterologous UDP-GalNAc transporter.
- the host cell is such that (a) the first open reading frame (ORF) encoding the first GalNAc transferase and and the third ORF encoding the first heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module; and/or (b) the second open reading frame (ORF) encoding the second GalNAc transferase and and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module.
- ORF open reading frame
- the host cell is such that (a) the first ORF encoding the first GalNAc transferase and the second ORF encoding the second GalNAc transferase are integrated into the host cell in separate genetic modules; and/or (b) the third ORF encoding the first heterologous UDP-GalNAc transporter and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in separate genetic modules.
- the first ORF encoding the first GalNAc transferase, the second ORF encoding the second GalNAc transferase, the third ORF encoding the first heterologous UDP-GalNAc transporter, and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module.
- the first ORF encoding the first GalNAc transferase, the second ORF encoding the second GalNAc transferase, the third ORF encoding the first heterologous UDP-GalNAc transporter, and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the [ssuPolI] locus of the host cell.
- the first and the second GalNAc transferases are different GalNAc transferases.
- the first and the second heterologous UDP- GalNAc transporter proteins are the same UDP-GalNAc transporter protein.
- the first and the second heterologous UDP-GalNAc transporter proteins are different UDP-GalNAc transporter proteins.
- the first GalNAc transferase, the second GalNAc transferase, the first heterologous UDP-GalNAc transporter protein, and the second heterologous UDP-GalNAc transporter protein are selected as a combination of GalNAc transferases and heterologous UDP-GalNAc transporter proteins listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the first and the second GalNAc transferases are human p4-GalNAcT3 and CeP4GalNAcT, respectively; and the first and the second heterologous UDP-GalNAc transporter proteins are CeC03H5.2, and GnJ, respectively.
- the first and the second GalNAc transferases are human p4-GalNAcT3 and Ptp4GalNAcT, respectively; and the first and the second heterologous UDP-GalNAc transporter proteins are each CeC03H5.2.
- the one or more GalNAc transferases and the polypeptide of interest are co-localized in the secretory pathway. In certain embodiments, the GalNAc transferase and the polypeptide of interest are co-localized in the secretory pathway. In certain embodiments, the one or more GalNAc transferases and the additional recombinant glycosyltransferase are co-localized in the secretory pathway. In certain embodiments, the GalNAc transferase and the additional recombinant glycosyltransferase are co-localized in the secretory pathway.
- the one or more GalNAc transferases each independently comprise a signal peptide localizing the one or more GalNAc transferases in the secretory pathway. In certain embodiments, the one or more GalNAc transferases each independently comprise a retention sequence retaining the one or more GalNAc transferases in the secretory pathway. In certain embodiments, the GalNAc transferase comprises a signal peptide localizing the GalNAc transferase in the secretory pathway. In certain embodiments, the additional recombinant glycosyltransferase comprises a signal peptide localizing the additional recombinant glycosyltransferase in the secretory pathway.
- the additional recombinant glycosyltransferase comprises a retention sequence retaining the additional recombinant glycosyltransferase in the secretory pathway.
- the signal peptide is added to an N-terminally truncated variant of the GalNAc transferase and/or the additional recombinant glycosyltransferase.
- the retention sequence is added to an N-terminally truncated variant of the GalNAc transferase and/or the additional recombinant glycosyltransferase.
- the polypeptide of interest comprises a signal peptide localizing the polypeptide of interest to the secretory pathway and/or a retention sequence retaining the polypeptide of interest in the secretory pathway.
- the signal peptide and/or the retention sequence is derived from Leishmania species.
- the signal peptide is derived from Leishmania tarentolae.
- the signal peptide is an invertase signal peptide from derived from Leishmania tarentolae.
- the signal peptide is processed and removed.
- the host cell is a Leishmania tarentolae host cell.
- culturing the Leishmania host cell produces a composition of the polypeptide of interest, wherein said composition of the polypeptide of interest comprises an N-glycan of the following structure: wherein the black square represents an N-acetyl galactosamine (GalNAc), the white square represents an N-acetylglucosamine (GlcNAc) residue and the black circle represents a mannose (Man) residue, and wherein X represents an amino acid residue of the polypeptide of interest.
- the host cell is stable to passaging and/or continuous fermentation for 100 or more generations.
- the host cell is any one of the strains listed in Table 3 or
- a subject refers to an animal (e.g., birds, reptiles, and mammals).
- a subject is a mammal including a non-primate (e.g., a camel, donkey, zebra, cow, pig, horse, goat, sheep, cat, dog, rat, and mouse) and a primate (e.g., a monkey, chimpanzee, and a human).
- a subject is a non-human animal.
- a subject is a farm animal or pet (e.g., a dog, cat, horse, goat, sheep, pig, donkey, or chicken).
- a subject is a human.
- the terms “subject” and “patient” may be used herein interchangeably.
- the term “effective amount,” in the context of administering a therapy (e.g, a composition described herein) to a subject refers to the amount of a therapy which has a prophylactic and/or therapeutic effect(s).
- an “effective amount” refers to the amount of a therapy which is sufficient to achieve one, two, three, four, or more of the following effects: (i) reduce or ameliorate the severity of a disease/disorder or symptom associated therewith; (ii) reduce the duration of a disease/disorder or symptom associated therewith; (iii) prevent the progression of a disease/disorder or symptom associated therewith; (iv) cause regression of a disease/disorder or symptom associated therewith; (v) prevent the development or onset of a disease/disorder, or symptom associated therewith; (vi) prevent the recurrence of a disease/disorder or symptom associated therewith; (vii) reduce organ failure associated with a disease/disorder; (viii) reduce hospitalization of a subject having a disease/disorder; (ix) reduce hospitalization length of a subject having a disease/disorder; (x) increase the survival of a subject with a disease/disorder; (i) reduce or
- proteins referred to herein as “colocalized in the secretory pathway” have at least partially overlapping subcellular distribution in the secretory pathway, for example in the endoplasmic reticulum or Golgi apparatus.
- the subcellular distribution of one protein referred to herein as “colocalized in the secretory pathway” with another protein is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% overlapping with with the subcellular distribution of the other protein.
- the overlapping subcellular distribution of two or more proteins referred to herein as “co-localized in the secretory pathway” may be attributed to a signal peptide localizing and/or a retention sequence retaining the two or more proteins in the secretory pathway, for example in the endoplasmic reticulum or Golgi apparatus.
- FIG. 1 depicts the general pathways of UDP-GlcNAc, UDP-GalNAc and UDP- Gal biosynthesis.
- the enzymes involved in each step are shown besides the arrows.
- Galactokinase (GK), UDP-sugar pyrophosphorylase (USP), UDP -galactose 4-epimerase (GalE), hexokinase (HXK), phosphoglucomutase (PGM) and UDP-glucose pyrophosphorylase (UGP) are identified in Leishmania tarentolae genome and presumed biosynthetic steps are indicated with black arrows. Enzymes not being present in L.
- N- acetylglucosamine kinase N- acetylglucosamine kinase (NAGK), human UDP -galactose 4-epimerase (hGalE), Campylobacter jejuni UDP-GlcNAc/Glc 4-epimerase (CjGne), N-acetyl galactosamine kinase (GALK2), UDP -N-acetyl hexosamine pyrophosphorylase (UAP1), Beta-1, 4-N- acetylgalactosaminyltransferase T3 (
- NAGK N- acetylglucos
- FIG. 2 depicts UDP-GalNAc biosynthetic pathways and GalNAc-transferases for engineering host cells. The enzymatic activities are shown besides the arrows.
- FIG. 3A depicts UDP-GalNAc measurements in Leishmania tarentolae.
- a standard containing UDP-GalNAc and UDP-GlcNAc is indicated with sold grey line, L.
- tarentolae wt extract is shown as solid black line, and the same extract spiked with UDP- GalNAc and UDP-GlcNAc standard in a High performance anion exchange chromatography coupled with pulsed amperometric detection (HPAEC-PAD) measurement is shown as dotted black line.
- HPAEC-PAD pulsed amperometric detection
- FIG. 3B depicts UDP-GalNAc measurement of engineered Leishmania tarentolae host cells containing recombinant proteins for UDP-GalNAc biosynthetic pathways.
- Different cell lines contain different combinations of recombinant enzymes for the different UDP-GalNAc biosynthetic pathways, for example Transporter +Salvage + Epimerase “TSE”; or Transporter + Salvage (“TS”); or Transporter-i- Epimerization (“TE”) with genetic constructs of coding sequences spaced by different intergenic regions derived from Leishmania major (J, AC vs. Y, Z) and different site-specific integration loci (pfr vs. aTub). Only two strains StCGP2805 and St2848, shown with black and black dashed lines respectively, were supplemented with lOmM GalNAc to the growth medium and UDP- GalNAc peaks were detected.
- TSE Transporter +Salvage + Epimerase
- TS Transporter + Salvage
- TE Transporter-i- Epimerization
- FIG 4A depicts the recombinant pathway engineered in Leishmania tarentolae strain StCGP2879.
- FIG. 4B depicts high levels of A2GalNAc2 N-glycans produced by engineered Leishmania tarentolae StCGP2879 containing UDP-GalNAc biosynthetic pathways and GalNAc-transferases.
- Strain StCGP2879 secreting adalimumab antibody was analyzed for its N-glycan composition on its Fab and Fc glycosites.
- Fab glycosites show 80% A2GalNAc2 N-glycans analyzed by HILIC-UPLC-MS (Top) and N297 canonical Fc glycosite show the main N-glycan A2 (bottom).
- the N-glycan structure is shown with black circle representing mannose (Man), white square representing N-acetyl glucosamine (GlcNAc), and black square representing N-acetyl galactosamine (GalNAc).
- FIG. 5 depicts a flowchart of CGP engineered host cell lines.
- the left panel indicates the main N-glycan (M3, A2 or A2GalNAc2) for the strains listed on the right. Strains are in bold. Arrows show the genetic modification step with brief description of the genetic module in italics along with the selection marker, and with the genomic integration locus in brackets. Intergenic regions (IRs) are indicated where relevant. Boxes at the bottom show the quantitative content of A2GalNAc2 on adalimumab (“Fab glycosite”) or endogenous surface glycoproteins (“cell surface”), andn.d. means not determined for respective strain.
- Fab glycosite adalimumab
- cell surface endogenous surface glycoproteins
- FIG. 6 depicts another flowchart of CGP engineered host cell lines.
- the left panel indicates the main N-glycan (M3, A2 or A2GalNAc2) for the strains listed on the right.
- Strains are in bold. Arrows show the genetic modification step with brief description of the genetic module in italics along with the selection marker, and with the genomic integration locus in brackets. Dashed arrows represent the intended integration of polypeptide of interest or mAb expression modules.
- FIG. 7A depicts N-glycan traces of Fab part of Adalimumab (K84N/D86N) secreted from StCGP3127 CGP engineered host cell lines.
- N-glycans (A2, A2GalNacl and A2GalNAc2) were analyzed by HILIC-UPLC-MS from Adalimumab (K84N/D86N) in strain StCGP3127, which was derived from StCGP3053 (OGNT+).
- Adalimumab was cleaved with IdeZ, and the resulting subunits to F(ab’)2 and Fc/2 separated by SDS-PAGE, released by PNGaseF and procainamide labelled.
- the N-glycan structure is shown with black circle representing mannose (Man), white square representing N-acetyl glucosamine (GlcNAc), and black square representing N-acetyl galactosamine (GalNAc).
- FIG. 7B depicts N-glycan traces of Fab part of Adalimumab (K84N/D86N) secreted from StCGP3220 CGP engineered host cell lines.
- N-glycans (A2, A2GalNacl and A2GalNAc2) were analyzed by HILIC-UPLC-MS from Adalimumab (K84N/D86N) from StCGP3220, which was derived from strain StCGP3169 (OGNT triple deletion mutant).
- Adalimumab was cleaved with IdeZ, and the resulting subunits to F(ab’)2 and Fc/2 separated by SDS-PAGE, released by PNGaseF and procainamide labelled.
- the N-glycan structure is shown with black striped circle representing mannose (Man), white square representing N- acetyl glucosamine (GlcNAc), and black square representing N-acetyl galactosamine (Gal
- FIG. 8A depicts N-glycan traces of Fab part of mAb 5C9 (D86N) secreted from CGP engineered host cell lines.
- FIG. 8B depicts N-glycan traces of Fab part of mAb 1 lk2 (D86N) secreted from the same CGP engineered host cell lines.
- N-glycans (A2, A2GalNAcl and A2GalNAc2) were analyzed by HILIC-UPLC from two different IgG4 antibodies, containing engineered glycosite at LC, D86N.
- N-glycans were analyzed from reduced LC, which was separated by SDS-PAGE, released by PNGaseF and procainamide labelled.
- the N-glycan structure is shown with black circle representing mannose (Man), white square representing N-acetyl glucosamine (GlcNAc), and black square representing N-acetyl galactosamine (GalNAc).
- FIG. 9A depicts N-glycan distribution (%) of surface glycoproteins derived from CGP engineered host cell lines encoding different GalNAc transferases.
- FIG. 9B depicts N- glycan distribution (%) of mAb Adalimumab (K84N/D86N) derived from CGP engineered host cell lines encoding different GalNAc transferases.
- FIG. 9C depicts N-glycan distribution (%) of mAb 1 lk2 (S84N/D86N) derived from CGP engineered host cell lines encoding different GalNAc transferases.
- N-glycans (A2, A2GalNAcl and A2GalNAc2) were analyzed by HILIC-UPLC and quantified, from cell surface glycoprotein of the empty parental strains and from two different mAbs, glycan distribution derived from the Fab of Adali (K84N/D86N), and total N-glycans (“in solution”, includes Fc N297 site) of 1 lk2 (S84N/D86N).
- the different GalNAc transferases from the parental different parental strains are indicated at the bottom of the corresponding graphs, indicating varying efficiency in A2GalNAcl and A2GalNAc2 conversion on different native (cell surfaces glycoproteins) or engineered glycosite on the different mAbs.
- FIG. 10A depicts a flowchart of engineered host cell lines testing different UDP- GalNAc transporter CeC03H5.2 and selected homologs GnF, GnG, GnH, GnI and GnJ (Table 10) in the StCGP4334 parental cell line background.
- StCGP4334 contains a GalNAc synthesis module with salvage and epimerization enzymes (“S+E”) and the HsGalNAcT3 transferase, integrated into the ssu-PolI genomic locus; and Adalimumab (K84N/D86N).
- the left panel indicates the main N-glycan (M3, A2 or A2GalNAc2) for the strains listed on the right. Strain designations are in bold. Arrows show the genetic modification step with brief description of the genetic module in italics along with the selection marker, and with the genomic integration locus in brackets.
- FIG. 10B depicts a flowchart of engineered host cell lines testing different UDP- GalNAc transporter UGTREL7 and selected homologs GnL, GnM, GnN and GnO (Table 11) in the StCGP4334 parental cell line background.
- StCGP4334 contains a GalNAc synthesis module with salvage and epimerization enzymes (“S+E”) and the HsGalNAcT3 transferase, integrated into the ssu-PolI genomic locus; and Adalimumab (K84N/D86N).
- the left panel indicates the main N-glycan (M3, A2 or A2GalNAc2) for the strains listed on the right. Strain designations are in bold. Arrows show the genetic modification step with brief description of the genetic module in italics along with the selection marker, and with the genomic integration locus in brackets.
- FIG. 11 depicts A2GalNAc2 N-glycans in % produced by engineered Leishmania tarentolae StCGP4334 (parental cell line) and cell lines modified with putative UDP-GalNAc transporters (indicated in parentheses in the following).
- Left Panel Strains StCGP5003 (+CeC03H5.2), StCGP5006 (+GnF), StCGP5007 (+GnG), StCGP5010 (+GnH), StCGP5012 (with GnI), and StCGP5013(+GnJ).
- FIG. 12 depicts a flowchart of engineered host cell lines testing UDP-GalNAc transporter homologs in the StCGP4106 parental cell line background, that already contains Adalimumab (K84N/D86N) by introducing a combined module that contains the UDP- GalNAc biosynthesis pathway (T+S+E), where T is the designated GalNAc transporter or homolog (either CeC03H5.2, GnF, GnJ or GnM, respectively) along with the PtGalNAc transferase.
- the left panel indicates the main N-glycan (M3, A2 or A2GalNAc2, respectively) for the strains listed on the right. Strain designations are in bold. Arrows show the genetic modification step with brief description of the genetic module in italics along with the selection marker, and with the genomic integration locus in brackets.
- FIG. 13 depicts A2GalNAc2 N-glycans in %, produced by engineered Leishmania tarentolae StCGP4978, StCGP5351, StCGP5352, and StCGP5694 expressing putative UDP-GalNAc transporters, the PtGalNAcT transferase and each of them secreting Adalimumab (K84N/D86N).
- Fab glycosites were evaluated after Protein A purification for the N-glycan composition and bars represent N-gly can % of A2, A2GalNAcl and A2GalNAc2, released from Adalimumab Fab glycosites and analyzed by HILIC-UPLC-MS.
- FIG. 14 shows the flowchart of engineering entry host cell lines StCGP5359 and StCGP5942.
- the left panel indicates the main N-glycan (M3, A2 or A2GalNAc2, respectively) for the strains listed on the right. Strain designations are in bold. Arrows show the genetic modification step with brief description of the genetic module in italics along with the selection marker, and with the genomic integration locus in brackets. Dashed arrow indicates that any polypeptide (“target proteins”, mAbs, Ab scaffolds, etc.) containing N- glycosylation consensus site(s) can be introduced in described host cell lines to produce polypeptides comprising a biantennary, GalNAc-terminated N-glycan, specifically A2GalNAc2, which mediates protein degradation.
- target proteins mAbs, Ab scaffolds, etc.
- FIG. 15 shows A2GalNAc2 N-glycans analyzed by HILIC-UPLC-MS (Top Panel) and quantified in % (Bottom Panel), from engineered Leishmania tarentolae StCGP6044, expressing a VHH containing a C-terminal glycotag, which is a peptide stretch harboring a N-glycosylation consensus site N-X-S/T.
- StCGP6044 is a representative for the performance of entry cell line StCGP5359, which does not express a target polypeptide.
- StCGP6044 was continuously passaged for 37 and 66 generations, respectively, without addition of any selection pressure.
- VHH was affinity -purified for N-glycan analysis and bars represent N-glycan % of A2, A2GalNAcl and A2GalNAc2, released from purified protein (Graph at Bottom Panel).
- FIG. 16 shows A2GalNAc2 N-glycans analyzed by HILIC-UPLC-MS (Top Panel) and quantified in % (Bottom Panel), from engineered Leishmania tarentolae StCGP6631, expressing a VHH containing a C-terminal glycotag, which is a peptide stretch harboring a N-glycosylation consensus site N-X-S/T.
- StCGP663 l is a representative for the performance of entry cell line StCGP5942, which does not express a target polypeptide.
- StCGP6631 was continuously passaged for 35 and 63 generations, respectively, without addition of any selection pressure.
- VHH was affinity -purified for N-glycan analysis and bars represent N-glycan % of A2, A2GalNAcl and A2GalNAc2, released from purified protein (Graph at Bottom Panel).
- the present invention relates to Leishmania host cells, methods of engineering Leishmania host cells, methods of culturing Leishmania host cells, methods of making a polypeptide of interest using a Leishmania host cell, and polypeptides of interest produced by the methods described herein.
- Leishmania host cells comprising: (a) a recombinant nucleic acid encoding a polypeptide of interest; and (b) a recombinant nucleic acid encoding one or more recombinant N-acetylgalactosamine (GalNAc) transferases.
- the Leishmania host cells provided herein are capable of producing polypeptides comprising a biantennary, GalNAc-terminated N-glycan.
- the Leishmania host cells provided herein are capable of producing polypeptides comprising an N-glycan of the following structure: wherein the black square represents an N-acetyl galactosamine (GalNAc), the white square represents an N-acetylglucosamine (GlcNAc) residue and the black circle represents a mannose (Man) residue, and wherein X represents an amino acid residue of the polypeptide of interest.
- GalNAc N-acetyl galactosamine
- Man mannose
- the Leishmania host cells provided herein comprise a recombinant nucleic acid encoding one or more recombinant N-acetylgalactosamine (GalNAc) transferases described in Section 7.1.1.
- the Leishmania host cells provided herein comprise a recombinant nucleic acid encoding one or more additional recombinant glycosyltransferases described in Section 7.1.2.
- one or more endogenous enzymes described in Section 7.1.3 from the glycan biosynthesis pathway of the the Leishmania host cells provided herein have been deleted, mutated and/or functionally inactivated.
- the Leishmania host cells provided herein further comprise a recombinant nucleic acid encoding heterologous UDP- GalNAc biosynthetic pathway proteins as described in Section 7.1.4 capable of generating UDP-GalNAc.
- the Leishmania host cells provided herein comprise a recombinant nucleic acid encoding a heterologous UDP-GalNAc transporter protein as described in Section 7.1.5 capable of transporting UDP-GalNAc to the secretory pathway.
- the strain of the Leishmania host cells provided herein is described in Section 7.1.6.
- the Leishmania host cells provided herein below are genetically engineered using the methods described in Section 7.2.
- the Leishmania host cells provided herein below are cultured according to the methods described in Section 7.3.
- the Leishmania host cells provided herein may be used as an expression system as described in Section 7.4.
- the Leishmania host cells provided herein may be used to make a polypeptide of interest as described in Section 7.5.
- the Leishmania host cells provided herein comprise a recombinant nucleic acid encoding one or more recombinant N-acetylgalactosamine (GalNAc) transferases.
- the GalNAc transferase or a functionally active variant thereof, is capable of catalyzing the addition of a GalNAc to a N-acetyl glucosamine-terminated glycan.
- the GalNAc transferase is heterologous to the Leishmania host cell.
- the GalNAc transferase is derived from Homo sapiens, Caenorhabditis elegans, Parasteatoda lepidarionim, Salmo Irulla, or Hucho hucho.
- the GalNAc transferase is derived from a mammalian source.
- the mammalian source is Homo sapiens.
- the GalNAc transferase is selected from the group consisting of P4-GalNAcT3, [34-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or functionally active variants thereof.
- the GalNAc transferase is selected from the group consisting of P4-GalNAcT3, P4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the GalNAc transferase comprises P4-GalNAcT3, or a functionally active variant thereof. In certain embodiments, the GalNAc transferase comprises P4-GalNAcT3. In certain embodiments, the GalNAc transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to P4-GalNAcT3. In certain embodiments, the GalNAc transferase comprises an N-terminally truncated variant of P4-GalNAcT3.
- the P4-GalNAcT3 comprises P4-GalNAcT3 of Homo sapiens, or a functionally active variant thereof.
- the GalNAc transferase comprises P4-GalNAcT3 of Homo sapiens.
- the GalNAc transferase comprises an amino acid sequence of SEQ ID NO: 1.
- the GalNAc transferase comprises one that is homologous to P4-GalNAcT3 of Homo sapiens.
- the GalNAc transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to P4-GalNAcT3 of Homo sapiens.
- the GalNAc transferase comprises an N-terminally truncated variant of P4- GalNAcT3 of Homo sapiens comprising an amino acid sequence of SEQ ID NO: 2.
- the GalNAc transferase comprises P4-GalNAcT4, or a functionally active variant thereof. In certain embodiments, the GalNAc transferase comprises P4-GalNAcT4. In certain embodiments, the GalNAc transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to P4-GalNAcT4. In certain embodiments, the GalNAc transferase comprises an N-terminally truncated variant of P4-GalNAcT4.
- the P4-GalNAcT4 comprises P4-GalNAcT4 of Homo sapiens, or a functionally active variant thereof.
- the GalNAc transferase comprises P4-GalNAcT4 of Homo sapiens.
- the GalNAc transferase comprises an amino acid sequence of SEQ ID NO: 3.
- the GalNAc transferase comprises one that is homologous to P4-GalNAcT4 of Homo sapiens.
- the GalNAc transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to P4-GalNAcT4 of Homo sapiens.
- the GalNAc transferase comprises an N-terminally truncated variant of P4- GalNAcT4 of Homo sapiens comprising an amino acid sequence of SEQ ID NO: 4.
- the GalNAc transferases comprise P4-GalNAcT3 and P- GalNAcT4, or functionally active variants thereof.
- the GalNAc transferases comprise P4-GalNAcT3 and P4-GalNAcT4.
- the GalNAc transferases comprise variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to P4-GalNAcT3 and P-GalNAcT4, respectively.
- the GalNAc transferases comprise N-terminally truncated variants of P4-GalNAcT3 and/or [34-GalNAcT4.
- the GalNAc transferases comprise P4-GalNAcT3 and P4-GalNAcT4 of Homo sapiens, or functionally active variants thereof. In certain embodiments, the GalNAc transferases comprise P4-GalNAcT3 and P4-GalNAcT4 of Homo sapiens. In certain embodiments, the GalNAc transferases comprise amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 3. In certain embodiments, the GalNAc transferases comprise ones that are homologous to 4- GalNAcT3 and P4-GalNAcT4 of Homo sapiens.
- the GalNAc transferases comprise variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to P4-GalNAcT3 and P4-GalNAcT4 of Homo sapiens, respectively.
- the GalNAc transferases comprise N- terminally truncated variants of P4-GalNAcT3 and/or [34-GalNAcT4 of Homo sapiens comprising amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4, respectively.
- the GalNAc transferase is CeP4GalNAcT, or a functionally active variant thereof.
- the GalNAc transferase is CeP4GalNAcT. In certain embodiments, the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to CeP4GalNAcT. In certain embodiments, the GalNAc transferase is an N-terminally truncated variant of CeP4GalNAcT. In certain embodiments, the CeP4GalNAcT is a P4GalNAcT of Caenorhabditis elegans, or a functionally active variant thereof.
- the GalNAc transferase is a P4GalNAcT of Caenorhabditis elegans. In certain embodiments, the GalNAc transferase comprises an amino acid sequence of SEQ ID NO: 5. In certain embodiments, the GalNAc transferase is one that is homologous to a CeP4GalNAcT of Caenorhabditis elegans. In certain embodiments, the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to a CeP4GalNAcT of Caenorhabditis elegans.
- the GalNAc transferase comprises an N-terminally truncated variant of CeP4GalNAcT of Caenorhabditis elegans comprising an amino acid sequence of SEQ ID NO: 6.
- the GalNAc transferase is Ptp4GalNAcT, or a functionally active variant thereof.
- the GalNAc transferase is Ptp4GalNAcT.
- the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to Ptp4GalNAcT.
- the GalNAc transferase is an N-terminally truncated variant of Ptp4GalNAcT.
- the Ptp4GalNAcT is a P4GalNAcT of Parasteatoda tepidariorum. or a functionally active variant thereof.
- the GalNAc transferase is a Ptp4GalNAcT of Parasteatoda tepidariorum.
- the GalNAc transferase comprises an amino acid sequence of SEQ ID NO: 7.
- the GalNAc transferase is one that is homologous to a Ptp4GalNAcT of Parasteatoda tepidariorum. In certain embodiments, the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to a Ptp4GalNAcT of Parasteatoda tepidariorum. In certain embodiments, the GalNAc transferase comprises an N-terminally truncated variant of Ptp4GalNAcT of Parasteatoda tepidariorum comprising an amino acid sequence of SEQ ID NO: 8.
- the GalNAc transferase is Stp4GalNAcT, or a functionally active variant thereof. In certain embodiments, the GalNAc transferase is Stp4GalNAcT. In certain embodiments, the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to Stp4GalNAcT. In certain embodiments, the GalNAc transferase is an N-terminally truncated variant of Stp4GalNAcT. In certain embodiments, the Stp4GalNAcT is a P4GalNAcT of Salmo IruUa.
- the GalNAc transferase is a p4GalNAcT of Salmo trutta.
- the GalNAc transferase comprises an amino acid sequence of SEQ ID NO: 9.
- the GalNAc transferase is one that is homologous to a P4GalNAcT of Salmo trutta.
- the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to a p4GalNAcT of Salmo trutta.
- the GalNAc transferase is Hhp4GalNAcT, or a functionally active variant thereof. In certain embodiments, the GalNAc transferase is Hhp4GalNAcT. In certain embodiments, the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to Hhp4GalNAcT. In certain embodiments, the GalNAc transferase is an N-terminally truncated variant of Hhp4GalNAcT.
- the Hhp4GalNAcT is a P4GalNAcT of Hucho hucho, or a functionally active variant thereof.
- the GalNAc transferase is a P4GalNAcT of Hucho hucho.
- the GalNAc transferase comprises an amino acid sequence of SEQ ID NO: 10.
- the GalNAc transferase is one that is homologous to a p4GalNAcT of Hucho hucho.
- the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to a P4GalNAcT of Hucho hucho.
- combinations of at least two GalNAc transferases can be beneficial for optimizing the glycosylation profile of polypetides of interest, for example by increasing the extent and/or homogeneity of glycoylsation with N-glycan(s) described herein.
- the recombinant nucleic acid encodes at least two GalNAc transferases. In certain embodiments, the recombinant nucleic acid encodes two GalNAc transferases. In certain embodiments, the at least two GalNAc transferases are different GalNAc transferases.
- the at least two GalNAc transferases are selected from the group consisting of p4-GalNAcT3, p4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto.
- the at least two GalNAc transferases are human p4-GalNAcT3 and human P4- GalNAcT4; or human p4-GalNAcT3 and CeP4GalNAcT; or human p4-GalNAcT3 and Ptp4GalNAcT; or functionally active variants thereof.
- the GalNAc transferase is localized in the secretory pathway.
- localization within the secretory pathway includes, but is not limited to, localization to one or more of the following sub-cellular compartments: the endoplasmic reticulum, the Golgi apparatus, lysosomes, intracellular membrane proteins, cell surface anchored proteins, and membrane proteins.
- localization in the secretory pathway comprises localization to one or more of said sub-cellular compartments.
- the GalNAc transferase comprises a signal peptide localizing the GalNAc transferase in the secretory pathway.
- the signal peptide is derived from the same source as the GalNAc transferase (i.e. the signal peptide is not added to the GalNAc transferase, but is one contained in the GalNAc transferase when naturally expressed in the source).
- the GalNAc transferase is localized in the secretory pathway without adding Leishmania signal peptide to the GalNAc transferase. In other embodiments, the signal peptide is added to the GalNAc transferase.
- the signal peptide is fused to the C-terminus of the GalNAc transferase. In certain embodiments, the signal peptide is fused to the N-terminus of the GalNAc transferase. In certain embodiments, the signal peptides is fused to one or more amino acids within the polypeptide of the GalNAc transferase. In certain embodiments, the signal peptide is fused to the N-terminus of an N-terminally truncated variant of the GalNAc transferase. In certain embodiments, the signal peptide is fused to one or more amino acids within the polypeptide of an N-terminally truncated variant of the GalNAc transferase.
- the signal peptide is derived from Leishmania species. In certain embodiments, the signal peptide is a modified version of a signal peptide derived from a Leishmania species. In certain embodiments, the signal peptide is derived from Leishmania tarentolae. In certain embodiments, the signal peptide is a modified version of a signal peptide derived from Leishmania tarentolae. In certain embodiments, the signal peptide is an invertase signal peptide derived from Leishmania tarentolae. In certain embodiments, the signal peptide is a modified version of the invertase signal peptide derived from Leishmania tarentolae.
- the signal peptide comprises an amino acid sequence of SEQ ID NO: 11. In certain embodiments, the signal peptide comprises an amino acid sequence of SEQ ID NO: 12. In certain embodiments, the signal peptide is processed and removed from the GalNAc transferase.
- the GalNAc transferase comprises a retention sequence retaining the GalNAc transferase in the secretory pathway.
- the retention sequence is derived from the same source as the GalNAc transferase (i.e. the retention sequence is not added to the GalNAc transferase, but is one contained in the GalNAc transferase when naturally expressed in the source).
- the GalNAc transferase is retained in the secretory pathway without adding a Leishmania retention sequence to the GalNAc transferase.
- the retention sequence is added to the GalNAc transferase.
- the retention sequence is fused to the C-terminus of the GalNAc transferase.
- the retention sequence is fused to the N-terminus of the GalNAc transferase. In certain embodiments, the retention sequence is fused to one or more amino acids within the polypeptide of the GalNAc transferase. In certain embodiments, the retention sequence is fused to the N-terminus of an N-terminally truncated variant of the GalNAc transferase. In certain embodiments, the retention sequence is fused to one or more amino acids within the polypeptide of an N- terminally truncated variant of the GalNAc transferase. In certain embodiments, the retention sequence is derived from a Leishmania species. In certain embodiments, the retention sequence is a modified version of a retention sequence from derived from a Leishmania species. In certain embodiments, the retention sequence is derived from Leishmania tarentolae. In certain embodiments, the retention sequence is a modified version of a retention sequence derived from Leishmania tarentolae.
- the GalNAc transferase and the recombinant UDP- GalNAc transporter protein described in Section 7.1.5 are co-localized in the secretory pathway.
- the GalNAc transferase and the additional recombinant glycosyltransferase described in Section 7.1.2 are co-localized in the secretory pathway.
- the GalNAc transferase and the polypeptide of interest described in Section 7.5 are co-localized in the secretory pathway.
- the Leishmania host cells provided herein comprise a recombinant nucleic acid encoding one or more additional recombinant glycosyltransferases.
- the additional recombinant glycosyltransferase, or a functionally active variant thereof is capable of catalyzing the addition of a first glycan to a second glycan.
- the additional recombinant glycosyltransferase is a N-acetyl glucosamine transferase, or a functionally active variant thereof, capable of catalyzing the addition of a N-acetyl glucosamine (GlcNAc) to a mannose-terminated glycan, for example, a Man3GlcNAc2 glycan (Man3, see Section 5.3).
- GlcNAc N-acetyl glucosamine transferase
- Man3GlcNAc2 glycan Man3, see Section 5.3
- the additional recombinant glycosyltransferase comprises one or more N-acetyl glucosamine transferases.
- the N-acetyl glucosamine transferase is heterologous to the host cell.
- the N- acetyl glucosamine transferase is derived from Homo sapiens, Spodoptera frugiperda, Trypanosoma brucei.
- the additional recombinant glycosyltransferase is derived from a mammalian source.
- the mammalian source is Homo sapiens.
- the N-acetyl glucosamine transferase is selected from the group consisting of MGAT1 (alpha-1, 3-mannosyl-glycoprotein 2-beta-N- acetylglucosaminyltransf erase) and MGAT2 (alpha- 1,6-mannosylgly coprotein 2-beta-N- acetylglucosaminyltransferase), or functionally active variants thereof.
- the additional recombinant glycosyltransferases comprise MGAT1 and MGAT2.
- the N-acetyl glucosamine transferase comprises MGAT1, or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Homo sapiens (accession number P26572), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MGAT1 of Homo sapiens. In certain embodiments, the N-acetyl glucosamine transferase comprises an amino acid sequence of SEQ ID NO: 13. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MG ATI of Homo sapiens. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Homo sapiens.
- the N-acetyl glucosamine transferase comprises MGAT2, or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT2. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT2. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT2 of Homo sapiens (accession number: Q10469.1), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MGAT2 of Homo sapiens. In certain embodiments, the N-acetyl glucosamine transferase comprises an amino acid sequence of SEQ ID NO: 14. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT2 of Homo sapiens. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT2 of Homo sapiens.
- the N-acetyl glucosamine transferases comprise MGAT1 and MGAT2, or functionally active variants thereof. In certain embodiments, the N-acetyl glucosamine transferases comprise MGAT1 and MGAT2. In certain embodiments, the N- acetyl glucosamine transferases are variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 and MGAT2, respectively. In certain embodiments, the N-acetyl glucosamine transferases are MGAT1 and MGAT2 of Homo sapiens, or functionally active variants thereof.
- the N-acetyl glucosamine transferases are MGAT1 and MGAT2 of Homo sapiens. In certain embodiments, the N-acetyl glucosamine transferases comprise amino acid sequences of SEQ ID NO: 13 and SEQ ID NO: 14, respectively. In certain embodiments, the N-acetyl glucosamine transferases are ones that are homologous to MGAT1 and MGAT2 of Homo sapiens.
- the N-acetyl glucosamine transferases are variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 and MGAT2 of Homo sapiens, respectively.
- the N-acetyl glucosamine transferase comprises MGAT1 of Spodoptera frugiperda (SfGnT-I, accession number: AEX00082), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MG ATI of Spodoptera frugiperda.
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 of Spodoptera frugiperda.
- the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MG ATI of Spodoptera frugiperda.
- the N-acetyl glucosamine transferase comprises MGAT1 of Trypanosoma brucei (TbGnT-I, accession number: XP 844156), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MG ATI of Trypanosoma brucei.
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 of Trypanosoma brucei.
- the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Trypanosoma brucei.
- the N-acetyl glucosamine transferase comprises MGAT1 of Pan troglodytes (PtMGATl, accession number: XP 001155433.2), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MG ATI of Pan troglodytes .
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 of Pan troglodytes.
- the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Pan troglodytes.
- the N-acetyl glucosamine transferase comprises MGAT1 Macaco. mulatto (MaMGATl, accession number: NP_001244759), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MGAT1 oiMacaca mulatta.
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 oiMacaca mulatta.
- the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 Macaco mulatta.
- the N-acetyl glucosamine transferase comprises MGAT1 of Mus musculus (MuMGATl, accession number: NP_001103620.1), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MGAT1 oi Mus musculus.
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 oi Mus musculus.
- the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Mus musculus.
- the N-acetyl glucosamine transferase comprises MGAT1 of Rattus norvegicus (RnMGATl, accession number: NP_110488.1), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MG ATI of Rattus norvegicus.
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 of Rattus norvegicus.
- the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Rattus norvegicus.
- the N-acetyl glucosamine transferase comprises MGAT1 of Danio rerio A (DrMGATla, accession number: NP 956970.1), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MG ATI of Danio rerio A.
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 of Danio rerio A.
- the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Danio rerio A.
- the N-acetyl glucosamine transferase comprises an MGAT1 of Caenorhabditis elegans (Cel4MGATl, accession number: NP 497719.1 or Cel3MGATl, accession number: NP 509566.1), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MGAT1 of Caenorhabditis elegans.
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 of Caenorhabditis elegans.
- the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Caenorhabditis elegans.
- the N-acetyl glucosamine transferase comprises MGAT1 of Arabidopsis thaliana (AtMGATl, accession number: NP 195537.2), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Arabidopsis thaliana. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 of Arabidopsis thaliana.
- the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Arabidopsis thaliana.
- the N-acetyl glucosamine transferase comprises MGAT1 of Oryza sativa Japonica (OsJMGATl, accession number: XP 015624616.1), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MGAT1 of Oryza sativa Japonica.
- the N- acetyl glucosamine transferase comprises one that is homologous to MGAT1 Oryza sativa Japonica.
- the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Oryza sativa Japonica.
- the N-acetyl glucosamine transferase comprises MGAT1 oi Xenopus tropicalis (XtMGATl, accession number: NP 001011350.1), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MGAT1 oi Xenopus tropicalis.
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 Xenopus tropicalis.
- the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Xenopus tropicalis.
- the N-acetyl glucosamine transferase comprises MGAT1 of Canis lupus (C1MGAT1, accession number: XP 855658.1), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MGAT1 of Canis lupus.
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 Canis lupus.
- the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Canis lupus.
- the N-acetyl glucosamine transferase comprises MGAT1 of Bos taurus (BtMGATl, accession number: NP 001015653.1), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MG ATI of Bos taurus.
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 Bos taurus.
- the N- acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Bos taurus.
- the N-acetyl glucosamine transferase comprises MGAT1 of Danio rerio B (DrMGATlb, accession number: NP 001073440.1), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MG ATI of Danio rerio B.
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 Danio rerio B.
- the N- acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Danio rerio B.
- the N-acetyl glucosamine transferase comprises MGAT1 of Gekko japonicus (GjMGATl, accession number: XP 015280466.1), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MGAT1 of Gekko japonicus.
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 Gekko japonicus. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Gekko japonicus.
- the N-acetyl glucosamine transferase comprises MGAT2 of Rattus norvegicus (rMGAT2, accession number: NP 446056), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MGAT2 of Rattus norvegicus.
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT2 of Rattus norvegicus.
- the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT2 of Rattus norvegicus.
- the N-acetyl glucosamine transferase comprises MGAT2 of Spodoptera frugiperda (SfGnT-II, accession number: AEX00083), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MGAT2 of Spodoptera frugiperda.
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT2 of Spodoptera frugiperda.
- the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT2 of Spodoptera frugiperda.
- the N-acetyl glucosamine transferase comprises MGAT2 of Trypanosoma brucei (TbGnT-II, accession number: XP 845654), or a functionally active variant thereof.
- the N-acetyl glucosamine transferase comprises MGAT2 of Trypanosoma brucei.
- the N-acetyl glucosamine transferase comprises one that is homologous to MGAT2 of Trypanosoma brucei.
- the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT2 of Trypanosoma brucei.
- the additional recombinant glycosyltransferase is localized in the secretory pathway.
- localization within the secretory pathway includes, but is not limited to, localization to one or more of the following sub-cellular compartments: the endoplasmic reticulum, the Golgi apparatus, lysosomes, intracellular membrane proteins, cell surface anchored proteins, and membrane proteins.
- localization in the secretory pathway comprises localization to one or more of said sub-cellular compartments.
- the additional recombinant glycosyltransferase comprises a signal peptide localizing the additional recombinant glycosyltransferase in the secretory pathway.
- the signal peptide is derived from the same source as the additional recombinant glycosyltransferase (i.e. the signal peptide is not added to additional recombinant glycosyltransferase, but is one fused to the additional recombinant glycosyltransferase when naturally expressed in the source).
- the additional recombinant glycosyltransferase is localized in the secretory pathway without adding a Leishmania signal peptide to the additional recombinant glycosyltransferase.
- the signal peptide is added to the additional recombinant glycosyltransferase.
- the signal peptide is fused to the C-terminus of the additional recombinant glycosyltransferase.
- the signal peptide is fused to the N-terminus of the additional recombinant glycosyltransferase.
- the signal peptide is fused to one or more amino acids within the polypeptide of the additional recombinant glycosyltransferase.
- the signal peptide is derived from Leishmania species.
- the signal peptide is a modified version of a signal peptide derived from a Leishmania species.
- the signal peptide is derived from Leishmania tarentolae.
- the signal peptide is a modified version of a signal peptide derived from Leishmania tarentolae.
- the signal peptide is an invertase signal peptide derived from Leishmania tarentolae.
- the signal peptide is a modified version of the invertase signal peptide derived from Leishmania tarentolae.
- the signal peptide comprises an amino acid sequence of SEQ ID NO: 11.
- the signal peptide comprises an amino acid sequence of SEQ ID NO: 12.
- the signal peptide is processed and removed from the additional recombinant glycosyltransferase.
- the additional recombinant glycosyltransferase comprises a retention sequence retaining the additional recombinant glycosyltransferase in the secretory pathway.
- the retention sequence is derived from the same source as the additional recombinant glycosyltransferase (i.e. the retention sequence is not added to additional recombinant glycosyltransferase, but is one fused to the additional recombinant glycosyltransferase when naturally expressed in the source).
- the additional recombinant glycosyltransferase is retained in the secretory pathway without adding a Leishmania retention sequence to the additional recombinant glycosyltransferase.
- the retention sequence is added to the additional recombinant glycosyltransferase.
- the retention sequence is fused to the C- terminus of the additional recombinant glycosyltransferase.
- the retention sequence is fused to the N-terminus of the additional recombinant glycosyltransferase.
- the retention sequence is fused to one or more amino acids within the polypeptide of the additional recombinant glycosyltransferase.
- the retention sequence is derived from a Leishmania species.
- the retention sequence is a modified version of a retention sequence derived from a Leishmania species.
- the retention sequence is derived from Leishmania tarentolae.
- the retention sequence is a modified version of a retention sequence derived from Leishmania tarentolae.
- the GalNAc transferase described in Section 7.1.1 and the additional recombinant glycosyltransferase are co-localized in the secretory pathway. 7.1.3 Deletion, Mutation and/or Functionally Inactivation of Endogenous Enzymes from the Glycan Biosynthesis Pathway
- the Leishmania host cells provided herein are characterized in that one or more endogenous enzymes from the glycan biosynthesis pathway have been deleted, mutated and/or functionally inactivated.
- the Leishmania host cell does not have endogenous N-glycan elongation.
- the Leishmania host cells do not have endogenous N-glycan elongation as described in WO 2019/002512, which is incorporated herein by reference in its entirety.
- the Leishmania host cell has been genetically engineered such that the formation of an O-linked GlcNAc on a polypeptide in the host cell is reduced or eliminated.
- the formation of O-linked GlcNAc in the Leishmania host cell prior to genetic engineering is catalyzed by at least one N-acetylglucosamine (GlcNAc)- transferase.
- the gene encoding the at least one GlcNAc-transferase in the Leishmania host cell is functionally inactivated, downregulated, deleted, and/or mutated.
- the enzyme that catalyzes the formation of O-linked GlcNAc is an N-acetylglucosamine (GlcNAc)-transferase.
- the GlcNAc-transferase is selected from the group consisting of OGNT1, OGNT2, OGNTL, and homologous GlcNAc-transf erases thereof.
- OGNT1, OGNT2, OGNTL were identified based on homology to Trypanosoma enzymes and not mammalian (e.g. human) enzymes (Heise, N., et al Glycobiology, 19(8), 918-933 (2009) and Chiribao, M.L.
- the GlcNAc-transferase is OGNTL In other embodiments, the GlcNAc-transferase is OGNT2. In yet other embodiments, the GlcNAc-transferase is OGNTL. In certain embodiments, the GlcNAc-transferase is a GlcNAc-transferase that is homologous to OGNTL In certain embodiments, the GlcNAc- transferase is a GlcNAc-transferase that is homologous to OGNT2.
- the GlcNAc-transferase is a GlcNAc-transferase that is homologous to OGNTL. In certain embodiments, the GlcNAc-transferase is derived from Leishmania tarentolae. In certain embodiments, the GlcNAc-transferase is derived from other Trypanosomatida species. Nonlimiting examples of GlcNAc-transferases in Trypanosomatida are listed in Table 1, in which one representative genome per species is listed.
- Table 1 Exemplary GlcNAc-transferases in Trypanosomatida.
- GlcNAc is derived from species other than Trypanosomatida species.
- the enzyme is a human O-GlcNAc transferase (OGT, Uniprot: 015294) and homologous enzymes thereof.
- the O-GlcNAc transferase (OGT; uridine diphospho-N-acetylglucosamine:polypeptide P-N-acetylglucosaminyltransferase; EC 2.4.1.255) can catalyze the transfer of a single N-acetylglucosamine from UDP-GlcNAc to a serine or threonine residue in cytoplasmic and nuclear proteins resulting in their modification with a beta-linked N-acetylglucosamine (O-GlcNAc).
- the enzyme that catalyzes the formation of O-linked GlcNAc may be different isoforms of OGT.
- Exemplary isoforms of OGT include but are not limited to: (1) the nucleocytoplasmic or full- length variant (ncOGT), which may be 110 kDa; (2) a short isoform of OGT (sOGT), which may be 78 kDa; and (3) a variant of OGT that is targeted to the mitochondria (mOGT; which may be 90 kDa).
- OGT may appear to form multimers in the nucleus and cytoplasm, consisting of one or more 110-kDa subunits and 78-kDa subunits (Varki, Ajit, et al. (Eds.) (2015): Essentials of Glycobiology. Cold Spring Harbor Laboratory Press. 3rd. Cold Spring Harbor (NY)).
- the enzyme that catalyzes the formation of O-linked GlcNAc is human EOGT (Uniprot: Q5NDL2).
- the enzyme catalyzes the transfer of a single N-acetylglucosamine from UDP-GlcNAc to a serine or threonine residue in extracellular proteins resulting in their modification with a beta-linked N-acetylglucosamine (O-GlcNAc).
- the enzyme catalyzes Specific glycosylation of the Thr residue located between the fifth and sixth conserved cysteines of folded EGF-like domains.
- the enzyme that catalyzes the formation of O-linked GlcNAc may transfer in alpha-linkage. In other embodiments, the enzyme that catalyzes the formation of O-linked GlcNAc may transfer in beta-linkage.
- the formation of O-linked GlcNAc in the Leishmania host cell prior to genetic engineering is catalyzed by at least one enzyme as described in this Section, for example one, two, three, four, five, six, seven, eight, nine or ten enzymes as described in this Section.
- the formation of O-linked GlcNAc in the Leishmania host cell prior to genetic engineering is catalyzed by at least one GlcNAc-transferase derived from Trypanosomatida species, for example Leishmania tarentolae.
- the formation of O-linked GlcNAc in the Leishmania host cell prior to genetic engineering is catalyzed by at least one GlcNAc-transferase, for example one, two, three, four, five, six, seven, eight, nine or ten GlcNAc-transferases, one or more of which is derived from Trypanosomatida species.
- the number of the at least one GlcNAc- transferase is one, two or three.
- the at least one GlcNAc-transferase is selected from the group consisting of 0GNT1, 0GNT2, OGNTL and homologous GlcNAc-transferases thereof.
- at least one GlcNAc-transferase is a GlcNAc-transferase that is homologous to 0GNT1, 0GNT2 and/or OGNTL.
- the formation of O-linked GlcNAc in the Leishmania host cell prior to genetic engineering is catalyzed by at least one GlcNAc-transferase derived from species that is other than Trypanosomatida species, for example human.
- the formation of O-linked GlcNAc in the Leishmania host cell prior to genetic engineering is catalyzed by at least one GlcNAc-transferase, for example one, two, three, four, five, six, seven, eight, nine or ten GlcNAc-transferases, one or more of which is derived from human.
- the number of the at least one GlcNAc-transferase is one, two or three.
- the at least one GlcNAc-transferase is selected from the group consisting of human O-GlcNAc transferase and human EOGT and homologous enzymes thereof.
- at least one GlcNAc-transferase is an enzyme that is homologous to human O-GlcNAc transferase and/or human EOGT.
- the enzyme catalyzes the formation of O-linked GlcNAc prior to the genetic engineering of the Leishmania host cell. In certain embodiments, the enzyme still catalyzes the formation of O-linked GlcNAc after the genetic engineering of the Leishmania host cell. In certain embodiments, the enzyme does not catalyze the formation of O-linked GlcNAc after the genetic engineering of the Leishmania host cell.
- the gene encoding the at least one GlcNAc-transferase in the Leishmania host cell is functionally inactivated. In certain embodiments, the gene encoding the at least one GlcNAc-transferase in the Leishmania host cell is downregulated. In certain embodiments, the gene encoding the at least one GlcNAc-transferase in the Leishmania host cell is overexpressed.
- the Leishmania host cell provided herein comprises at least one gene deletion.
- the gene encoding the at least one GlcNAc- transferase is deleted.
- the gene encoding the at least one GlcNAc- transferase is mutated.
- the gene encoding the at least one GlcNAc- transferase is overexpressed.
- additional modifications may be introduced (e.g., using recombinant techniques) into the Leishmania host cell described herein.
- the genes encoding at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or at least 20 enzymes that each catalyzes the formation of O- linked GlcNAc may be functionally inactivated. In certain embodiments, the genes encoding 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 enzymes that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated. In certain embodiments, the genes encoding three enzymes that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated.
- the genes and/or genetic loci that may be functionally inactivated include but are not limited to OGNT1, OGNT2, and OGNTL. [00113] In certain embodiments, the genes encoding at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or at least 20 GlcNAc-transferase that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated. In certain embodiments, the genes encoding 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 GlcNAc- transferase that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated. In certain embodiments, the genes encoding three GlcNAc-transferases that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated.
- the genes encoding at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of all enzymes that each catalyzes the formation of O- linked GlcNAc may be functionally inactivated. In certain embodiments, the genes encoding 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of all enzymes that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated.
- the genes encoding at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of all GlcNAc-transferases that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated. In certain embodiments, the genes encoding 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of all GlcNAc-transferases that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated.
- the at least one GlcNAc-transferase is selected from the group consisting of OGNT1, OGNT2 and OGNTL, and homologous GlcNAc-transferases thereof.
- the Leishmania host cell is a OGNT1, OGNT2 and OGNTL triple knockout.
- the formation of the O-linked GlcNAc is reduced by at least 5%, 7%, 10%, 12%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% from the formation of the O-linked GlcNAc in a reference Leishmania cell.
- the formation of the O-linked GlcNAc is reduced by 5%, 7%, 10%, 12%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% from the formation of the O-linked GlcNAc in a reference Leishmania cell.
- the reference Leishmania cell is wild-type.
- the reference Leishmania cell is genetically engineered differently as the genetically engineered Leishmania cells described herein.
- some of the engineering of the reference Leishmania cell may be the same of the engineering of the genetically engineered Leishmania cells described herein, for example the deletion of one or more enzymes that catalyze the formation of O-linked GlcNAc.
- the reference Leishmania cell may comprise a recombinant nucleic acid encoding a heterologous glycosyltransferase, for example the Leishmania cells described in International Publication No. W02019/002512 A2, incorporated by reference in its entirety herein.
- the formation of the O-linked GlcNAc is reduced by at least 5%, 7%, 10%, 12%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% from the formation of the O-linked GlcNAc in a wild-type Leishmania cell.
- the formation of the O-linked GlcNAc is reduced by 5%, 7%, 10%, 12%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% from the formation of the O-linked GlcNAc in a wild-type Leishmania cell.
- the formation of the O-linked GlcNAc is reduced by at least 5%, 7%, 10%, 12%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% from the formation of the O- linked GlcNAc in a Leishmania cell that comprises a recombinant nucleic acid encoding a heterologous glycosyltransferase.
- the formation of the O-linked GlcNAc is reduced by 5%, 7%, 10%, 12%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% from the formation of the O-linked GlcNAc in a Leishmania cell that comprises a recombinant nucleic acid encoding a heterologous glycosyl transferase.
- the growth rate of the Leishmania host cell described herein is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the growth rate of a reference Leishmania cell. In certain embodiments, the growth rate of the Leishmania host cell is 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the growth rate of a reference Leishmania cell. In certain embodiments, the reference Leishmania cell is wildtype. In certain embodiments, the reference Leishmania cell is genetically engineered differently as the genetically engineered Leishmania cells described herein.
- some of the engineering of the reference Leishmania cell may be the same of the engineering of the genetically engineered Leishmania cells described herein, for example the deletion of one or more enzymes that catalyze the formation of O-linked GlcNAc.
- the growth rate of the Leishmania cell is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the growth rate of a wild-type Leishmania cell.
- the growth rate of the Leishmania cell is 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the growth rate of a wild-type Leishmania cell.
- the Leishmania host cells provided herein comprise a recombinant nucleic acid encoding UDP-GalNAc biosynthetic pathway proteins capable of generating UDP-GalNAc.
- the recombinant UDP-GalNAc biosynthetic pathway proteins are heterologous to the Leishmania host cell.
- the heterologous UDP-GalNAc biosynthetic pathway proteins are capable of converting GalNAc to UDP-GalNAc.
- the heterologous UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc are derived from a mammalian source.
- the mammalian source is Homo sapiens.
- the heterologous UDP-GalNAc biosynthetic pathway proteins are capable of converting N- Acetyl galactosamine 1 -phosphate (GalNAc- 1-P) to UDP-GalNAc.
- the heterologous UDP-GalNAc biosynthetic pathway proteins are capable of converting GalNAc- 1-P and UTP to UDP-GalNAc.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP-N-acetyl hexosamine pyrophosphorylase (UAP1), or a functionally active variant thereof.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP-N-acetyl hexosamine pyrophosphorylase (UAP1) of Homo sapiens, or a functionally active variant thereof.
- the heterologous UDP- GalNAc biosynthetic pathway proteins comprise UDP-N-acetyl hexosamine pyrophosphorylase (UAP1) of Homo sapiens, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP- N-acetyl hexosamine pyrophosphorylase (UAP1) of Homo sapiens.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise a variant of UDP-N- acetyl hexosamine pyrophosphorylase (UAP1) of Homo sapiens that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the AGX1 isoform of UDP-N-acetyl hexosamine pyrophosphorylase is about two to three times more active towards GalNAc-l-P than GlcNAc-1-P, whereas the AGX2 isoform is about eight times more active towards GlcNAc-1-P than GalNAc-l-P.
- the UDP-N-acetyl hexosamine pyrophosphorylase (UAP1) is the AGX1 isoform of UAP1.
- the UDP-N-acetyl hexosamine pyrophosphorylase (UAP1) is the AGX2 isoform of UAP1.
- the UDP-N-acetyl hexosamine pyrophosphorylase (UAP1) comprises an amino acid sequence of SEQ ID NO: 15.
- the heterologous UDP-GalNAc biosynthetic pathway proteins are capable of converting GalNAc to GalNAc-l-P.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise N-acetyl galactosamine kinase (GALK2), or a functionally active variant thereof.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise N-acetyl galactosamine kinase (GALK2) of Homo sapiens, or a functionally active variant thereof.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise N- acetyl galactosamine kinase (GALK2) of Homo sapiens, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise N-acetyl galactosamine kinase (GALK2) of Homo sapiens.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise a variant of N-acetyl galactosamine kinase (GALK2) of Homo sapiens that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the N-acetyl galactosamine kinase (GALK2) comprises an amino acid sequence of SEQ ID NO: 15.
- the heterologous UDP-GalNAc biosynthetic pathway proteins are capable of converting UDP-GlcNAc to UDP-GalNAc.
- the heterologous UDP-GalNAc biosynthetic pathway protein capable of converting UDP- GlcNAc to UDP-GalNAc comprises a NAD-dependent epimerase that converts UDP- GlcNAc to UDP-GalNAc.
- the heterologous UDP-GalNAc biosynthetic pathway proteins capable of converting UDP-GlcNAc to UDP-GalNAc is derived from a mammalian source.
- the mammalian source is Homo sapiens.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP -galactose 4-epimerase (GalE), or a functionally active variant thereof.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP -galactose 4-epimerase (GalE) of Homo sapiens (hGalE), or a functionally active variant thereof.
- the heterologous UDP-GalNAc biosynthetic pathway protein comprise hGalE, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise hGalE.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise a variant of hGalE that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the hGalE comprises an amino acid sequence of SEQ ID NO: 17.
- the heterologous UDP-GalNAc biosynthetic pathway proteins capable of converting UDP- GlcNAc to UDP-GalNAc are derived from a bacterial source.
- the bacterial source is Campylobacter jejuni.
- the heterologous UDP- GalNAc biosynthetic pathway proteins comprise UDP-GlcNAc/Glc 4-epimerase of Campylobacter jejuni (CjGne), or a functionally active variant thereof.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise CjGne, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise CjGne.
- the heterologous UDP-GalNAc biosynthetic pathway proteins comprise comprise a variant of CjGne that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the CjGne comprises an amino acid sequence of SEQ ID NO: 18.
- the Leishmania host cell comprises (a) a recombinant nucleic acid encoding recombinant UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc as described in this Section; and (b) a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway as described in Section 7.1.5.
- the recombinant nucleic acid in (a) encodes UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc- 1-P to UDP-GalNAc and UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to GalNAc- 1-P, as described in this Section.
- the Leishmania host cell comprises (a) a recombinant nucleic acid encoding a recombinant UDP-GalNAc biosynthetic pathway protein capable of converting UDP-GlcNAc to UDP-GalNAc as described in this Section; and (b) a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway as described in Section 7.1.5.
- the Leishmania host cell comprises (a) a recombinant nucleic acid encoding recombinant UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc as described in this Section; and (b) a recombinant nucleic acid encoding a recombinant UDP-GalNAc biosynthetic pathway protein capable of converting UDP-GlcNAc to UDP-GalNAc as described in this Section.
- the recombinant nucleic acid in (a) encodes UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc- 1-P to UDP-GalNAc and UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to GalNAc- 1-P, as described in this Section.
- the Leishmania host cell comprises (a) a recombinant nucleic acid encoding recombinant UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc as described in this Section; and (b) a recombinant nucleic acid encoding a recombinant UDP-GalNAc biosynthetic pathway protein capable of converting UDP-GlcNAc to UDP-GalNAc as described in this Section; and (c) a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway as described in Section 7.1.5.
- the recombinant nucleic acid in (a) encodes UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc- 1-P to UDP-GalNAc and UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to GalNAc- 1-P, as described in this Section.
- the Leishmania host cells provided herein comprise a recombinant nucleic acid encoding a UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway.
- the UDP- GalNAc transporter protein is heterologous to the Leishmania host cell.
- the heterologous UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is derived from a nematode source, a mammalian source, a brachiopod source, a chordate source, choanoflagellate source, a gyrista source, a fungi source, a mollusk source, or a placozoan source.
- the heterologous UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is derived from a nematode source.
- the nematode source is C.
- the mammalian source is Homo sapiens
- the brachiopod source is Lingula unguis
- the chordate source is Parambassis ranga
- Geotrypetes seraphini or Scophthalmus maximus
- the choanoflagellate source is Salpingoeca rosetta
- the gyrista source is Fragilariopsis cylindrus
- the fungi source is Dentipellis fragilis
- the mollusk source is Octopus bimaculoides
- the placozoan source is trichoplax sp. H2.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is derived from a nematode source.
- the nematode source is C. elegans.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises UDP-GalNAc transporter of C. elegans (CeC03H5.2), or a functionally active variant thereof.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises CeC03H5.2, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises CeC03H5.2.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is CeC03H5.2. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP- GalNAc to the secretory pathway comprises a variant of CeC03H5.2 that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the UDP-GalNAc transporter protein capable of transporting UDP- GalNAc to the secretory pathway is a variant of CeC03H5.2 that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the CeC03H5.2 has an amino acid sequence of SEQ ID NO: 19.
- the variant of CeC03H5.2 is UDP-N-acetylglucosamine transporter isoform XI of Lingula unguis (GnF).
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises GnF.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnF.
- GnF has an amino acid sequence of SEQ ID NO: 132.
- the variant of CeC03H5.2 is UDP-N-acetylglucosamine transporter-like isoform XI of Parambassis ranga (GnG).
- the UDP- GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises GnG.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnG.
- GnG has an amino acid sequence of SEQ ID NO: 133.
- the variant of CeC03H5.2 is UDP-N-acetylglucosamine transporter of Salpingoeca rosetta (GnH).
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises GnH.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnH.
- GnH has an amino acid sequence of SEQ ID NO: 134.
- the variant of CeC03H5.2 is UDP-N-acetylglucosamine transporter-like protein of Fragilariopsis cylindrus (GnI).
- the UDP- GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises GnI.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnI.
- GnI has an amino acid sequence of SEQ ID NO: 135.
- the variant of CeC03H5.2 is previously uncharacterized protein of Dentipellis fragilis (GnJ) identified by homology search of CeC03H5.2.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises GnJ.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnJ.
- GnJ has an amino acid sequence of SEQ ID NO: 136.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises UDP-GalNAc transporter of Homo sapiens (UGTREL7), or a functionally active variant thereof.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises UGTREL7, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises UGTREL7.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is UGTREL7.
- the UDP-GalNAc transporter protein capable of transporting UDP- GalNAc to the secretory pathway comprises a variant of UGTREL7 that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the UDP-GalNAc transporter protein capable of transporting UDP- GalNAc to the secretory pathway is a variant of UGTREL7 that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the UGTREL7 has an amino acid sequence of SEQ ID NO: 137.
- the variant of UGTREL7 is UDP -glucuronic acid/UDP- N-acetylgalactosamine transporter of Geotrypetes seraphini (GnL).
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises GnL.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnL.
- GnL has an amino acid sequence of SEQ ID NO: 138.
- the variant of UGTREL7 is putative UDP-N- acetylglucosamine/UDP-glucose/GDP-mannose transporter-like protein of Scophthalmus maximus (GnM).
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises GnM.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnM.
- GnL has an amino acid sequence of SEQ ID NO: 139.
- the variant of UGTREL7 is TPT domain-containing protein of Octopus bimaculoides (GnN).
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises GnN.
- the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnN.
- GnL has an amino acid sequence of SEQ ID NO: 140.
- the variant of UGTREL7 is UDP-N- acetylglucosamine/UDP-glucose/GDP -mannose transporter of trichoplax sp. H2 (GnO).
- the UDP-GalNAc transporter protein capable of transporting UDP- GalNAc to the secretory pathway comprises GnO.
- the UDP- GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnO.
- GnL has an amino acid sequence of SEQ ID NO: 141.
- the heterologous UDP-GalNAc transporter protein comprises a signal peptide localizing the heterologous UDP-GalNAc transporter protein in the secretory pathway.
- the signal peptide is derived from the same source as the heterologous UDP-GalNAc transporter protein (i.e. the signal peptide is not added to the heterologous UDP-GalNAc transporter protein, but is one fused to the heterologous UDP-GalNAc transporter protein when naturally expressed in the source).
- the heterologous UDP-GalNAc transporter protein is localized in the secretory pathway without adding a Leishmania signal peptide to the heterologous UDP- GalNAc transporter protein.
- the signal peptide is added to the heterologous UDP-GalNAc transporter protein.
- the signal peptide is derived from Leishmania species.
- the signal peptide is a modified version of a signal peptide from derived from a. Leishmania species.
- the signal peptide is derived from Leishmania tarentolae.
- the signal peptide is a modified version of a signal peptide from derived from Leishmania tarentolae.
- the signal peptide is an invertase signal peptide derived from Leishmania tarentolae.
- the signal peptide is a modified version of the invertase signal peptide derived from Leishmania tarentolae.
- the signal peptide comprises an amino acid sequence of SEQ ID NO: 11.
- the signal peptide comprises an amino acid sequence of SEQ ID NO: 12.
- the signal peptide is processed and removed from the heterologous UDP-GalNAc transporter protein.
- the heterologous UDP-GalNAc transporter protein comprises a retention sequence retaining the heterologous UDP-GalNAc transporter protein in the secretory pathway.
- the retention sequence is derived from the same source as the heterologous UDP-GalNAc transporter protein (i.e. the retention sequence is not added to the heterologous UDP-GalNAc transporter protein, but is one fused to the heterologous UDP-GalNAc transporter protein when naturally expressed in the source).
- the heterologous UDP-GalNAc transporter protein is retained in the secretory pathway without adding a Leishmania retention sequence to the heterologous UDP- GalNAc transporter protein.
- the retention sequence is added to the heterologous UDP-GalNAc transporter protein. In certain embodiments, the retention sequence is fused to the C-terminus of the heterologous UDP-GalNAc transporter protein. In certain embodiments, the retention sequence is fused to one or more amino acids within the polypeptide of the heterologous UDP-GalNAc transporter protein. In certain embodiments, the retention sequence is derived from a Leishmania species. In certain embodiments, the retention sequence is a modified version of a retention sequence derived from a Leishmania species. In certain embodiments, the retention sequence is derived from Leishmania tarentolae.
- the retention sequence is a modified version of a retention sequence derived from Leishmania tarentolae.
- host cells encoding at least two heterologous UDP-GalNAc transporter proteins can be beneficial for optizimizing the extent and/or homogeneity of glycosylation of a polypeptide of interest.
- the recombinant nucleic acid encodes at least two heterologous UDP-GalNAc transporter proteins. In certain embodiments, the recombinant nucleic acid encodes two heterologous UDP-GalNAc transporter proteins.
- the recombinant nucleic acid encodes two copies of the same heterologous UDP-GalNAc transporter protein. In certain embodiments, the recombinant nucleic acid encodes two different heterologous UDP-GalNAc transporter proteins. In certain embodiments, the heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2 and UGTREL7, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2, GnF, GnG, GnH, GnI, GnJ, UGTREL7, GnL, GnM, GnN, or GnO, or functionally active variants thereof.
- the heterologous UDP-GalNAc transporter proteins are selected as a combination of heterologous UDP-GalNAc transporters listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the heterologous UDP-GalNAc transporter proteins comprise CeC03H5.2.
- the heterologous UDP-GalNAc transporter protein is CeC03H5.2.
- the host cell has two gene copies encoding CeC03H5.2.
- the heterologous UDP-GalNAc transporter proteins comprise CeC03H5.2 and GnJ.
- the heterologous UDP- GalNAc transporter proteins are CeC03H5.2 and GnJ.
- the recombinant nucleic acid encoding a heterologous UDP-GalNAc transporter comprises a first ORF encoding a first heterologous UDP-GalNAc transporter and a second ORF encoding a second heterologous UDP-GalNAc transporter.
- the first ORF encoding the first heterologous UDP-GalNAc transporter and the second ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module.
- the first ORF encoding the first heterologous UDP-GalNAc transporter and the second ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in separate genetic modules. In certain embodiments, the first ORF encoding the first heterologous UDP-GalNAc transporter and the second ORF encoding the second heterologous UDP- GalNAc transporter are integrated into the [ssuPolI] locus of the host cell.
- the first and the second heterologous UDP-GalNAc transporter are selected as a combination of heterologous UDP-GalNAc transporters listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the first and the second heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2 and UGTREL7, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the first and the second heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2, GnF, GnG, GnH, GnI, GnJ, UGTREL7, GnL, GnM, GnN, or GnO, or functionally active variants thereof.
- the first and the second heterologous UDP-GalNAc transporter proteins are the same UDP-GalNAc transporter protein. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter proteins are each CeC03H5.2. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter proteins are different UDP-GalNAc transporter proteins. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter proteins are CeC03H5.2 and GnJ, respectively.
- the extent and/or homogeneity of glycosylation of a polypeptide of interest may be optimized by appropriate combination of recombinant GalNAc transferase(s) and heterologous UDP-GalNAc transporter protein(s).
- the combination of recombinant GalNAc transferase(s) and heterologous UDP-GalNAc transporter protein(s) is selected from a combination listed in Table 12 or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2, GnF, GnH, GnJ, UGTREL7, GnM, GnN, and GnO.
- the heterologous UDP-GalNAc transporter proteins comprise CeC03H5.2.
- the heterologous UDP-GalNAc transporter proteins comprise GnJ.
- the heterologous UDP-GalNAc transporter proteins comprise GnM. In certain embodiments, when the one or more GalNAc transferases comprise human p4-GalNAcT3, the heterologous UDP-GalNAc transporter proteins comprise GnN. In certain embodiments, when the one or more GalNAc transferases comprise human p4-GalNAcT3, the heterologous UDP-GalNAc transporter proteins comprise GnO.
- the heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2, GnF, GnJ, and GnM. In certain embodiments, when the one or more GalNAc transferases comprise Ptp4GalNAcT, the heterologous UDP- GalNAc transporter proteins comprise CeC03H5.2. In certain embodiments, when the one or more GalNAc transferases comprise Ptp4GalNAcT, the heterologous UDP-GalNAc transporter proteins comprise GnF. In certain embodiments, when the one or more GalNAc transferases comprise CeP4GalNAcT, the heterologous UDP-GalNAc transporter proteins comprise CeC03H5.2 and/or GnF.
- the recombinant nucleic acids encode at least two GalNAc transferases and at least two heterologous UDP-GalNAc transporter proteins. In certain embodiments, the recombinant nucleic acids encode two GalNAc transferases and two heterologous UDP-GalNAc transporter proteins. In certain embodiments, the at least two GalNAc transferases are different. In certain embodiments, the recombinant nucleic acids encode two copies of the same heterologous UDP-GalNAc transporter protein. In certain embodiments, the recombinant nucleic acids encode two different heterologous UDP- GalNAc transporter proteins.
- the at least two GalNAc transferases are selected from the group consisting of human p4-GalNAcT3, human p4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto; and the at least two heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2, GnF, GnG, GnH, GnI, GnJ, UGTREL7, GnL, GnM, GnN, or GnO, or functionally active variants thereof.
- the at least two GalNAc transferases and the at least two heterologous UDP-GalNAc transporter proteins are selected from a combination listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the recombinant nucleic acids encode human p4-GalNAcT3, CeP4GalNAcT, CeC03H5.2, and GnJ.
- the recombinant nucleic acids encode human P4-GalNAcT3, Ptp4GalNAcT, and CeC03H5.2.
- the host cell is such that (a) the recombinant nucleic acid encoding one or more GalNAc transferases comprises a first ORF encoding a first GalNAc transferase and a second ORF encoding a second GalNAc transferase; and (b) the recombinant nucleic acid encoding a heterologous UDP-GalNAc transporter comprises a third ORF encoding a first heterologous UDP-GalNAc transporter and a fourth ORF encoding a second heterologous UDP-GalNAc transporter.
- the host cell is such that (a) the first open reading frame (ORF) encoding the first GalNAc transferase and and the third ORF encoding the first heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module; and/or (b) the second open reading frame (ORF) encoding the second GalNAc transferase and and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module.
- ORF open reading frame
- the host cell is such that (a) the first ORF encoding the first GalNAc transferase and the second ORF encoding the second GalNAc transferase are integrated into the host cell in separate genetic modules; and/or (b) the third ORF encoding the first heterologous UDP-GalNAc transporter and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in separate genetic modules.
- the first ORF encoding the first GalNAc transferase, the second ORF encoding the second GalNAc transferase, the third ORF encoding the first heterologous UDP-GalNAc transporter, and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module.
- the first ORF encoding the first GalNAc transferase, the second ORF encoding the second GalNAc transferase, the third ORF encoding the first heterologous UDP-GalNAc transporter, and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the [ssuPolI] locus of the host cell.
- the first and the second GalNAc transferases are different GalNAc transferases.
- the first and the second heterologous UDP- GalNAc transporter proteins are the same UDP-GalNAc transporter protein.
- the first and the second heterologous UDP-GalNAc transporter proteins are different UDP-GalNAc transporter proteins.
- the first GalNAc transferase, the second GalNAc transferase, the first heterologous UDP-GalNAc transporter protein, and the second heterologous UDP-GalNAc transporter protein are selected as a combination of GalNAc transferases and heterologous UDP-GalNAc transporter proteins listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
- the first and the second GalNAc transferases are human p4-GalNAcT3 and CeP4GalNAcT, respectively; and the first and the second heterologous UDP-GalNAc transporter proteins are CeC03H5.2, and GnJ, respectively.
- the first and the second GalNAc transferases are human p4-GalNAcT3 and Ptp4GalNAcT, respectively; and the first and the second heterologous UDP-GalNAc transporter proteins are each CeC03H5.2.
- the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein are co-localized in the secretory pathway.
- the one or more GalNAc transferases and the heterologous UDP- GalNAc transporter protein each independently comprise: (a) a signal peptide localizing the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein in the secretory pathway; and/or (b) a retention sequence retaining the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein in the secretory pathway.
- the one or more GalNAc transferases and the heterologous UDP- GalNAc transporter protein each independently comprise the same signal peptide and/or retention sequence. In certain embodiments, the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein comprise different signal peptides and/or retention sequences. In certain embodiments, the signal peptide is derived from the same source as the one or more GalNAc transferases (i.e. the signal peptide is not added to the one or more GalNAc transferases, but is one fused to the one or more GalNAc transferases when naturally expressed in the source).
- the one or more GalNAc transferases is localized in the secretory pathway without adding a Leishmania signal peptide to the one or more GalNAc transferases.
- the signal peptide is derived from the same source as the heterologous UDP-GalNAc transporter protein (i.e. the signal peptide is not added to the heterologous UDP-GalNAc transporter protein, but is one fused to the heterologous UDP-GalNAc transporter protein when naturally expressed in the source).
- the heterologous UDP-GalNAc transporter protein is localized in the secretory pathway without adding a Leishmania signal peptide to the heterologous UDP-GalNAc transporter protein.
- the signal peptide of the one or more GalNAc transferases and/or the signal peptide of the heterologous UDP- GalNAc transporter protein is derived from a Leishmania species. In certain embodiments, the signal peptide of the one or more GalNAc transferases and/or the signal peptide of the heterologous UDP-GalNAc transporter protein are processed and removed. In certain embodiments, the retention sequence is derived from the same source as the one or more GalNAc transferases (i.e. the retention sequence is not added to the one or more GalNAc transferases, but is one fused to the one or more GalNAc transferases when naturally expressed in the source).
- the one or more GalNAc transferases is retained in the secretory pathway without adding a Leishmania retention sequence to the one or more GalNAc transferases.
- the retention sequence is derived from the same source as the heterologous UDP-GalNAc transporter protein (i.e. the retention sequence is not added to the heterologous UDP-GalNAc transporter protein, but is one fused to the heterologous UDP-GalNAc transporter protein when naturally expressed in the source).
- the heterologous UDP-GalNAc transporter protein is retained in the secretory pathway without adding a Leishmania retention sequence to the heterologous UDP- GalNAc transporter protein.
- the retention sequence of the one or more GalNAc transferases and/or the retention sequence of the heterologous UDP-GalNAc transporter protein are derived from a Leishmania species.
- the Leishmania species is Leishmania tarentolae.
- the Leishmania host cell is a Leishmania tarentolae cell. In certain embodiments, the Leishmania host cell is a Leishmania aethiopica cell. In certain embodiments, the Leishmania host cell is part of the Leishmania aethiopica species complex. In certain embodiments, the Leishmania host cell is a Leishmania aristidesi cell. In certain embodiments, the Leishmania host cell is a Leishmania deanei cell. In certain embodiments, the Leishmania host cell is part of the Leishmania donovani species complex. In certain embodiments, the Leishmania host cell is a Leishmania donovani cell.
- the Leishmania host cell is a Leishmania chagasi cell. In certain embodiments, the Leishmania host cell is a Leishmania infantum cell. In certain embodiments, the Leishmania host cell is a Leishmania hertigi cell. In certain embodiments, the Leishmania host cell is part of the Leishmania major species complex. In certain embodiments, the Leishmania host cell is a Leishmania major cell. In certain embodiments, the Leishmania host cell is a Leishmania martiniquensis cell. In certain embodiments, the Leishmania host cell is part of the Leishmania mexicana species complex. In certain embodiments, the Leishmania host cell is a Leishmania mexicana cell.
- the Leishmania host cell is a Leishmania pifanoi cell. In certain embodiments, the Leishmania host cell is part of the Leishmania tropica species complex. In certain embodiments, the Leishmania host cell is a Leishmania tropica cell.
- the method may be used to accomplish the introduction of one or more genes encoding a GalNAc transferase as described in Section 7.1.1. In certain embodiments, the method may be used to accomplish the introduction of one or more genes encoding an additional recombinant glycosyltransferase as described in Section 7.1.2. In certain embodiments, the method may be used to accomplish the functional inactivation of one or more genes encoding an enzyme that catalyzes the formation of O-linked GlcNAc as described in Section 7.1.3.
- the method may be used to accomplish the introduction of one or more genes encoding a heterologous UDP-GalNAc biosynthetic pathway proteins as described in Section 7.1.4. In certain embodiments, the method may be used to accomplish the introduction of one or more genes encoding a heterologous UDP-GalNAc transporter protein as described in Section 7.1.5. In certain embodiments, the strain of the engineered Leishmania host cell is described in Section 7.1.6.
- nucleic acids are introduced into the host cells described herein using a plasmid, e.g., the heterologous nucleic acids are expressed in the host cells by a plasmid (e.g., an expression vector), and the plasmid is introduced into the modified host cells by transfection, infection, or electroporation, chemical transformation by heat shock, natural transformation, phage transduction, or conjugation.
- a plasmid e.g., an expression vector
- said plasmid is introduced into the modified host cells by stable transfection.
- linearized nucleic acids are introduced into the host cells described herein using transfection, infection, or electroporation, chemical transformation by heat shock, natural transformation, phage transduction, or conjugation.
- heterologous nucleic acids are integrated site-specifically into the host cell genome by homologous recombination.
- the method of engineering the Leishmania host cell comprises introducing one or more genes encoding a GalNAc transferase as described in Section 7.1.1.
- the method of engineering the Leishmania host cell comprises introducing one or more genes encoding an additional recombinant glycosyltransferase as described in Section 7.1.2.
- the method of engineering the Leishmania host cell comprises functionally inactivating one or more genes encoding an enzyme that catalyzes the formation of O-linked GlcNAc as described in Section 7.1.3.
- the method comprises downregulating the gene encoding the at least one GlcNAc-transferase.
- the method comprises deleting the gene encoding the at least one GlcNAc-transferase.
- the method comprises mutating the gene encoding the at least one GlcNAc-transferase.
- the method comprises overexpressing the gene encoding the at least one GlcNAc-transferase.
- the method comprises functionally inactivating the gene encoding an enzyme that catalyzes the formation of O-linked GlcNAc using the methods described in the Assay or Example Sections (Sections 7.6 and 8. , respectively). In certain embodiments, the method comprises functionally inactivating the gene encoding an enzyme that catalyzes the formation of O-linked GlcNAc using any method known in the art, for example methods described in International Publication No. W02019/002512 A2, incorporated by reference in its entirety herein.
- Non-limiting exemplary mutagenesis approaches include site directed mutagenesis using targeted gene editing techniques such as TALENs , ZFNs, CRISPR/Cas9; in combination with a repair scaffold for directed, homologous recombination mediated repair (Zhang, W et al. (2017) mSphere 2 (1); Gupta, R. and Musunuru, K. (2014) The Journal of clinical investigation 124 (10):4154— 4161), transposon mutagenesis (Damasceno, J. et al. (2015) Christopher Peacock (Ed.): Parasite Genomics Protocols, vol. 1201. New York, NY : Springer New York (Methods in Molecular Biology), pp.
- targeted gene editing techniques such as TALENs , ZFNs, CRISPR/Cas9
- a repair scaffold for directed, homologous recombination mediated repair Zhang, W et al. (2017) mSphere 2 (1); Gupta, R. and Mus
- RNA interference (Lye, L. et al. (2010) PLoS Pathog 6 (10), elOOl 161), conditional knock-down using Cre/LoxP or FRT/FLP (Duncan, S. (2017) Molecular and Biochemical Parasitology 216: 30-38).
- Overexpression may be accomplished by the following non-limiting exemplary approaches, such as gene copy number increase by introduction of additional copies into separate loci (Beverley, S. (1991): Gene amplification in Leishmania. In d/z/w. Rev. Microbiol. 45, pp. 417-444), high expression loci (ribosomal DNA loci) or episomal constructs (Lodes, M. et al. (1995) Mol Cell Biol 15 (12), pp. 6845-6853. DOI: 10.1128/mcb.15.12.6845; Boucher, N.
- the method of engineering the Leishmania host cell comprises introducing one or more genes encoding a heterologous UDP-GalNAc biosynthetic pathway proteins as described in Section 7.1.4.
- the method of engineering the Leishmania host cell comprises introducing one or more genes encoding a heterologous UDP-GalNAc transporter protein as described in Section 7.1.5.
- the method of engineering the Leishmania host cell comprises (i) functionally inactivating one or more genes encoding an enzyme that catalyzes the formation of O-linked GlcNAc as described in Section 7.1.3; (ii) introducing one or more genes encoding a heterologous UDP-GalNAc biosynthetic pathway proteins as described in Section 7.1.4; (iii) introducing one or more genes encoding a heterologous UDP-GalNAc transporter protein as described in Section 7.1.5; and (iv) introducing one or more genes encoding a GalNAc transferase as described in Section 7.1.1.
- the method of engineering the Leishmania host cell comprises (i) functionally inactivating one or more genes encoding an enzyme that catalyzes the formation of O-linked GlcNAc as described in Section 7.1.3; (ii) introducing one or more genes encoding a heterologous UDP-GalNAc biosynthetic pathway proteins as described in Section 7.1.4; (iii) introducing one or more genes encoding a heterologous UDP-GalNAc transporter protein as described in Section 7.1.5; (iv) introducing one or more genes encoding a GalNAc transferase as described in Section 7.1.1; and (v) introducing one or more genes encoding an additional recombinant glycosyltransferase as described in Section 7.1.2.
- the method comprises conducting steps (i)-(v) in sequential order. In other embodiments, steps (i)-(v) are conducted in a different order. For example, in certain embodiments, steps (ii) and (iii) are conducted before step (i). In other embodiments, steps (ii) and (iii) are conducted after step (i). In other embodiments, step (iv) and/or (v) are conducted before step (i). In certain embodiments, step (v) is conducted before step (iv). In certain embodiments, step (v) is conducted first.
- steps (i)-(v) may be conducted simultaneously, for example by introducing the genes in a single module.
- steps (ii) and (iii) are conducted simultaneously.
- steps (ii), (iii), and (iv) are conducted simultaneously.
- step (v) is conducted before step (iv).
- step (v) is conducted first.
- step (i) is conducted, followed by steps (ii) and (iii), which are conducted simultaneously, and then step (iv) separately.
- steps (ii) and (iii) are conducted simultaneously and before step (iv), and step (iv) is conducted before step (i).
- step (i) is conducted, and steps (ii), (iii), and (iv) are conducted simultaneously after step (i).
- step (v) is conducted before step (iv).
- step (v) is conducted first.
- the method comprises conducting steps (i)-(v) in the order shown in any one of FIG. 5, FIG. 6, and FIG. 14. In certain embodiments, step (v) is conducted first.
- the Leishmania host cells may be engineered using the methods described in the Assay and Examples Sections (Sections 7.6 and 8. , respectively).
- Non-limiting exemplary Leishmania strains produced and plasmids used as donors for their production are provided in Table 3 and Table 9.
- the Leishmania host cells are cultured using any of the standard culturing techniques known in the art. For example, cells are routinely grown in rich media like Brain Heart Infusion, Trypticase Soy Broth or Yeast Extract, all containing 5 pg /ml Hemin. Additionally, incubation is done at 26°C in the dark as static or shaking cultures for 2-3 days. In some embodiments, cultures of recombinant cell lines contain the appropriate selective agents. Non-limiting exemplary selective agents are provided in Table 2.
- the Leishmania host cells are cultured in a growth medium comprising GalNAc.
- the growth medium comprises at least 1 mM, at least 2 mM, at least 3 mM, at least 4 mM, at least 5 mM, at least 6 mM, at least 7 mM, at least 8 mM, at least 9 mM, at least 10 mM, at least 11 mM, at least 12 mM, at least 13 mM, at least 14 mM, at least 15 mM, at least 16 mM, at least 17 mM, at least 18 mM, at least 19 mM, or at least 20 mM GalNAc.
- the growth medium comprises about 1 mM to about 5 mM, about 5 mM to about 10 mM, about 10 mM to about 15 mM, or about 15 mM to about 20 mM GalNAc. In certain embodiments, the growth medium comprises about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, or about 20 mM GalNAc. In certain embodiments, the growth medium comprises about about 10 mM GalNAc.
- the Leishmania host cells are cultured in a growth medium comprising GlcNAc.
- the growth medium comprises at least 1 mM, at least 2 mM, at least 3 mM, at least 4 mM, at least 5 mM, at least 6 mM, at least 7 mM, at least 8 mM, at least 9 mM, at least 10 mM, at least 11 mM, at least 12 mM, at least 13 mM, at least 14 mM, at least 15 mM, at least 16 mM, at least 17 mM, at least 18 mM, at least 19 mM, or at least 20 mM GlcNAc.
- the growth medium comprises about 1 mM to about 5 mM, about 5 mM to about 10 mM, about 10 mM to about 15 mM, or about 15 mM to about 20 mM GlcNAc. In certain embodiments, the growth medium comprises about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, or about 20 mM GlcNAc.
- the Leishmania host cells may be cultured using the methods described in the Assay and Examples Sections (Sections 7.6 and 8. , respectively).
- Non-limiting exemplary Leishmania strains and plasmids used as donors for their production are provided in Table 3 and Table 9.
- a Leishmania host cell described in Section 7.1 may be used as an expression system for making a polypeptide of interest.
- the polypeptide of interest may be a heterologous, non-Leishmania protein, such as a therapeutic protein (e.g., an antibody).
- the Leishmania host cells may be engineered as described in Sections 7.2 and cultured as described in Section 7.3.
- Other methods of producing Leishmania host cells for use as expression systems are known and may also be used, for example, see WO 2019/002512, WO 2021/140144 and WO 2021/140143, each of which are incorporated herein by reference in their entirety.
- Use of Leishmania host cells to make monoclonal antibodies are also known. Exemplary methods are described in WO 2022/053673, which is incorporated herein by reference in its entirety.
- the Leishmania host cells may be used as an expression system for producing a polypeptide of interest according to the methods described in the Assay and Examples Sections (Sections 7.6 and 8. , respectively).
- compositions comprising the Leishmania host cells described in Section 7.1. Such compositions can be used in methods for generating a polypeptide of interest as described in Section 7.5.
- the compositions comprising Leishmania host cells can be cultured under conditions suitable for the production of polypeptides of interest. Subsequently, the polypeptides of interest can be isolated from said compositions comprising Leishmania host cells using methods known in the art.
- compositions comprising the Leishmania host cells can comprise additional components suitable for maintenance and survival of the Leishmania host cells, and can additionally comprise additional components required or beneficial to the production of polypeptides of interest by the Leishmania host cells, e.g., inducers for inducible promoters, such as arabinose, IPTG.
- inducers for inducible promoters such as arabinose, IPTG.
- provided herein are methods for making a polypeptide of interest, for example, one described in Section 7.5.
- a method of producing a polypeptide of interest in vivo using a Leishmania host cell described in Section 7.1.
- a method for producing a polypeptide of interest comprising (i) culturing a. Leishmania host cell described in Section 7.1 under conditions suitable for polypeptide production and (ii) isolating said polypeptide of interest.
- the Leishmania host cell comprises: (a) a recombinant nucleic acid encoding a polypeptide of interest; and (b) a recombinant nucleic acid encoding one or more recombinant N-acetylgalactosamine (GalNAc) transferases.
- the Leishmania host cell is capable of producing polypeptides comprising a biantennary, GalNAc-terminated N-glycan.
- the Leishmania host cells provided herein is capable of producing polypeptides comprising an N-glycan of the following structure: wherein the black square represents an N-acetyl galactosamine (GalNAc), the white square represents an N-acetylglucosamine (GlcNAc) residue and the black circle represents a mannose (Man) residue, and wherein X represents an amino acid residue of the polypeptide of interest.
- GalNAc N-acetyl galactosamine
- Man mannose
- the polypeptide of interest produced by the Leishmania host cell is a therapeutic polypeptide, ie., a polypeptide used in the treatment of a disease or disorder.
- the target polypeptide produced by the Leishmania host cell can be an enzyme, a cytokine, or an antibody.
- a list of non-limiting exemplary polypeptides of interest is provided in Section 7.5.
- the polypeptide of interest produced by the Leishmania host cell provided in Section 7.1 is a therapeutic polypeptide, z.e., a polypeptide used in the treatment of a disease or disorder.
- the polypeptide of interest produced by the Leishmania host cell can be an enzyme, a cytokine, or an antibody.
- the polypeptide of interest is selected from the group consisting of adalimumab, rituximab and erythropoietin (EPO).
- polypeptide or peptide/polypeptide corresponding to the polypeptide
- Any polypeptide (or peptide/polypeptide corresponding to the polypeptide) known in the art can be used as a polypeptide of interest in accordance with the methods described herein.
- One of skill in the art will readily appreciate that the nucleic acid sequence of a known polypeptide, as well as a newly identified polypeptide, can easily be deduced using methods known in the art, and thus it would be well within the capacity of one of skill in the art to introduce a nucleic acid that encodes any polypeptide of interest into a host cell provided herein (e.g., via an expression vector, e.g., a plasmid, e.g., a site specific integration by homologous recombination).
- an expression vector e.g., a plasmid, e.g., a site specific integration by homologous recombination.
- the polypeptide of interest is glycosylated, e.g., with an N-glycan of the following structure: wherein the black square represents an N-acetyl galactosamine (GalNAc), the white square represents an N-acetylglucosamine (GlcNAc) residue and the black circle represents a mannose (Man) residue, and wherein X represents an amino acid residue of the polypeptide of interest.
- GalNAc N-acetyl galactosamine
- Man mannose
- polypeptides of interest may be glycosylated using the methods described herein, e.g., either in vivo using Leishmania host cell in Section 7.1 or in vitro, possess therapeutic benefit (e.g., due to improved pharmacokinetics) and thus can be used in the treatment of subjects having diseases/disorders that will benefit from treatment with the glycosylated polypeptides of interest.
- the polypeptide of interest comprises the amino acid sequence of human Interferon-a (INF -a), Interferon-P (INF-P), Interferon-y (INF-y), Interleukin-2 (IL2), Chimeric diphteria toxin-IL-2 (Denileukin diftitox), Interleukin-1 (IL1), IL1B, IL3, IL4, IL11, IL21, IL22, IL1 receptor antagonist (anakinra), Tumor necrosis factor alpha (TNF-a), Insulin, Pramlintide, Growth hormone (GH), Insulin-like growth factor (IGF1), Human parathyroid hormone, Calcitonin, Glucagon-like peptide-1 agonist (GLP-1), Glucagon, Growth hormone-releasing hormone (GHRH), Secretin, Thyroid stimulating hormone (TSH), Human bone morphogenic polypeptide 2 (hBMP2), Human bone morphogenic proetin 7
- the target polypeptide used in accordance with the methods and host cells described herein is an enzyme or an inhibitor.
- Exemplary enzymes and inhibitors that can be used as a target polypeptide include, without limitation, Factor VII, Factor VIII, Factor IX, Factor X, Factor XIII, Factor Vila, Antithrombin III (AT -III), Polypeptide C, Tissue plasminogen activator (tPA) and tPA variants, Urokinase, Hirudin, Streptokinase, Glucocerebrosidase, Alglucosidase-a, Laronidase (a-L-iduronidase), Idursulphase (Iduronate- 2-sulphatase), Galsulphase, Agalsidase-P (human a-galactosidase A), Botulinum toxin, Collagenase, Human DNAse-I, Hyaluronidase, Papain, L- Asparagina
- the polypeptide of interest used in accordance with the methods and Leishmania host cells provided herein is a cytokine.
- cytokines that can be used as a polypeptide of interest include, without limitation, Interferon-a (INF-a), Interferon-P (INF-P), Interferon -y (INF-y), Interleukin-2 (IL2), Chimeric diphteria toxin-IL-2 (Denileukin diftitox), Interleukin- 1 (IL1), IL IB, IL3, IL4, IL11, IL21, IL22, IL1 receptor antagonist (anakinra), and Tumor necrosis factor alpha (TNF-a).
- the polypeptide of interest used in accordance with the methods and Leishmania host cells provided herein is a hormone or growth factor.
- hormones and growth factors that can be used as a polypeptides of interest include, without limitation, Insulin, Pramlintide, Growth hormone (GH), Insulin-like growth factor (IGF1), Human parathyroid hormone, Calcitonin, Glucagon-like peptide- 1 agonist (GLP-1), Glucagon, Growth horm one-releasing hormone (GHRH), Secretin, Thyroid stimulating hormone (TSH), Human bone morphogenic polypeptide 2 (hBMP2), Human bone morphogenic proetin 7 (hBMP7), Gonadotropin releasing hormone (GnRH), Keratinocyte growth factor (KGF), Platelet-derived growth factor (PDGF), Fibroblast growth factor 7 (FGF7), Fibroblast growth factor 20 (FGF20), Fibroblast growth factor 21 (FGF21), Epidermal growth factor (EG), EG 12), prodermal growth
- the polypeptide of interest used in accordance with the methods and Leishmania host cells provided herein is a receptor.
- exemplary receptors that can be used as a polypeptide of interest include, without limitation, the extracellular domain of human CTLA4 (e.g., fused to an Fc) and the soluble TNF receptor (e.g., fused to an Fc).
- the polypeptide of interest is a therapeutic polypeptide.
- the polypeptide of interest is an approved biologic drug.
- the therapeutic polypeptide comprises the amino acid sequence of Abatacept (e.g., Orencia® (Bristol-Myers Squibb)), Aducanumab-avwa (e.g., Aduhelm® (Biogen Corporation)), Aflibercept (e.g., Eylea® (Regeneron Corp.)), Agalsidase beta (e.g., Fabrazyme® (Genzyme Corp.)), Albiglutide (e.g., Eperzan® (GlaxoSmithKline Corp.)), Aldesleukin (e.g., Proleukin® (Clinigen, Inc.)), Alefacept (e.g., Amevive® (Astellas Pharma, Inc.)), Alglucerase (e.g., Ceredase® (Gen
- Vectibix® (Amgen, Inc.)
- Pembrolizumab e.g., Keytruda® (Merck & Co.)
- Pertuzumab e.g., Perjeta® (Genentech, Inc.)
- Polatuzumab e.g., Polivy® (Genentech, Inc.)
- Pozelimab® e.g., Veopoz (Regeneron Pharmaceuticals, Inc.)
- Ramucirumab e.g., Cyramza® (Eli Lilly and Company
- Ranibizumab e.g., Lucentis® (Genentech, Inc.)
- Ravulizumab-cwvz e.g., Ultomoris® (AstraZeneca)
- Raxibacumab e.g., Raxibacumab (GlaxoSmithKline)
- Risankizumab e.g., Risanizumab-r
- the polypeptide of interest is an antibody.
- the antibody has the amino acid sequence of adalimumab (Humira® (Abb Vie Inc.)); Remicade® (Janssen Biotech, Inc.) (Infliximab); ReoPro® (Janssen Biotech, Inc.) (Abciximab); Rituxan® (Genentech, Inc.) (Rituximab); Simulect® (Novartis Pharmaceuticals Corporation) (Basiliximab); Synagis® (Medimmune, LLC) (Palivizumab); Herceptin® (Genentech, Inc.) (Trastuzumab); Mylotarg® (Pfizer) (Gemtuzumab ozogamicin); Campath® (Takeda Oncology Corporation) (Alemtuzumab); Zevalin® (Acrotech Biopharma Inc.) (Ibritumomab tiuxetan
- Cimzia® (UCB Pharma Ltd.) (Certolizumab pegol); Simponi® (Janssen Biotech, Inc.) (Golimumab); Haris® (Novartis Pharmaceuticals Corporation) (Canakinumab); Stelara® (Janssen Biotech, Inc.) (Ustekinumab); Arzerra® (GlaxoSmithKline) (Ofatumumab); Prolia® and Xgeva® (Amgen, Inc.) (Denosumab); Numax® (Medimmune, LLC) (Motavizumab); ABThrax® (GlaxoSmithKline) (Raxibacumab); Benlysta® (GlaxoSmithKline) (Belimumab); Yervoy® (Bristol-Myers Squibb) (Ipilimumab); Adcetris® (Seagen, Inc.) (Brentuximab Vedotin); Perjeta® (Genen
- the antibody is a full length antibody, an Fab, an F(ab')2, an Scfv, or a sdAb.
- the polypeptide of interest is a camelid heavy-chain antibody domain, such as a VHH, sdAbs, or nanobody.
- the polypeptide of interest comprises the amino acid sequence of an enzyme or an inhibitor thereof.
- the polypeptide of interest comprises the amino acid sequence of Factor VII, Factor VIII, Factor IX, Factor X, Factor XIII, Factor Vila, Antithrombin III (AT-III), Polypeptide C, Tissue plasminogen activator (tPA) and tPA variants, Urokinase, Hirudin, Streptokinase, Glucocerebrosidase, Alglucosidase-a, Laronidase (a-L-iduronidase), Idursulphase (Iduronate-2-sulphatase), Galsulphase, Agalsidase-P (human a-galactosidase A), Botulinum toxin, Collagenase, Human DNAse-I, Hyaluronidase, Papain, L- Asparaginase, Uricase (Urate oxidase), glutamate carboxypeptidase (glucarpidase), al Protease inhibitor (al
- the polypeptide of interest used in accordance with the methods and Leishmania host cells provided herein is a receptor.
- exemplary receptors that can be used as a polypeptide of interest include, without limitation, the extracellular domain of human CTLA4 (e.g., fused to an Fc) and the soluble TNF receptor (e.g., fused to an Fc).
- the polypeptide of interest is secreted into the culture media.
- the polypeptide of interest is purified from the culture media.
- the polypeptide of interest is purified from the culture media via affinity purification or ion exchange chromatography.
- the polypeptide of interest contains an FC domain and is affinity purified from the culture media via polypeptide-A.
- the polypeptide of interest contains an affinity tag and is affinity purified.
- the polypeptide of interest used in accordance with the methods and Leishmania host cells provided herein can be a full length polypeptide, a truncation, a polypeptide domain, a region, a motif or a peptide thereof.
- the polypeptide of interest is an Fc-fusion polypeptide.
- the polypeptide of interest is a biologic comprising an Fc domain of an IgG.
- the polypeptide of interest produced by a method described herein is a bifunctional degrader described in ‘GLYCAN-MEDIATED PROTEIN DEGRADATION’, filed September 27, 2023 as an international application with the European Receiving Office, which claims priority to U.S. Provisional Application Nos. 63/410,955 and 63/410,936, and which is incorporated herein in its entirety.
- the polypeptide of interest is localized in the secretory pathway.
- localization within the secretory pathway includes, but is not limited to, localization to one or more of the following sub-cellular compartments: the endoplasmic reticulum, the Golgi apparatus, lysosomes, intracellular membrane proteins, cell surface anchored proteins, and membrane proteins.
- localization in the secretory pathway comprises localization to one or more of said sub-cellular compartments.
- the polypeptide of interest comprises a signal peptide localizing the polypeptide of interest in the secretory pathway.
- the signal peptide is derived from the same source as the polypeptide of interest (i.e. the signal peptide is not added to the polypeptide of interest, but is one fused to the polypeptide of interest when naturally expressed in the source).
- the polypeptide of interest is localized in the secretory pathway without adding a Leishmania signal peptide to the polypeptide of interest.
- the signal peptide is added to the polypeptide of interest.
- the signal peptide is derived from a Leishmania species.
- the signal peptide is a modified version of a signal peptide from derived from a Leishmania species. In certain embodiments, the signal peptide is derived from Leishmania tarentolae. In certain embodiments, the signal peptide is a modified version of a signal peptide from derived from Leishmania tarentolae. In certain embodiments, the signal peptide is an invertase signal peptide derived from Leishmania tarentolae. In certain embodiments, the signal peptide is a modified version of the invertase signal peptide derived from Leishmania tarentolae. In certain embodiments, the signal peptide comprises an amino acid sequence of SEQ ID NO: 11. In certain embodiments, the signal peptide comprises an amino acid sequence of SEQ ID NO: 12. In certain embodiments, the signal peptide is processed and removed from the polypeptide of interest.
- the polypeptide of interest comprises a retention sequence retaining the polypeptide of interest in the secretory pathway.
- the retention sequence is derived from the same source as the polypeptide of interest (i.e. the retention sequence is not added to the polypeptide of interest, but is one fused to the polypeptide of interest when naturally expressed in the source).
- the polypeptide of interest is retained in the secretory pathway without adding a Leishmania retention sequence to the polypeptide of interest.
- the retention sequence is added to the polypeptide of interest.
- the retention sequence is fused to the C-terminus of the polypeptide of interest.
- the retention sequence is fused to the N-terminus of the polypeptide of interest. In certain embodiments, the retention sequence is fused to one or more amino acids within the polypeptide of the polypeptide of interest. In certain embodiments, the retention sequence is derived from a Leishmania species. In certain embodiments, the retention sequence is a modified version of a retention sequence derived from a Leishmania species. In certain embodiments, the retention sequence is derived from Leishmania tarentolae. In certain embodiments, the retention sequence is a modified version of a retention sequence derived from Leishmania tarentolae.
- the polypeptide of interest has been engineered to comprise one or more tag(s).
- the tag is processed and removed from the polypeptide of interest.
- the GalNAc transferase described in Section 7.1.1 and the polypeptide of interest are co-localized in the secretory pathway.
- compositions comprising one or more of the polypeptides of interest described herein.
- the compositions described herein are useful in the treatment and/or prevention of diseases/disorders in subjects (e.g., human subjects) (see Section 7.5.2).
- compositions in addition to comprising a polypeptide of interest described herein, the compositions (e.g., pharmaceutical compositions) described herein comprise a pharmaceutically acceptable carrier.
- pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeiae for use in animals, and more particularly in humans.
- carrier refers to a diluent, adjuvant, excipient, or vehicle with which the pharmaceutical composition is administered.
- Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- Suitable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E.W. Martin.
- the compositions described herein are formulated to be suitable for the intended route of administration to a subject.
- compositions described herein may be formulated to be suitable for subcutaneous, parenteral, oral, intradermal, transdermal, colorectal, intraperitoneal, and rectal administration.
- the pharmaceutical composition may be formulated for intravenous, oral, intraperitoneal, intranasal, intratracheal, subcutaneous, intramuscular, topical, intradermal, transdermal or pulmonary administration.
- compositions described herein additionally comprise one or more buffers, e.g., phosphate buffer and sucrose phosphate glutamate buffer. In other embodiments, the compositions described herein do not comprise buffers.
- compositions described herein additionally comprise one or more salts, e.g., sodium chloride, calcium chloride, sodium phosphate, monosodium glutamate, and aluminum salts (e.g., aluminum hydroxide, aluminum phosphate, alum (potassium aluminum sulfate), or a mixture of such aluminum salts).
- salts e.g., sodium chloride, calcium chloride, sodium phosphate, monosodium glutamate
- aluminum salts e.g., aluminum hydroxide, aluminum phosphate, alum (potassium aluminum sulfate), or a mixture of such aluminum salts.
- the compositions described herein do not comprise salts.
- compositions described herein can be included in a kit, container, pack, or dispenser together with instructions for administration.
- compositions described herein can be stored before use, e.g., the compositions can be stored frozen (e.g., at about -20°C or at about -70°C); stored in refrigerated conditions (e.g., at about 4°C); or stored at room temperature.
- provided herein are methods of preventing or treating a disease or disorder in a subject comprising administering to the subject a polypeptide of interest described herein or a composition thereof. Further provided herein are methods of preventing a disease or disorder in a subject comprising administering to the subject a polypeptide of interest described herein or a composition thereof.
- provided herein are methods of treating a disease or disorder in a subject comprising administering to the subject a polypeptide of interest described herein or a composition thereof.
- methods of preventing a disease or disorder in a subject comprising administering to the subject a polypeptide of interest described herein or a composition thereof.
- a method for treating or preventing a disease or disorder in a subject comprising administering to the subject a polypeptide of interest produced according to the methods described herein, wherein the polypeptide of interest is glycosylated with an N-glycan of the following structure: wherein the black square represents an N-acetylgalactosamine (GalNAc), the white square represents an N-acetylglucosamine (GlcNAc) residue and the black circle represents a mannose (Man) residue, and wherein X represents an amino acid residue of the polypeptide of interest.
- GalNAc N-acetylgalactosamine
- Man mannose
- the disease or disorder may be caused by the presence of a defective version of a polypeptide of interest in a subject, the absence of a polypeptide of interest in a subject, diminished expression of a polypeptide of interest in a subject can be treated or prevented using the polypeptides of interest produced using the methods described herein.
- the diseases or disorder may be mediated by a receptor that is bound by a polypeptide of interest produced using the methods described herein, or mediated by a ligand that is bound by a polypeptide of interest produced using the methods described herein (e.g., where the polypeptide of interest is a receptor for the ligand).
- the methods of preventing or treating a disease or disorder in a subject comprise administering to the subject an effective amount of a polypeptide of interest described herein or a composition thereof.
- the effective amount is the amount of a therapy which has a prophylactic and/or therapeutic effect(s).
- an “effective amount” refers to the amount of a therapy which is sufficient to achieve one, two, three, four, or more of the following effects: (i) reduce or ameliorate the severity of a disease/disorder or symptom associated therewith; (ii) reduce the duration of a disease/disorder or symptom associated therewith; (iii) prevent the progression of a disease/disorder or symptom associated therewith; (iv) cause regression of a disease/disorder or symptom associated therewith; (v) prevent the development or onset of a disease/disorder, or symptom associated therewith; (vi) prevent the recurrence of a disease/disorder or symptom associated therewith; (vii) reduce organ failure associated with a disease/disorder; (viii) reduce hospitalization of a subject having a disease/disorder; (ix) reduce hospitalization length of a subject having a disease/disorder; (x) increase the survival of a subject with a disease/disorder; (i) reduce or
- Host cells are cultured using any of the standard culturing techniques known in the art. For example, cells are routinely grown in rich media like Brain Heart Infusion, Trypticase Soy Broth or Yeast Extract, all containing 5 pg/ml Hemin. In some embodiments, incubation is done at 26°C in the dark as static or shaking cultures for 2-3 days. In some embodiments, cultures of recombinant cell lines contain the appropriate selective agents. In some embodiments, cultures contain Biopterin at a final concentration of 10 pM to support growth.
- Table 2 Selective agents used during transfection (50% concentration for preselection and 100% concentration for main selection) and standard culturing of L. tarentolae. Double amounts of the selective agents could be used if higher selection pressure was intended.
- Table 3 Summary of strains presented in the examples. Some of the strains were produced by several rounds of transfection building on top of each other.
- Plasmids were derived from a pUC57 vector backbone for E. coli propagation and contained an ampicillin or kanamycin section marker.
- the expression cassettes are flanked by restriction sites suitable for excision. The composition of the cassettes depends on the intended use and is described in the respective methods and examples.
- the genes of interest are included as ORFs that were codon usage optimized for L. tarentolae. Optimized sequences were manually curated for avoidance of restriction sites and deletion of repeats or homopolymer stretches.
- the plasmids were generated and sequenced by a gene synthesis provider. Plasmids and descriptions are found in the sequence listings.
- codon usage optimization protein sequences were back-translated to nucleotide sequences using a custom Python3 script that stochastically selects codons based on the /.. tarentolae codon usage frequency while excluding rare codons (frequency ⁇ 10%).
- the codon usage has been calculated using cusp (Rice, et al. (2000) Trends in genetics : TIG 16 (6), pp. 276-277) on all annotated L. tarentolae nucleotide coding sequences.
- Restriction digest (12 pg DNA in total volume of 240 pL) was performed using standard restriction enzymes (ThermoFisher, preferably FastDigest) according to the manufacturer’s instructions. The restriction digest was performed until completion or o/n at 30°C and DNA was purified by EtOH precipitation (2 volume 100% ice cold EtOH was added to 1 volume digested DNA, incubated 30min on ice, centrifuged for 30 min 17'500 x g at 4°C. Pellet was washed with 70% EtOH and subsequently dried for maximum 15 min and resuspended in ddH20.
- EtOH precipitation 2 volume 100% ice cold EtOH was added to 1 volume digested DNA, incubated 30min on ice, centrifuged for 30 min 17'500 x g at 4°C. Pellet was washed with 70% EtOH and subsequently dried for maximum 15 min and resuspended in ddH20.
- the cell pellet was resuspended in the DNA mix and transfected using a 16-well electroporation strip with pulse FI-158 (in some examples alternative pulses FP167, CM150, EO115, DN100, FP 158, FBI 58 were used).
- pulse FI-158 in some examples alternative pulses FP167, CM150, EO115, DN100, FP 158, FBI 58 were used.
- a ribonucleoprotein complex formed of the endonuclease SpCas9 and bipartite guideRNAs (gRNA) are transfected into L.
- tarentolae to introduce double-strand breaks in the 5’ and 3’ regions of the open reading frames encoding OGNT1, OGNT2 and OGNTL.
- the gRNAs are formed by a scaffold RNA (tracrRNA) and one of the six sequence specific targeting RNAs (crRNA), used in this method.
- crRNA sequence specific targeting RNAs
- a selection marker expression construct consisting of two linear DNA fragments is transfected into the cells.
- the linear DNA pieces are integrated at the former OGNT expression sites by homologous recombination with each other and the 5’ and 3’ untranslated regions of the OGNT gene.
- the selection marker expression construct does not introduce additional flanking untranslated regions and thus results in transcription of the marker by endogenous PolII.
- gRNA for CRISPR/Cas9 mediated genome editing was assembled from equimolar amounts of tracrRNA and crRNA (Microsynth) as above by denaturation for 5 min at 95°C and subsequent slow cool down at 0. l°C/s in a thermo cycler. This was done separately for every crRNA used before the different gRNAs were subsequently mixed in equimolar amounts.
- 122 pmol recombinantly expressed Cas9 protein i.e. Alt-R® S.p. HiFi Cas9 Nuclease V3 (IDT, #1081061) were added to 360 pmol of the gRNA mix and incubated for 15 min at RT to allow RNP formation.
- the final volume used for a transfection by Nucleofector should not exceed 6 pl.
- the RNP mix was added to the repair DNA containing transfection solution described below along with 1 pl of Alt-R® Cas9 Electroporation Enhancer (IDT, #1081072).
- the cell pellet was resuspended in 20 pl of the DNA (or DNA/RNA or DNA/RNP) mix and transfected using a 16-well electroporation strip with pulse FI-158 (in some examples alternative pulses FP167, CM150, EO115, DN100, FP158, FBI 58 were used).
- pulse FI-158 in some examples alternative pulses FP167, CM150, EO115, DN100, FP158, FBI 58 were used.
- FI-158 in some examples alternative pulses FP167, CM150, EO115, DN100, FP158, FBI 58 were used.
- PAM SpCas9
- EuPaGDT http://grna.ctegd.uga.edu/
- PCR confirmation of OGNT knock-outs was performed by either amplification of the complete locus (OGNT1, OGNT2, OGNTL or OGNT1+L, where OGNT1+L comprises OGNT1 and OGNTL in tandem on the chromosome) or by amplification of the shorter fragments covering the integration sites.
- amplification of shorter regions with primer binding within the OGNT coding sequence was preferred to test for presence of remaining wt genes (see Table 6).
- the DreamTaq DNA polymerase (Thermo Fisher Scientific) was used.
- the correct integration of the selection marker gene into the respective OGNT locus could be tested by combinations of a primer binding in the genome with one primer binding to the selection marker CDS or the intergenic regions of the integrated construct and the other one targeting the genome.
- Table 5 PCRs for analysis of OGNT deletions. PCR primers used for confirmation OGNT knock-outs by absence of the respective OGNT wt gene and the expected amplicon sizes are summarized. * KO amplicon length for whole locus PCRs depends on the combination of selection marker and intergenic regions used. Table 6: Listing of primer sequences used in the described examples.
- HRP horse reddish peroxidase
- secondary antibodies anti-mouse polyvalent-HRP (A0412, Sigma) 1 :2000 diluted or anti-rabbit-HRP conjugate (Jackson ImmunoResearch #111-035-008) 1 :2000 diluted
- TMB 3,3’,5,5’-tetramethylbenzidine
- Host cells were routinely grown in 50 ml culture in BHIH or YEH for 48 h at 26°C shaking at 140 rpm. Cultures were harvested and centrifuged for 10 min at 1800*g at RT. Media SN was filtered through 0.22 pm filter (Steriflip, SCGP00525) and EDTA(0.5 M pH8) was added to each load in a 1 : 100 dilution. Media SNs of each strain were subjected to 4h incubation with 100 pl of proteinA resin (ProteinA-Sepharose 4B Fast Flow, Sigma Aldrich, P9424) per Falcon tube in batch while rotating at RT.
- proteinA resin ProteinA resin
- Elution fractions were pooled and immediately neutralized by adding 100 mM Tris-HCl (1 M pH8). Afterwards, the pooled elutions were buffer exchanged to PBS pH 6 using 2 ml 7K ZebaSpin desalting columns and optionally concentrated using Amicon 0.5 ml 30 K concentrators.
- SDS PAGE was performed under reduced or non-reducing conditions using 10 pg for Coomassie, 2.5 pg for WB, separated on 4-12% Gel with MOPS buffer for 55 minutes. Determination of Protein purity was done by Coomassie Stained SDS-PAGE with 10 pg protein sample and compared to a BSA standard curve. Impurities were quantified by ImageQuant. Capillary Gel Electrophoresis (CGE) was performed using an Agilent Protein 230 Kit (5067-1518), according to protocol.
- CGE Capillary Gel Electrophoresis
- MAbPac SEC-1 (4x300 mm) is a size exclusion chromatography (SEC) column specifically designed for separation and characterization of monoclonal antibodies (mAbs) and was used according to manufacturer’s recommendation (Temperature: 30 °C; Eluent: PBS 50mM NaPO4, 300 mM NaCl pH 6.8; Elution: isocratic, 30 minutes; Flow: 0.2 mL/minute; Detection: 215 nm; Injection V: 5 pL corresponding to 5 pg protein).
- SEC size exclusion chromatography
- Intact monoclonal antibodies were analyzed by mass spectrometry employing the state-of-the-art instrumentation (Orbitrap FTMS), data processing and data analysis (bioinformatics) tools by SpectroSwiss. In addition to the intact measurement the antibody was reduced with TCEP or enzymatically cleaved (IdeS) to generate Fd, LC and Fc/2 subunits, which were analyzed using the same instrumentation.
- Orbitrap FTMS state-of-the-art instrumentation
- bioinformatics bioinformatics
- Intact Mass Protein Metrics
- MASH Suite software tool open access, Wisconsin University, Ying Ge Group
- the employed resolution enabled obtaining isotopically-resolved data.
- Peak-by-Peak software tool Spectroswiss
- the employed methods enabled obtaining high spectral dynamic range data.
- Enzymatic release of N-glycans from cell surfaces was performed using PNGase F (New England Biolabs). Cells (grown for 48 or 72 h at 26°C shaking at 140 rpm) were harvested and washed with PBS by centrifugation for 10 min at 1800*g at RT.50 mg of cell pellet were re-suspended in Glyco Buffer 2 and incubated with 1 pl PNGase F for 1 h at 37 °C and 650 rpm. Cells were again pelleted by centrifugation and 75 pl of the supernatant was dried down in a SpeedVac concentrator. Glycans were resuspended in 10 pl of water.
- PNGase F New England Biolabs
- glycans were directly labeled with procainamide as described previously (Behrens, et al. (2016) Glycobiology 28 (11), pp. 825-831). Briefly, released glycans were mixed with 1 pl acetic acid, 8 pl of a procainamide stock solution (550 mg/ml in DMSO) and 12 pl of a sodium cyanoborohydride stock solution (200 mg/ml in H2O). Samples were incubated for 60 min at 65 °C and cleaned up using LC-PROC-96 clean up plates (Ludger Ltd) according to the manufacturer’s instructions.
- Enzymatic release of N-glycans from purified proteins was performed using Rapid PNGase F (New England Biolabs) as recommended by the supplier. 8 pl of sample (15 pg of protein) were mixed with 2 pl Rapid Buffer and 1 pl of Rapid PNGase F. The mixture was incubated at 50 °C for 10 min followed by 1 min at 90 °C.
- IgGl mAb was either cleaved with IdeZ to F(ab’)2 and Fc/2, or heavy and light chains were reduced before separation on SDS PAGE. Bands were excised and enzymatic release of N-glycans from the monoclonal antibody was performed using PNGase F. Following release, glycans were directly labeled with procainamide (PC).
- PC procainamide
- Procainamide-labeled N-glycans were analyzed by hydrophilic interaction chromatography-ultra performance liquid chromatography-mass spectrometry (HILIC- UPLC-MS) using am Acquity UPLC System (Waters) with fluorescence detection coupled to a Synapt G2-Si mass spectrometer (Waters). Glycans were separated using an Acquity BEH Amide column (130 A, 1.7 pm, 2.1 mM x 150 mM; Waters) with 50 mM ammonium formate, pH 4.4 as solvent A and acetonitrile as solvent B. The separation was performed using a linear gradient of 72-55 % solvent B at 0.5 ml/min for 40 min.
- the Synapt G2-Si mass spectrometer fitted with a Zspray electrospray source was used for mass detection in positive resolution mode using the following parameters: Scan range: m/z 300- 3500; scan time: 1 sec; capillary: 2.2 kV; source temperature: 120 °C and sampling cone: 75 V. MassLynx 4.2 (Waters) was used for data acquisition. Data processing and analysis was performed using Unifi 1.9.4.053 (Waters).
- Glucose units were assigned using a fifth-order polynomial distribution curve based on the retention times of a procainamide-labeled dextran ladder (Ludger Ltd). Glycan structures were assigned based on their m/z values and their retention times and matched against a previously constructed N-glycan library. For individual samples the UPLC was coupled to a Synapt HDMS mass spectrometer using comparable settings.
- MeOH/Chloroform extraction procedure for L. tarentolae cell pellets was performed on 2 OD of each sample, which were harvested by centrifugation and washed 2x with IxPBS (2200 g, 10 min, RT) and frozen.
- pellets were thawed, resuspended in 480 pl MeOH, supplemented with 20 pl water and sonicated in a water bath at RT for 15 min.
- the samples were spun in a table-top centrifuge at 18000 g and 4°C for 10 min.
- the SN was transferred into a glass vial, supplemented with 268 pl chloroform and vortexed.
- HPAEC-PAD High performance anion exchange chromatography coupled with pulsed amperometric detection (HPAEC-PAD) using CarboPac PAI, 4x250 mm (Thermo), based on Tomiya et al. 2001 : Determination of Nucleotides and Sugar Nucleotides Involved in Protein Glycosylation by High-Performance Anion-Exchange Chromatography: Sugar Nucleotide Contents in Cultured Insect Celles and Mammalian Cells. Analytical Biochemistry 293, p. 129-137, with an adjusted gradient.
- Glycoengineered Leishmania larenlolae the CGP (CustomGlycan Platform) host cells have performed efficiently to generate specific human N-glycans such as A2, A2G2 or A2G2S2, and for expression of different recombinant therapeutic proteins such as monoclonal antibodies (mAbs) and Erythropoietin, as described in detail in WO 2019/002512, WO 2021/140144, WO 2021/140143 and WO 2022/053673.
- mAbs monoclonal antibodies
- Erythropoietin Erythropoietin
- Described herein is the engineering of host cells to produce native and recombinant proteins having a biantennary GalNAc terminated N-glycan, namely A2GalNAc2 (for nomenclature, see Section 5.3).
- the Leishmania host cells provided herein produce surprisingly efficient ASGPR ligands that can be exploited for generating innovative therapeutics designed, for example, but not limited to, targeted protein degradation, such as clearing soluble targets quickly from circulation.
- A2GalNAc2 containing N-glycans in Leishmania host cells (as referred to herein as CGP, or CGP host cells) were identified.
- CGP Leishmania host cells
- the enzymes required for generating UDP-GalNAc and second, the enzymes that mediate the transfer of GalNAc from UDP-GalNAc to GlcNAc acceptors with a beta-l,4-linkage, to form monoantennary and biantennary GalNAc-beta-l,4-GlcNAc (A2GalNAc2) structures in N-linked glycans.
- A2GalNAc2 monoantennary and biantennary GalNAc-beta-l,4-GlcNAc
- a genomic search was performed to identify enzymes involved in the generation of nucleotide activated sugar donors in L. tarentolae '.
- UDP-Glc and UDP-Gal the enzymes and reactions are as follows: a-D-Glc-1- P + UTP is converted by UDP -glucose pyrophosphorylase (UGP) to UDP-Glc, which can be further epimerized by GalE (UDP -galactose 4-epimerase) to UDP-Gal.
- UDP-glucose pyrophosphorylase UDP -glucose pyrophosphorylase
- GalE UDP -galactose 4-epimerase
- the UDP-sugar pyrophosphorylase can therefore activate both Gal-l-P and Glc-l-P n Lei hmania major. Deletion of the UGP encoding gene in L. major strongly reduced but did not abolish the biosynthesis of UDP-Gal and its immediate precursor UDP-Glc, since USP enabled the limited biosynthesis of both nucleotide sugars. (Roper 2002, Urbaniak 2006, Capul 2007, Damerow 2004). For illustration, see FIG. 1.
- UDP-Gal is readily available in Leishmania tarentolae, as determined by (1) the presence of USP, UGP and GalE orthologues (see Table 7) and (2) the efficient generation of galactosylated N-glycans from engineered L. tarentolae, for which the recombinant galactosyltransferases need UDP-Gal as activated sugar donor for their activity (see A2G2 and A2G2S2 in WO 2019/002512, WO 2021/140144, WO 2021/140143, and WO 2022/053673). While UDP-Gal is natively produced by L.
- UDP-GalNAc can be generated by the salvage pathway in mammalian cells.
- UDP-N-acetyl hexosamine pyrophosphorylase (UAP1) converts UTP and GlcNAc-1-P into UDP-GlcNAc, and UTP and GalNAc-l-P into UDP-GalNAc.
- the isoform AGX1 is about 2 to 3 times more active towards GalNAc-l-P
- the isoform AGX2 is about 8 times more active towards GlcNAc-1-P.
- GalNAc-l-P is formed by a specific kinase which is GALK2 (N-acetyl galactosamine kinase) that is distinct from galactose- 1 -kinase.
- GALK2 N-acetyl galactosamine kinase
- GalNAc Salvage pathway enzymes are not present in L. tarentolae and were selected to be recombinantly expressed in CGP host cells.
- UDP-GalNAc can also be formed by epimerization of UDP- GlcNAc using the same NAD-dependent epimerase that converts UDP-Glc to UDP-Gal.
- the human GalE catalyzes two distinct but analogous reactions: the reversible epimerization of UDP-Glc to UDP-Gal and the reversible epimerization of UDP-GlcNAc to UDP-GalNAc.
- the reaction with UDP-Gal plays a critical role in the Leloir pathway of galactose catabolism in which galactose is converted to the glycolytic intermediate Glc-6-P.
- the human GalE was selected to be recombinantly expressed in CGP host cells.
- Another epimerase was selected from a bacterial source.
- the major cell-surface carbohydrates (lipooligosaccharide, capsule, and glycoprotein N-linked heptasaccharide) of Campylobacter jejuni contain Gal and/or GalNAc residues.
- GalNAc residues in these carbohydrates suggested that GalE, the initially annotated UDP-glucose 4-epimerase might be a UDP-GlcNAc 4-epimerase.
- GalE was indeed shown to epimerize UDP-Glc and UDP-GlcNAc in coupled assays with C. jejuni glycosyltransferases and in sugar nucleotide epimerization equilibria studies.
- GalE possesses UDP-GlcNAc 4-epimerase activity and was renamed Gne (Bematchez et al., (2005) J Biol Chem.; 280(6):4792-802. doi: 10.1074/jbc.M407767200).
- a transporter of UDP-GlcNAc and UDP-GalNAc is encoded by the Caenorhabditis elegans gene C03H5.2. Surprisingly, translocation of these substrates occurs in an independent and simultaneous manner that is neither a competitive nor a symport transport (Caffaro et al., (2006). Proc Natl Acad Sci U S A;103(44): 16176-81). This transporter was selected to be recombinantly expressed along with the salvage and epimerization pathway enzymes. 8.1.4 GalNAc Transferases
- N-acetyl-beta-glucosaminyl-glycoprotein 4-P-N-acetyl galactosaminyl-transferase activity was described by Sato et al., (2003): Journal of Biological Chemistry 278 (48), pp. 47534-47544.
- This human p4GalNAc-T3 (“P4-GalNAcT3”) effectively synthesizes N,N'-diacetylgalactosediamine, GalNAc P 1-4 GlcNAc, at non-reducing termini of various acceptors derived not only from N-glycans but also from O-glycans.
- p4-GalNAcT3 could transfer GalNAc residues, producing N,N'-diacetylgalactosediamine structures at least in N-glycans and probably in both N- and O-glycans.
- p4-GalNAcT3, (Sato et al., (2003): Journal of Biological Chemistry 278 (48), pp. 47534-47544), and P4- GalNAcT4 (Gotoh et al., (2004): FEBS Letters 562 (1-3), pp. 134-140) were therefore identified for GalNAc transfer and described have a broad tissue expression coverage including fetal kidney and brain in human.
- Human p4-GalNAcT3 and p4-GalNAcT4 were selected to be recombinantly expressed in CGP host cells.
- the A2GalNAc2 motif occurs in mammalian pituitary glycoprotein hormones, where the terminal GalNAc residues are 4-O-sulfated functions as a recognition marker for clearance by the endothelial cell CD206 (ManR) receptor.
- Mammalian glycoprotein hormones where the terminal GalNAc residues are 4-O-sulfated functions as a recognition marker for clearance by the endothelial cell CD206 (ManR) receptor.
- nonpituitary mammalian glycoproteins also contain A2GalNAc2 determinants, indicating that expression of A2GalNAc2 determinants in vertebrate glycoconjugates is more widespread than once thought.
- A2GalNAc2 and modifications of A2GalNAc2 sequences are common antigenic determinants in many parasitic nematodes and trematodes.
- CeP4GalNAcT is a member of the P4GalT family, a 383-amino acid type 2 membrane glycoprotein. Its soluble, epitope-tagged recombinant form of CeP4GalNAcT expressed in CHO-Lec8 cells was functional using UDP-GalNAc, but not UDP-Gal, as a donor toward different acceptor substrates containing terminal P-linked GlcNAc in both A- and ( -glycan type structures (Kawar et al., (2002). J Biol Chem.;277(38): 34924-32 Kawar et al., (2005). J Biol Chem. (13): 12810-9). This enzyme was also selected to be recombinantly expressed in CGP host cells.
- these candidates were primarily selected from sufficiently well described human source but extended to other species such as bacterial organisms or nematodes, that do generate GalNAc containing glycoconjugates.
- Transporter +Salvage + Epimerase (“T+S+E” or “TSE”); or Transporter + Salvage (“T+S” or “TS”) ; or Transporter ⁇ - Epimerization (“T+E” or “TE”) with genetic constructs of codon usage optimized (cuo) coding sequences spaced by different intergenic regions derived from Leishmania major (J, AC, AJ, T, AF vs Y, Z, AJ, T, AF) and different site-specific integration loci (pfr and aTub).
- StLMTB19915 a strain expressing an mAb with 2 exposed glycosites (Adalimumab K84N, D86N), >98% A2 N-glycans and devoid of O-glycosylation.
- the resulting strains (StCGP2801, 2803, 2805, 2807, 2847/2848) were not yet containing any GalNAc transferase, but their suitability to generate UDP-GalNAc as nucleotide activated sugar donor was tested by HPAEC-PAD on Chloroform/MetOH extracted cell pellets.
- Extracts from strains StCGP2805 and StCGP2848 clearly show detectable levels of UDP-GalNAc whereas in other extract samples, UDP-GalNAc is not or only detectable at minor amounts. Highest level of UDP-GalNAc was determined for the extract from StCGP2848.
- StCGP2847 another clone tested containing the same “T+S+E” construct (a second clone from the same transfection), but was not supplemented with GalNAc in the medium, did not show UDP-GalNAc.
- StCGP2801 and StCGP2803 both “T+S+E” were not fed with GalNAc and also did not show any significant amounts of UDP-GalNAc, See FIG. 3B.
- Example 2 The cell lines discussed in Example 2 containing different UDP-GalNAc biosynthesis pathways were further transfected with different human GalNAc transferase constructs (P4-GalNAcT3 and/or p4-GalNAcT4), and N-glycan profiles on the purified mAb were evaluated.
- the mAb was cleaved by IdeZ to generate F(ab’)2 and Fc subunits, which were separated on SDS PAGE. Bands were cut from the gel and subjected to PNGaseF N-glycan release and labeling with PC (see method vi).
- the non-fed strain (StCGP2860) showed a good A2GalNAc2 amount (33% on Fab sites) despite no major UDP-GalNAc level having been observed in its parental strain (StCGP2807) by HPAEC-PAD.
- intergenic region variants IrLmJ and IrLmAC seem to be beneficial over IrLmY and IrLmZ.
- StCGP3169 was generated using the following modifications, also described in FIG. 6
- StLMTB 18407 was analyzed with 1.7% Man3, 0.8% Al and 97.5% A2 N-glycans on its surface glycoproteins.
- the next engineering step was integrating the UDP-GalNAc biosynthesis module, called “GalNAc synth (T+S+E)_ blefPfr]” into the Pfr locus, using 7 fragments.
- This resulting strain, StCGP3023 was further transfected to integrate the P4-GalNAcT3 enzyme by using genetic module “GalNAcT3_ bsd [ssuPolI]” by recombining 5 fragments and integrating into the ribosomal rDNA locus [ssu-PolI], benefitting from a high-level expression of the integrated construct by the RNA Poll polymerase.
- the strain called StCGP3053 showed 37% A2GalNAc2 on its cell surface glycoproteins.
- OGNT triple deletion mutant devoid of O-glycosylation was generated by the method of CRISPR/Cas9 based knock-outs for L. tarentolae (as described in the Assays above).
- the initial cell surface N-glycans of newly generated StCGP3169 had 29% A2GalNAc2.
- StCGP3558 was constructed as follows and described in FIG. 6. [00291] StLMTB 19462 was engineered with a triple OGNT deletion, to yield
- StLMTB20097 was created by RNP mediated replacement of all three OGNTs with the selection marker for geneticin resistance. Comparison of the N-glycan profiles released from L. tarentolae surface proteins of the parental cell line Stl9462 and the triple OGNT knock-out cell line St20097 demonstrated that the efficiency of N-glycan conversion to A2 was not affected by OGNT knock-outs introduced by the RNP transfection method (see, e.g., FIG. 12C in WO 2021/140143).
- Adalimumab (K84N/D86N) had 73% A2GalNAc2, and 1 lk2 D86N 40% A2GalNAc2 on the Fab glycosites. This is comparable to the other strain performance. Interestingly, both strains, StCGP3169 and StCGP3558, had -70% A2GalNAc2 levels on Fab site of Adalimumab even without supplementing GalNAc to the medium.
- nucleotide sugars are synthesized in the cytoplasm or nucleus, whereas most glycosylation occurs inside the ER or Golgi compartments. Therefore, newly synthesized nucleotide sugars must be transported into the ER and Golgi lumen. Negative charge prevents these donors from simply diffusing into these compartments.
- eukaryotic cells have a set of energy-independent nucleotide sugar antiporters that deliver nucleotide sugars into the lumen of these organelles, with the simultaneous exiting of nucleoside monophosphates.
- the Km of the transporters ranges from 1 to 10 pm.
- the transporters Using in vitro systems, the transporters have been shown to increase the concentration of the nucleotide sugars within the Golgi lumen by 10- to 50-fold. This is usually sufficient to reach or exceed the calculated Km of glycosyltransferases that use these donors.
- glycosylation may be controlled in part by regulating the availability of nucleotide sugars within the Golgi, presumably by regulating the transporters.
- the subcompartmental location (cis, medial, trans) of the transporters in the Golgi is not known nor are the physical relationships of the transporters to the various glycosyltransferases they service.
- Many putative transporters were previously identified by homology in the genomes of mammals, Drosophila melanogaster, C. elegans, plants, and yeast, but the level of amino acid identity does not provide any information to the substrate specificity.
- UDP-GlcNAc transporters from mammalian cells and yeast are 22% identical, whereas mammalian CMP-Sia, UDP-Gal, and UDP-GlcNAc transporters have 40%-50% identity (Essentials of Glycobiology, 4th edition PMID: 35536922 DOI: 10.1101/9781621824213)
- UGTREL7 Uniprot Q9NTN3, also known as SLC35D1.
- UGTREL7 is described as a UDP- GalNAc and UDP -glucuronic acid transporter according to Muraoka (Muraoka, M., Kawakita, M. & Ishida, N.
- S+E Salvage and epimerization enzymes
- HsGalNAcT3 of Homo sapiens HsGalNAcT3 of Homo sapiens
- the parental strain StCGP4334 without any designated UDP-GalNAc transporter already showed 39% A2GalNAc2 N-glycans on the glycosites K84N and D86N of Adalimumab Fab, which indicates that there is some availability of UDP-GalNAc within the secretory pathway, either by being transported by a different (native) Leishmania tarentolae nucleotide- sugar transporter, or due to some other mechanism.
- a designated UDP-GalNAc transporter was introduced in StCGP4334, such as CeC03H5.2, an increase to 53% A2GalNAc2 was observed.
- GnJ (A0A4Y9Z8V0 Uncharacterized protein from Dentipellis fragilis) is therefore a suitable UDP-GalNAc transporter for incorporating to Leishmania host cell lines producing polypeptides comprising a biantennary, GalNAc-terminated N-glycan, specifically A2GalNAc2.
- UGTREL7 containing cell line showed 54% A2GalNAc2 N- glycans, which is a similar improvement as seen for CeC03H5.2 when compared to 39% of the parental cell line without any designated transporter.
- the GnM, GnN and GnO generated even higher A2GalNAc2 % with up to 67% for GnN. Only GnL was achieving less (FIG.ll).
- the combined genetic module containing PtGalNAcT, the UDP- GalNAc biosynthesis pathway and the GalNAc transporter CeC03H5.2 or a UDP-GalNAc transporter homolog, either GnF, GnJ or GnM, ⁇ GalNAc wtA(Transporter +5'+E PtGalNAcT ble ”) was introduced by multiple homologous recombination of 10 fragments into the ssu-PolI locus (FIG. 12).
- StCGP5351 expressing the UPD-GalNAc transporter GnF and the P.
- this study indicates that (1) incorporating a heterologous UDP- GalNAc transporter protein is beneficial for obtaining high proportions of A2GalNAc2 glycans in glycoengineered Leishmania cells; (2) appropriate transporters can be selected based on sequence homology to known UDP-GalNAc transporters from other organisms; and (3) specific combinations of heterologous GalNAc transferases and heterologous UDP- GalNAc transporter proteins can be advantageous to optimize UDP-GalNAc availability and/or obtain high proportions of A2GalNAc2 glycans in glycoengineered Leishmania cells.
- Example 6 The results from Example 6 prompted to combine different UDP-GalNAc transporter homologs with different GalNAc transferases to create potent entry cell lines for introducing different polypeptides and therapeutic modalities that contain one or more N- glycosylation consensus sites (including but not limited to Ab scaffolds like mAbs, Fabs, scFvs, VHH, nanobodies, etc.) comprising A2GalNAc2 N-glycans. 8.7.1 Strain StCGP5359
- StCGP5359 was constructed as follows and described in FIG. 14.
- StCGP3558 contains the GalNAc biosynthesis module with the UDP-GalNAc transporter CeC03H5.2 and the human GalNAcT3 transferase (“HsGalNAcT3”) as described in 6.4.2 and FIG. 6.
- HsGalNAcT3 human GalNAcT3 transferase
- the UPD-GalNAc transporter GnJ (A0A4Y9Z8V0 Uncharacterized protein from Dentipellis fragilis) and the C. elegans GalNAc transferase (“CeGalNAcT”) were used as a second combined genetic module.
- CeGalNAcT C. elegans GalNAc transferase
- hVHH2-l 1-FHGT4 camelid VHH scaffold
- A2GalNAc2 levels on a C-terminal glycotag which is a peptide stretch harboring a N-glycosylation consensus site N-X-S/T, optimized for high site occupancy and tag integrity.
- StCGP5359 is therefore a suitable host cell line producing polypeptides comprising a biantennary, GalNAc-terminated N-glycan, specifically A2GalNAc2 which mediates protein degradation.
- StCGP5942 was constructed as follows and is described in FIG. 14. A combined module containing both the UDP-GalNAc biosynthesis pathway with the UPD-GalNAc transporter CeC03H5.2 and a combination of human and P. tepidariorum GalNAc transferases (“HsGalNAcT3” and “PtGalNAcT”, respectively) was introduced in StCGP552 by multiple homologous recombination of 10 fragments into the ssu-PolI locus.
- StCGP6631 is stable and the phenotype like viability, growth, protein expression yield and engineered N-glycosylation is maintained, thereby proving the applicability of parental entry strain StCGP5942 as host cell line for expressing therapeutic protein scaffolds harboring one or more glycosylation sites.
- These Leishmania host cells are capable of producing polypeptides comprising a biantennary, GalNAc-terminated N-glycan, specifically A2GalNAc2, which mediates protein degradation.
- Table 9 Genetic constructs used for generating StCGP2879, StCGP3169, StCGP3558, StCGP2801, StCGP2803, StCGP2805, StCGP2807, StCGP2847, StCGP5003, StCGP5006, StCGP5007, StCGP5010, StCGP5012, StCGP5013, StCGP5016, StCGP5017, StCGP5049, StCGP5019, StCGP5021, StCGP4978, StCGP5351, StCGP5352, StCGP5694, StCGP5359, StCGP6044, StCGP5942, and StCGP6631. Flowcharts of strain construction are shown in FIGS. 5, 6, 10A, 10B, 12, and 14.
- Table 10 Selected UDP-GalNAc transporter homologs. Query sequences CeC03H5.2 in bold.
- Table 11 Selected UDP-GalNAc transporter homologs. Query sequence UGTREL7 in bold.
- Table 12 A multitude of parental (entry) strains harboring different combinations of GalNAc transferases and different UDP-GalNAc transporters were tested for their capability of expressing A2GalNAc2 N-glycans by transfecting test scaffolds Adalimumab (K84N/D86N) and/or hVHH2-ll-FHGT4. Strains were rated for % A2GalNAc2 by "+++” for >80%, “++” for 60-80%, “+” for 30-60%, and “+/-“ for 1-30% A2GalNAc2.
- GaNAc synth contains CeC03H5.2, salvage, and epimerization biosynthesis pathway. If another transporter was used instead of CeC03H5.2, it is captured in the description e.g. “GalNAc synth(cuo, GnJ)” harbors GnJ instead of CeC03H5.2.
- viruses, nucleic acids, methods, host cells, and compositions disclosed herein are not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the viruses, nucleic acids, methods, host cells, and compositions in addition to those described will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present application relates to Leishmania host cells, methods of engineering Leishmania host cells, methods of culturing Leishmania host cells, methods of making a polypeptide of interest using a Leishmania host cell, and polypeptides of interest produced by the methods. In particular, the Leishmania host cells provided herein are capable of producing polypeptides comprising a biantennary, GalNAc-terminated N-glycan, specifically A2GalNAc2.
Description
GLYCOENGINEERING USING LEISHMANIA CELLS
1. CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S. Serial No. 63/410,936, filed September 28, 2022, and U.S. Serial No. 63/410,955, filed September 28, 2022, each of which is incorporated herein by reference in its entirety.
2. SEQUENCE LISTING
[0002] This application contains a computer readable Sequence Listing which has been submitted in XML file format with this application, the entire content of which is incorporated by reference herein in its entirety. The Sequence Listing XML file submitted with this application is entitled “14688-006-228_SEQLISTING.xml”, was created on September 22, 2023 and is 330,759 bytes in size.
3. INTRODUCTION
[0003] The present application relates to Leishmania host cells, methods of engineering Leishmania host cells, methods of culturing Leishmania host cells, methods of making a polypeptide of interest using a Leishmania host cell, and polypeptides of interest produced by the methods. In particular, the Leishmania host cells provided herein are capable of producing polypeptides comprising a biantennary, GalNAc-terminated N-glycan, specifically A2GalNAc2.
4. BACKGROUND
[0004] A glycoprotein is a glycoconjugate in which a protein carries one or more glycans covalently attached to a polypeptide backbone, usually via N- or O-linkages. An N-glycan (N-linked oligosaccharide, N-[Asn]-linked oligosaccharide) is a sugar chain covalently linked to an asparagine residue of a polypeptide chain, commonly involving a GlcNAc residue in eukaryotes, and the consensus peptide sequence: Asn-X-Ser/Thr (Varki, Ajit (2009): Essentials of glycobiology. 2ed. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press).
[0005] Protein glycosylation is a ubiquitous post-translational modification found in all domains of life. There is a significant complexity in animal systems and glycan structures have crucial biological and physiological roles, from contributions in protein folding and quality, control to involvement in a large number of biological events, like recognition, stability, action, and turnover of these molecules (Moremen et al. 2012). Therapeutic
Glycoproteins like monoclonal antibodies, enzymes, and hormones are the major products of the biotechnology industry (Lagasse, H A Daniel et al. 2017; Dimitrov 2012) and the impact of glycan heterogeneity has more and more been recognized as “critical quality attribute”. Of the many properties determining product quality, glycosylation is regarded as even one of the most important ones: influencing the biological activity, serum half-life and immunogenicity of the protein. Glycans are relevant for increased serum circulation times and many of the biologies approved or under development suffer from an insufficient half-life necessitating frequent applications in order to maintain a therapeutic concentration over an extended period of time. Half-life extension strategies are key to allow the generation of long-lasting therapeutics with improved pharmacokinetics (Kontermann 2016). Glycosylation also appears to improve protein solubility and stability, for example, through a reduced propensity for aggregation and leads to increased circulatory lifetimes due to the prevention of proteolytic degradation. Additionally, N-glycans with different terminating monosaccharides can be recognized by lectins leading to their degradation (Blasko et al., 2013; Varki, 2017). Consequently, monitoring and control of glycosylation is critical in biopharmaceutical manufacturing and a requirement of regulatory agencies (Costa et al. 2014; Eon-Duval et al. 2012; Reusch and Tejada 2015). For these reasons, glycoengineering of expression platforms is increasingly recognized as an important strategy to improve biopharmaceuticals in many aspects (Dicker and Strasser 2015).
[0006] Endocytic lectins are involved in receptor-mediated endocytosis by capturing glycosylated proteins via specific glycan structures to mediate degradation (Cummings et al., Cold Spring Harbor Laboratory Press, (2017). Endocytic lectins are ubiquitous in humans and can recognize various glycan structures.
[0007] Carbohydrate binding receptors are highly diverse and can be exploited by glycoengineering to develop novel therapeutics with unprecedented effectiveness for different diseases, including but not limited to: inflammatory, blood disorders, autoimmune and cancer. This allows development of novel therapeutics based on the concept of glycan- mediated protein degradation. Leveraging natural protein degradation through the glycosylation of monoclonal antibodies can lead to novel therapeutics. The present invention shows a novel finding of Leishmania host cells are capable of producing polypeptides comprising a biantennary, GalNAc-terminated N-glycan, specifically A2GalNAc2, which mediates protein degradation.
[0008] The compositions and methods provided herein address the unmet medical need of patients suffering from various difficult to treat diseases such as cancer, autoimmune and
inflammatory diseases, and infectious diseases, treated with glycosylated proteins, such as monoclonal antibodies, and provide related advantages.
5. SUMMARY OF THE INVENTION
[0009] Provided herein are Leishmania host cells, methods of engineering Leishmania host cells, methods of culturing Leishmania host cells, methods of making a polypeptide of interest using a Leishmania host cell, and polypeptides of interest produced by the methods. [0010] Provided herein is a Leishmania host cell comprising: (a) a recombinant nucleic acid encoding a polypeptide of interest; and (b) a recombinant nucleic acid encoding one or more recombinant N-acetylgalactosamine (GalNAc) transferases, or functionally active variants thereof. In certain embodiments, the GalNAc transferase is heterologous to the host cell. In certain embodiments, the GalNAc transferase is p4-GalNAcT3, or a functionally active variant thereof. In certain embodiments, the P4-GalNAcT3 is human p4-GalNAcT3, or a functionally active variant thereof. In certain embodiments, the GalNAc transferases are P4-GalNAcT3 and P4-GalNAcT4, or functionally active variants thereof. In certain embodiments, the P4-GalNAcT3 and P4-GalNAcT4 are human p4-GalNAcT3 and P4- GalNAcT4, or functionally active variants thereof.
[0011] In certain embodiments, the host cell further comprises: (a) a recombinant nucleic acid encoding recombinant UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc; and (b) a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway.
[0012] In certain embodiments, the host cell further comprises: (a) a recombinant nucleic acid encoding a recombinant UDP-GalNAc biosynthetic pathway protein capable of converting UDP-GlcNAc to UDP-GalNAc; and (b) a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway.
[0013] In certain embodiments, the host cell further comprises: (a) a recombinant nucleic acid encoding recombinant UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc; and (b) a recombinant nucleic acid encoding a recombinant UDP-GalNAc biosynthetic pathway protein capable of converting UDP-GlcNAc to UDP-GalNAc; and (c) a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway.
[0014] Also provided herein is a Leishmania host cell comprising (a) a recombinant nucleic acid encoding a polypeptide of interest; (b) a recombinant nucleic acid encoding one or more recombinant N-acetylgalactosamine (GalNAc) transferases, or functionally active variants thereof; and (c) a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway. In certain embodiments, the host cell further comprises one or more recombinant nucleic acids encoding heterologous UDP-GalNAc biosynthetic pathway proteins capable of generating UDP-GalNAc. In certain embodiments, the host cell further comprises (a) a recombinant nucleic acid encoding recombinant UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc; and/or (b) a recombinant nucleic acid encoding a recombinant UDP-GalNAc biosynthetic pathway protein capable of converting UDP-GlcNAc to UDP-GalNAc. In certain embodiments, the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein are co-localized in the secretory pathway. In certain embodiments, the one or more GalNAc transferases and the heterologous UDP- GalNAc transporter protein each independently comprise: (a) a signal peptide localizing the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein in the secretory pathway; and/or (b) a retention sequence retaining the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein in the secretory pathway. In certain embodiments, the one or more GalNAc transferases and the heterologous UDP- GalNAc transporter protein each independently comprise the same signal peptide and/or retention sequence. In certain embodiments, the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein comprise different signal peptides and/or retention sequences. In certain embodiments, the signal peptide of the one or more GalNAc transferases and/or the signal peptide of the heterologous UDP-GalNAc transporter protein are derived from a Leishmania species. In certain embodiments, the retention sequence of the one or more GalNAc transferases and/or the retention sequence of the heterologous UDP- GalNAc transporter protein are derived from a Leishmania species. In certain embodiments, the Leishmania species is Leishmania tarentolae. In certain embodiments, the signal peptide of the one or more GalNAc transferases and/or the signal peptide of the heterologous UDP- GalNAc transporter protein are processed and removed.
[0015] In certain embodiments, the recombinant UDP-GalNAc biosynthetic pathway proteins and/or recombinant UDP-GalNAc transporter protein are heterologous to the host cell.
[0016] In certain embodiments, one or more of the recombinant nucleic acids are integrated into the [ssuPolI] locus of the host cell.
[0017] In certain embodiment, the one or more GalNAc transferases are derived from a mammalian source. In certain embodiment, the GalNAc transferase is derived from a mammalian source. In certain embodiments, the mammalian source is Homo sapiens. In certain embodiments, the one or more GalNAc transferases, or functionally active variants thereof, are capable of catalyzing the addition of a GalNAc to a N-acetyl glucosamine- terminated glycan. In certain embodiments, the GalNAc transferase, or a functionally active variant thereof, is capable of catalyzing the addition of a GalNAc to a N-acetyl glucosamine- terminated glycan. In certain embodiments, the one or more GalNAc transferases are selected from the group consisting of p4-GalNAcT3, p4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or functionally active variants thereof. In certain embodiments, the GalNAc transferase is selected from the group consisting of p4-GalNAcT3, P4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or functionally active variants thereof. In certain embodiments, the one or more GalNAc transferases are selected from the group consisting of P4-GalNAcT3, p4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto. In certain embodiments, the GalNAc transferase is selected from the group consisting of P4-GalNAcT3, p4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto. In certain embodiments, the one or more GalNAc transferases comprise P4-GalNAcT3, or an N- terminally truncated variant thereof. In certain embodiments, the GalNAc transferase is P4- GalNAcT3, or an N-terminally truncated variant thereof. In certain embodiments, the one or more GalNAc transferases comprise p4-GalNAcT3. In certain embodiments, the GalNAc transferase is p4-GalNAcT3. In certain embodiments, the one or more GalNAc transferases comprise an N-terminally truncated variant of P4-GalNAcT3. In certain embodiments, the GalNAc transferase is an N-terminally truncated variant of P4-GalNAcT3. In certain embodiments, the N-terminally truncated variant comprises an amino acid sequence of SEQ ID NO: 2. In certain embodiments, the one or more GalNAc transferases comprise a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to p4-GalNAcT3. In certain embodiments, the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to P4-GalNAcT3. In certain embodiments, the one or more GalNAc transferases
comprise P4-GalNAcT4, or an N-terminally truncated variant thereof. In certain embodiments, the GalNAc transferase is P4-GalNAcT4, or an N-terminally truncated variant thereof. In certain embodiments, the one or more GalNAc transferases comprise P4- GalNAcT4. In certain embodiments, the GalNAc transferase is P4-GalNAcT4. In certain embodiments, the one or more GalNAc transferases comprise an N-terminally truncated variant of P4-GalNAcT4. In certain embodiments, the GalNAc transferase is an N-terminally truncated variant of P4-GalNAcT4. In certain embodiments, the N-terminally truncated variant is comprises an amino acid sequence of SEQ ID NO: 4. In certain embodiments, the one or more GalNAc transferases comprise a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to p4-GalNAcT4. In certain embodiments, the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to p4-GalNAcT4. In certain embodiments, the one or more GalNAc transferases comprise CeP4GalNAcT, or a variant that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto. In certain embodiments, the one or more GalNAc transferases comprise CeP4GalNAcT. In certain embodiments, the one or more GalNAc transferases comprise Ptp4GalNAcT, or a variant that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto. In certain embodiments, the one or more GalNAc transferases comprise Ptp4GalNAcT.
[0018] In certain embodiments, the recombinant nucleic acid encodes at least two GalNAc transferases. In certain embodiments, the at least two GalNAc transferases are different GalNAc transferases. In certain embodiments, the at least two GalNAc transferases are selected as a combination of GalNAc transferases listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the at least two GalNAc transferases are selected from the group consisting of p4-GalNAcT3, p4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto. In certain embodiments, the at least two GalNAc transferases are human p4-GalNAcT3 and human P4- GalNAcT4; or human p4-GalNAcT3 and CeP4GalNAcT; or human p4-GalNAcT3 and Ptp4GalNAcT; or functionally active variants thereof.
[0019] In certain embodiments, the recombinant nucleic acid encoding one or more GalNAc transferases comprises a first open reading frame (ORF) encoding a first GalNAc
transferase and a second ORF encoding a second GalNAc transferase. In certain embodiments, the first ORF encoding the first GalNAc transferase and the second ORF encoding the second GalNAc transferase are integrated into the host cell in the same genetic module. In certain embodiments, the first ORF encoding the first GalNAc transferase and the second ORF encoding the second GalNAc transferase are integrated into the host cell in separate genetic modules. In certain embodiments, the first ORF encoding the first GalNAc transferase and the second ORF encoding the second GalNAc transferase are integrated into the [ssuPolI] locus of the host cell. In certain embodiments, the first and the second GalNAc transferases are different GalNAc transferases. In certain embodiments, the first and the second GalNAc transferases are selected as a combination of GalNAc transferases listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the first and the second GalNAc transferases are human p4-GalNAcT3 and human p4-GalNAcT4, respectively; or human p4-GalNAcT3 and CeP4GalNAcT, respectively; or human P4- GalNAcT3 and Ptp4GalNAcT, respectively; or functionally active variants thereof.
[0020] In certain embodiments, the host cell comprises a recombinant nucleic acid encoding one or more additional recombinant glycosyltransferases. In certain embodiments, the additional recombinant glycosyltransferase is heterologous to the host cell. In certain embodiments, the additional recombinant glycosyltransferase comprises one or more N- acetyl glucosamine transferases. In certain embodiments, the N-acetyl glucosamine transferase is selected from the group consisting of MGAT1 and MGAT2, or functionally active variants thereof. In certain embodiments, the additional recombinant glycosyltransferase comprises MG ATI and MGAT2.
[0021] In certain embodiments, the host cell is capable of producing polypepetides comprising a biantennary, GalNAc-terminated N-glycan. In certain embodiments, the host cell is capable of producing polypeptides comprising an N-glycan of the following structure:
wherein the black square represents an N-acetyl galactosamine (GalNAc), the white square represents an N-acetylglucosamine (GlcNAc) residue and the black circle represents a mannose (Man) residue, and wherein X represents an amino acid residue of the polypeptide of interest. In certain embodiments, the host cell attaches the N-glycan to an N-glycosylation site of the polypeptide. In certain embodiments, the amino acid residue is Asn. In certain embodiments, the N-glycosylation site comprises a consensus sequence of N-X-S/T or N-X- C, wherein X is any amino acid except proline.
[0022] In certain embodiments, one or more endogenous enzymes from the glycan biosynthesis pathway have been deleted, mutated and/or functionally inactivated. In certain embodiments, the host cell does not have endogenous N-glycan elongation. In certain embodiments, the host cell has been genetically engineered such that the formation of an O- linked GlcNAc on a polypeptide in the host cell is reduced or eliminated. In certain embodiments, the formation of O-linked GlcNAc in the Leishmania cell prior to genetic engineering is catalyzed by at least one N-acetylglucosamine (GlcNAc)-transferase. In certain embodiments, the gene encoding the at least one GlcNAc-transferase is functionally inactivated, downregulated, deleted, or mutated. In certain embodiments, the formation of the O-linked GlcNAc is reduced by at least 5%, 7%, 10%, 12%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% from the formation of the O-linked GlcNAc in a reference Leishmania cell. In certain embodiments, the at least one GlcNAc-transferase is selected from the group consisting of OGNT1, OGNT2 and OGNTL, and homologous GlcNAc-transferases thereof. In certain embodiments, the host cell is a OGNT1, OGNT2 and OGNTL triple knockout.
[0023] In certain embodiments, the host cell further comprises a recombinant nucleic acid encoding heterologous UDP-GalNAc biosynthetic pathway proteins capable of generating UDP-GalNAc. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins are capable of converting GalNAc to UDP-GalNAc. In certain
embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc are derived from a mammalian source. In certain embodiments, the mammalian source is Homo sapiens. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP-N-acetyl hexosamine pyrophosphorylase (UAP1), or a functionally active variant thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP- N-acetyl hexosamine pyrophosphorylase (UAP1), or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP- N-acetyl hexosamine pyrophosphorylase (UAP1). In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise N-acetyl galactosamine kinase (GALK2), or a functionally active variant thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise N-acetyl galactosamine kinase (GALK2), or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the heterologous UDP- GalNAc biosynthetic pathway proteins comprise N-acetyl galactosamine kinase (GALK2). In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins are capable of converting UDP-GlcNAc to UDP-GalNAc. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins capable of converting UDP- GlcNAc to UDP-GalNAc are derived from a mammalian source. In certain embodiments, the mammalian source is Homo sapiens. In certain embodiments, the heterologous UDP- GalNAc biosynthetic pathway proteins comprise hGalE, or a functionally active variant thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway protein comprise hGalE, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise hGalE. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins capable of converting UDP-GlcNAc to UDP-GalNAc are derived from a bacterial source. In certain embodiments, the bacterial source is Campylobacter jejuni. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise CjGne, or a functionally active variant thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise CjGne, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise CjGne.
[0024] In certain embodiments, the host cell further comprises a recombinant nucleic acid encoding a heterologous UDP-GalNAc transporter protein capable of transporting UDP- GalNAc to the secretory pathway. In certain embodiments, the heterologous UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is derived from a nematode source, a mammalian source, a brachiopod source, a chordate source, choanoflagellate source, a gyrista source, a fungi source, a mollusk source, or a placozoan source. In certain embodiments, the heterologous UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is derived from a nematode source. In certain embodiments, the nematode source is C. elegans,' the mammalian source is Homo sapiens,' the brachiopod source is Lingula unguis,' the chordate source is Parambassis ranga, Geotrypetes seraphini, or Scophthalmus maximus,' the choanoflagellate source is Salpingoeca rosetta, the gyrista source is Fragilariopsis cylindrus,' the fungi source is Dentipellis fragilis,' the mollusk source is Octopus bimaculoides; and/or the placozoan source is trichoplax sp. H2. In certain embodiments, the nematode source is C. elegans. In certain embodiments, the heterologous UDP-GalNAc transporter protein is CeC03H5.2, or a functionally active variant thereof. In certain embodiments, the heterologous UDP-GalNAc transporter protein is CeC03H5.2, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the heterologous UDP- GalNAc transporter protein is CeC03H5.2. In certain embodiments, the heterologous UDP- GalNAc transporter protein is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to CeC03H5.2. In certain embodiments, the heterologous UDP-GalNAc transporter protein is GnF, GnG, GnH, GnI, or GnJ. In certain embodiments, the heterologous UDP-GalNAc transporter protein is UGTREL7, or a functionally active variant thereof. In certain embodiments, the heterologous UDP-GalNAc transporter protein is UGTREL7, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the heterologous UDP-GalNAc transporter protein is UGTREL7. In certain embodiments, the heterologous UDP-GalNAc transporter protein is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to UGTREL7. In certain embodiments, the heterologous UDP-GalNAc transporter protein is GnL, GnM, GnN, or GnO.
[0025] In certain embodiments, the recombinant nucleic acid encodes at least two heterologous UDP-GalNAc transporter proteins. In certain embodiments, the recombinant nucleic acid encodes two copies of the same heterologous UDP-GalNAc transporter protein.
In certain embodiments, the recombinant nucleic acid encodes two different heterologous UDP-GalNAc transporter proteins. In certain embodiments, the heterologous UDP-GalNAc transporter proteins are selected as a combination of heterologous UDP-GalNAc transporters listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2, GnF, GnG, GnH, GnI, GnJ, UGTREL7, GnL, GnM, GnN, or GnO, or functionally active variants thereof. In certain embodiments, the heterologous UDP-GalNAc transporter proteins comprise CeC03H5.2. In certain embodiments, the heterologous UDP- GalNAc transporter protein is CeC03H5.2. In certain embodiments, the heterologous UDP- GalNAc transporter proteins are CeC03H5.2 and GnJ.
[0026] In certain embodiments, the recombinant nucleic acid encoding a heterologous UDP-GalNAc transporter comprises a first ORF encoding a first heterologous UDP-GalNAc transporter and a second ORF encoding a second heterologous UDP-GalNAc transporter. In certain embodiments, the first ORF encoding the first heterologous UDP-GalNAc transporter and the second ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module. In certain embodiments, the first ORF encoding the first heterologous UDP-GalNAc transporter and the second ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in separate genetic modules. In certain embodiments, the first ORF encoding the first heterologous UDP-GalNAc transporter and the second ORF encoding the second heterologous UDP- GalNAc transporter are integrated into the [ssuPolI] locus of the host cell. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter are selected as a combination of heterologous UDP-GalNAc transporters listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter proteins are the same UDP-GalNAc transporter protein. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter proteins are each CeC03H5.2. In certain embodiments, the first and the second heterologous UDP- GalNAc transporter proteins are different UDP-GalNAc transporter proteins. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter proteins are CeC03H5.2 and GnJ, respectively.
[0027] In certain embodiments, the recombinant nucleic acids encode at least two GalNAc transferases and at least two heterologous UDP-GalNAc transporter proteins. In certain embodiments, the at least two GalNAc transferases are different. In certain embodiments, the recombinant nucleic acids encode two copies of the same heterologous UDP-GalNAc transporter protein. In certain embodiments, the recombinant nucleic acids encode two different heterologous UDP-GalNAc transporter proteins. In certain embodiments, the at least two GalNAc transferases and at least two heterologous UDP- GalNAc transporter proteins are selected as a combination of GalNAc transferases and heterologous UDP-GalNAc transporter proteins listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof In certain embodiments, the recombinant nucleic acids encode human P4-GalNAcT3, CeP4GalNAcT, CeC03H5.2, and GnJ. In certain embodiments, the recombinant nucleic acids encode human p4-GalNAcT3, Ptp4GalNAcT, and CeC03H5.2. [0028] In certain embodiments, the host cell is such that (a) the recombinant nucleic acid encoding one or more GalNAc transferases comprises a first ORF encoding a first GalNAc transferase and a second ORF encoding a second GalNAc transferase; and (b) b. the recombinant nucleic acid encoding a heterologous UDP-GalNAc transporter comprises a third ORF encoding a first heterologous UDP-GalNAc transporter and a fourth ORF encoding a second heterologous UDP-GalNAc transporter. In certain embodiments, the host cell is such that (a) the first open reading frame (ORF) encoding the first GalNAc transferase and and the third ORF encoding the first heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module; and/or (b) the second open reading frame (ORF) encoding the second GalNAc transferase and and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module. In certain embodiments, the host cell is such that (a) the first ORF encoding the first GalNAc transferase and the second ORF encoding the second GalNAc transferase are integrated into the host cell in separate genetic modules; and/or (b) the third ORF encoding the first heterologous UDP-GalNAc transporter and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in separate genetic modules. In certain embodiments, the first ORF encoding the first GalNAc transferase, the second ORF encoding the second GalNAc transferase, the third ORF encoding the first heterologous UDP-GalNAc transporter, and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in the same
genetic module. In certain embodiments, the first ORF encoding the first GalNAc transferase, the second ORF encoding the second GalNAc transferase, the third ORF encoding the first heterologous UDP-GalNAc transporter, and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the [ssuPolI] locus of the host cell. In certain embodiments, the first and the second GalNAc transferases are different GalNAc transferases. In certain embodiments, the first and the second heterologous UDP- GalNAc transporter proteins are the same UDP-GalNAc transporter protein. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter proteins are different UDP-GalNAc transporter proteins. In certain embodiments, the first GalNAc transferase, the second GalNAc transferase, the first heterologous UDP-GalNAc transporter protein, and the second heterologous UDP-GalNAc transporter protein are selected as a combination of GalNAc transferases and heterologous UDP-GalNAc transporter proteins listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the first and the second GalNAc transferases are human p4-GalNAcT3 and CeP4GalNAcT, respectively; and the first and the second heterologous UDP-GalNAc transporter proteins are CeC03H5.2, and GnJ, respectively. In certain embodiments, the first and the second GalNAc transferases are human p4-GalNAcT3 and Ptp4GalNAcT, respectively; and the first and the second heterologous UDP-GalNAc transporter proteins are each CeC03H5.2.
[0029] In certain embodiments, the one or more GalNAc transferases and the polypeptide of interest are co-localized in the secretory pathway. In certain embodiments, the GalNAc transferase and the polypeptide of interest are co-localized in the secretory pathway. In certain embodiments, the one or more GalNAc transferases and the additional recombinant glycosyltransferase are co-localized in the secretory pathway. In certain embodiments, the GalNAc transferase and the additional recombinant glycosyltransferase are co-localized in the secretory pathway. In certain embodiments, the one or more GalNAc transferases each independently comprise a signal peptide localizing the one or more GalNAc transferases in the secretory pathway. In certain embodiments, the one or more GalNAc transferases each independently comprise a retention sequence retaining the one or more GalNAc transferases in the secretory pathway. In certain embodiments, the GalNAc transferase comprises a signal peptide localizing the GalNAc transferase in the secretory pathway. In certain embodiments, the additional recombinant glycosyltransferase comprises a signal peptide localizing the additional recombinant glycosyltransferase in the secretory pathway. In certain
embodiments, the additional recombinant glycosyltransferase comprises a retention sequence retaining the additional recombinant glycosyltransferase in the secretory pathway. In certain embodiments, the signal peptide is added to an N-terminally truncated variant of the GalNAc transferase and/or the additional recombinant glycosyltransferase. In certain embodiments, the retention sequence is added to an N-terminally truncated variant of the GalNAc transferase and/or the additional recombinant glycosyltransferase. In certain embodiments, the polypeptide of interest comprises a signal peptide localizing the polypeptide of interest to the secretory pathway and/or a retention sequence retaining the polypeptide of interest in the secretory pathway. In certain embodiments, the signal peptide and/or the retention sequence is derived from Leishmania species. In certain embodiments, the signal peptide is derived from Leishmania tarentolae. In certain embodiments, the signal peptide is an invertase signal peptide from derived from Leishmania tarentolae. In certain embodiments, the signal peptide is processed and removed.
[0030] In certain embodiments, the host cell is a Leishmania tarentolae host cell. In certain embodiments, culturing the Leishmania host cell produces a composition of the polypeptide of interest, wherein said composition of the polypeptide of interest comprises an N-glycan of the following structure:
wherein the black square represents an N-acetyl galactosamine (GalNAc), the white square represents an N-acetylglucosamine (GlcNAc) residue and the black circle represents a mannose (Man) residue, and wherein X represents an amino acid residue of the polypeptide of interest. In certain embodiments, the host cell is stable to passaging and/or continuous fermentation for 100 or more generations.
[0031] In certain embodiments, the host cell is any one of the strains listed in Table 3 or
Table 9
5.1 Definitions
[0032] As used herein and unless otherwise indicated, the term “about,” when used in conjunction with a number, refers to any number within ±1, ±5 or ±10% of the referenced number.
[0033] As used herein and unless otherwise indicated, the term “subject” refers to an animal (e.g., birds, reptiles, and mammals). In another embodiment, a subject is a mammal including a non-primate (e.g., a camel, donkey, zebra, cow, pig, horse, goat, sheep, cat, dog, rat, and mouse) and a primate (e.g., a monkey, chimpanzee, and a human). In certain embodiments, a subject is a non-human animal. In some embodiments, a subject is a farm animal or pet (e.g., a dog, cat, horse, goat, sheep, pig, donkey, or chicken). In a specific embodiment, a subject is a human. The terms “subject” and “patient” may be used herein interchangeably.
[0034] As used herein and unless otherwise indicated, the term “effective amount,” in the context of administering a therapy (e.g, a composition described herein) to a subject refers to the amount of a therapy which has a prophylactic and/or therapeutic effect(s). In certain embodiments, an “effective amount” refers to the amount of a therapy which is sufficient to achieve one, two, three, four, or more of the following effects: (i) reduce or ameliorate the severity of a disease/disorder or symptom associated therewith; (ii) reduce the duration of a disease/disorder or symptom associated therewith; (iii) prevent the progression of a disease/disorder or symptom associated therewith; (iv) cause regression of a disease/disorder or symptom associated therewith; (v) prevent the development or onset of a disease/disorder, or symptom associated therewith; (vi) prevent the recurrence of a disease/disorder or symptom associated therewith; (vii) reduce organ failure associated with a disease/disorder; (viii) reduce hospitalization of a subject having a disease/disorder; (ix) reduce hospitalization length of a subject having a disease/disorder; (x) increase the survival of a subject with a disease/disorder; (xi) eliminate a disease/disorder in a subject; and/or (xii) enhance or improve the prophylactic or therapeutic effect(s) of another therapy.
[0035] As used herein and unless otherwise indicated, proteins referred to herein as “colocalized in the secretory pathway” have at least partially overlapping subcellular distribution in the secretory pathway, for example in the endoplasmic reticulum or Golgi apparatus. In certain embodiments, the subcellular distribution of one protein referred to herein as “colocalized in the secretory pathway” with another protein is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%
overlapping with with the subcellular distribution of the other protein. Without being bound by theory, in certain embodiments, the overlapping subcellular distribution of two or more proteins referred to herein as “co-localized in the secretory pathway” may be attributed to a signal peptide localizing and/or a retention sequence retaining the two or more proteins in the secretory pathway, for example in the endoplasmic reticulum or Golgi apparatus.
' Mx: number (x) of residues within the oligomannose series; Ax: number (x) of antennae; F: core fucose; Gx: number (x) of galactoses; S: number (x) of sialic acids. Note: Linkage information is given in () parentheses if applicable, e.g. A2G1S1(6) - a2-6 linked sialic acid. Brackets [x] before G or GalNAc indicate which arm of the mannosyl core is galactosylated e.g. [3] G1 indicates that the galactose is on the antenna of the al-3 mannose. 2This typically with IgG associated naming system indicates the presence of core fucose (F), the number of galactoses (G) and the presence of biantennary glycans. It is limited in the number of structures and linkages it can describe but is often used for simplicity. 3 black circle represents mannose (Man), white square is N-acetyl glucosamine (GlcNAc), black square is N-acetyl galactosamine (GalNAc), white circle is galactose (Gal), white diamond is sialic acid, N-acetyl neuraminic acid (Neu5Ac) and white triangle is fucose (Fuc).
6. BRIEF DESCRIPTION OF THE FIGURES
[0036] FIG. 1 depicts the general pathways of UDP-GlcNAc, UDP-GalNAc and UDP- Gal biosynthesis. The enzymes involved in each step are shown besides the arrows. Galactokinase (GK), UDP-sugar pyrophosphorylase (USP), UDP -galactose 4-epimerase (GalE), hexokinase (HXK), phosphoglucomutase (PGM) and UDP-glucose pyrophosphorylase (UGP) are identified in Leishmania tarentolae genome and presumed biosynthetic steps are indicated with black arrows. Enzymes not being present in L. tarentolae genome are shown in italics with biosynthesis steps shown as dashed arrows: N- acetylglucosamine kinase (NAGK), human UDP -galactose 4-epimerase (hGalE), Campylobacter jejuni UDP-GlcNAc/Glc 4-epimerase (CjGne), N-acetyl galactosamine kinase (GALK2), UDP -N-acetyl hexosamine pyrophosphorylase (UAP1), Beta-1, 4-N- acetylgalactosaminyltransferase T3 (|34-GalNAcT3), Beta-1,4-N- acetylgalactosaminyltransferase T4 (|34-GalNAcT4), and Beta- 1,4-galactosyltransferase 1 (P4GalTl). These enzymes or transferases chosen for recombinant expression are shown in italics, bold and underlined. The resulting biantennary glycan structure attached to a N-X- S/T polypeptide site is shown, with black circle representing mannose (Man), white square
representing N-acetyl glucosamine (GlcNAc), black square representing N-acetyl galactosamine (GalNAc), and white circle representing galactose (Gal).
[0037] FIG. 2 depicts UDP-GalNAc biosynthetic pathways and GalNAc-transferases for engineering host cells. The enzymatic activities are shown besides the arrows. Human UDP- galactose 4-epimerase (hGalE), Campylobacter jejuni UDP-GlcNAc/Glc 4-epimerase (CjGne), N-acetyl galactosamine kinase (GALK2), UDP-N-acetyl hexosamine pyrophosphorylase (UAP1), Beta-l,4-N-acetylgalactosaminyltransferase T3 (|34-GalNAcT3), Beta-l,4-N-acetylgalactosaminyltransferase T4 (|34-GalNAcT3), and Beta-1,4- N-acetyl galactosaminyltransferase (CeGalNAcT). The enzymes or transferases chosen for recombinant expression are shown in italics, bold and underlined. The N-glycan is depicted with black circle representing mannose (Man), white square representing N-acetyl glucosamine (GlcNAc), and black square representing N-acetyl galactosamine (GalNAc). [0038] FIG. 3A depicts UDP-GalNAc measurements in Leishmania tarentolae. A standard containing UDP-GalNAc and UDP-GlcNAc is indicated with sold grey line, L. tarentolae wt extract is shown as solid black line, and the same extract spiked with UDP- GalNAc and UDP-GlcNAc standard in a High performance anion exchange chromatography coupled with pulsed amperometric detection (HPAEC-PAD) measurement is shown as dotted black line.
[0039] FIG. 3B depicts UDP-GalNAc measurement of engineered Leishmania tarentolae host cells containing recombinant proteins for UDP-GalNAc biosynthetic pathways.
Different cell lines contain different combinations of recombinant enzymes for the different UDP-GalNAc biosynthetic pathways, for example Transporter +Salvage + Epimerase “TSE”; or Transporter + Salvage (“TS”); or Transporter-i- Epimerization (“TE”) with genetic constructs of coding sequences spaced by different intergenic regions derived from Leishmania major (J, AC vs. Y, Z) and different site-specific integration loci (pfr vs. aTub). Only two strains StCGP2805 and St2848, shown with black and black dashed lines respectively, were supplemented with lOmM GalNAc to the growth medium and UDP- GalNAc peaks were detected. This indicates that the salvage pathway is active when supplemented with GalNAc during growth. Additionally, the epimerization pathway alone (StCGP2807) or in combination with salvage pathway such as StCGP2801, 2803, 2847, which were not fed with GalNAc during growth, did not generate measurable amounts of UDP-GalNAc, or if at all at very low levels.
[0040] FIG 4A depicts the recombinant pathway engineered in Leishmania tarentolae strain StCGP2879.
[0041] FIG. 4B depicts high levels of A2GalNAc2 N-glycans produced by engineered Leishmania tarentolae StCGP2879 containing UDP-GalNAc biosynthetic pathways and GalNAc-transferases. Strain StCGP2879 secreting adalimumab antibody was analyzed for its N-glycan composition on its Fab and Fc glycosites. Fab glycosites show 80% A2GalNAc2 N-glycans analyzed by HILIC-UPLC-MS (Top) and N297 canonical Fc glycosite show the main N-glycan A2 (bottom). The N-glycan structure is shown with black circle representing mannose (Man), white square representing N-acetyl glucosamine (GlcNAc), and black square representing N-acetyl galactosamine (GalNAc).
[0042] FIG. 5 depicts a flowchart of CGP engineered host cell lines. The left panel indicates the main N-glycan (M3, A2 or A2GalNAc2) for the strains listed on the right. Strains are in bold. Arrows show the genetic modification step with brief description of the genetic module in italics along with the selection marker, and with the genomic integration locus in brackets. Intergenic regions (IRs) are indicated where relevant. Boxes at the bottom show the quantitative content of A2GalNAc2 on adalimumab (“Fab glycosite”) or endogenous surface glycoproteins (“cell surface”), andn.d. means not determined for respective strain.
[0043] FIG. 6 depicts another flowchart of CGP engineered host cell lines. The left panel indicates the main N-glycan (M3, A2 or A2GalNAc2) for the strains listed on the right.
Strains are in bold. Arrows show the genetic modification step with brief description of the genetic module in italics along with the selection marker, and with the genomic integration locus in brackets. Dashed arrows represent the intended integration of polypeptide of interest or mAb expression modules.
[0044] FIG. 7A depicts N-glycan traces of Fab part of Adalimumab (K84N/D86N) secreted from StCGP3127 CGP engineered host cell lines. N-glycans (A2, A2GalNacl and A2GalNAc2) were analyzed by HILIC-UPLC-MS from Adalimumab (K84N/D86N) in strain StCGP3127, which was derived from StCGP3053 (OGNT+). Adalimumab was cleaved with IdeZ, and the resulting subunits to F(ab’)2 and Fc/2 separated by SDS-PAGE, released by PNGaseF and procainamide labelled. The N-glycan structure is shown with black circle representing mannose (Man), white square representing N-acetyl glucosamine (GlcNAc), and black square representing N-acetyl galactosamine (GalNAc).
[0045] FIG. 7B depicts N-glycan traces of Fab part of Adalimumab (K84N/D86N) secreted from StCGP3220 CGP engineered host cell lines. N-glycans (A2, A2GalNacl and
A2GalNAc2) were analyzed by HILIC-UPLC-MS from Adalimumab (K84N/D86N) from StCGP3220, which was derived from strain StCGP3169 (OGNT triple deletion mutant). Adalimumab was cleaved with IdeZ, and the resulting subunits to F(ab’)2 and Fc/2 separated by SDS-PAGE, released by PNGaseF and procainamide labelled. The N-glycan structure is shown with black striped circle representing mannose (Man), white square representing N- acetyl glucosamine (GlcNAc), and black square representing N-acetyl galactosamine (GalNAc).
[0046] FIG. 8A depicts N-glycan traces of Fab part of mAb 5C9 (D86N) secreted from CGP engineered host cell lines. FIG. 8B depicts N-glycan traces of Fab part of mAb 1 lk2 (D86N) secreted from the same CGP engineered host cell lines. N-glycans (A2, A2GalNAcl and A2GalNAc2) were analyzed by HILIC-UPLC from two different IgG4 antibodies, containing engineered glycosite at LC, D86N. The same position of the glycosite within the Framework Region (FR) 3 in the light chain variable domain of the different antibodies show varying degrees of A2GalNAc2 content, when expressed and secreted from the same parental cell line, namely StCGP3169. N-glycans were analyzed from reduced LC, which was separated by SDS-PAGE, released by PNGaseF and procainamide labelled. The N-glycan structure is shown with black circle representing mannose (Man), white square representing N-acetyl glucosamine (GlcNAc), and black square representing N-acetyl galactosamine (GalNAc).
[0047] FIG. 9A depicts N-glycan distribution (%) of surface glycoproteins derived from CGP engineered host cell lines encoding different GalNAc transferases. FIG. 9B depicts N- glycan distribution (%) of mAb Adalimumab (K84N/D86N) derived from CGP engineered host cell lines encoding different GalNAc transferases. FIG. 9C depicts N-glycan distribution (%) of mAb 1 lk2 (S84N/D86N) derived from CGP engineered host cell lines encoding different GalNAc transferases. N-glycans (A2, A2GalNAcl and A2GalNAc2) were analyzed by HILIC-UPLC and quantified, from cell surface glycoprotein of the empty parental strains and from two different mAbs, glycan distribution derived from the Fab of Adali (K84N/D86N), and total N-glycans (“in solution”, includes Fc N297 site) of 1 lk2 (S84N/D86N). The different GalNAc transferases from the parental different parental strains are indicated at the bottom of the corresponding graphs, indicating varying efficiency in A2GalNAcl and A2GalNAc2 conversion on different native (cell surfaces glycoproteins) or engineered glycosite on the different mAbs.
[0048] FIG. 10A depicts a flowchart of engineered host cell lines testing different UDP- GalNAc transporter CeC03H5.2 and selected homologs GnF, GnG, GnH, GnI and GnJ
(Table 10) in the StCGP4334 parental cell line background. StCGP4334 contains a GalNAc synthesis module with salvage and epimerization enzymes (“S+E”) and the HsGalNAcT3 transferase, integrated into the ssu-PolI genomic locus; and Adalimumab (K84N/D86N). The left panel indicates the main N-glycan (M3, A2 or A2GalNAc2) for the strains listed on the right. Strain designations are in bold. Arrows show the genetic modification step with brief description of the genetic module in italics along with the selection marker, and with the genomic integration locus in brackets.
[0049] FIG. 10B depicts a flowchart of engineered host cell lines testing different UDP- GalNAc transporter UGTREL7 and selected homologs GnL, GnM, GnN and GnO (Table 11) in the StCGP4334 parental cell line background. StCGP4334 contains a GalNAc synthesis module with salvage and epimerization enzymes (“S+E”) and the HsGalNAcT3 transferase, integrated into the ssu-PolI genomic locus; and Adalimumab (K84N/D86N). The left panel indicates the main N-glycan (M3, A2 or A2GalNAc2) for the strains listed on the right. Strain designations are in bold. Arrows show the genetic modification step with brief description of the genetic module in italics along with the selection marker, and with the genomic integration locus in brackets.
[0050] FIG. 11 depicts A2GalNAc2 N-glycans in % produced by engineered Leishmania tarentolae StCGP4334 (parental cell line) and cell lines modified with putative UDP-GalNAc transporters (indicated in parentheses in the following). Left Panel: Strains StCGP5003 (+CeC03H5.2), StCGP5006 (+GnF), StCGP5007 (+GnG), StCGP5010 (+GnH), StCGP5012 (with GnI), and StCGP5013(+GnJ). Right Panel: Strains StCGP5016 (+UGTREL7), StCGP5017 (+GnL), StCGP5049 (+GnM), StCGP5019 (+GnN), and StCGP5021(+GnO). These cell lines, each secreting Adalimumab (K84N/D86N), were analyzed for the N-glycan composition on the Fab glycosites. Bars represent N-glycan composition in % of A2, A2GalNAcl and A2GalNAc2, released from Adalimumab Fab glycosites and analyzed by HILIC-UPLC-MS.
[0051] FIG. 12 depicts a flowchart of engineered host cell lines testing UDP-GalNAc transporter homologs in the StCGP4106 parental cell line background, that already contains Adalimumab (K84N/D86N) by introducing a combined module that contains the UDP- GalNAc biosynthesis pathway (T+S+E), where T is the designated GalNAc transporter or homolog (either CeC03H5.2, GnF, GnJ or GnM, respectively) along with the PtGalNAc transferase. The left panel indicates the main N-glycan (M3, A2 or A2GalNAc2, respectively) for the strains listed on the right. Strain designations are in bold. Arrows show
the genetic modification step with brief description of the genetic module in italics along with the selection marker, and with the genomic integration locus in brackets.
[0052] FIG. 13 depicts A2GalNAc2 N-glycans in %, produced by engineered Leishmania tarentolae StCGP4978, StCGP5351, StCGP5352, and StCGP5694 expressing putative UDP-GalNAc transporters, the PtGalNAcT transferase and each of them secreting Adalimumab (K84N/D86N). Fab glycosites were evaluated after Protein A purification for the N-glycan composition and bars represent N-gly can % of A2, A2GalNAcl and A2GalNAc2, released from Adalimumab Fab glycosites and analyzed by HILIC-UPLC-MS. [0053] FIG. 14 shows the flowchart of engineering entry host cell lines StCGP5359 and StCGP5942. The left panel indicates the main N-glycan (M3, A2 or A2GalNAc2, respectively) for the strains listed on the right. Strain designations are in bold. Arrows show the genetic modification step with brief description of the genetic module in italics along with the selection marker, and with the genomic integration locus in brackets. Dashed arrow indicates that any polypeptide (“target proteins”, mAbs, Ab scaffolds, etc.) containing N- glycosylation consensus site(s) can be introduced in described host cell lines to produce polypeptides comprising a biantennary, GalNAc-terminated N-glycan, specifically A2GalNAc2, which mediates protein degradation.
[0054] FIG. 15 shows A2GalNAc2 N-glycans analyzed by HILIC-UPLC-MS (Top Panel) and quantified in % (Bottom Panel), from engineered Leishmania tarentolae StCGP6044, expressing a VHH containing a C-terminal glycotag, which is a peptide stretch harboring a N-glycosylation consensus site N-X-S/T. StCGP6044 is a representative for the performance of entry cell line StCGP5359, which does not express a target polypeptide. StCGP6044 was continuously passaged for 37 and 66 generations, respectively, without addition of any selection pressure. VHH was affinity -purified for N-glycan analysis and bars represent N-glycan % of A2, A2GalNAcl and A2GalNAc2, released from purified protein (Graph at Bottom Panel).
[0055] FIG. 16 shows A2GalNAc2 N-glycans analyzed by HILIC-UPLC-MS (Top Panel) and quantified in % (Bottom Panel), from engineered Leishmania tarentolae StCGP6631, expressing a VHH containing a C-terminal glycotag, which is a peptide stretch harboring a N-glycosylation consensus site N-X-S/T. StCGP663 l is a representative for the performance of entry cell line StCGP5942, which does not express a target polypeptide. StCGP6631 was continuously passaged for 35 and 63 generations, respectively, without addition of any selection pressure. VHH was affinity -purified for N-glycan analysis and bars
represent N-glycan % of A2, A2GalNAcl and A2GalNAc2, released from purified protein (Graph at Bottom Panel).
7. DETAILED DESCRIPTION OF THE INVENTION
[0056] The present invention relates to Leishmania host cells, methods of engineering Leishmania host cells, methods of culturing Leishmania host cells, methods of making a polypeptide of interest using a Leishmania host cell, and polypeptides of interest produced by the methods described herein.
7.1 Leishmania Host Cells
[0057] Provided herein are Leishmania host cells comprising: (a) a recombinant nucleic acid encoding a polypeptide of interest; and (b) a recombinant nucleic acid encoding one or more recombinant N-acetylgalactosamine (GalNAc) transferases. In certain embodiments, the Leishmania host cells provided herein are capable of producing polypeptides comprising a biantennary, GalNAc-terminated N-glycan. In particular, the Leishmania host cells provided herein are capable of producing polypeptides comprising an N-glycan of the following structure:
wherein the black square represents an N-acetyl galactosamine (GalNAc), the white square represents an N-acetylglucosamine (GlcNAc) residue and the black circle represents a mannose (Man) residue, and wherein X represents an amino acid residue of the polypeptide of interest.
[0058] In certain embodiments, the Leishmania host cells provided herein comprise a recombinant nucleic acid encoding one or more recombinant N-acetylgalactosamine (GalNAc) transferases described in Section 7.1.1. In certain embodiments, the Leishmania host cells provided herein comprise a recombinant nucleic acid encoding one or more additional recombinant glycosyltransferases described in Section 7.1.2. In certain
embodiments, one or more endogenous enzymes described in Section 7.1.3 from the glycan biosynthesis pathway of the the Leishmania host cells provided herein have been deleted, mutated and/or functionally inactivated. In certain embodiments, the Leishmania host cells provided herein further comprise a recombinant nucleic acid encoding heterologous UDP- GalNAc biosynthetic pathway proteins as described in Section 7.1.4 capable of generating UDP-GalNAc. In certain embodiments, the Leishmania host cells provided herein comprise a recombinant nucleic acid encoding a heterologous UDP-GalNAc transporter protein as described in Section 7.1.5 capable of transporting UDP-GalNAc to the secretory pathway. In certain embodiments, the strain of the Leishmania host cells provided herein is described in Section 7.1.6. In certain embodiments, the Leishmania host cells provided herein below are genetically engineered using the methods described in Section 7.2. In certain embodiments, the Leishmania host cells provided herein below are cultured according to the methods described in Section 7.3. In certain embodiments, the Leishmania host cells provided herein may be used as an expression system as described in Section 7.4. In certain embodiments, the Leishmania host cells provided herein may be used to make a polypeptide of interest as described in Section 7.5.
7.1.1 N-Acetylgalactosamine (GalNAc) Transferases
[0059] The Leishmania host cells provided herein comprise a recombinant nucleic acid encoding one or more recombinant N-acetylgalactosamine (GalNAc) transferases. In certain embodiments, the GalNAc transferase, or a functionally active variant thereof, is capable of catalyzing the addition of a GalNAc to a N-acetyl glucosamine-terminated glycan.
[0060] In certain embodiments, the GalNAc transferase is heterologous to the Leishmania host cell. In certain embodiments, the GalNAc transferase is derived from Homo sapiens, Caenorhabditis elegans, Parasteatoda lepidarionim, Salmo Irulla, or Hucho hucho. In certain embodiments, the GalNAc transferase is derived from a mammalian source. In certain embodiments, the mammalian source is Homo sapiens.
[0061] In certain embodiments, the GalNAc transferase is selected from the group consisting of P4-GalNAcT3, [34-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or functionally active variants thereof. In certain embodiments, the GalNAc transferase is selected from the group consisting of P4-GalNAcT3, P4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
[0062] In certain embodiments, the GalNAc transferase comprises P4-GalNAcT3, or a functionally active variant thereof. In certain embodiments, the GalNAc transferase comprises P4-GalNAcT3. In certain embodiments, the GalNAc transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to P4-GalNAcT3. In certain embodiments, the GalNAc transferase comprises an N-terminally truncated variant of P4-GalNAcT3. In certain embodiments, the P4-GalNAcT3 comprises P4-GalNAcT3 of Homo sapiens, or a functionally active variant thereof. In certain embodiments, the GalNAc transferase comprises P4-GalNAcT3 of Homo sapiens. In certain embodiments, the GalNAc transferase comprises an amino acid sequence of SEQ ID NO: 1. In certain embodiments, the GalNAc transferase comprises one that is homologous to P4-GalNAcT3 of Homo sapiens. In certain embodiments, the GalNAc transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to P4-GalNAcT3 of Homo sapiens. In certain embodiments, the GalNAc transferase comprises an N-terminally truncated variant of P4- GalNAcT3 of Homo sapiens comprising an amino acid sequence of SEQ ID NO: 2.
[0063] In certain embodiments, the GalNAc transferase comprises P4-GalNAcT4, or a functionally active variant thereof. In certain embodiments, the GalNAc transferase comprises P4-GalNAcT4. In certain embodiments, the GalNAc transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to P4-GalNAcT4. In certain embodiments, the GalNAc transferase comprises an N-terminally truncated variant of P4-GalNAcT4. In certain embodiments, the P4-GalNAcT4 comprises P4-GalNAcT4 of Homo sapiens, or a functionally active variant thereof. In certain embodiments, the GalNAc transferase comprises P4-GalNAcT4 of Homo sapiens. In certain embodiments, the GalNAc transferase comprises an amino acid sequence of SEQ ID NO: 3. In certain embodiments, the GalNAc transferase comprises one that is homologous to P4-GalNAcT4 of Homo sapiens. In certain embodiments, the GalNAc transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to P4-GalNAcT4 of Homo sapiens. In certain embodiments, the GalNAc transferase comprises an N-terminally truncated variant of P4- GalNAcT4 of Homo sapiens comprising an amino acid sequence of SEQ ID NO: 4.
[0064] In certain embodiments, the GalNAc transferases comprise P4-GalNAcT3 and P- GalNAcT4, or functionally active variants thereof. In certain embodiments, the GalNAc
transferases comprise P4-GalNAcT3 and P4-GalNAcT4. In certain embodiments, the GalNAc transferases comprise variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to P4-GalNAcT3 and P-GalNAcT4, respectively. In certain embodiments, the GalNAc transferases comprise N-terminally truncated variants of P4-GalNAcT3 and/or [34-GalNAcT4. In certain embodiments, the GalNAc transferases comprise P4-GalNAcT3 and P4-GalNAcT4 of Homo sapiens, or functionally active variants thereof. In certain embodiments, the GalNAc transferases comprise P4-GalNAcT3 and P4-GalNAcT4 of Homo sapiens. In certain embodiments, the GalNAc transferases comprise amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 3. In certain embodiments, the GalNAc transferases comprise ones that are homologous to 4- GalNAcT3 and P4-GalNAcT4 of Homo sapiens. In certain embodiments, the GalNAc transferases comprise variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to P4-GalNAcT3 and P4-GalNAcT4 of Homo sapiens, respectively. In certain embodiments, the GalNAc transferases comprise N- terminally truncated variants of P4-GalNAcT3 and/or [34-GalNAcT4 of Homo sapiens comprising amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4, respectively. [0065] In certain embodiments, the GalNAc transferase is CeP4GalNAcT, or a functionally active variant thereof. In certain embodiments, the GalNAc transferase is CeP4GalNAcT. In certain embodiments, the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to CeP4GalNAcT. In certain embodiments, the GalNAc transferase is an N-terminally truncated variant of CeP4GalNAcT. In certain embodiments, the CeP4GalNAcT is a P4GalNAcT of Caenorhabditis elegans, or a functionally active variant thereof. In certain embodiments, the GalNAc transferase is a P4GalNAcT of Caenorhabditis elegans. In certain embodiments, the GalNAc transferase comprises an amino acid sequence of SEQ ID NO: 5. In certain embodiments, the GalNAc transferase is one that is homologous to a CeP4GalNAcT of Caenorhabditis elegans. In certain embodiments, the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to a CeP4GalNAcT of Caenorhabditis elegans. In certain embodiments, the GalNAc transferase comprises an N-terminally truncated variant of CeP4GalNAcT of Caenorhabditis elegans comprising an amino acid sequence of SEQ ID NO: 6.
[0066] In certain embodiments, the GalNAc transferase is Ptp4GalNAcT, or a functionally active variant thereof. In certain embodiments, the GalNAc transferase is Ptp4GalNAcT. In certain embodiments, the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to Ptp4GalNAcT. In certain embodiments, the GalNAc transferase is an N-terminally truncated variant of Ptp4GalNAcT. In certain embodiments, the Ptp4GalNAcT is a P4GalNAcT of Parasteatoda tepidariorum. or a functionally active variant thereof. In certain embodiments, the GalNAc transferase is a Ptp4GalNAcT of Parasteatoda tepidariorum. In certain embodiments, the GalNAc transferase comprises an amino acid sequence of SEQ ID NO: 7. In certain embodiments, the GalNAc transferase is one that is homologous to a Ptp4GalNAcT of Parasteatoda tepidariorum. In certain embodiments, the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to a Ptp4GalNAcT of Parasteatoda tepidariorum. In certain embodiments, the GalNAc transferase comprises an N-terminally truncated variant of Ptp4GalNAcT of Parasteatoda tepidariorum comprising an amino acid sequence of SEQ ID NO: 8.
[0067] In certain embodiments, the GalNAc transferase is Stp4GalNAcT, or a functionally active variant thereof. In certain embodiments, the GalNAc transferase is Stp4GalNAcT. In certain embodiments, the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to Stp4GalNAcT. In certain embodiments, the GalNAc transferase is an N-terminally truncated variant of Stp4GalNAcT. In certain embodiments, the Stp4GalNAcT is a P4GalNAcT of Salmo IruUa. or a functionally active variant thereof. In certain embodiments, the GalNAc transferase is a p4GalNAcT of Salmo trutta. In certain embodiments, the GalNAc transferase comprises an amino acid sequence of SEQ ID NO: 9. In certain embodiments, the GalNAc transferase is one that is homologous to a P4GalNAcT of Salmo trutta. In certain embodiments, the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to a p4GalNAcT of Salmo trutta.
[0068] In certain embodiments, the GalNAc transferase is Hhp4GalNAcT, or a functionally active variant thereof. In certain embodiments, the GalNAc transferase is Hhp4GalNAcT. In certain embodiments, the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to Hhp4GalNAcT. In certain embodiments, the GalNAc transferase is an N-terminally truncated variant of Hhp4GalNAcT. In certain embodiments, the Hhp4GalNAcT is a
P4GalNAcT of Hucho hucho, or a functionally active variant thereof. In certain embodiments, the GalNAc transferase is a P4GalNAcT of Hucho hucho. In certain embodiments, the GalNAc transferase comprises an amino acid sequence of SEQ ID NO: 10. In certain embodiments, the GalNAc transferase is one that is homologous to a p4GalNAcT of Hucho hucho. In certain embodiments, the GalNAc transferase is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to a P4GalNAcT of Hucho hucho.
[0069] Without being bound by theory, combinations of at least two GalNAc transferases can be beneficial for optimizing the glycosylation profile of polypetides of interest, for example by increasing the extent and/or homogeneity of glycoylsation with N-glycan(s) described herein. In certain embodiments, the recombinant nucleic acid encodes at least two GalNAc transferases. In certain embodiments, the recombinant nucleic acid encodes two GalNAc transferases. In certain embodiments, the at least two GalNAc transferases are different GalNAc transferases. In certain embodiments, the at least two GalNAc transferases are selected from the group consisting of p4-GalNAcT3, p4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto. In certain embodiments, the at least two GalNAc transferases are human p4-GalNAcT3 and human P4- GalNAcT4; or human p4-GalNAcT3 and CeP4GalNAcT; or human p4-GalNAcT3 and Ptp4GalNAcT; or functionally active variants thereof.
[0070] In certain embodiments, the GalNAc transferase is localized in the secretory pathway. Without being bound by theory, localization within the secretory pathway includes, but is not limited to, localization to one or more of the following sub-cellular compartments: the endoplasmic reticulum, the Golgi apparatus, lysosomes, intracellular membrane proteins, cell surface anchored proteins, and membrane proteins. In certain embodiments, localization in the secretory pathway comprises localization to one or more of said sub-cellular compartments.
[0071] In certain embodiments, the GalNAc transferase comprises a signal peptide localizing the GalNAc transferase in the secretory pathway. In certain embodiments, the signal peptide is derived from the same source as the GalNAc transferase (i.e. the signal peptide is not added to the GalNAc transferase, but is one contained in the GalNAc transferase when naturally expressed in the source). In certain embodiments, the GalNAc transferase is localized in the secretory pathway without adding Leishmania signal peptide to the GalNAc transferase. In other embodiments, the signal peptide is added to the GalNAc
transferase. In certain embodiments, the signal peptide is fused to the C-terminus of the GalNAc transferase. In certain embodiments, the signal peptide is fused to the N-terminus of the GalNAc transferase. In certain embodiments, the signal peptides is fused to one or more amino acids within the polypeptide of the GalNAc transferase. In certain embodiments, the signal peptide is fused to the N-terminus of an N-terminally truncated variant of the GalNAc transferase. In certain embodiments, the signal peptide is fused to one or more amino acids within the polypeptide of an N-terminally truncated variant of the GalNAc transferase. In certain embodiments, the signal peptide is derived from Leishmania species. In certain embodiments, the signal peptide is a modified version of a signal peptide derived from a Leishmania species. In certain embodiments, the signal peptide is derived from Leishmania tarentolae. In certain embodiments, the signal peptide is a modified version of a signal peptide derived from Leishmania tarentolae. In certain embodiments, the signal peptide is an invertase signal peptide derived from Leishmania tarentolae. In certain embodiments, the signal peptide is a modified version of the invertase signal peptide derived from Leishmania tarentolae. In certain embodiments, the signal peptide comprises an amino acid sequence of SEQ ID NO: 11. In certain embodiments, the signal peptide comprises an amino acid sequence of SEQ ID NO: 12. In certain embodiments, the signal peptide is processed and removed from the GalNAc transferase.
[0072] In certain embodiments, the GalNAc transferase comprises a retention sequence retaining the GalNAc transferase in the secretory pathway. In certain embodiments, the retention sequence is derived from the same source as the GalNAc transferase (i.e. the retention sequence is not added to the GalNAc transferase, but is one contained in the GalNAc transferase when naturally expressed in the source). In certain embodiments, the GalNAc transferase is retained in the secretory pathway without adding a Leishmania retention sequence to the GalNAc transferase. In other embodiments, the retention sequence is added to the GalNAc transferase. In certain embodiments, the retention sequence is fused to the C-terminus of the GalNAc transferase. In certain embodiments, the retention sequence is fused to the N-terminus of the GalNAc transferase. In certain embodiments, the retention sequence is fused to one or more amino acids within the polypeptide of the GalNAc transferase. In certain embodiments, the retention sequence is fused to the N-terminus of an N-terminally truncated variant of the GalNAc transferase. In certain embodiments, the retention sequence is fused to one or more amino acids within the polypeptide of an N- terminally truncated variant of the GalNAc transferase. In certain embodiments, the retention sequence is derived from a Leishmania species. In certain embodiments, the retention
sequence is a modified version of a retention sequence from derived from a Leishmania species. In certain embodiments, the retention sequence is derived from Leishmania tarentolae. In certain embodiments, the retention sequence is a modified version of a retention sequence derived from Leishmania tarentolae.
[0073] In certain embodiments, the GalNAc transferase and the recombinant UDP- GalNAc transporter protein described in Section 7.1.5 are co-localized in the secretory pathway. In certain embodiments, the GalNAc transferase and the additional recombinant glycosyltransferase described in Section 7.1.2 are co-localized in the secretory pathway. In certain embodiments, the GalNAc transferase and the polypeptide of interest described in Section 7.5 are co-localized in the secretory pathway.
7.1.2 Additional Recombinant Glycosyltransferases
[0074] In certain embodiments, the Leishmania host cells provided herein comprise a recombinant nucleic acid encoding one or more additional recombinant glycosyltransferases. In certain embodiments, the additional recombinant glycosyltransferase, or a functionally active variant thereof, is capable of catalyzing the addition of a first glycan to a second glycan. In certain embodiments, the additional recombinant glycosyltransferase is a N-acetyl glucosamine transferase, or a functionally active variant thereof, capable of catalyzing the addition of a N-acetyl glucosamine (GlcNAc) to a mannose-terminated glycan, for example, a Man3GlcNAc2 glycan (Man3, see Section 5.3).
[0075] In certain embodiments, the additional recombinant glycosyltransferase comprises one or more N-acetyl glucosamine transferases. In certain embodiments, the N-acetyl glucosamine transferase is heterologous to the host cell. In certain embodiments, the N- acetyl glucosamine transferase is derived from Homo sapiens, Spodoptera frugiperda, Trypanosoma brucei. Pan troglodytes, Macaca mulatto, Mus musculus, Rattus norvegicus, Danio rerio A, Drosophila melanogaster, Anopheles gambiae, Caenorhabditis elegans, Arabidopsis thaliana, Oryza sativa Japonica, Xenopus tropicalis, Canis lupus, Bos taurus, Danio rerio B, or Gekko japonicus. In certain embodiments, the additional recombinant glycosyltransferase is derived from a mammalian source. In certain embodiments, the mammalian source is Homo sapiens.
[0076] In certain embodiments, the N-acetyl glucosamine transferase is selected from the group consisting of MGAT1 (alpha-1, 3-mannosyl-glycoprotein 2-beta-N- acetylglucosaminyltransf erase) and MGAT2 (alpha- 1,6-mannosylgly coprotein 2-beta-N- acetylglucosaminyltransferase), or functionally active variants thereof. In certain
embodiments, the additional recombinant glycosyltransferases comprise MGAT1 and MGAT2.
[0077] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1, or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Homo sapiens (accession number P26572), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Homo sapiens. In certain embodiments, the N-acetyl glucosamine transferase comprises an amino acid sequence of SEQ ID NO: 13. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MG ATI of Homo sapiens. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Homo sapiens.
[0078] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT2, or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT2. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT2. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT2 of Homo sapiens (accession number: Q10469.1), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT2 of Homo sapiens. In certain embodiments, the N-acetyl glucosamine transferase comprises an amino acid sequence of SEQ ID NO: 14. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT2 of Homo sapiens. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT2 of Homo sapiens.
[0079] In certain embodiments, the N-acetyl glucosamine transferases comprise MGAT1 and MGAT2, or functionally active variants thereof. In certain embodiments, the N-acetyl glucosamine transferases comprise MGAT1 and MGAT2. In certain embodiments, the N- acetyl glucosamine transferases are variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 and MGAT2, respectively. In certain embodiments, the N-acetyl glucosamine transferases are MGAT1 and
MGAT2 of Homo sapiens, or functionally active variants thereof. In certain embodiments, the N-acetyl glucosamine transferases are MGAT1 and MGAT2 of Homo sapiens. In certain embodiments, the N-acetyl glucosamine transferases comprise amino acid sequences of SEQ ID NO: 13 and SEQ ID NO: 14, respectively. In certain embodiments, the N-acetyl glucosamine transferases are ones that are homologous to MGAT1 and MGAT2 of Homo sapiens. In certain embodiments, the N-acetyl glucosamine transferases are variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 and MGAT2 of Homo sapiens, respectively.
[0080] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Spodoptera frugiperda (SfGnT-I, accession number: AEX00082), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MG ATI of Spodoptera frugiperda. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 of Spodoptera frugiperda. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MG ATI of Spodoptera frugiperda.
[0081] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Trypanosoma brucei (TbGnT-I, accession number: XP 844156), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MG ATI of Trypanosoma brucei. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 of Trypanosoma brucei. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Trypanosoma brucei.
[0082] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Pan troglodytes (PtMGATl, accession number: XP 001155433.2), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MG ATI of Pan troglodytes . In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 of Pan troglodytes. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Pan troglodytes.
[0083] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 Macaco. mulatto (MaMGATl, accession number: NP_001244759), or a functionally active
variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 oiMacaca mulatta. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 oiMacaca mulatta. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1
Macaco mulatta.
[0084] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Mus musculus (MuMGATl, accession number: NP_001103620.1), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 oi Mus musculus. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 oi Mus musculus. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Mus musculus.
[0085] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Rattus norvegicus (RnMGATl, accession number: NP_110488.1), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MG ATI of Rattus norvegicus. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 of Rattus norvegicus. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Rattus norvegicus.
[0086] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Danio rerio A (DrMGATla, accession number: NP 956970.1), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MG ATI of Danio rerio A. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 of Danio rerio A. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Danio rerio A.
[0087] In certain embodiments, the N-acetyl glucosamine transferase comprises an MGAT1 of Caenorhabditis elegans (Cel4MGATl, accession number: NP 497719.1 or Cel3MGATl, accession number: NP 509566.1), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of
Caenorhabditis elegans. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 of Caenorhabditis elegans. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Caenorhabditis elegans.
[0088] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Arabidopsis thaliana (AtMGATl, accession number: NP 195537.2), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Arabidopsis thaliana. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 of Arabidopsis thaliana. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Arabidopsis thaliana.
[0089] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Oryza sativa Japonica (OsJMGATl, accession number: XP 015624616.1), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Oryza sativa Japonica. In certain embodiments, the N- acetyl glucosamine transferase comprises one that is homologous to MGAT1 Oryza sativa Japonica. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Oryza sativa Japonica.
[0090] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 oi Xenopus tropicalis (XtMGATl, accession number: NP 001011350.1), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 oi Xenopus tropicalis. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 Xenopus tropicalis. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Xenopus tropicalis.
[0091] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Canis lupus (C1MGAT1, accession number: XP 855658.1), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Canis lupus. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 Canis lupus. In certain embodiments, the N-acetyl
glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Canis lupus.
[0092] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Bos taurus (BtMGATl, accession number: NP 001015653.1), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MG ATI of Bos taurus. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 Bos taurus. In certain embodiments, the N- acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Bos taurus.
[0093] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Danio rerio B (DrMGATlb, accession number: NP 001073440.1), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MG ATI of Danio rerio B. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 Danio rerio B. In certain embodiments, the N- acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Danio rerio B. [0094] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Gekko japonicus (GjMGATl, accession number: XP 015280466.1), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT1 of Gekko japonicus. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT1 Gekko japonicus. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT1 of Gekko japonicus.
[0095] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT2 of Rattus norvegicus (rMGAT2, accession number: NP 446056), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT2 of Rattus norvegicus. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT2 of Rattus norvegicus. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT2 of Rattus norvegicus.
[0096] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT2 of Spodoptera frugiperda (SfGnT-II, accession number: AEX00083), or a functionally active
variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT2 of Spodoptera frugiperda. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT2 of Spodoptera frugiperda. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT2 of Spodoptera frugiperda.
[0097] In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT2 of Trypanosoma brucei (TbGnT-II, accession number: XP 845654), or a functionally active variant thereof. In certain embodiments, the N-acetyl glucosamine transferase comprises MGAT2 of Trypanosoma brucei. In certain embodiments, the N-acetyl glucosamine transferase comprises one that is homologous to MGAT2 of Trypanosoma brucei. In certain embodiments, the N-acetyl glucosamine transferase comprises a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to MGAT2 of Trypanosoma brucei.
[0098] In certain embodiments, the additional recombinant glycosyltransferase is localized in the secretory pathway. Without being bound by theory, localization within the secretory pathway includes, but is not limited to, localization to one or more of the following sub-cellular compartments: the endoplasmic reticulum, the Golgi apparatus, lysosomes, intracellular membrane proteins, cell surface anchored proteins, and membrane proteins. In certain embodiments, localization in the secretory pathway comprises localization to one or more of said sub-cellular compartments.
[0099] In certain embodiments, the additional recombinant glycosyltransferase comprises a signal peptide localizing the additional recombinant glycosyltransferase in the secretory pathway. In certain embodiments, the signal peptide is derived from the same source as the additional recombinant glycosyltransferase (i.e. the signal peptide is not added to additional recombinant glycosyltransferase, but is one fused to the additional recombinant glycosyltransferase when naturally expressed in the source). In certain embodiments, the additional recombinant glycosyltransferase is localized in the secretory pathway without adding a Leishmania signal peptide to the additional recombinant glycosyltransferase. In other embodiments, the signal peptide is added to the additional recombinant glycosyltransferase. In certain embodiments, the signal peptide is fused to the C-terminus of the additional recombinant glycosyltransferase. In certain embodiments, the signal peptide is fused to the N-terminus of the additional recombinant glycosyltransferase. In certain embodiments, the signal peptide is fused to one or more amino acids within the polypeptide
of the additional recombinant glycosyltransferase. In certain embodiments, the signal peptide is derived from Leishmania species. In certain embodiments, the signal peptide is a modified version of a signal peptide derived from a Leishmania species. In certain embodiments, the signal peptide is derived from Leishmania tarentolae. In certain embodiments, the signal peptide is a modified version of a signal peptide derived from Leishmania tarentolae. In certain embodiments, the signal peptide is an invertase signal peptide derived from Leishmania tarentolae. In certain embodiments, the signal peptide is a modified version of the invertase signal peptide derived from Leishmania tarentolae. In certain embodiments, the signal peptide comprises an amino acid sequence of SEQ ID NO: 11. In certain embodiments, the signal peptide comprises an amino acid sequence of SEQ ID NO: 12. In certain embodiments, the signal peptide is processed and removed from the additional recombinant glycosyltransferase.
[00100] In certain embodiments, the additional recombinant glycosyltransferase comprises a retention sequence retaining the additional recombinant glycosyltransferase in the secretory pathway. In certain embodiments, the retention sequence is derived from the same source as the additional recombinant glycosyltransferase (i.e. the retention sequence is not added to additional recombinant glycosyltransferase, but is one fused to the additional recombinant glycosyltransferase when naturally expressed in the source). In certain embodiments, the additional recombinant glycosyltransferase is retained in the secretory pathway without adding a Leishmania retention sequence to the additional recombinant glycosyltransferase. In other embodiments, the retention sequence is added to the additional recombinant glycosyltransferase. In certain embodiments, the retention sequence is fused to the C- terminus of the additional recombinant glycosyltransferase. In certain embodiments, the retention sequence is fused to the N-terminus of the additional recombinant glycosyltransferase. In certain embodiments, the retention sequence is fused to one or more amino acids within the polypeptide of the additional recombinant glycosyltransferase. In certain embodiments, the retention sequence is derived from a Leishmania species. In certain embodiments, the retention sequence is a modified version of a retention sequence derived from a Leishmania species. In certain embodiments, the retention sequence is derived from Leishmania tarentolae. In certain embodiments, the retention sequence is a modified version of a retention sequence derived from Leishmania tarentolae.
[00101] In certain embodiments, the GalNAc transferase described in Section 7.1.1 and the additional recombinant glycosyltransferase are co-localized in the secretory pathway.
7.1.3 Deletion, Mutation and/or Functionally Inactivation of Endogenous Enzymes from the Glycan Biosynthesis Pathway
[00102] In certain embodiments, the Leishmania host cells provided herein are characterized in that one or more endogenous enzymes from the glycan biosynthesis pathway have been deleted, mutated and/or functionally inactivated. In certain embodiments, the Leishmania host cell does not have endogenous N-glycan elongation. In certain embodiments, the Leishmania host cells do not have endogenous N-glycan elongation as described in WO 2019/002512, which is incorporated herein by reference in its entirety. In certain embodiments, the Leishmania host cell has been genetically engineered such that the formation of an O-linked GlcNAc on a polypeptide in the host cell is reduced or eliminated. In certain embodiments, the formation of O-linked GlcNAc in the Leishmania host cell prior to genetic engineering is catalyzed by at least one N-acetylglucosamine (GlcNAc)- transferase. In certain embodiments, the gene encoding the at least one GlcNAc-transferase in the Leishmania host cell is functionally inactivated, downregulated, deleted, and/or mutated.
[00103] In certain embodiments, the enzyme that catalyzes the formation of O-linked GlcNAc is an N-acetylglucosamine (GlcNAc)-transferase. In certain embodiments, the GlcNAc-transferase is selected from the group consisting of OGNT1, OGNT2, OGNTL, and homologous GlcNAc-transf erases thereof. Without being bound by theory, OGNT1, OGNT2, OGNTL were identified based on homology to Trypanosoma enzymes and not mammalian (e.g. human) enzymes (Heise, N., et al Glycobiology, 19(8), 918-933 (2009) and Chiribao, M.L. et al Gene, 498(2), 147-154 (2012), each of which is incorporated herein by reference in its entirety). In certain embodiments, the GlcNAc-transferase is OGNTL In other embodiments, the GlcNAc-transferase is OGNT2. In yet other embodiments, the GlcNAc-transferase is OGNTL. In certain embodiments, the GlcNAc-transferase is a GlcNAc-transferase that is homologous to OGNTL In certain embodiments, the GlcNAc- transferase is a GlcNAc-transferase that is homologous to OGNT2. In certain embodiments, the GlcNAc-transferase is a GlcNAc-transferase that is homologous to OGNTL. In certain embodiments, the GlcNAc-transferase is derived from Leishmania tarentolae. In certain embodiments, the GlcNAc-transferase is derived from other Trypanosomatida species. Nonlimiting examples of GlcNAc-transferases in Trypanosomatida are listed in Table 1, in which one representative genome per species is listed.
[00104] In certain embodiments, the enzyme that catalyzes the formation of O-linked
GlcNAc is derived from species other than Trypanosomatida species. In certain
embodiments, the enzyme is a human O-GlcNAc transferase (OGT, Uniprot: 015294) and homologous enzymes thereof. In certain embodiments, the O-GlcNAc transferase (OGT; uridine diphospho-N-acetylglucosamine:polypeptide P-N-acetylglucosaminyltransferase; EC 2.4.1.255) can catalyze the transfer of a single N-acetylglucosamine from UDP-GlcNAc to a serine or threonine residue in cytoplasmic and nuclear proteins resulting in their modification with a beta-linked N-acetylglucosamine (O-GlcNAc). In certain embodiments, the enzyme that catalyzes the formation of O-linked GlcNAc may be different isoforms of OGT. Exemplary isoforms of OGT include but are not limited to: (1) the nucleocytoplasmic or full- length variant (ncOGT), which may be 110 kDa; (2) a short isoform of OGT (sOGT), which may be 78 kDa; and (3) a variant of OGT that is targeted to the mitochondria (mOGT; which may be 90 kDa). In certain embodiments, OGT may appear to form multimers in the nucleus and cytoplasm, consisting of one or more 110-kDa subunits and 78-kDa subunits (Varki, Ajit, et al. (Eds.) (2015): Essentials of Glycobiology. Cold Spring Harbor Laboratory Press. 3rd. Cold Spring Harbor (NY)). In certain embodiments, the enzyme that catalyzes the formation of O-linked GlcNAc is human EOGT (Uniprot: Q5NDL2). In certain embodiments, the enzyme catalyzes the transfer of a single N-acetylglucosamine from UDP-GlcNAc to a serine or threonine residue in extracellular proteins resulting in their modification with a beta-linked N-acetylglucosamine (O-GlcNAc). In certain embodiments, the enzyme catalyzes Specific glycosylation of the Thr residue located between the fifth and sixth conserved cysteines of folded EGF-like domains.
[00105] In certain embodiments, the enzyme that catalyzes the formation of O-linked GlcNAc may transfer in alpha-linkage. In other embodiments, the enzyme that catalyzes the formation of O-linked GlcNAc may transfer in beta-linkage.
[00106] In certain embodiments, the formation of O-linked GlcNAc in the Leishmania host cell prior to genetic engineering is catalyzed by at least one enzyme as described in this Section, for example one, two, three, four, five, six, seven, eight, nine or ten enzymes as described in this Section.
[00107] In certain embodiments, the formation of O-linked GlcNAc in the Leishmania host cell prior to genetic engineering is catalyzed by at least one GlcNAc-transferase derived from Trypanosomatida species, for example Leishmania tarentolae. In certain embodiments, the formation of O-linked GlcNAc in the Leishmania host cell prior to genetic engineering is catalyzed by at least one GlcNAc-transferase, for example one, two, three, four, five, six, seven, eight, nine or ten GlcNAc-transferases, one or more of which is derived from Trypanosomatida species. In certain embodiments, the number of the at least one GlcNAc-
transferase is one, two or three. In certain embodiments, the at least one GlcNAc-transferase is selected from the group consisting of 0GNT1, 0GNT2, OGNTL and homologous GlcNAc-transferases thereof. In certain embodiments, at least one GlcNAc-transferase is a GlcNAc-transferase that is homologous to 0GNT1, 0GNT2 and/or OGNTL.
[00108] In certain embodiments, the formation of O-linked GlcNAc in the Leishmania host cell prior to genetic engineering is catalyzed by at least one GlcNAc-transferase derived from species that is other than Trypanosomatida species, for example human. In certain embodiments, the formation of O-linked GlcNAc in the Leishmania host cell prior to genetic engineering is catalyzed by at least one GlcNAc-transferase, for example one, two, three, four, five, six, seven, eight, nine or ten GlcNAc-transferases, one or more of which is derived from human. In certain embodiments, the number of the at least one GlcNAc-transferase is one, two or three. In certain embodiments, the at least one GlcNAc-transferase is selected from the group consisting of human O-GlcNAc transferase and human EOGT and homologous enzymes thereof. In certain embodiments, at least one GlcNAc-transferase is an enzyme that is homologous to human O-GlcNAc transferase and/or human EOGT.
[00109] In certain embodiments, the enzyme catalyzes the formation of O-linked GlcNAc prior to the genetic engineering of the Leishmania host cell. In certain embodiments, the enzyme still catalyzes the formation of O-linked GlcNAc after the genetic engineering of the Leishmania host cell. In certain embodiments, the enzyme does not catalyze the formation of O-linked GlcNAc after the genetic engineering of the Leishmania host cell.
[00110] In certain embodiments, the gene encoding the at least one GlcNAc-transferase in the Leishmania host cell is functionally inactivated. In certain embodiments, the gene encoding the at least one GlcNAc-transferase in the Leishmania host cell is downregulated. In certain embodiments, the gene encoding the at least one GlcNAc-transferase in the Leishmania host cell is overexpressed.
[00111] In certain embodiments, the Leishmania host cell provided herein comprises at least one gene deletion. In certain embodiments, the gene encoding the at least one GlcNAc- transferase is deleted. In certain embodiments, the gene encoding the at least one GlcNAc- transferase is mutated. In certain embodiments, the gene encoding the at least one GlcNAc- transferase is overexpressed. In certain embodiments, additional modifications may be introduced (e.g., using recombinant techniques) into the Leishmania host cell described herein.
[00112] In certain embodiments, the genes encoding at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or at least 20 enzymes that each catalyzes the formation of O-
linked GlcNAc may be functionally inactivated. In certain embodiments, the genes encoding 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 enzymes that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated. In certain embodiments, the genes encoding three enzymes that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated. In certain embodiments, the genes and/or genetic loci that may be functionally inactivated include but are not limited to OGNT1, OGNT2, and OGNTL. [00113] In certain embodiments, the genes encoding at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or at least 20 GlcNAc-transferase that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated. In certain embodiments, the genes encoding 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 GlcNAc- transferase that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated. In certain embodiments, the genes encoding three GlcNAc-transferases that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated.
[00114] In certain embodiments, the genes encoding at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of all enzymes that each catalyzes the formation of O- linked GlcNAc may be functionally inactivated. In certain embodiments, the genes encoding 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of all enzymes that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated.
[00115] In certain embodiments, the genes encoding at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of all GlcNAc-transferases that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated. In certain embodiments, the genes encoding 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of all GlcNAc-transferases that each catalyzes the formation of O-linked GlcNAc may be functionally inactivated.
[00116] In certain embodiments, the at least one GlcNAc-transferase is selected from the group consisting of OGNT1, OGNT2 and OGNTL, and homologous GlcNAc-transferases thereof. In certain embodiments, the Leishmania host cell is a OGNT1, OGNT2 and OGNTL triple knockout.
[00117] In certain embodiments, in the Leishmania host cell, the formation of the O-linked GlcNAc is reduced by at least 5%, 7%, 10%, 12%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% from the formation of the O-linked GlcNAc in a reference Leishmania cell. In certain embodiments, in the Leishmania host cell, the formation of the O-linked GlcNAc is reduced by 5%, 7%, 10%, 12%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, or 100% from the formation of the O-linked GlcNAc in a reference Leishmania cell. In certain embodiments, the reference Leishmania cell is wild-type. In certain embodiments, the reference Leishmania cell is genetically engineered differently as the genetically engineered Leishmania cells described herein. In certain embodiments, some of the engineering of the reference Leishmania cell may be the same of the engineering of the genetically engineered Leishmania cells described herein, for example the deletion of one or more enzymes that catalyze the formation of O-linked GlcNAc. In certain embodiments, the reference Leishmania cell may comprise a recombinant nucleic acid encoding a heterologous glycosyltransferase, for example the Leishmania cells described in International Publication No. W02019/002512 A2, incorporated by reference in its entirety herein. In certain embodiments, the formation of the O-linked GlcNAc is reduced by at least 5%, 7%, 10%, 12%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% from the formation of the O-linked GlcNAc in a wild-type Leishmania cell. In certain embodiments, the formation of the O-linked GlcNAc is reduced by 5%, 7%, 10%, 12%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% from the formation of the O-linked GlcNAc in a wild-type Leishmania cell. In certain embodiments, the formation of the O-linked GlcNAc is reduced by at least 5%, 7%, 10%, 12%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% from the formation of the O- linked GlcNAc in a Leishmania cell that comprises a recombinant nucleic acid encoding a heterologous glycosyltransferase. In certain embodiments, the formation of the O-linked GlcNAc is reduced by 5%, 7%, 10%, 12%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% from the formation of the O-linked GlcNAc in a Leishmania cell that comprises a recombinant nucleic acid encoding a heterologous glycosyl transferase.
[00118] In certain embodiments, the growth rate of the Leishmania host cell described herein is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the growth rate of a reference Leishmania cell. In certain embodiments, the growth rate of the Leishmania host cell is 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the growth rate of a reference Leishmania cell. In certain embodiments, the reference Leishmania cell is wildtype. In certain embodiments, the reference Leishmania cell is genetically engineered differently as the genetically engineered Leishmania cells described herein. In certain embodiments, some of the engineering of the reference Leishmania cell may be the same of the engineering of the genetically engineered Leishmania cells described herein, for example
the deletion of one or more enzymes that catalyze the formation of O-linked GlcNAc. In certain embodiments, the growth rate of the Leishmania cell is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the growth rate of a wild-type Leishmania cell. In certain embodiments, the growth rate of the Leishmania cell is 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the growth rate of a wild-type Leishmania cell.
7.1.4 Heterologous UDP-GalNAc Biosynthetic Pathway Proteins
[00119] In certain embodiments, the Leishmania host cells provided herein comprise a recombinant nucleic acid encoding UDP-GalNAc biosynthetic pathway proteins capable of generating UDP-GalNAc. In certain embodiments, the recombinant UDP-GalNAc biosynthetic pathway proteins are heterologous to the Leishmania host cell.
[00120] In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins are capable of converting GalNAc to UDP-GalNAc. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc are derived from a mammalian source. In certain embodiments, the mammalian source is Homo sapiens.
[00121] In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins are capable of converting N- Acetyl galactosamine 1 -phosphate (GalNAc- 1-P) to UDP-GalNAc. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins are capable of converting GalNAc- 1-P and UTP to UDP-GalNAc. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP-N-acetyl hexosamine pyrophosphorylase (UAP1), or a functionally active variant thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP-N-acetyl hexosamine pyrophosphorylase (UAP1) of Homo sapiens, or a functionally active variant thereof. In certain embodiments, the heterologous UDP- GalNAc biosynthetic pathway proteins comprise UDP-N-acetyl hexosamine pyrophosphorylase (UAP1) of Homo sapiens, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP- N-acetyl hexosamine pyrophosphorylase (UAP1) of Homo sapiens. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise a variant of UDP-N- acetyl hexosamine pyrophosphorylase (UAP1) of Homo sapiens that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. Without being bound by theory, the AGX1 isoform of UDP-N-acetyl hexosamine pyrophosphorylase
is about two to three times more active towards GalNAc-l-P than GlcNAc-1-P, whereas the AGX2 isoform is about eight times more active towards GlcNAc-1-P than GalNAc-l-P. In certain embodiments, the UDP-N-acetyl hexosamine pyrophosphorylase (UAP1) is the AGX1 isoform of UAP1. In other embodiments, the UDP-N-acetyl hexosamine pyrophosphorylase (UAP1) is the AGX2 isoform of UAP1. In certain embodiments, the UDP-N-acetyl hexosamine pyrophosphorylase (UAP1) comprises an amino acid sequence of SEQ ID NO: 15.
[00122] In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins are capable of converting GalNAc to GalNAc-l-P. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise N-acetyl galactosamine kinase (GALK2), or a functionally active variant thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise N-acetyl galactosamine kinase (GALK2) of Homo sapiens, or a functionally active variant thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise N- acetyl galactosamine kinase (GALK2) of Homo sapiens, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise N-acetyl galactosamine kinase (GALK2) of Homo sapiens. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise a variant of N-acetyl galactosamine kinase (GALK2) of Homo sapiens that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the N-acetyl galactosamine kinase (GALK2) comprises an amino acid sequence of SEQ ID NO: 15.
[00123] In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins are capable of converting UDP-GlcNAc to UDP-GalNAc. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway protein capable of converting UDP- GlcNAc to UDP-GalNAc comprises a NAD-dependent epimerase that converts UDP- GlcNAc to UDP-GalNAc. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins capable of converting UDP-GlcNAc to UDP-GalNAc is derived from a mammalian source. In certain embodiments, the mammalian source is Homo sapiens. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP -galactose 4-epimerase (GalE), or a functionally active variant thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise UDP -galactose 4-epimerase (GalE) of Homo sapiens (hGalE), or a
functionally active variant thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway protein comprise hGalE, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise hGalE. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise a variant of hGalE that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the hGalE comprises an amino acid sequence of SEQ ID NO: 17. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins capable of converting UDP- GlcNAc to UDP-GalNAc are derived from a bacterial source. In certain embodiments, the bacterial source is Campylobacter jejuni. In certain embodiments, the heterologous UDP- GalNAc biosynthetic pathway proteins comprise UDP-GlcNAc/Glc 4-epimerase of Campylobacter jejuni (CjGne), or a functionally active variant thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise CjGne, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise CjGne. In certain embodiments, the heterologous UDP-GalNAc biosynthetic pathway proteins comprise comprise a variant of CjGne that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the CjGne comprises an amino acid sequence of SEQ ID NO: 18.
[00124] In certain embodiments, the Leishmania host cell comprises (a) a recombinant nucleic acid encoding recombinant UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc as described in this Section; and (b) a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway as described in Section 7.1.5. In certain embodiments, the recombinant nucleic acid in (a) encodes UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc- 1-P to UDP-GalNAc and UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to GalNAc- 1-P, as described in this Section.
[00125] In certain embodiments, the Leishmania host cell comprises (a) a recombinant nucleic acid encoding a recombinant UDP-GalNAc biosynthetic pathway protein capable of converting UDP-GlcNAc to UDP-GalNAc as described in this Section; and (b) a recombinant
nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway as described in Section 7.1.5. [00126] In certain embodiments, the Leishmania host cell comprises (a) a recombinant nucleic acid encoding recombinant UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc as described in this Section; and (b) a recombinant nucleic acid encoding a recombinant UDP-GalNAc biosynthetic pathway protein capable of converting UDP-GlcNAc to UDP-GalNAc as described in this Section. In certain embodiments, the recombinant nucleic acid in (a) encodes UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc- 1-P to UDP-GalNAc and UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to GalNAc- 1-P, as described in this Section.
[00127] In certain embodiments, the Leishmania host cell comprises (a) a recombinant nucleic acid encoding recombinant UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc as described in this Section; and (b) a recombinant nucleic acid encoding a recombinant UDP-GalNAc biosynthetic pathway protein capable of converting UDP-GlcNAc to UDP-GalNAc as described in this Section; and (c) a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway as described in Section 7.1.5. In certain embodiments, the recombinant nucleic acid in (a) encodes UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc- 1-P to UDP-GalNAc and UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to GalNAc- 1-P, as described in this Section.
7.1.5 Heterologous UDP-GalNAc Transporter Proteins
[00128] In certain embodiments, the Leishmania host cells provided herein comprise a recombinant nucleic acid encoding a UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway. In certain embodiments, the UDP- GalNAc transporter protein is heterologous to the Leishmania host cell.
[00129] In certain embodiments, the heterologous UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is derived from a nematode source, a mammalian source, a brachiopod source, a chordate source, choanoflagellate source, a gyrista source, a fungi source, a mollusk source, or a placozoan source. In certain embodiments, the heterologous UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is derived from a nematode source. In certain
embodiments, the nematode source is C. elegans the mammalian source is Homo sapiens,' the brachiopod source is Lingula unguis,' the chordate source is Parambassis ranga, Geotrypetes seraphini, or Scophthalmus maximus,' the choanoflagellate source is Salpingoeca rosetta, the gyrista source is Fragilariopsis cylindrus,' the fungi source is Dentipellis fragilis,' the mollusk source is Octopus bimaculoides,' and/or the placozoan source is trichoplax sp. H2.
[00130] In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is derived from a nematode source. In certain embodiments, the nematode source is C. elegans.
[00131] In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises UDP-GalNAc transporter of C. elegans (CeC03H5.2), or a functionally active variant thereof. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises CeC03H5.2, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises CeC03H5.2. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is CeC03H5.2. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP- GalNAc to the secretory pathway comprises a variant of CeC03H5.2 that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP- GalNAc to the secretory pathway is a variant of CeC03H5.2 that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the CeC03H5.2 has an amino acid sequence of SEQ ID NO: 19.
[00132] In certain embodiments, the variant of CeC03H5.2 is UDP-N-acetylglucosamine transporter isoform XI of Lingula unguis (GnF). In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises GnF. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnF. In certain embodiments, GnF has an amino acid sequence of SEQ ID NO: 132.
[00133] In certain embodiments, the variant of CeC03H5.2 is UDP-N-acetylglucosamine transporter-like isoform XI of Parambassis ranga (GnG). In certain embodiments, the UDP- GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway
comprises GnG. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnG. In certain embodiments, GnG has an amino acid sequence of SEQ ID NO: 133.
[00134] In certain embodiments, the variant of CeC03H5.2 is UDP-N-acetylglucosamine transporter of Salpingoeca rosetta (GnH). In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises GnH. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnH. In certain embodiments, GnH has an amino acid sequence of SEQ ID NO: 134.
[00135] In certain embodiments, the variant of CeC03H5.2 is UDP-N-acetylglucosamine transporter-like protein of Fragilariopsis cylindrus (GnI). In certain embodiments, the UDP- GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises GnI. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnI. In certain embodiments, GnI has an amino acid sequence of SEQ ID NO: 135.
[00136] In certain embodiments, the variant of CeC03H5.2 is previously uncharacterized protein of Dentipellis fragilis (GnJ) identified by homology search of CeC03H5.2. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises GnJ. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnJ. In certain embodiments, GnJ has an amino acid sequence of SEQ ID NO: 136.
[00137] In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises UDP-GalNAc transporter of Homo sapiens (UGTREL7), or a functionally active variant thereof. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises UGTREL7, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises UGTREL7. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is UGTREL7. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP- GalNAc to the secretory pathway comprises a variant of UGTREL7 that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-
GalNAc to the secretory pathway is a variant of UGTREL7 that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the UGTREL7 has an amino acid sequence of SEQ ID NO: 137.
[00138] In certain embodiments, the variant of UGTREL7 is UDP -glucuronic acid/UDP- N-acetylgalactosamine transporter of Geotrypetes seraphini (GnL). In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises GnL. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnL. In certain embodiments, GnL has an amino acid sequence of SEQ ID NO: 138.
[00139] In certain embodiments, the variant of UGTREL7 is putative UDP-N- acetylglucosamine/UDP-glucose/GDP-mannose transporter-like protein of Scophthalmus maximus (GnM). In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises GnM. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnM. In certain embodiments, GnL has an amino acid sequence of SEQ ID NO: 139.
[00140] In certain embodiments, the variant of UGTREL7 is TPT domain-containing protein of Octopus bimaculoides (GnN). In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway comprises GnN. In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnN. In certain embodiments, GnL has an amino acid sequence of SEQ ID NO: 140.
[00141] In certain embodiments, the variant of UGTREL7 is UDP-N- acetylglucosamine/UDP-glucose/GDP -mannose transporter of trichoplax sp. H2 (GnO). In certain embodiments, the UDP-GalNAc transporter protein capable of transporting UDP- GalNAc to the secretory pathway comprises GnO. In certain embodiments, the UDP- GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is GnO. In certain embodiments, GnL has an amino acid sequence of SEQ ID NO: 141.
[00142] In certain embodiments, the heterologous UDP-GalNAc transporter protein comprises a signal peptide localizing the heterologous UDP-GalNAc transporter protein in the secretory pathway. In certain embodiments, the signal peptide is derived from the same source as the heterologous UDP-GalNAc transporter protein (i.e. the signal peptide is not added to the heterologous UDP-GalNAc transporter protein, but is one fused to the heterologous UDP-GalNAc transporter protein when naturally expressed in the source). In
certain embodiments, the heterologous UDP-GalNAc transporter protein is localized in the secretory pathway without adding a Leishmania signal peptide to the heterologous UDP- GalNAc transporter protein. In other embodiments, the signal peptide is added to the heterologous UDP-GalNAc transporter protein. In certain embodiments, the signal peptide is derived from Leishmania species. In certain embodiments, the signal peptide is a modified version of a signal peptide from derived from a. Leishmania species. In certain embodiments, the signal peptide is derived from Leishmania tarentolae. In certain embodiments, the signal peptide is a modified version of a signal peptide from derived from Leishmania tarentolae. In certain embodiments, the signal peptide is an invertase signal peptide derived from Leishmania tarentolae. In certain embodiments, the signal peptide is a modified version of the invertase signal peptide derived from Leishmania tarentolae. In certain embodiments, the signal peptide comprises an amino acid sequence of SEQ ID NO: 11. In certain embodiments, the signal peptide comprises an amino acid sequence of SEQ ID NO: 12. In certain embodiments, the signal peptide is processed and removed from the heterologous UDP-GalNAc transporter protein.
[00143] In certain embodiments, the heterologous UDP-GalNAc transporter protein comprises a retention sequence retaining the heterologous UDP-GalNAc transporter protein in the secretory pathway. In certain embodiments, the retention sequence is derived from the same source as the heterologous UDP-GalNAc transporter protein (i.e. the retention sequence is not added to the heterologous UDP-GalNAc transporter protein, but is one fused to the heterologous UDP-GalNAc transporter protein when naturally expressed in the source). In certain embodiments, the heterologous UDP-GalNAc transporter protein is retained in the secretory pathway without adding a Leishmania retention sequence to the heterologous UDP- GalNAc transporter protein. In other embodiments, the retention sequence is added to the heterologous UDP-GalNAc transporter protein. In certain embodiments, the retention sequence is fused to the C-terminus of the heterologous UDP-GalNAc transporter protein. In certain embodiments, the retention sequence is fused to one or more amino acids within the polypeptide of the heterologous UDP-GalNAc transporter protein. In certain embodiments, the retention sequence is derived from a Leishmania species. In certain embodiments, the retention sequence is a modified version of a retention sequence derived from a Leishmania species. In certain embodiments, the retention sequence is derived from Leishmania tarentolae. In certain embodiments, the retention sequence is a modified version of a retention sequence derived from Leishmania tarentolae.
[00144] Without wishing to be bound by theory, host cells encoding at least two heterologous UDP-GalNAc transporter proteins, including those with two gene copies of the same transporter protein, can be beneficial for optizimizing the extent and/or homogeneity of glycosylation of a polypeptide of interest. In certain embodiments, the recombinant nucleic acid encodes at least two heterologous UDP-GalNAc transporter proteins. In certain embodiments, the recombinant nucleic acid encodes two heterologous UDP-GalNAc transporter proteins. In certain embodiments, the recombinant nucleic acid encodes two copies of the same heterologous UDP-GalNAc transporter protein. In certain embodiments, the recombinant nucleic acid encodes two different heterologous UDP-GalNAc transporter proteins. In certain embodiments, the heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2 and UGTREL7, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2, GnF, GnG, GnH, GnI, GnJ, UGTREL7, GnL, GnM, GnN, or GnO, or functionally active variants thereof. In certain embodiments, the heterologous UDP-GalNAc transporter proteins are selected as a combination of heterologous UDP-GalNAc transporters listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the heterologous UDP-GalNAc transporter proteins comprise CeC03H5.2. In certain embodiments, the heterologous UDP-GalNAc transporter protein is CeC03H5.2. In certain embodiments, the host cell has two gene copies encoding CeC03H5.2. In certain embodiments, the heterologous UDP-GalNAc transporter proteins comprise CeC03H5.2 and GnJ. In certain embodiments, the heterologous UDP- GalNAc transporter proteins are CeC03H5.2 and GnJ.
[00145] In certain embodiments, the recombinant nucleic acid encoding a heterologous UDP-GalNAc transporter comprises a first ORF encoding a first heterologous UDP-GalNAc transporter and a second ORF encoding a second heterologous UDP-GalNAc transporter. In certain embodiments, the first ORF encoding the first heterologous UDP-GalNAc transporter and the second ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module. In certain embodiments, the first ORF encoding the first heterologous UDP-GalNAc transporter and the second ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in separate genetic modules. In certain embodiments, the first ORF encoding the first heterologous
UDP-GalNAc transporter and the second ORF encoding the second heterologous UDP- GalNAc transporter are integrated into the [ssuPolI] locus of the host cell. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter are selected as a combination of heterologous UDP-GalNAc transporters listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2 and UGTREL7, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2, GnF, GnG, GnH, GnI, GnJ, UGTREL7, GnL, GnM, GnN, or GnO, or functionally active variants thereof. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter proteins are the same UDP-GalNAc transporter protein. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter proteins are each CeC03H5.2. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter proteins are different UDP-GalNAc transporter proteins. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter proteins are CeC03H5.2 and GnJ, respectively.
[00146] Without wishing to be bound by theory, the extent and/or homogeneity of glycosylation of a polypeptide of interest may be optimized by appropriate combination of recombinant GalNAc transferase(s) and heterologous UDP-GalNAc transporter protein(s). In certain embodiments, the combination of recombinant GalNAc transferase(s) and heterologous UDP-GalNAc transporter protein(s) is selected from a combination listed in Table 12 or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, when the one or more GalNAc transferases comprise human p4-GalNAcT3, the heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2, GnF, GnH, GnJ, UGTREL7, GnM, GnN, and GnO. In certain embodiments, when the one or more GalNAc transferases comprise human p4-GalNAcT3, the heterologous UDP-GalNAc transporter proteins comprise CeC03H5.2. In certain embodiments, when the one or more GalNAc transferases comprise human p4-GalNAcT3, the heterologous UDP-GalNAc transporter proteins comprise GnJ. In certain embodiments, when the one or more GalNAc
transferases comprise human p4-GalNAcT3, the heterologous UDP-GalNAc transporter proteins comprise GnM. In certain embodiments, when the one or more GalNAc transferases comprise human p4-GalNAcT3, the heterologous UDP-GalNAc transporter proteins comprise GnN. In certain embodiments, when the one or more GalNAc transferases comprise human p4-GalNAcT3, the heterologous UDP-GalNAc transporter proteins comprise GnO. In certain embodiments, when the one or more GalNAc transferases comprise Ptp4GalNAcT, the heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2, GnF, GnJ, and GnM. In certain embodiments, when the one or more GalNAc transferases comprise Ptp4GalNAcT, the heterologous UDP- GalNAc transporter proteins comprise CeC03H5.2. In certain embodiments, when the one or more GalNAc transferases comprise Ptp4GalNAcT, the heterologous UDP-GalNAc transporter proteins comprise GnF. In certain embodiments, when the one or more GalNAc transferases comprise CeP4GalNAcT, the heterologous UDP-GalNAc transporter proteins comprise CeC03H5.2 and/or GnF.
[00147] In certain embodiments, the recombinant nucleic acids encode at least two GalNAc transferases and at least two heterologous UDP-GalNAc transporter proteins. In certain embodiments, the recombinant nucleic acids encode two GalNAc transferases and two heterologous UDP-GalNAc transporter proteins. In certain embodiments, the at least two GalNAc transferases are different. In certain embodiments, the recombinant nucleic acids encode two copies of the same heterologous UDP-GalNAc transporter protein. In certain embodiments, the recombinant nucleic acids encode two different heterologous UDP- GalNAc transporter proteins. In certain embodiments, the at least two GalNAc transferases are selected from the group consisting of human p4-GalNAcT3, human p4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto; and the at least two heterologous UDP-GalNAc transporter proteins are selected from the group consisting of CeC03H5.2, GnF, GnG, GnH, GnI, GnJ, UGTREL7, GnL, GnM, GnN, or GnO, or functionally active variants thereof. In certain embodiments, the at least two GalNAc transferases and the at least two heterologous UDP-GalNAc transporter proteins are selected from a combination listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the recombinant nucleic acids encode human p4-GalNAcT3, CeP4GalNAcT,
CeC03H5.2, and GnJ. In certain embodiments, the recombinant nucleic acids encode human P4-GalNAcT3, Ptp4GalNAcT, and CeC03H5.2.
[00148] In certain embodiments, the host cell is such that (a) the recombinant nucleic acid encoding one or more GalNAc transferases comprises a first ORF encoding a first GalNAc transferase and a second ORF encoding a second GalNAc transferase; and (b) the recombinant nucleic acid encoding a heterologous UDP-GalNAc transporter comprises a third ORF encoding a first heterologous UDP-GalNAc transporter and a fourth ORF encoding a second heterologous UDP-GalNAc transporter. In certain embodiments, the host cell is such that (a) the first open reading frame (ORF) encoding the first GalNAc transferase and and the third ORF encoding the first heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module; and/or (b) the second open reading frame (ORF) encoding the second GalNAc transferase and and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module. In certain embodiments, the host cell is such that (a) the first ORF encoding the first GalNAc transferase and the second ORF encoding the second GalNAc transferase are integrated into the host cell in separate genetic modules; and/or (b) the third ORF encoding the first heterologous UDP-GalNAc transporter and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in separate genetic modules. In certain embodiments, the first ORF encoding the first GalNAc transferase, the second ORF encoding the second GalNAc transferase, the third ORF encoding the first heterologous UDP-GalNAc transporter, and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module. In certain embodiments, the first ORF encoding the first GalNAc transferase, the second ORF encoding the second GalNAc transferase, the third ORF encoding the first heterologous UDP-GalNAc transporter, and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the [ssuPolI] locus of the host cell. In certain embodiments, the first and the second GalNAc transferases are different GalNAc transferases. In certain embodiments, the first and the second heterologous UDP- GalNAc transporter proteins are the same UDP-GalNAc transporter protein. In certain embodiments, the first and the second heterologous UDP-GalNAc transporter proteins are different UDP-GalNAc transporter proteins. In certain embodiments, the first GalNAc transferase, the second GalNAc transferase, the first heterologous UDP-GalNAc transporter protein, and the second heterologous UDP-GalNAc transporter protein are selected as a combination of GalNAc transferases and heterologous UDP-GalNAc transporter proteins
listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof. In certain embodiments, the first and the second GalNAc transferases are human p4-GalNAcT3 and CeP4GalNAcT, respectively; and the first and the second heterologous UDP-GalNAc transporter proteins are CeC03H5.2, and GnJ, respectively. In certain embodiments, the first and the second GalNAc transferases are human p4-GalNAcT3 and Ptp4GalNAcT, respectively; and the first and the second heterologous UDP-GalNAc transporter proteins are each CeC03H5.2.
[00149] In certain embodiments, the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein are co-localized in the secretory pathway. In certain embodiments, the one or more GalNAc transferases and the heterologous UDP- GalNAc transporter protein each independently comprise: (a) a signal peptide localizing the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein in the secretory pathway; and/or (b) a retention sequence retaining the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein in the secretory pathway. In certain embodiments, the one or more GalNAc transferases and the heterologous UDP- GalNAc transporter protein each independently comprise the same signal peptide and/or retention sequence. In certain embodiments, the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein comprise different signal peptides and/or retention sequences. In certain embodiments, the signal peptide is derived from the same source as the one or more GalNAc transferases (i.e. the signal peptide is not added to the one or more GalNAc transferases, but is one fused to the one or more GalNAc transferases when naturally expressed in the source). In certain embodiments, the one or more GalNAc transferases is localized in the secretory pathway without adding a Leishmania signal peptide to the one or more GalNAc transferases. In certain embodiments, the signal peptide is derived from the same source as the heterologous UDP-GalNAc transporter protein (i.e. the signal peptide is not added to the heterologous UDP-GalNAc transporter protein, but is one fused to the heterologous UDP-GalNAc transporter protein when naturally expressed in the source). In certain embodiments, the heterologous UDP-GalNAc transporter protein is localized in the secretory pathway without adding a Leishmania signal peptide to the heterologous UDP-GalNAc transporter protein. In certain embodiments, the signal peptide of the one or more GalNAc transferases and/or the signal peptide of the heterologous UDP- GalNAc transporter protein is derived from a Leishmania species. In certain embodiments, the signal peptide of the one or more GalNAc transferases and/or the signal peptide of the
heterologous UDP-GalNAc transporter protein are processed and removed. In certain embodiments, the retention sequence is derived from the same source as the one or more GalNAc transferases (i.e. the retention sequence is not added to the one or more GalNAc transferases, but is one fused to the one or more GalNAc transferases when naturally expressed in the source). In certain embodiments, the one or more GalNAc transferases is retained in the secretory pathway without adding a Leishmania retention sequence to the one or more GalNAc transferases. In certain embodiments, the retention sequence is derived from the same source as the heterologous UDP-GalNAc transporter protein (i.e. the retention sequence is not added to the heterologous UDP-GalNAc transporter protein, but is one fused to the heterologous UDP-GalNAc transporter protein when naturally expressed in the source). In certain embodiments, the heterologous UDP-GalNAc transporter protein is retained in the secretory pathway without adding a Leishmania retention sequence to the heterologous UDP- GalNAc transporter protein. In certain embodiments, the retention sequence of the one or more GalNAc transferases and/or the retention sequence of the heterologous UDP-GalNAc transporter protein are derived from a Leishmania species. In certain embodiments, the Leishmania species is Leishmania tarentolae.
7.1.6 Strains of the Leishmania Host Cell
[00150] In certain embodiments, the Leishmania host cell is a Leishmania tarentolae cell. In certain embodiments, the Leishmania host cell is a Leishmania aethiopica cell. In certain embodiments, the Leishmania host cell is part of the Leishmania aethiopica species complex. In certain embodiments, the Leishmania host cell is a Leishmania aristidesi cell. In certain embodiments, the Leishmania host cell is a Leishmania deanei cell. In certain embodiments, the Leishmania host cell is part of the Leishmania donovani species complex. In certain embodiments, the Leishmania host cell is a Leishmania donovani cell. In certain embodiments, the Leishmania host cell is a Leishmania chagasi cell. In certain embodiments, the Leishmania host cell is a Leishmania infantum cell. In certain embodiments, the Leishmania host cell is a Leishmania hertigi cell. In certain embodiments, the Leishmania host cell is part of the Leishmania major species complex. In certain embodiments, the Leishmania host cell is a Leishmania major cell. In certain embodiments, the Leishmania host cell is a Leishmania martiniquensis cell. In certain embodiments, the Leishmania host cell is part of the Leishmania mexicana species complex. In certain embodiments, the Leishmania host cell is a Leishmania mexicana cell. In certain embodiments, the Leishmania host cell is a Leishmania pifanoi cell. In certain embodiments, the Leishmania host cell is part
of the Leishmania tropica species complex. In certain embodiments, the Leishmania host cell is a Leishmania tropica cell.
7.2 Methods of Genetically Engineering a Leishmania Cell
[00151] Also provided herein are methods of genetically engineering Leishmania host cell as described in Section 7.1. In certain embodiments, the method may be used to accomplish the introduction of one or more genes encoding a GalNAc transferase as described in Section 7.1.1. In certain embodiments, the method may be used to accomplish the introduction of one or more genes encoding an additional recombinant glycosyltransferase as described in Section 7.1.2. In certain embodiments, the method may be used to accomplish the functional inactivation of one or more genes encoding an enzyme that catalyzes the formation of O-linked GlcNAc as described in Section 7.1.3. In certain embodiments, the method may be used to accomplish the introduction of one or more genes encoding a heterologous UDP-GalNAc biosynthetic pathway proteins as described in Section 7.1.4. In certain embodiments, the method may be used to accomplish the introduction of one or more genes encoding a heterologous UDP-GalNAc transporter protein as described in Section 7.1.5. In certain embodiments, the strain of the engineered Leishmania host cell is described in Section 7.1.6.
[00152] Any method known in the art can be used to engineer the Leishmania host cell, e.g., Leishmania tarentolae. In certain embodiments, nucleic acids are introduced into the host cells described herein using a plasmid, e.g., the heterologous nucleic acids are expressed in the host cells by a plasmid (e.g., an expression vector), and the plasmid is introduced into the modified host cells by transfection, infection, or electroporation, chemical transformation by heat shock, natural transformation, phage transduction, or conjugation. In a specific embodiment, said plasmid is introduced into the modified host cells by stable transfection. [00153] In specific embodiments, linearized nucleic acids are introduced into the host cells described herein using transfection, infection, or electroporation, chemical transformation by heat shock, natural transformation, phage transduction, or conjugation. In a further embodiment, heterologous nucleic acids are integrated site-specifically into the host cell genome by homologous recombination.
[00154] In certain embodiments, the method of engineering the Leishmania host cell comprises introducing one or more genes encoding a GalNAc transferase as described in Section 7.1.1.
[00155] In certain embodiments, the method of engineering the Leishmania host cell comprises introducing one or more genes encoding an additional recombinant glycosyltransferase as described in Section 7.1.2.
[00156] In certain embodiments, the method of engineering the Leishmania host cell comprises functionally inactivating one or more genes encoding an enzyme that catalyzes the formation of O-linked GlcNAc as described in Section 7.1.3. In certain embodiments, the method comprises downregulating the gene encoding the at least one GlcNAc-transferase. In certain embodiments, the method comprises deleting the gene encoding the at least one GlcNAc-transferase. In certain embodiments, the method comprises mutating the gene encoding the at least one GlcNAc-transferase. In certain embodiments, the method comprises overexpressing the gene encoding the at least one GlcNAc-transferase. In certain embodiments, the method comprises functionally inactivating the gene encoding an enzyme that catalyzes the formation of O-linked GlcNAc using the methods described in the Assay or Example Sections (Sections 7.6 and 8. , respectively). In certain embodiments, the method comprises functionally inactivating the gene encoding an enzyme that catalyzes the formation of O-linked GlcNAc using any method known in the art, for example methods described in International Publication No. W02019/002512 A2, incorporated by reference in its entirety herein.
[00157] Non-limiting exemplary mutagenesis approaches include site directed mutagenesis using targeted gene editing techniques such as TALENs , ZFNs, CRISPR/Cas9; in combination with a repair scaffold for directed, homologous recombination mediated repair (Zhang, W et al. (2017) mSphere 2 (1); Gupta, R. and Musunuru, K. (2014) The Journal of clinical investigation 124 (10):4154— 4161), transposon mutagenesis (Damasceno, J. et al. (2015) Christopher Peacock (Ed.): Parasite Genomics Protocols, vol. 1201. New York, NY : Springer New York (Methods in Molecular Biology), pp. 235-245); replacing the endogenous copy in situ with selectional markers, potentially in combination with a mutated gene version, that are integrated by homologous recombination (Roberts, S. (2011) Bioeng Bugs 2 (6): 320-326); RNA interference (RNAi) (Lye, L. et al. (2010) PLoS Pathog 6 (10), elOOl 161), conditional knock-down using Cre/LoxP or FRT/FLP (Duncan, S. (2017) Molecular and Biochemical Parasitology 216: 30-38).
[00158] Overexpression may be accomplished by the following non-limiting exemplary approaches, such as gene copy number increase by introduction of additional copies into separate loci (Beverley, S. (1991): Gene amplification in Leishmania. In d/z/w. Rev. Microbiol. 45, pp. 417-444), high expression loci (ribosomal DNA loci) or episomal
constructs (Lodes, M. et al. (1995) Mol Cell Biol 15 (12), pp. 6845-6853. DOI: 10.1128/mcb.15.12.6845; Boucher, N. (2004) Nucleic Acids Res 32 (9): 2925-2936), modification of the native UTRs flanking the coding sequence; introduction of additional promoter regions such as the endogenous Poll promoter or a T7 promoter in combination with expression of bacterial T7 polymerase to increase the expression levels (Boucher, N. et al. (2002) Molecular and Biochemical Parasitology 119 (1): 153-158; Gu, P. et al. (2015) Scientific reports 5, p. 9684), use of transposable elements or recombinase based systems such as FRT-FLP or Cre/LoxP to introduce multiple copies of an expression construct (Duncan, S. et al. (2017) Molecular and Biochemical Parasitology 216, pp. 30-38), minichromosome integration (Zomerdijk, J. et al. (1992) Nucleic acids research 20 (11): 2725-2734), and forced chromosomal translocation by CRISPR (Zhang, W. et al. (2017) mSphere 2 (1). DOI: 10.1128/mSphere.00340-16).
[00159] In certain embodiments, the method of engineering the Leishmania host cell comprises introducing one or more genes encoding a heterologous UDP-GalNAc biosynthetic pathway proteins as described in Section 7.1.4.
[00160] In certain embodiments, the method of engineering the Leishmania host cell comprises introducing one or more genes encoding a heterologous UDP-GalNAc transporter protein as described in Section 7.1.5.
[00161] In certain embodiments, the method of engineering the Leishmania host cell comprises (i) functionally inactivating one or more genes encoding an enzyme that catalyzes the formation of O-linked GlcNAc as described in Section 7.1.3; (ii) introducing one or more genes encoding a heterologous UDP-GalNAc biosynthetic pathway proteins as described in Section 7.1.4; (iii) introducing one or more genes encoding a heterologous UDP-GalNAc transporter protein as described in Section 7.1.5; and (iv) introducing one or more genes encoding a GalNAc transferase as described in Section 7.1.1.
[00162] In certain embodiments, the method of engineering the Leishmania host cell comprises (i) functionally inactivating one or more genes encoding an enzyme that catalyzes the formation of O-linked GlcNAc as described in Section 7.1.3; (ii) introducing one or more genes encoding a heterologous UDP-GalNAc biosynthetic pathway proteins as described in Section 7.1.4; (iii) introducing one or more genes encoding a heterologous UDP-GalNAc transporter protein as described in Section 7.1.5; (iv) introducing one or more genes encoding a GalNAc transferase as described in Section 7.1.1; and (v) introducing one or more genes encoding an additional recombinant glycosyltransferase as described in Section 7.1.2.
[00163] In certain embodiments, the method comprises conducting steps (i)-(v) in sequential order. In other embodiments, steps (i)-(v) are conducted in a different order. For example, in certain embodiments, steps (ii) and (iii) are conducted before step (i). In other embodiments, steps (ii) and (iii) are conducted after step (i). In other embodiments, step (iv) and/or (v) are conducted before step (i). In certain embodiments, step (v) is conducted before step (iv). In certain embodiments, step (v) is conducted first.
[00164] In some embodiments, one or more of steps (i)-(v) may be conducted simultaneously, for example by introducing the genes in a single module. For example, in certain embodiments, steps (ii) and (iii) are conducted simultaneously. In certain embodiments, steps (ii), (iii), and (iv) are conducted simultaneously. In certain embodiments, step (v) is conducted before step (iv). In certain embodiments, step (v) is conducted first.
[00165] In a specific embodiment, step (i) is conducted, followed by steps (ii) and (iii), which are conducted simultaneously, and then step (iv) separately. In another specific embodiment, steps (ii) and (iii) are conducted simultaneously and before step (iv), and step (iv) is conducted before step (i). In yet another specific embodiment, step (i) is conducted, and steps (ii), (iii), and (iv) are conducted simultaneously after step (i). In certain embodiments, step (v) is conducted before step (iv). In certain embodiments, step (v) is conducted first.
[00166] In certain embodiments, the method comprises conducting steps (i)-(v) in the order shown in any one of FIG. 5, FIG. 6, and FIG. 14. In certain embodiments, step (v) is conducted first.
[00167] In certain embodiments, the Leishmania host cells may be engineered using the methods described in the Assay and Examples Sections (Sections 7.6 and 8. , respectively). Non-limiting exemplary Leishmania strains produced and plasmids used as donors for their production are provided in Table 3 and Table 9.
7.3 Methods of Culturing Leishmania Host Cells
[00168] Provided herein are methods for culturing Leishmania host cells described in Section 7.1.
[00169] In one embodiment, the Leishmania host cells are cultured using any of the standard culturing techniques known in the art. For example, cells are routinely grown in rich media like Brain Heart Infusion, Trypticase Soy Broth or Yeast Extract, all containing 5 pg /ml Hemin. Additionally, incubation is done at 26°C in the dark as static or shaking cultures for 2-3 days. In some embodiments, cultures of recombinant cell lines contain the
appropriate selective agents. Non-limiting exemplary selective agents are provided in Table 2.
[00170] In certain embodiments, the Leishmania host cells are cultured in a growth medium comprising GalNAc. In certain embodiments, the growth medium comprises at least 1 mM, at least 2 mM, at least 3 mM, at least 4 mM, at least 5 mM, at least 6 mM, at least 7 mM, at least 8 mM, at least 9 mM, at least 10 mM, at least 11 mM, at least 12 mM, at least 13 mM, at least 14 mM, at least 15 mM, at least 16 mM, at least 17 mM, at least 18 mM, at least 19 mM, or at least 20 mM GalNAc. In certain embodiments, the growth medium comprises about 1 mM to about 5 mM, about 5 mM to about 10 mM, about 10 mM to about 15 mM, or about 15 mM to about 20 mM GalNAc. In certain embodiments, the growth medium comprises about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, or about 20 mM GalNAc. In certain embodiments, the growth medium comprises about about 10 mM GalNAc.
[00171] In certain embodiments, the Leishmania host cells are cultured in a growth medium comprising GlcNAc. In certain embodiments, the growth medium comprises at least 1 mM, at least 2 mM, at least 3 mM, at least 4 mM, at least 5 mM, at least 6 mM, at least 7 mM, at least 8 mM, at least 9 mM, at least 10 mM, at least 11 mM, at least 12 mM, at least 13 mM, at least 14 mM, at least 15 mM, at least 16 mM, at least 17 mM, at least 18 mM, at least 19 mM, or at least 20 mM GlcNAc. In certain embodiments, the growth medium comprises about 1 mM to about 5 mM, about 5 mM to about 10 mM, about 10 mM to about 15 mM, or about 15 mM to about 20 mM GlcNAc. In certain embodiments, the growth medium comprises about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, or about 20 mM GlcNAc.
[00172] In certain embodiments, the Leishmania host cells may be cultured using the methods described in the Assay and Examples Sections (Sections 7.6 and 8. , respectively). Non-limiting exemplary Leishmania strains and plasmids used as donors for their production are provided in Table 3 and Table 9.
7.4 Uses of the Leishmania Host Cell as an Expression System
[00173] In certain embodiments, a Leishmania host cell described in Section 7.1 may be used as an expression system for making a polypeptide of interest. In certain embodiments, the polypeptide of interest may be a heterologous, non-Leishmania protein, such as a therapeutic protein (e.g., an antibody). The Leishmania host cells may be engineered as described in Sections 7.2 and cultured as described in Section 7.3. Other methods of producing Leishmania host cells for use as expression systems are known and may also be used, for example, see WO 2019/002512, WO 2021/140144 and WO 2021/140143, each of which are incorporated herein by reference in their entirety. Use of Leishmania host cells to make monoclonal antibodies are also known. Exemplary methods are described in WO 2022/053673, which is incorporated herein by reference in its entirety.
[00174] In certain embodiments, the Leishmania host cells may be used as an expression system for producing a polypeptide of interest according to the methods described in the Assay and Examples Sections (Sections 7.6 and 8. , respectively).
7.4.1 Compositions Comprising Host Cells
[00175] In one aspect, provided herein are compositions comprising the Leishmania host cells described in Section 7.1. Such compositions can be used in methods for generating a polypeptide of interest as described in Section 7.5. In certain embodiments, the compositions comprising Leishmania host cells can be cultured under conditions suitable for the production of polypeptides of interest. Subsequently, the polypeptides of interest can be isolated from said compositions comprising Leishmania host cells using methods known in the art.
[00176] The compositions comprising the Leishmania host cells can comprise additional components suitable for maintenance and survival of the Leishmania host cells, and can additionally comprise additional components required or beneficial to the production of polypeptides of interest by the Leishmania host cells, e.g., inducers for inducible promoters, such as arabinose, IPTG.
7.4.2 Methods of Making Polypeptides of Interest
[00177] In one aspect, provided herein are methods for making a polypeptide of interest, for example, one described in Section 7.5. In one embodiment, provided herein is a method of producing a polypeptide of interest in vivo, using a Leishmania host cell described in Section 7.1. In a specific embodiment, provided herein is a method for producing a polypeptide of interest, said method comprising (i) culturing a. Leishmania host cell described in Section 7.1 under conditions suitable for polypeptide production and (ii) isolating said polypeptide of interest. In a specific embodiment, the Leishmania host cell comprises: (a) a
recombinant nucleic acid encoding a polypeptide of interest; and (b) a recombinant nucleic acid encoding one or more recombinant N-acetylgalactosamine (GalNAc) transferases. In certain embodiments, the Leishmania host cell is capable of producing polypeptides comprising a biantennary, GalNAc-terminated N-glycan. In particular, the Leishmania host cells provided herein is capable of producing polypeptides comprising an N-glycan of the following structure:
wherein the black square represents an N-acetyl galactosamine (GalNAc), the white square represents an N-acetylglucosamine (GlcNAc) residue and the black circle represents a mannose (Man) residue, and wherein X represents an amino acid residue of the polypeptide of interest.
[00178] In certain embodiments, the polypeptide of interest produced by the Leishmania host cell is a therapeutic polypeptide, ie., a polypeptide used in the treatment of a disease or disorder. For example, the target polypeptide produced by the Leishmania host cell can be an enzyme, a cytokine, or an antibody. A list of non-limiting exemplary polypeptides of interest is provided in Section 7.5.
7.5 Polypeptides of Interest
[00179] In certain embodiments, the polypeptide of interest produced by the Leishmania host cell provided in Section 7.1 is a therapeutic polypeptide, z.e., a polypeptide used in the treatment of a disease or disorder. For example, the polypeptide of interest produced by the Leishmania host cell can be an enzyme, a cytokine, or an antibody. In certain embodiments, the polypeptide of interest is selected from the group consisting of adalimumab, rituximab and erythropoietin (EPO).
[00180] Any polypeptide (or peptide/polypeptide corresponding to the polypeptide) known in the art can be used as a polypeptide of interest in accordance with the methods described
herein. One of skill in the art will readily appreciate that the nucleic acid sequence of a known polypeptide, as well as a newly identified polypeptide, can easily be deduced using methods known in the art, and thus it would be well within the capacity of one of skill in the art to introduce a nucleic acid that encodes any polypeptide of interest into a host cell provided herein (e.g., via an expression vector, e.g., a plasmid, e.g., a site specific integration by homologous recombination).
[00181] In certain embodiments, the polypeptide of interest is glycosylated, e.g., with an N-glycan of the following structure:
wherein the black square represents an N-acetyl galactosamine (GalNAc), the white square represents an N-acetylglucosamine (GlcNAc) residue and the black circle represents a mannose (Man) residue, and wherein X represents an amino acid residue of the polypeptide of interest. One of skill in the art will further recognize that the polypeptides of interest may be glycosylated using the methods described herein, e.g., either in vivo using Leishmania host cell in Section 7.1 or in vitro, possess therapeutic benefit (e.g., due to improved pharmacokinetics) and thus can be used in the treatment of subjects having diseases/disorders that will benefit from treatment with the glycosylated polypeptides of interest.
[00182] In certain embodiments, the polypeptide of interest comprises the amino acid sequence of human Interferon-a (INF -a), Interferon-P (INF-P), Interferon-y (INF-y), Interleukin-2 (IL2), Chimeric diphteria toxin-IL-2 (Denileukin diftitox), Interleukin-1 (IL1), IL1B, IL3, IL4, IL11, IL21, IL22, IL1 receptor antagonist (anakinra), Tumor necrosis factor alpha (TNF-a), Insulin, Pramlintide, Growth hormone (GH), Insulin-like growth factor (IGF1), Human parathyroid hormone, Calcitonin, Glucagon-like peptide-1 agonist (GLP-1), Glucagon, Growth hormone-releasing hormone (GHRH), Secretin, Thyroid stimulating hormone (TSH), Human bone morphogenic polypeptide 2 (hBMP2), Human bone morphogenic proetin 7 (hBMP7), Gonadotropin releasing hormone (GnRH), Keratinocyte
growth factor (KGF), Platelet-derived growth factor (PDGF), Fibroblast growth factor 7 (FGF7), Fibroblast growth factor 20 (FGF20), Fibroblast growth factor 21 (FGF21), Epidermal growth factor (EGF), Vascular endothelial growth factor (VEGF), Neurotrophin-3, Human follicle-stimulating hormone (FSH), Human chorionic gonadotropin (HCG), Lutropin-a, Erythropoietin, Granulocyte colony-stimulating factor (G-CSF), Granulocytemacrophage colony-stimulating factor (GM-CSF), the extracellular domain of CTLA4 (e.g., an FC-fusion), or the extracellular domain of TNF receptor (e.g., an FC-fusion). In a specific embodiment, the target polypeptide used in accordance with the methods and host cells described herein is an enzyme or an inhibitor. Exemplary enzymes and inhibitors that can be used as a target polypeptide include, without limitation, Factor VII, Factor VIII, Factor IX, Factor X, Factor XIII, Factor Vila, Antithrombin III (AT -III), Polypeptide C, Tissue plasminogen activator (tPA) and tPA variants, Urokinase, Hirudin, Streptokinase, Glucocerebrosidase, Alglucosidase-a, Laronidase (a-L-iduronidase), Idursulphase (Iduronate- 2-sulphatase), Galsulphase, Agalsidase-P (human a-galactosidase A), Botulinum toxin, Collagenase, Human DNAse-I, Hyaluronidase, Papain, L- Asparaginase, Uricase (Urate oxidase), glutamate carboxypeptidase (glucarpidase), al Protease inhibitor (al antitrypsin), Lactase, Pancreatic enzymes (lipase, amylase, protease), and Adenosine deaminase.
[00183] In a specific embodiment, the polypeptide of interest used in accordance with the methods and Leishmania host cells provided herein is a cytokine. Exemplary cytokines that can be used as a polypeptide of interest include, without limitation, Interferon-a (INF-a), Interferon-P (INF-P), Interferon -y (INF-y), Interleukin-2 (IL2), Chimeric diphteria toxin-IL-2 (Denileukin diftitox), Interleukin- 1 (IL1), IL IB, IL3, IL4, IL11, IL21, IL22, IL1 receptor antagonist (anakinra), and Tumor necrosis factor alpha (TNF-a).
[00184] In a specific embodiment, the polypeptide of interest used in accordance with the methods and Leishmania host cells provided herein is a hormone or growth factor. Exemplary hormones and growth factors that can be used as a polypeptides of interest include, without limitation, Insulin, Pramlintide, Growth hormone (GH), Insulin-like growth factor (IGF1), Human parathyroid hormone, Calcitonin, Glucagon-like peptide- 1 agonist (GLP-1), Glucagon, Growth horm one-releasing hormone (GHRH), Secretin, Thyroid stimulating hormone (TSH), Human bone morphogenic polypeptide 2 (hBMP2), Human bone morphogenic proetin 7 (hBMP7), Gonadotropin releasing hormone (GnRH), Keratinocyte growth factor (KGF), Platelet-derived growth factor (PDGF), Fibroblast growth factor 7 (FGF7), Fibroblast growth factor 20 (FGF20), Fibroblast growth factor 21 (FGF21),
Epidermal growth factor (EGF), Vascular endothelial growth factor (VEGF), Neurotrophin-3, Human follicle-stimulating hormone (FSH), Human chorionic gonadotropin (HCG), Lutropin-a, Erythropoietin, Granulocyte colony-stimulating factor (G-CSF), and Granulocyte-macrophage colony-stimulating factor (GM-CSF).
[00185] In a specific embodiment, the polypeptide of interest used in accordance with the methods and Leishmania host cells provided herein is a receptor. Exemplary receptors that can be used as a polypeptide of interest include, without limitation, the extracellular domain of human CTLA4 (e.g., fused to an Fc) and the soluble TNF receptor (e.g., fused to an Fc).
[00186] In other embodiments, the polypeptide of interest is a therapeutic polypeptide. In other embodiments, the polypeptide of interest is an approved biologic drug. In another embodiment, the therapeutic polypeptide comprises the amino acid sequence of Abatacept (e.g., Orencia® (Bristol-Myers Squibb)), Aducanumab-avwa (e.g., Aduhelm® (Biogen Corporation)), Aflibercept (e.g., Eylea® (Regeneron Corp.)), Agalsidase beta (e.g., Fabrazyme® (Genzyme Corp.)), Albiglutide (e.g., Eperzan® (GlaxoSmithKline Corp.)), Aldesleukin (e.g., Proleukin® (Clinigen, Inc.)), Alefacept (e.g., Amevive® (Astellas Pharma, Inc.)), Alglucerase (e.g., Ceredase® (Genzyme Corp.)), Alglucosidase alfa (e.g., Lumizyme® (Genzyme Corp.)), Aliskiren (e.g., Tekturna® (Noden Pharma)), Alpha- 1-polypeptidease inhibitor (e.g., Aralast® (Takeda Pharmaceuticals, Inc.)), Alteplase (e.g., Activase® (Genentech)), Anakinra (e.g., Kineret® (Sobi, Inc.)), Anistreplase (e.g., Eminase® (SmithKlineBeecham)), Anthrax immune globulin human (e.g., Anthrasil® (Cangene Corp.)), Antihemophilic Factor (e.g., Advate® (Baxter Healthcare Corp.)), Antihemophelic Factor Fc- VWF-XTEN fusion protein (e.g., Altuviiio® (Bioverativ Therapeutics, Inc.)), Anti-inhibitor coagulant complex (e.g., Feiba Nf® (Takeda Pharmaceuticals, Inc.)), Antithrombin Alfa, Antithrombin III human, Antithymocyte globulin (e.g., Antithymocyte globulin), Antithymocyte Globulin (Equine) (e.g., ATGAM® (Pfizer)), Anti -thymocyte Globulin (Rabbit) (e.g., ATG-Fresenius), Aprotinin (e.g., Trasylol® (Bayer AG)), Asfotase Alfa (e.g., Strensiq® (AstraZeneca)),, Asparaginase (e.g., Elspar® (Merck & Co., Inc.)), Asparaginase erwinia chrysanthemi (e.g., Erwinaze® (EUSA Pharma, Inc.)), Becaplermin (e.g., Regranex® (Smith & Nephew, Inc.)), Belatacept (e.g., Nulojix® (Bristol-Myers Squibb)), Beractant, Bivalirudin (e.g., Angiomax® (The Medicines Co.)), Botulinum Toxin Type A (e.g., Botox® (Allergan, Inc.)), Botulinum Toxin Type B (e.g., Myobloc® (Supernus Pharmaceuticals)), Brentuximab vedotin (e.g., Adcetris® (Seagen Inc.)), Buserelin (e.g., Suprecur® (Sanofi-Aventis)), Cl Esterase Inhibitor (Human) (e.g., Cinryze® (Takeda Corporation)), Cl Esterase Inhibitor
(Recombinant) (e.g., Ruconest® (Salix Pharmaceuticals, Inc.)), Cerliponase alfa (e.g.,Brineura® Biomarin Pharmaceutical, Inc.)), Certolizumab pegol (e.g., Cimzia® (UCB Pharma Ltd.)), Choriogonadotropin alfa (e.g., Choriogonadotropin alfa), Chorionic Gonadotropin (Human) (e.g., Ovidrel® (EMD Serono)), Chorionic Gonadotropin (Recombinant) (e.g., Ovitrelle® (Merck Serono)), Coagulation factor ix (e.g., Alprolix® (Bioverativ Therapeutics, Inc.)), Coagulation factor Vila (e.g., NovoSeven® (Novo Nordisk A/S)), Coagulation factor X human (e.g., Coagadex® (Bio Products Laboratory, Ltd.)), Coagulation Factor XIII A-Subunit (Recombinant), Collagenase (e.g., Cordase® (Headway Pharma PVT Ltd.)), Conestat alfa, Corticotropin (e.g., H.P. Acthar® (Mallinckrodt Pharmaceuticals)), Cosyntropin (e.g., Cortrosyn® (Amphastar Pharmaceuticals, Inc.)), Darbepoetin alfa (e.g., Aranesp® (Amgen Inc.)), Defibrotide (e.g., Noravid® (Gentium S.p.A.)), Denileukin diftitox (e.g., Ontak® (Eisai Medical Research)), Desirudin, Digoxin Immune Fab (Ovine) (e.g., Digibind® (GlaxoSmithKline LLC)), Domase alfa (e.g., Pulmozyme® (Genentech Inc.)), Drotrecogin alfa (e.g., Xigris® (Eli Lilly & Co.)), Dulaglutide (e.g., Trulicity® (Eli Lilly and Co.)), Efgartigimod alfa (e.g., Vyvgart® Hytrulo (Argenx, US, Inc.)), Ecallantide (e.g., Kalbitor® (Dyax Corp.)), Elapegademase (e.g., Revcovi® (Leadiant Biosciences, Inc.)), Efmoroctocog alfa (e.g., Elocta® (Swedish Orphan Biovitrum AB)), Elosulfase alfa (e.g., Vimizim® (Biomarin Pharmaceutical, Inc.)), Enfuvirtide (e.g., Fuzeon® (Genentech)), Eptinezumab (e.g., Vyepti® (Lundbeck Seattle Biopharmaceuticals, Inc.)), Epoetin alfa (e.g., Binocrit® (Sandoz GmbH)), Epoetin zeta (e.g., Retacrit® (Pfizer)), Eptifibatide (e.g., Integrilin® (COR Therapeutics, Inc.)), Etanercept (e.g., Enbrel® (Amgen Inc.)), Exenatide (e.g., Byetta® (AstraZeneca)), Factor IX Complex (Human) (e.g., AlphaNine® (Grifols Biologicals LLC)), Fibrinolysin aka plasmin (e.g., Elase® (Parke-Davis)), Filgrastim (e.g., N.A.), Filgrastim-sndz, Follitropin alfa (e.g., Gonal- F® (EMD Serono)), Follitropin beta (e.g., Follistim AQ® (Organon & Co.)), Galsulfase (e.g., Naglazyme® (Biomarin Pharmaceutical Inc.)), Gastric intrinsic factor, Gemtuzumab ozogamicin (e.g., Mylotarg® (Pfizer)), Glatiramer acetate (e.g., Copaxone® (Teva Neuroscience)), Glucagon recombinant (e.g., GlucaGen® (Novo Nordisk, Inc.)), Glucarpidase (e.g., Voraxaze® (BTG Pharmaceuticals)), Gramicidin D (e.g., Neosporin® (Johnson & Johnson Consumer, Inc.)), Hepatitis B immune globulin, Human calcitonin, Human Clostridium tetani toxoid immune globulin, Human rabies virus immune globulin (e.g., Hyperab Rabies Immune Globulin Human), Human Rho(D) immune globulin (e.g., Hyp Rho D Inj 16.5%), Human Serum Albumin (e.g., Albuminar® (CSL Behring LLC)), Human Varicella-Zoster Immune Globulin (e.g., Varizig® (Cangene Corporation)), Hyaluronidase
(e.g., Hylenex® (Henry Schein, Inc.)), Hyaluronidase (Human Recombinant), Ibritumomab tiuxetan (e.g., Zevalin® (Acrotech Biopharma Inc.)), Idursulfase (e.g., Elaprase® (Takeda Pharmaceuticals, Inc.)), Imiglucerase (e.g., Cerezyme® (Genzyme Corporation)), Immune Globulin Human, Insulin aspart (e.g., NovoLog® (Novo Nordisk A/S)), Insulin Beef, Insulin Degludec (e.g., Tresiba® (Novo Nordisk A/S)), Insulin detemir (e.g., Levemir® (Novo Nordisk A/S)), Insulin Glargine (e.g., Lantus® (Sanofi-Aventis US LLC)), Insulin glulisine (e.g., Apidra® (Sanofi-Aventis US LLC)), Insulin Lispro (e.g., Humalog® (Eli Lilly Corp.)), Insulin Pork (e.g., Iletin II® (Eli Lilly Corporation)), Insulin Regular (e.g., Humulin R® (Eli Lilly Corp.), Insulin, porcine (e.g., Vetsulin® (Merck & Co.)), Insulin, isophane (e.g., Novolin N® (Novo Nordisk A/S)), Interferon Alfa-2a, Recombinant (e.g., Roferon A® (Hoffman- LaRoche, Inc.)), Interferon alfa-2b (e.g., Intron A® (Merck & Co., Inc.)), Interferon alfacon-1 (e.g., Infergen® (Three Rivers Pharmaceuticals, LLC)), Interferon alfa-nl (e.g., Wellferon® (GlaxoSmithKline)), Interferon alfa-n3 (e.g., Alferon® (AIM Immunotech Inc.)), Interferon beta-la (e.g., Avonex® (Biogen-Idec Corporation)), Interferon beta-lb (e.g., Betaseron® (Bayer Healthcare Pharmaceuticals)), Interferon gamma- lb (e.g., Actimmune® (Horizon Pharma USA, Inc.)), Intravenous Immunoglobulin (e.g., Xembify® (Griffols Therapeutics LLC)), Laronidase (e.g., Aldurazyme® (Genzyme Corporation)), Lenograstim (e.g., Granocyte® (Chugai Pharmaceuticals, Inc.)), Lepirudin (e.g., Refludan® (Behring GmbH)), Leuprolide (e.g., Eligard® (Sanofi -Aventis US, LLC)), Liraglutide (e.g., Saxenda® (Novo- Nordisk, Inc.)), Lucinactant (e.g., Surfaxin®), Lutropin alfa (e.g., Luveris® (EMD Serono)), Mecasermin (e.g., N.A.), Menotropins (e.g., Menopur® (F erring Pharmaceuticals)), Methoxy polyethylene glycol-epoetin beta (e.g., Mircera® (Vifor Pharma)), Metreleptin (e.g., Myalept® (AstraZeneca)), Natural alpha interferon OR multiferon (e.g., Intron/Roferon-A® (Merck & Co./Hoffman-LaRoche, Inc.)), Nesiritide (e.g., Natrecor® (Scios, Inc.)), Ocriplasmin (e.g., Jetrea® (ThromboGenics, Inc.)), Oprelvekin (e.g., Neumega® (Wyeth Pharmaceuticals, Inc.)), OspA lipopolypeptide (e.g., Lymerix® (GlaxoSmithKline)), Oxytocin (e.g., Pitocin® (Pfizer)), Palifermin (e.g., Kepivance® (Amgen, Inc.)), Pancrelipase (e.g., Creon® (Abb Vie Inc.)), Pegademase bovine (e.g., Adagen® (Enzon Pharmaceuticals, Inc.)), Pegaspargase (e.g., Oncaspar® (Sigma-Tau Pharmaceuticals, Inc.)), Pegfilgrastim (e.g., Neulasta® (Amgen, Inc.)), Peginterferon alfa-2a (e.g., Pegasys® (Genentech USA, Inc.)), Peginterferon alfa-2b (e.g., PEG-Intron® (Merck & Co.)), Peginterferon beta-la (e.g., Plegridy® (Biogen Corporation)), Pegloticase (e.g., Krystexxa® (Horizon Therapeutics)), Pegvisomant (e.g., Somavert® (Pfizer)), Poractant alfa (e.g., Curosurf® (Chiesi USA, Inc/Cornerstone Therapeutics, Inc.)), Pramlintide (e.g., Symlin® (AstraZeneca Pharmaceuticals)), Preotact
(e.g., Preotact® (Nycomed A/S)), Protamine sulfate (e.g., Protamine Sulfate Injection, USP), Polypeptide S human (e.g., Polypeptide S human), Prothrombin (e.g., Feiba Nf® (Takeda Pharmaceuticals, Inc.)), Prothrombin complex (e.g., Cofact® (Sanquin Plasma Products B.V.)), Prothrombin complex concentrate (e.g., Kcentra® (CSL Behring LLC)), Rasburicase (e.g., Elitek® (Sanofi-Aventis US, LLC)), Reteplase (e.g., Retavase® (Chiesi USA, Inc.)), Rilonacept (e.g., Arcalyst® (Kiniksa Pharmaceuticals, Ltd.)), Romiplostim (e.g., Nplate® (Amgen, Inc.)), Sacrosidase (e.g., Sucraid® (QOL Medical, LLC)), Salmon Calcitonin (e.g., Calcimar® (Sandoz GmbH)), Sargramostim (e.g., Leucomax® (Novartis)), Satumomab Pendetide (e.g., OncoScint® (Cytogen Corporation)), Sebelipase alfa (e.g., Kanuma® (Alexion Pharmaceuticals, Inc.)), Secretin (e.g., SecreFlo® (Repligen Corp.)), Sermorelin (e.g., Sermorelin acetate), Serum albumin (e.g., Albunex® (Mallinckrodt Medical, Inc.)), Serum albumin iodonated (e.g., Megatope® (Iso-Tex Diagnostics, Inc.)), Simoctocog Alfa (e.g., Nuwiq® (Octapharma USA, Inc.)), Sipuleucel-T (e.g., Provenge® (Dendreon Corporation)), Somatotropin Recombinant (e.g., NutropinAQ® (Genentech)), Somatropin recombinant (e.g., BioTropin® (Bio-Technology General )), Streptokinase (e.g., Streptase® (CSL Behring LLC)), Susoctocog alfa (e.g., Obizur® (Baxalta US, Inc.)), Taliglucerase alfa (e.g., Elelyso® (Pfizer, Inc.)), Teduglutide (e.g., Gattex® (NPS Pharmaceuticals, Inc.)), Tenecteplase (e.g., TNKase® (Genentech, Inc.)), Teriparatide (e.g., Forteo® (Lilly US, LLC)), Tesamorelin (e.g., Egrifta® (Theratechnologies, Inc.)), Thrombomodulin Alfa (e.g., Recomodulin® (Asahi Kasei Pharma)), Thymalfasin (e.g., Zadaxin® (SciClone Pharmaceuticals, IntT.)), Thyroglobulin, Thyrotropin Alfa (e.g., Thyrogen® (Genzyme Corporation)), Tuberculin Purified Polypeptide Derivative (e.g., Aplisol® (Par Pharmaceuticals)), Turoctocog alfa (e.g., Zonovate® (Novo Nordisk)), Urofollitropin (e.g., Bravelle® (Ferring Pharmaceuticals, Inc.)), Urokinase (e.g., Kinlytic® (ImaRx Therapeutics, Inc.)), Vasopressin (e.g., Pitressin® (JHP Pharmaceuticals, LLC)), Velaglucerase alfa (e.g., Vpriv® (Takeda Pharmaceuticals)), Abciximab (e.g., ReoPro® (Janssen Biotech, Inc.)), Adalimumab (e.g., Humira® (Abb Vie, Inc.)), Alemtuzumab (e.g., Campath® (Takeda Oncology, Inc.)), Alirocumab (e.g., Praluent® (Regeneron/Sanofi)), Arcitumomab (e.g., CEA-Scan® (Immunomedics, Inc.)), Atezolizumab (e.g., Tecentriq® (Genentech)), Basiliximab (e.g., Simulect® (Novartis Pharmaceuticals Corporation)), Belimumab (e.g., Benlysta® (GlaxoSmithKline Inc.)), Benralizumab (e.g., Fasenra® (AstraZeneca)), Bevacizumab (e.g., Avastin® (Genentech, Inc.)), Bezlotoxumab (e.g., Zinplava® (Merck & Co., Inc.)), Blinatumomab (e.g., Blincyto® (Amgen, Inc.)), Brodalumab (e.g., Siliq® (Valeant Pharmaceuticals)), Brolucizumab (e.g., Beovu® (Novartis Pharmaceuticals Corporation)),
Burosumab (e.g., Crysvita® (Ultragenyx, Inc.)), Calaspargase pegol (e.g., Asparlas® (Servier Pharmaceuticals, LLC)), Canakinumab (e.g., Haris® (Novartis Pharaceuticals Corporation)), Caplacizumab (e.g., Cablivi® (Ablynx, N.V.)), Capromab (e.g., ProstaScint® (EUSA Pharma (USA), Inc.)), Cemiplimab (e.g., Libtayo® (Regeneron Pharmaceuticals, Inc.)), Cetuximab (e.g., Erbitux® (Lilly USA, LLC)), Crizanlizumab (e.g., Adakveo® (Novartis Pharmaceuticals Corporation)), Daclizumab (e.g., Zenapax® (Hoffmann-LaRoche, Inc.)), Daratumumab (e.g., Darzalex® (Janssen Biotech, Inc.)), Denosumab (e.g., Prolia® (Amgen, Inc.)), Xgeva® (Amgen, Inc.)), Dinutuximab (e.g., Unituxin® (United Therapeutics Corp.)), Dostarlimab (e.g., Jemperli® (GlaxoSmithKline, LLC)), Durvalumab (e.g., Imfinzi® (AstraZeneca)), Dupilimab (e.g., Dupixent® (Regeneron Pharmaceuticals, Inc.)), Eculizumab (e.g., Soliris® (Alexion Pharmaceuticals, Inc.)), Efalizumab (e.g., Raptiva® (Genentech, Inc.)), Elotuzumab (e.g., Empliciti® (Bristol-Myers Squibb)), Elranatamab (e.g., Elrexfio® (Pfizer, Inc.)), Emapalumab (e.g., Gamifant® (Sobi, Inc.)), Emicizumab (e.g., Hemlibra® (Genentech, Inc.)), Erenumab (e.g., Aimovig® (Amgen, Inc.)), Evinacumab (e.g., Evkeeza® (Regeneron Pharmaceuticals, Inc.)), Evolocumab (e.g., Repatha® (Amgen, Inc.)), fam-trastuzumab deruxtecan-nxki (e.g., Enhertu® (Daiichi Sankyo, Inc.)), Fremanezumab (e.g., Ajovy® (Teva Pharmaceuticals, Inc.)), Galcanezumab (e.g., Emgality® (Eli Lilly and Company)), Golimumab (e.g., Simponi® (Janssen Biotech, Inc.)), Guselkumab (e.g., Tremfya® (Janssen Biotech, Inc.)), Ibalizumab (e.g., Trogarzo® (Theratechnologies, Inc.)), Ibritumomab (e.g., Zevalin® (Acrotech Biopharma Inc.)), Idarucizumab (e.g., Praxbind® (Boehringer Ingelheim Pharmaceuticals, Inc.)), Infliximab (e.g., Remicade® (Janssen Biotech, Inc.)), Ipilimumab (e.g., Yervoy® (Bristol-Myers Squibb)), Isatuximab (e.g., Sarclisa® (Sanofi -Aventis, US, LLC)), Ixekizumab (e.g., Taltz® (Eli Lilly & Co.)), Lanadelumab (e.g., Takhzyro® (Takeda Pharmaceuticals, USA, Inc.)), Magrolimab (Gilead Sciences, Inc.), Margetuximab (e.g., Margenza® (Macrogenics, Inc.)), Mepolizumab (e.g., Nucala® (GlaxoSmithKline)), Muromonab (e.g., Orthoclone 0KT3® (Centocor Ortho Biotech Products, LP)), Natalizumab (e.g., Tysabri® (Biogen Idee Corporation)), Necitumumab (e.g., Portrazza® (Eli Lilly and Company)), Nivolumab (e.g., Opdivo® (Bristol-Myers Squibb)), Obiltoxaximab (e.g., Anthim® (Elysys Therapeutics, Inc.)), Obinutuzumab (e.g., Gazyva® (Genentech, Inc.)), Ofatumumab (e.g., Arzerra® (GlaxoSmithKline)), Omalizumab (e.g., Xolair® (Genentech, Inc.)), Palivizumab (e.g., Synagis® (Medimmune, LLC)), Panitumumab (e.g. Vectibix® (Amgen, Inc.)), Pembrolizumab (e.g., Keytruda® (Merck & Co.)), Pertuzumab (e.g., Perjeta® (Genentech, Inc.)), Polatuzumab (e.g., Polivy® (Genentech, Inc.)), Pozelimab® (e.g., Veopoz (Regeneron Pharmaceuticals, Inc.)), Ramucirumab (e.g., Cyramza® (Eli Lilly and
Company)), Ranibizumab (e.g., Lucentis® (Genentech, Inc.)), Ravulizumab-cwvz (e.g., Ultomoris® (AstraZeneca)), Raxibacumab (e.g., Raxibacumab (GlaxoSmithKline)), Risankizumab (e.g., Risanizumab-rzaa, Skyrizi® (Abb Vie Inc.)), Rituximab (e.g., Rituxan® (Genentech, Inc.)), Rozanolixizumab (e.g., Rystiggo® (UCB, Inc.)), Sarilumab (e.g., Kevzara® (Sanofi-Aventis, US, LLC)), Satrilizumab® (e.g., Enspryng (Genentech, Inc.)), Secukinumab (e.g., Cosentyx® (Novartis Pharmaceuticals Corporation)), Siltuximab (e.g., Sylvant® (Janssen Biotech, Inc.)), Tildrakizumab (e.g., Ilumya® (Merck & Co.), Talquetamab (e.g., Talvey® (Janssen Biotech, Inc.)), Teclistamab (e.g., Tecvayli® (Janssen Biotech, Inc.)), Tocilizumab (e.g., Actemra® (Genentech, Inc.)), Tositumomab (e.g., Bexxar® (GlaxoSmithKline)), Trastuzumab (e.g., Herceptin® (Genentech, Inc.)), Ustekinumab (e.g., Stelara® (Janssen Biotech, Inc.)), or Vedolizumab (e.g., Entyvio® (Takeda Pharmaceuticals, USA, Inc.)).
[00187] In other embodiments, the polypeptide of interest is an antibody. In further embodiments, the antibody has the amino acid sequence of adalimumab (Humira® (Abb Vie Inc.)); Remicade® (Janssen Biotech, Inc.) (Infliximab); ReoPro® (Janssen Biotech, Inc.) (Abciximab); Rituxan® (Genentech, Inc.) (Rituximab); Simulect® (Novartis Pharmaceuticals Corporation) (Basiliximab); Synagis® (Medimmune, LLC) (Palivizumab); Herceptin® (Genentech, Inc.) (Trastuzumab); Mylotarg® (Pfizer) (Gemtuzumab ozogamicin); Campath® (Takeda Oncology Corporation) (Alemtuzumab); Zevalin® (Acrotech Biopharma Inc.) (Ibritumomab tiuxetan); Xolair® (Genentech, Inc.) (Omalizumab); Bexxar® (GlaxoSmithKline) (Tositumomab-I-131); Erbitux® (Lilly USA, Inc.) (Cetuximab); Avastin® (Genentech, Inc.) (Bevacizumab); Tysabri® (Biogen Idee Corporation) (Natalizumab); Actemra® (Genentech) (Tocilizumab); Vectibix® (Amgen, Inc.) (Panitumumab); Lucentis® (Genentech, Inc.) (Ranibizumab); Soliris® (Alexion Pharmaceuticals Inc.) (Eculizumab);
Cimzia® (UCB Pharma Ltd.) (Certolizumab pegol); Simponi® (Janssen Biotech, Inc.) (Golimumab); Haris® (Novartis Pharmaceuticals Corporation) (Canakinumab); Stelara® (Janssen Biotech, Inc.) (Ustekinumab); Arzerra® (GlaxoSmithKline) (Ofatumumab); Prolia® and Xgeva® (Amgen, Inc.) (Denosumab); Numax® (Medimmune, LLC) (Motavizumab); ABThrax® (GlaxoSmithKline) (Raxibacumab); Benlysta® (GlaxoSmithKline) (Belimumab); Yervoy® (Bristol-Myers Squibb) (Ipilimumab); Adcetris® (Seagen, Inc.) (Brentuximab Vedotin); Perjeta® (Genentech, Inc.) (Pertuzumab); Kadcyla® (Genentech, Inc.) (Ado- trastuzumab emtansine); or Gazyva® (Genentech, Inc.) (Obinutuzumab).
[00188] In other embodiments, the antibody is a full length antibody, an Fab, an F(ab')2, an Scfv, or a sdAb. In certain embodiments, the polypeptide of interest is a camelid heavy-chain
antibody domain, such as a VHH, sdAbs, or nanobody. In other embodiments, the polypeptide of interest comprises the amino acid sequence of an enzyme or an inhibitor thereof. In another embodiment, the polypeptide of interest comprises the amino acid sequence of Factor VII, Factor VIII, Factor IX, Factor X, Factor XIII, Factor Vila, Antithrombin III (AT-III), Polypeptide C, Tissue plasminogen activator (tPA) and tPA variants, Urokinase, Hirudin, Streptokinase, Glucocerebrosidase, Alglucosidase-a, Laronidase (a-L-iduronidase), Idursulphase (Iduronate-2-sulphatase), Galsulphase, Agalsidase-P (human a-galactosidase A), Botulinum toxin, Collagenase, Human DNAse-I, Hyaluronidase, Papain, L- Asparaginase, Uricase (Urate oxidase), glutamate carboxypeptidase (glucarpidase), al Protease inhibitor (al antitrypsin), Lactase, Pancreatic enzymes (lipase, amylase, protease), and Adenosine deaminase.
[00189] In a specific embodiment, the polypeptide of interest used in accordance with the methods and Leishmania host cells provided herein is a receptor. Exemplary receptors that can be used as a polypeptide of interest include, without limitation, the extracellular domain of human CTLA4 (e.g., fused to an Fc) and the soluble TNF receptor (e.g., fused to an Fc).
[00190] In another embodiment, the polypeptide of interest is secreted into the culture media. In certain embodiments, the polypeptide of interest is purified from the culture media. In another embodiment, the polypeptide of interest is purified from the culture media via affinity purification or ion exchange chromatography. In another embodiment, the polypeptide of interest contains an FC domain and is affinity purified from the culture media via polypeptide-A. In another embodiment, the polypeptide of interest contains an affinity tag and is affinity purified.
[00191] In certain embodiments, the polypeptide of interest used in accordance with the methods and Leishmania host cells provided herein can be a full length polypeptide, a truncation, a polypeptide domain, a region, a motif or a peptide thereof.
[00192] In certain embodiments, the polypeptide of interest is an Fc-fusion polypeptide.
[00193] In certain embodiments, the polypeptide of interest is a biologic comprising an Fc domain of an IgG.
[00194] In certain embodiments, the polypeptide of interest produced by a method described herein is a bifunctional degrader described in ‘GLYCAN-MEDIATED PROTEIN DEGRADATION’, filed September 27, 2023 as an international application with the European Receiving Office, which claims priority to U.S. Provisional Application Nos. 63/410,955 and 63/410,936, and which is incorporated herein in its entirety.
[00195] In certain embodiments, the polypeptide of interest is localized in the secretory pathway. Without being bound by theory, localization within the secretory pathway includes, but is not limited to, localization to one or more of the following sub-cellular compartments: the endoplasmic reticulum, the Golgi apparatus, lysosomes, intracellular membrane proteins, cell surface anchored proteins, and membrane proteins. In certain embodiments, localization in the secretory pathway comprises localization to one or more of said sub-cellular compartments.
[00196] In certain embodiments, the polypeptide of interest comprises a signal peptide localizing the polypeptide of interest in the secretory pathway. In certain embodiments, the signal peptide is derived from the same source as the polypeptide of interest (i.e. the signal peptide is not added to the polypeptide of interest, but is one fused to the polypeptide of interest when naturally expressed in the source). In certain embodiments, the polypeptide of interest is localized in the secretory pathway without adding a Leishmania signal peptide to the polypeptide of interest. In other embodiments, the signal peptide is added to the polypeptide of interest. In certain embodiments, the signal peptide is derived from a Leishmania species. In certain embodiments, the signal peptide is a modified version of a signal peptide from derived from a Leishmania species. In certain embodiments, the signal peptide is derived from Leishmania tarentolae. In certain embodiments, the signal peptide is a modified version of a signal peptide from derived from Leishmania tarentolae. In certain embodiments, the signal peptide is an invertase signal peptide derived from Leishmania tarentolae. In certain embodiments, the signal peptide is a modified version of the invertase signal peptide derived from Leishmania tarentolae. In certain embodiments, the signal peptide comprises an amino acid sequence of SEQ ID NO: 11. In certain embodiments, the signal peptide comprises an amino acid sequence of SEQ ID NO: 12. In certain embodiments, the signal peptide is processed and removed from the polypeptide of interest.
[00197] In certain embodiments, the polypeptide of interest comprises a retention sequence retaining the polypeptide of interest in the secretory pathway. In certain embodiments, the retention sequence is derived from the same source as the polypeptide of interest (i.e. the retention sequence is not added to the polypeptide of interest, but is one fused to the polypeptide of interest when naturally expressed in the source). In certain embodiments, the polypeptide of interest is retained in the secretory pathway without adding a Leishmania retention sequence to the polypeptide of interest. In other embodiments, the retention sequence is added to the polypeptide of interest. In certain embodiments, the retention sequence is fused to the C-terminus of the polypeptide of interest. In certain
embodiments, the retention sequence is fused to the N-terminus of the polypeptide of interest. In certain embodiments, the retention sequence is fused to one or more amino acids within the polypeptide of the polypeptide of interest. In certain embodiments, the retention sequence is derived from a Leishmania species. In certain embodiments, the retention sequence is a modified version of a retention sequence derived from a Leishmania species. In certain embodiments, the retention sequence is derived from Leishmania tarentolae. In certain embodiments, the retention sequence is a modified version of a retention sequence derived from Leishmania tarentolae.
[00198] In another embodiment, the polypeptide of interest has been engineered to comprise one or more tag(s). In other embodiments, the tag is processed and removed from the polypeptide of interest.
[00199] In certain embodiments, the GalNAc transferase described in Section 7.1.1 and the polypeptide of interest are co-localized in the secretory pathway.
7.5.1 Composition and/or Formulation Comprising the Polypeptide
[00200] In another aspect, provided herein are compositions (e.g., pharmaceutical compositions) comprising one or more of the polypeptides of interest described herein. The compositions described herein are useful in the treatment and/or prevention of diseases/disorders in subjects (e.g., human subjects) (see Section 7.5.2).
[00201] In certain embodiments, in addition to comprising a polypeptide of interest described herein, the compositions (e.g., pharmaceutical compositions) described herein comprise a pharmaceutically acceptable carrier. As used herein, the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeiae for use in animals, and more particularly in humans. The term “carrier,” as used herein in the context of a pharmaceutically acceptable carrier, refers to a diluent, adjuvant, excipient, or vehicle with which the pharmaceutical composition is administered. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. Examples of suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E.W. Martin.
[00202] In certain embodiments, the compositions described herein are formulated to be suitable for the intended route of administration to a subject. For example, the compositions described herein may be formulated to be suitable for subcutaneous, parenteral, oral, intradermal, transdermal, colorectal, intraperitoneal, and rectal administration. In a specific embodiment, the pharmaceutical composition may be formulated for intravenous, oral, intraperitoneal, intranasal, intratracheal, subcutaneous, intramuscular, topical, intradermal, transdermal or pulmonary administration.
[00203] In certain embodiments, the compositions described herein additionally comprise one or more buffers, e.g., phosphate buffer and sucrose phosphate glutamate buffer. In other embodiments, the compositions described herein do not comprise buffers.
[00204] In certain embodiments, the compositions described herein additionally comprise one or more salts, e.g., sodium chloride, calcium chloride, sodium phosphate, monosodium glutamate, and aluminum salts (e.g., aluminum hydroxide, aluminum phosphate, alum (potassium aluminum sulfate), or a mixture of such aluminum salts). In other embodiments, the compositions described herein do not comprise salts.
[00205] The compositions described herein can be included in a kit, container, pack, or dispenser together with instructions for administration.
[00206] The compositions described herein can be stored before use, e.g., the compositions can be stored frozen (e.g., at about -20°C or at about -70°C); stored in refrigerated conditions (e.g., at about 4°C); or stored at room temperature.
7.5.2 Prophylactic and Therapeutic Uses
[00207] In one aspect, provided herein are methods of preventing or treating a disease or disorder in a subject comprising administering to the subject a polypeptide of interest described herein or a composition thereof. Further provided herein are methods of preventing a disease or disorder in a subject comprising administering to the subject a polypeptide of interest described herein or a composition thereof.
[00208] In one aspect, provided herein are methods of treating a disease or disorder in a subject comprising administering to the subject a polypeptide of interest described herein or a composition thereof. In another aspect, provided herein are methods of preventing a disease or disorder in a subject comprising administering to the subject a polypeptide of interest described herein or a composition thereof. In a specific embodiment, provided herein is a method for treating or preventing a disease or disorder in a subject comprising administering to the subject a polypeptide of interest produced according to the methods described herein,
wherein the polypeptide of interest is glycosylated with an N-glycan of the following structure:
wherein the black square represents an N-acetylgalactosamine (GalNAc), the white square represents an N-acetylglucosamine (GlcNAc) residue and the black circle represents a mannose (Man) residue, and wherein X represents an amino acid residue of the polypeptide of interest.
[00209] In certain embodiments, the disease or disorder may be caused by the presence of a defective version of a polypeptide of interest in a subject, the absence of a polypeptide of interest in a subject, diminished expression of a polypeptide of interest in a subject can be treated or prevented using the polypeptides of interest produced using the methods described herein. In certain embodiments, the diseases or disorder may be mediated by a receptor that is bound by a polypeptide of interest produced using the methods described herein, or mediated by a ligand that is bound by a polypeptide of interest produced using the methods described herein (e.g., where the polypeptide of interest is a receptor for the ligand).
[00210] In certain embodiments, the methods of preventing or treating a disease or disorder in a subject comprise administering to the subject an effective amount of a polypeptide of interest described herein or a composition thereof. In certain embodiments, the effective amount is the amount of a therapy which has a prophylactic and/or therapeutic effect(s). In certain embodiments, an “effective amount” refers to the amount of a therapy which is sufficient to achieve one, two, three, four, or more of the following effects: (i) reduce or ameliorate the severity of a disease/disorder or symptom associated therewith; (ii) reduce the duration of a disease/disorder or symptom associated therewith; (iii) prevent the progression of a disease/disorder or symptom associated therewith; (iv) cause regression of a disease/disorder or symptom associated therewith; (v) prevent the development or onset of a
disease/disorder, or symptom associated therewith; (vi) prevent the recurrence of a disease/disorder or symptom associated therewith; (vii) reduce organ failure associated with a disease/disorder; (viii) reduce hospitalization of a subject having a disease/disorder; (ix) reduce hospitalization length of a subject having a disease/disorder; (x) increase the survival of a subject with a disease/disorder; (xi) eliminate a disease/disorder in a subject; and/or (xii) enhance or improve the prophylactic or therapeutic effect(s) of another therapy.
7.6 Assay
7.6.1 Strains, Growth and Genetic Methods
[00211] Provided herein are methods for culturing Leishmania host cells described in Section 7.1.
[00212] Host cells are cultured using any of the standard culturing techniques known in the art. For example, cells are routinely grown in rich media like Brain Heart Infusion, Trypticase Soy Broth or Yeast Extract, all containing 5 pg/ml Hemin. In some embodiments, incubation is done at 26°C in the dark as static or shaking cultures for 2-3 days. In some embodiments, cultures of recombinant cell lines contain the appropriate selective agents. In some embodiments, cultures contain Biopterin at a final concentration of 10 pM to support growth.
[00213] A non-limiting list of selective agents is provided in Table 2.
Table 2: Selective agents used during transfection (50% concentration for preselection and 100% concentration for main selection) and standard culturing of L. tarentolae. Double amounts of the selective agents could be used if higher selection pressure was intended.
Attorney Docket No. 14688-006-228
Table 3: Summary of strains presented in the examples. Some of the strains were produced by several rounds of transfection building on top of each other.
Attorney Docket No. 14688-006-228
(i) Plasmids
[00214] Plasmids were derived from a pUC57 vector backbone for E. coli propagation and contained an ampicillin or kanamycin section marker. The expression cassettes are flanked by restriction sites suitable for excision. The composition of the cassettes depends on the intended use and is described in the respective methods and examples. The genes of interest are included as ORFs that were codon usage optimized for L. tarentolae. Optimized sequences were manually curated for avoidance of restriction sites and deletion of repeats or homopolymer stretches. The plasmids were generated and sequenced by a gene synthesis provider. Plasmids and descriptions are found in the sequence listings.
[00215] For codon usage optimization, protein sequences were back-translated to nucleotide sequences using a custom Python3 script that stochastically selects codons based on the /.. tarentolae codon usage frequency while excluding rare codons (frequency <10%). The codon usage has been calculated using cusp (Rice, et al. (2000) Trends in genetics : TIG 16 (6), pp. 276-277) on all annotated L. tarentolae nucleotide coding sequences.
(ii) Transfection Method
(A) Preparation of DNA
[00216] Restriction digest (12 pg DNA in total volume of 240 pL) was performed using standard restriction enzymes (ThermoFisher, preferably FastDigest) according to the manufacturer’s instructions. The restriction digest was performed until completion or o/n at 30°C and DNA was purified by EtOH precipitation (2 volume 100% ice cold EtOH was added to 1 volume digested DNA, incubated 30min on ice, centrifuged for 30 min 17'500 x g at 4°C. Pellet was washed with 70% EtOH and subsequently dried for maximum 15 min and resuspended in ddH20. For optimized removal of circularized plasmid, 1 or 2 restriction enzymes with recognition sites in the vector backbones were chosen and digest was done for Ih at 37°C and purified by EtOH as described above. The digest was analyzed by agarose gel electrophoresis in 0.7-2% agarose gels (TAE buffer). Optionally, gel extraction was performed with the NucleoSpin® Gel and PCR Clean-up kit (Macherey&Nagel) according to manufacturer’s instructions to remove undigested plasmid from the preparation.
(B) Transfection with Nucleofactor
[00217] One day before transfection, a densely grown culture of the parental strain was diluted 1 : 10 into fresh media (Brain Heart Infusion plus Hemin, “BHIH”; or Yeast Extract plus Hemin, “YEH”) containing all antibiotics for which selection markers were previously integrated and cultured overnight at 26°C.
[00218] The linear DNA fragments for integration are mixed for transfection in the needed combinations for multiple DNA fragment- homologous recombination at 1 pg per fragment. The volume of the mix was reduced to approximately 2 pl per transfection in a vacuum concentrator at 30°C. For episomal transfection of plasmids, 0.1-1 pg of plasmid DNA were directly used for transfection.
[00219] Transfection was performed using the 4D-Nucleofector™_Core_X with the P3 Primary Cell 4D-NucleofectorTM X Kit (Lonza). For this, DNA as prepared above was mixed with 16.4 pl P3 Primary Cell solution and 3.6 pl Supplement Solution. The equivalent culture volume of 107 cells (OD should be around 0.3-1.0/ml, cell shape round to drop-like) was pelleted by centrifugation at 1800 g for 5 min and the supernatant was removed. The cell pellet was resuspended in the DNA mix and transfected using a 16-well electroporation strip with pulse FI-158 (in some examples alternative pulses FP167, CM150, EO115, DN100, FP 158, FBI 58 were used). As negative control, an additional culture was transfected with ddH2O only.
[00220] 80 pl of fresh media (BHIH or YEH plus parental selection markers) was added to each well and 2x45 pl of the mix were transferred to individual wells of a 96 well culture plate that were prefilled with 200 pl of fresh medium. After incubation for 24 h at 26°C in the dark (recovery), the new selection marker was added at 50% concentration (preselection; see Table 2). After further incubation for 1-2 days, the selection marker was topped up to 100% (main selection, see Table 2) and several dilutions between 1 :2 and 1 : 10 were performed in 96 well format (final volume 250 pl). Cultures were further incubated at 26°C in the dark for up to 7 days. If no growth was observed, the culture medium was replaced (centrifugation at 1800 g, 10 min, RT) and cultures were again incubated for up to 7 days. This step was repeated if necessary. Growing cultures were expanded in to higher culture volumes by dilutions in the range of 1 :5 and 1 :20 before analysis.
[00221] For clonal selection, cells were streaked on BHIH or YEH plates (containing 1.4% agar and the appropriate 100% selective agent) as soon as the liquid culture turned turbid. Plates were sealed with parafilm and incubated 7-10 days upside down in dark at 26°C. Single colonies (1-2 mm size) were transferred into 24-well plates containing 1 ml BHIH or YEH, sealed with parafilm and incubated in dark at 26°C for around 7-10 days. 1 ml culture was then transferred from 24-well plate into 10 ml BHI or YEH in a flask and further grown statically as usual.
(iii) Method of Engineering Leishmania tarentolae Cells Devoid of O-glycosylation
[00222] Without wishing to be bound by theory, one of the most effective methods to control O-linked GlcNAc modification in L. tarentolae has been found to be an RNP transfection for CRISPR/Cas9 mediated replacement of all three OGNT genes with a single selection marker. See WO 2021/140143. However, other methods have been reported and may be employed, See WO 2021/140143 which is incorporated herein by reference in its entirety. In one embodiment, a ribonucleoprotein complex formed of the endonuclease SpCas9 and bipartite guideRNAs (gRNA) are transfected into L. tarentolae to introduce double-strand breaks in the 5’ and 3’ regions of the open reading frames encoding OGNT1, OGNT2 and OGNTL. The gRNAs are formed by a scaffold RNA (tracrRNA) and one of the six sequence specific targeting RNAs (crRNA), used in this method. Along with the RNP complexes a selection marker expression construct consisting of two linear DNA fragments is transfected into the cells. During double-strand break repair in L. tarentolae the linear DNA pieces are integrated at the former OGNT expression sites by homologous recombination with each other and the 5’ and 3’ untranslated regions of the OGNT gene. In the setup described here, the selection marker expression construct does not introduce additional flanking untranslated regions and thus results in transcription of the marker by endogenous PolII.
(A) Preparation of Ribonucleoprotein (RNP) Complexes for Transfection
[00223] gRNA for CRISPR/Cas9 mediated genome editing was assembled from equimolar amounts of tracrRNA and crRNA (Microsynth) as above by denaturation for 5 min at 95°C and subsequent slow cool down at 0. l°C/s in a thermo cycler. This was done separately for every crRNA used before the different gRNAs were subsequently mixed in equimolar amounts. Next, 122 pmol recombinantly expressed Cas9 protein (i.e. Alt-R® S.p. HiFi Cas9 Nuclease V3 (IDT, #1081061) were added to 360 pmol of the gRNA mix and incubated for 15 min at RT to allow RNP formation. The final volume used for a transfection by Nucleofector (as described in this Section) should not exceed 6 pl. Lastly, the RNP mix was added to the repair DNA containing transfection solution described below along with 1 pl of Alt-R® Cas9 Electroporation Enhancer (IDT, #1081072).
(B) DNA Preparation for Transfection
[00224] The linear DNA fragments for integration are mixed for transfection in the needed combinations at 1 pg per fragment and the gRNA was prepared as described above and mixed with the integration fragments. The volume of the mix was reduced to maximum 2 pl per transfection in a vacuum concentrator at 30°C.
(C) Transfection with Nucleofector
[00225] One day before transfection, a densely grown culture of the parental strain was diluted 1 : 10 into fresh media (BHIH) containing all antibiotics for which selection markers were previously integrated and cultured over night at 26°C.
[00226] Transfection was performed using the 4D-Nucleofector™_Core_X with the P3 Primary Cell 4D-NucleofectorTM X Kit (Lonza). For this, DNA (or DNA/RNA or DNA/RNP) as prepared above was mixed with 16.4 pl P3 Primary Cell solution and 3.6 pl Supplement Solution. The equivalent culture volume of 107 cells (OD should be around 0.3- 1.0/ml, cell shape round to drop-like) was pelleted by centrifugation at 1800 g for 5 min and the supernatant was removed. The cell pellet was resuspended in 20 pl of the DNA (or DNA/RNA or DNA/RNP) mix and transfected using a 16-well electroporation strip with pulse FI-158 (in some examples alternative pulses FP167, CM150, EO115, DN100, FP158, FBI 58 were used). As negative control, an additional culture was transfected with ddH2O only.
[00227] 80 pl of fresh media (containing selection markers for the parental cell line) was added to each well and 2x45 pl of the mix were transferred to individual wells of a 96 well culture plate that were prefilled with 200 pl of fresh medium. After incubation for 24 h at 26°C in the dark (recovery), the new selection marker was added at 50% concentration (preselection; see Table 2). After further incubation for 1-2 days, the selection marker was topped up to 100% (main selection) and several dilutions between 1 :2 and 1 : 10 were performed in 96 well format (final volume 250 pl). Cultures were further incubated at 26°C in the dark for up to 7 days. If no growth was observed, the culture medium was replaced (centrifugation at 1800 g, 10 min, RT) and cultures were again incubated for up to 7 days. This step was repeated if necessary. Growing cultures were expanded into higher culture volumes by dilutions in the range of 1 :5 and 1 :20 before analysis.
(D) crRNA Design
[00228] crRNAs were designed based on the target regions (usually coding sequences of OGNT genes) for use with SpCas9 (PAM=NGG) by EuPaGDT (http://grna.ctegd.uga.edu/) and were counterchecked for on-/off-target effects by blast against the whole genome of L.
tarentolae. crRNAs were then selected such that they are ideally targeting the extremities of the coding sequence to be replaced.
Table 4: crRNAs designed for knockout of OGNT genes. Information about stabilizing modifications of tracrRNA and crRNA ordered at Microsynth. * = PTO bond (Phosphorothioate bond); 5 = 2'-O-Methyl-RNA-A; 6 = 2'-O-Methyl-RNA-C, 7 = 2'-O- Methyl-RNA-G; 8 = 2'-O-Methyl-RNA-U; HPL = IEX-HPLC purified.
(iv) PCR and Sequence Analysis of Deletion Strains
(A) Preparation of gDNA - Genomic DNA Isolation by Tissue Kit
[00229] 2 ml of densely grown L. tarentolae culture were pelleted at 1800 g and the supernatant was discarded. The pellet was used for preparation of genomic DNA by the NucleoSpin® Tissue Kit (Macherey-Nagel). For this, the pellet is resuspended in 200 pl of Buffer T1 and further treated according to the manufacturer’s instructions until elution. For efficient elution, 50 pl of prewarmed (50°C) Buffer BE are added to the column and incubated at RT for 3 min. The eluate is collected by centrifugation for 1 min at 11000g. Repetition of this step as well as reloading of the eluate can be used to increase the yield.
(B) Preparation of Crude Cell Extracts for PCR Analysis
[00230] 50 pl of culture were washed in 1ml PBS and pelleted at 1800 g for 5 min. The supernatant was removed and the pellet was resuspended in 50 pl of PBS and boiled at 95°C
for 5 min with intermitted vortexing. 1 pl was used instead of template DNA in the PCR reaction.
(C) PCR Analysis of OGNT KOs
[00231] PCR confirmation of OGNT knock-outs was performed by either amplification of the complete locus (OGNT1, OGNT2, OGNTL or OGNT1+L, where OGNT1+L comprises OGNT1 and OGNTL in tandem on the chromosome) or by amplification of the shorter fragments covering the integration sites.
[00232] Usually the successful replacement of the wildtype OGNT sequence (OGNT1 = 3.4 kbp, OGNT2=1.9 kbp and OGNTL=3.4 kbp) by the selection marker coding sequences (0.4- 1.0 kbp) with or without the additional intergenic regions (together approx. 0.9 kbp) could be easily confirmed by the size of the amplicon resulting from the PCR targeting the whole native locus, since correct replacement of the wt gene would lead to a much shorter amplicon. For these PCRs LATaq DNA polymerase (TaKaRa) was used in combination with a buffer for amplification of GC rich sequences that allowed the amplification of the long wildtype regions (see Table 5). In some cases, amplification of shorter regions with primer binding within the OGNT coding sequence was preferred to test for presence of remaining wt genes (see Table 6). For these, the DreamTaq DNA polymerase (Thermo Fisher Scientific) was used. Alternatively, the correct integration of the selection marker gene into the respective OGNT locus could be tested by combinations of a primer binding in the genome with one primer binding to the selection marker CDS or the intergenic regions of the integrated construct and the other one targeting the genome.
Table 5: PCRs for analysis of OGNT deletions. PCR primers used for confirmation OGNT knock-outs by absence of the respective OGNT wt gene and the expected amplicon sizes are summarized. * KO amplicon length for whole locus PCRs depends on the combination of selection marker and intergenic regions used.
Table 6: Listing of primer sequences used in the described examples.
(v) Expression analysis
(A) Sample Preparation from Leishmania tarentolae
[00233] Cells were grown for 2-3 days at 26°C, static (e.g.in 3 ml in a 6-well plates). Whole cell extract (WCE) cell free culture supernatants were analyzed by Western blot. For supernatant analysis, grown culture was centrifuged at 1800 g at RT for 5 min and cell free supernatant was transferred to a new tube and mixed with Laemmli dye under reducing or non-reducing conditions. Cell pellets for WCE were washed with lx PBS, centrifuged again at 1800 g at RT for 5 min and frozen at -80°C for minimally 30 min. After thawing it again at RT pellet was then resolved in Leammli (reducing) buffer, boiled again at 95 °C for 10 min and vortexed intensively.
(B) Expression Analysis by Western Blot
[00234] Samples were run on 4-12% Bis-Tris SDS PAGE, using a MOPS running buffer with 200 V for 60 min. Gels were blotted using an Iblot device for 7 min on PVDF membranes. Membranes were blocked for at least 30 min at RT in 10% milk. Primary antibodies (i.e. goat anti-Human IgG-HRP (A6029, Sigma) 1 :2000 diluted, mouse antiHuman Kappa Light Chain (K4377, Sigma) 1 :5000 diluted were used diluted in 1% milk, lx PBST for o/n incubation at 4°C. Afterwards, the blot was washed with lx PBST three times
for 5 min before detection with horse reddish peroxidase (HRP) coupled secondary antibodies (anti-mouse polyvalent-HRP (A0412, Sigma) 1 :2000 diluted or anti-rabbit-HRP conjugate (Jackson ImmunoResearch #111-035-008) 1 :2000 diluted) in 1% milk, lx PBST for 3h rotating at 30°C, followed by three washes for 5 min in IxPBST and one component 3,3’,5,5’-tetramethylbenzidine (TMB) substrate staining for colorimetric detection (TMBM- 1000-01, Surmodics).
7.6.2 Small Scale Expression and Purification of Monoclonal Antibodies
[00235] Host cells were routinely grown in 50 ml culture in BHIH or YEH for 48 h at 26°C shaking at 140 rpm. Cultures were harvested and centrifuged for 10 min at 1800*g at RT. Media SN was filtered through 0.22 pm filter (Steriflip, SCGP00525) and EDTA(0.5 M pH8) was added to each load in a 1 : 100 dilution. Media SNs of each strain were subjected to 4h incubation with 100 pl of proteinA resin (ProteinA-Sepharose 4B Fast Flow, Sigma Aldrich, P9424) per Falcon tube in batch while rotating at RT. After treatment with ProteinA resin, the samples were centrifuged at 500*g for 5 min, the FT was discarded and the resin was transferred to spin columns. Washes were performed with 3 x 5 CV using Buffer A (pH 7.2, 20 mM Na2HPO4, 150 mM NaCl, pH was adjusted with HC1 to 7.20) using 500 pl for 100 pl resin; with centrifugation at 1000*g, RT, 1 min between each step. Elution was performed with several CV of Buffer B (0.1 M acetic acid, 100 mM NaCl, pH was adjusted with 1 M NaOH to 3.20) using 100 pl for 100 pl resin, with centrifugation at 1000*g, RT, 1 min between each step (e.g. 3xlCV and 1x0.5 CV). Elution fractions were pooled and immediately neutralized by adding 100 mM Tris-HCl (1 M pH8). Afterwards, the pooled elutions were buffer exchanged to PBS pH 6 using 2 ml 7K ZebaSpin desalting columns and optionally concentrated using Amicon 0.5 ml 30 K concentrators.
[00236] Elution fractions were pooled and immediately neutralized by adding 100 mM Tris-HCl (1 M pH8). Afterwards, the pooled elutions were buffer exchanged to PBS pH 6 using 2 ml 7K ZebaSpin desalting columns and optionally concentrated using Amicon 0.5 ml 30 K concentrators.
[00237] Samples were then subjected to analyses such as HILIC-UPLC-MS as described below.
7.6.3 Analysis
(i) SDS PAGE and Capillary Gel Electrophoresis
[00238] SDS PAGE was performed under reduced or non-reducing conditions using 10 pg for Coomassie, 2.5 pg for WB, separated on 4-12% Gel with MOPS buffer for 55 minutes.
Determination of Protein purity was done by Coomassie Stained SDS-PAGE with 10 pg protein sample and compared to a BSA standard curve. Impurities were quantified by ImageQuant. Capillary Gel Electrophoresis (CGE) was performed using an Agilent Protein 230 Kit (5067-1518), according to protocol.
(ii) Analytical SEC
[00239] MAbPac SEC-1 (4x300 mm) is a size exclusion chromatography (SEC) column specifically designed for separation and characterization of monoclonal antibodies (mAbs) and was used according to manufacturer’s recommendation (Temperature: 30 °C; Eluent: PBS 50mM NaPO4, 300 mM NaCl pH 6.8; Elution: isocratic, 30 minutes; Flow: 0.2 mL/minute; Detection: 215 nm; Injection V: 5 pL corresponding to 5 pg protein).
(iii) O-HexNAc identification
[00240] Intact monoclonal antibodies were analyzed by mass spectrometry employing the state-of-the-art instrumentation (Orbitrap FTMS), data processing and data analysis (bioinformatics) tools by SpectroSwiss. In addition to the intact measurement the antibody was reduced with TCEP or enzymatically cleaved (IdeS) to generate Fd, LC and Fc/2 subunits, which were analyzed using the same instrumentation.
(iv) Sample preparation for IdeS derived subunit analysis
[00241] To generate mAb subunits of about 25 kDa each, IdeS (FabRICATOR, Genovis, Lund, Sweden) digestion of mAbs was performed in formulation buffers. One unit of IdeS was added to each pg of mAbs and left to react for 30 minutes at 37° C. Then, mAbs were denatured and reduced by incubation with 6 M GdnCl and 30 mM TCEP at room temperature for 30 minutes. Finally, the reaction was quenched by acidifying the solution to 1 % TFA. For the analysis samples were diluted with 0.1% FA in water to a final concentration of 1 pg/pl.
(v) Mass spectrometry for intact and subunit analysis, Bioinformatics and Data processing.
[00242] A standard Orbitrap-based intact protein mass measurement set-up (a triplicate LC-MS experiment) was employed using:
[00243] - Analytical HPLC (Dionex) with 30 min run duration,
[00244] - Analytical column (Waters), C4 Aquity, BEH, 90 pl/min @60C,
[00245] - Q Exactive HF FTMS (Thermo),
[00246] - FTMS Booster (Spectroswiss), advanced data acquisition system
[00247] - Full MS resolution: 30’000 @ m/z 200 for intact mAb and 60’000 @ m/z 200 for subunit analysis
[00248] - Charge target number (ion number): AGC of 3e6
[00249] Intact Mass (Protein Metrics) was employed for mass spectra deconvolution of intact mAbs. MASH Suite software tool (open access, Wisconsin University, Ying Ge Group) was used for deconvolution of the mass spectra of the subunit analysis. The employed resolution enabled obtaining isotopically-resolved data. Peak-by-Peak software tool (Spectroswiss) was employed for time domain signals and mass spectra processing. The employed methods enabled obtaining high spectral dynamic range data.
(vi) Analysis of N-glycans released from purified proteins and cells surfaces by HILIC-UPLC-MS
[00250] Enzymatic release of N-glycans from cell surfaces was performed using PNGase F (New England Biolabs). Cells (grown for 48 or 72 h at 26°C shaking at 140 rpm) were harvested and washed with PBS by centrifugation for 10 min at 1800*g at RT.50 mg of cell pellet were re-suspended in Glyco Buffer 2 and incubated with 1 pl PNGase F for 1 h at 37 °C and 650 rpm. Cells were again pelleted by centrifugation and 75 pl of the supernatant was dried down in a SpeedVac concentrator. Glycans were resuspended in 10 pl of water.
Following release, glycans were directly labeled with procainamide as described previously (Behrens, et al. (2018) Glycobiology 28 (11), pp. 825-831). Briefly, released glycans were mixed with 1 pl acetic acid, 8 pl of a procainamide stock solution (550 mg/ml in DMSO) and 12 pl of a sodium cyanoborohydride stock solution (200 mg/ml in H2O). Samples were incubated for 60 min at 65 °C and cleaned up using LC-PROC-96 clean up plates (Ludger Ltd) according to the manufacturer’s instructions.
[00251] Enzymatic release of N-glycans from purified proteins was performed using Rapid PNGase F (New England Biolabs) as recommended by the supplier. 8 pl of sample (15 pg of protein) were mixed with 2 pl Rapid Buffer and 1 pl of Rapid PNGase F. The mixture was incubated at 50 °C for 10 min followed by 1 min at 90 °C.
[00252] For site specific N-glycan analysis of monoclonal antibody subunits, IgGl mAb was either cleaved with IdeZ to F(ab’)2 and Fc/2, or heavy and light chains were reduced before separation on SDS PAGE. Bands were excised and enzymatic release of N-glycans from the monoclonal antibody was performed using PNGase F. Following release, glycans were directly labeled with procainamide (PC).
[00253] Procainamide-labeled N-glycans were analyzed by hydrophilic interaction chromatography-ultra performance liquid chromatography-mass spectrometry (HILIC-
UPLC-MS) using am Acquity UPLC System (Waters) with fluorescence detection coupled to a Synapt G2-Si mass spectrometer (Waters). Glycans were separated using an Acquity BEH Amide column (130 A, 1.7 pm, 2.1 mM x 150 mM; Waters) with 50 mM ammonium formate, pH 4.4 as solvent A and acetonitrile as solvent B. The separation was performed using a linear gradient of 72-55 % solvent B at 0.5 ml/min for 40 min. Fluorescence was detected at an excitation wavelength of 310 nm and a detection wavelength of 370 nm. The Synapt G2-Si mass spectrometer fitted with a Zspray electrospray source was used for mass detection in positive resolution mode using the following parameters: Scan range: m/z 300- 3500; scan time: 1 sec; capillary: 2.2 kV; source temperature: 120 °C and sampling cone: 75 V. MassLynx 4.2 (Waters) was used for data acquisition. Data processing and analysis was performed using Unifi 1.9.4.053 (Waters). Glucose units were assigned using a fifth-order polynomial distribution curve based on the retention times of a procainamide-labeled dextran ladder (Ludger Ltd). Glycan structures were assigned based on their m/z values and their retention times and matched against a previously constructed N-glycan library. For individual samples the UPLC was coupled to a Synapt HDMS mass spectrometer using comparable settings.
7.6.4 Analysis of UDP-GalNAc by High Performance Anion Exchange Chromatography Coupled with Pulsed Amperometric Detection (HPAEC-PAD)
[00254] MeOH/Chloroform extraction procedure for L. tarentolae cell pellets was performed on 2 OD of each sample, which were harvested by centrifugation and washed 2x with IxPBS (2200 g, 10 min, RT) and frozen. For extraction, pellets were thawed, resuspended in 480 pl MeOH, supplemented with 20 pl water and sonicated in a water bath at RT for 15 min. The samples were spun in a table-top centrifuge at 18000 g and 4°C for 10 min. The SN was transferred into a glass vial, supplemented with 268 pl chloroform and vortexed. Next, 500 pl H2O (MS grade) was added and the sample was vortexed again. The MeOH/chloroform/H2O (1/0.54/1) mixture was spun at 2200 g and RT for 20 min to remove proteins, lipids and DNA in the CHC13 phase. Approximately half (525 pl) of the upper Me0H/H20 phase was collected and transferred into Eppendorf tubes, corresponding to extracted material from 0.5 OD pellet. The samples were dried in a speed-vac and stored at - 20°C until analysis. Thawed samples were resuspended in H2O and amounts corresponding to 0.5 OD analyzed by High performance anion exchange chromatography coupled with pulsed amperometric detection (HPAEC-PAD) using CarboPac PAI, 4x250 mm (Thermo), based on Tomiya et al. 2001 : Determination of Nucleotides and Sugar Nucleotides Involved in Protein Glycosylation by High-Performance Anion-Exchange Chromatography: Sugar
Nucleotide Contents in Cultured Insect Celles and Mammalian Cells. Analytical Biochemistry 293, p. 129-137, with an adjusted gradient. A standard of UDP-GalNAc/- GlcNAc mix (each 25 ug/mL) in H2O was prepared in addition to the cell extract samples -> 1000 ug/mL UDP-GlcNAc and -GlcNAc solutions were pre-diluted 1 : 10 to 100 ug/mL solutions. 50 uL of each 100 ug/mL solution was added to 100 uL H2O for a solution containing 25 ug/mL from each component (corresponds to 38.4 uM from each component). Spiked UDP-GalNAc was detectable in cell extract samples as set for another control. Variability for three independent replicates of 0.5 OD injection is at 17.2% CV (n=3). Average recovery lies at 69%. For the 1.2 OD injection, spike recovery lies at 62% (n=l).
8. EXAMPLES
8.1 EXAMPLE 1
[00255] Glycoengineered Leishmania larenlolae. the CGP (CustomGlycan Platform) host cells have performed efficiently to generate specific human N-glycans such as A2, A2G2 or A2G2S2, and for expression of different recombinant therapeutic proteins such as monoclonal antibodies (mAbs) and Erythropoietin, as described in detail in WO 2019/002512, WO 2021/140144, WO 2021/140143 and WO 2022/053673. Described herein is the engineering of host cells to produce native and recombinant proteins having a biantennary GalNAc terminated N-glycan, namely A2GalNAc2 (for nomenclature, see Section 5.3). The Leishmania host cells provided herein produce surprisingly efficient ASGPR ligands that can be exploited for generating innovative therapeutics designed, for example, but not limited to, targeted protein degradation, such as clearing soluble targets quickly from circulation.
[00256] As a first step, the enzymatic steps required to generate A2GalNAc2 containing N-glycans in Leishmania host cells (as referred to herein as CGP, or CGP host cells) were identified. First, there are enzymes required for generating UDP-GalNAc and second, the enzymes that mediate the transfer of GalNAc from UDP-GalNAc to GlcNAc acceptors with a beta-l,4-linkage, to form monoantennary and biantennary GalNAc-beta-l,4-GlcNAc (A2GalNAc2) structures in N-linked glycans.
[00257] A genomic search was performed to identify enzymes involved in the generation of nucleotide activated sugar donors in L. tarentolae '.
[00258] For UDP-Glc and UDP-Gal the enzymes and reactions are as follows: a-D-Glc-1- P + UTP is converted by UDP -glucose pyrophosphorylase (UGP) to UDP-Glc, which can be
further epimerized by GalE (UDP -galactose 4-epimerase) to UDP-Gal. In addition to this de novo pathway, Leishmania parasites and plants possess also a UDP-sugar pyrophosphorylase (USP), which has broad substrate specificity and is involved in monosaccharide salvage. This means that a-D-Gal-l-P + UTP can be formed by USP to UDP-Gal. The UDP-sugar pyrophosphorylase can therefore activate both Gal-l-P and Glc-l-P n Lei hmania major. Deletion of the UGP encoding gene in L. major strongly reduced but did not abolish the biosynthesis of UDP-Gal and its immediate precursor UDP-Glc, since USP enabled the limited biosynthesis of both nucleotide sugars. (Roper 2002, Urbaniak 2006, Capul 2007, Damerow 2004). For illustration, see FIG. 1.
[00259] UDP-Gal is readily available in Leishmania tarentolae, as determined by (1) the presence of USP, UGP and GalE orthologues (see Table 7) and (2) the efficient generation of galactosylated N-glycans from engineered L. tarentolae, for which the recombinant galactosyltransferases need UDP-Gal as activated sugar donor for their activity (see A2G2 and A2G2S2 in WO 2019/002512, WO 2021/140144, WO 2021/140143, and WO 2022/053673). While UDP-Gal is natively produced by L. tarentolae presumably by a predominant de novo process involving epimerization of the abundant nucleotide sugar UDP- glucose by the UDP -galactose 4-epimerase (GalE), there was no evidence of genes generating UDP-GalNAc found by the bioinformatic search.
8.1.1 UDP-GalNAc Biosynthesis Pathway: the Salvage Pathway
[00260] UDP-GalNAc can be generated by the salvage pathway in mammalian cells. UDP-N-acetyl hexosamine pyrophosphorylase (UAP1) converts UTP and GlcNAc-1-P into UDP-GlcNAc, and UTP and GalNAc-l-P into UDP-GalNAc. Without wishing to be bound by theory, the isoform AGX1 is about 2 to 3 times more active towards GalNAc-l-P, while
the isoform AGX2 is about 8 times more active towards GlcNAc-1-P. GalNAc-l-P is formed by a specific kinase which is GALK2 (N-acetyl galactosamine kinase) that is distinct from galactose- 1 -kinase.
[00261] These GalNAc Salvage pathway enzymes are not present in L. tarentolae and were selected to be recombinantly expressed in CGP host cells.
8.1.2 UDP-GalNAc Biosynthesis Pathway: Epimerization Pathway
[00262] On the other hand, UDP-GalNAc can also be formed by epimerization of UDP- GlcNAc using the same NAD-dependent epimerase that converts UDP-Glc to UDP-Gal. The human GalE catalyzes two distinct but analogous reactions: the reversible epimerization of UDP-Glc to UDP-Gal and the reversible epimerization of UDP-GlcNAc to UDP-GalNAc. The reaction with UDP-Gal plays a critical role in the Leloir pathway of galactose catabolism in which galactose is converted to the glycolytic intermediate Glc-6-P. It contributes to the catabolism of dietary Gal and enables the endogenous biosynthesis of both UDP-Gal and UDP-GalNAc when exogenous sources are limited. The human GalE was selected to be recombinantly expressed in CGP host cells.
[00263] Another epimerase was selected from a bacterial source. The major cell-surface carbohydrates (lipooligosaccharide, capsule, and glycoprotein N-linked heptasaccharide) of Campylobacter jejuni contain Gal and/or GalNAc residues. The presence of GalNAc residues in these carbohydrates suggested that GalE, the initially annotated UDP-glucose 4-epimerase might be a UDP-GlcNAc 4-epimerase. GalE was indeed shown to epimerize UDP-Glc and UDP-GlcNAc in coupled assays with C. jejuni glycosyltransferases and in sugar nucleotide epimerization equilibria studies. Thus, GalE possesses UDP-GlcNAc 4-epimerase activity and was renamed Gne (Bematchez et al., (2005) J Biol Chem.; 280(6):4792-802. doi: 10.1074/jbc.M407767200).
8.1.3 UDP-GalNAc Biosynthesis Pathway: Transporter Protein
[00264] A transporter of UDP-GlcNAc and UDP-GalNAc is encoded by the Caenorhabditis elegans gene C03H5.2. Surprisingly, translocation of these substrates occurs in an independent and simultaneous manner that is neither a competitive nor a symport transport (Caffaro et al., (2006). Proc Natl Acad Sci U S A;103(44): 16176-81). This transporter was selected to be recombinantly expressed along with the salvage and epimerization pathway enzymes.
8.1.4 GalNAc Transferases
[00265] N-acetyl-beta-glucosaminyl-glycoprotein 4-P-N-acetyl galactosaminyl-transferase activity was described by Sato et al., (2003): Journal of Biological Chemistry 278 (48), pp. 47534-47544. This human p4GalNAc-T3 (“P4-GalNAcT3”) effectively synthesizes N,N'-diacetylgalactosediamine, GalNAc P 1-4 GlcNAc, at non-reducing termini of various acceptors derived not only from N-glycans but also from O-glycans. These results suggest that p4-GalNAcT3 could transfer GalNAc residues, producing N,N'-diacetylgalactosediamine structures at least in N-glycans and probably in both N- and O-glycans. p4-GalNAcT3, (Sato et al., (2003): Journal of Biological Chemistry 278 (48), pp. 47534-47544), and P4- GalNAcT4 (Gotoh et al., (2004): FEBS Letters 562 (1-3), pp. 134-140) were therefore identified for GalNAc transfer and described have a broad tissue expression coverage including fetal kidney and brain in human.
[00266] It has also been reported that adding a carboxyl-terminal 19-amino-acid a-helix stretch with several basic amino acids is sufficient to mediate GalNAc transfer to N-linked oligosaccharides. Other GalNAc motifs involve three structural loops with aromatic side chains, as well as additional unidentified motifs. Some glycohormones contain N,N'- diacetylgalactosediamine structures in their N-glycan. Fiete et al., (2012): J. Biol. Chem. 287 (34), pp. 29194-29203. Bonar et al., (2014): J. Biol. Chem. 289 (43), pp. 29677-29690.
[00267] Human p4-GalNAcT3 and p4-GalNAcT4, were selected to be recombinantly expressed in CGP host cells.
[00268] The A2GalNAc2 motif occurs in mammalian pituitary glycoprotein hormones, where the terminal GalNAc residues are 4-O-sulfated functions as a recognition marker for clearance by the endothelial cell CD206 (ManR) receptor. However, nonpituitary mammalian glycoproteins also contain A2GalNAc2 determinants, indicating that expression of A2GalNAc2 determinants in vertebrate glycoconjugates is more widespread than once thought. Noteworthy, A2GalNAc2 and modifications of A2GalNAc2 sequences are common antigenic determinants in many parasitic nematodes and trematodes. Caenorhabditis elegans CeP4GalNAcT is a member of the P4GalT family, a 383-amino acid type 2 membrane glycoprotein. Its soluble, epitope-tagged recombinant form of CeP4GalNAcT expressed in CHO-Lec8 cells was functional using UDP-GalNAc, but not UDP-Gal, as a donor toward different acceptor substrates containing terminal P-linked GlcNAc in both A- and ( -glycan type structures (Kawar et al., (2002). J Biol Chem.;277(38): 34924-32 Kawar et al., (2005). J
Biol Chem. (13): 12810-9). This enzyme was also selected to be recombinantly expressed in CGP host cells.
[00269] The UDP-GalNAc biosynthesis pathway enzymes and GalNAc transferases recombinantly expressed in CGP are listed in Table 8. “Tr” means truncated, as the candidate GalNAc-transferase was N-terminally truncated, to yield a soluble form, and a Leishmania tarentolae derived signal peptide was added.
Table 8: The UDP-GalNAc Biosynthesis Pathway Enzymes and GalNAc Transferases
[00270] To summarize, these candidates were primarily selected from sufficiently well described human source but extended to other species such as bacterial organisms or nematodes, that do generate GalNAc containing glycoconjugates.
8.2 EXAMPLE 2 - Strains for UDP-GalNAc Biosynthesis Pathway
[00271] While there was no evidence of genes generating UDP-GalNAc found by the bioinformatic search, the absence of UDP-GalNAc in HPAEC-PAD performed on MeOH/Chloroform extraction of L. tarentolae cell pellets was confirmed. (See FIG. 3A)
[00272] To then evaluate GalNAc biosynthesis pathways for CGP glycoengineering of A2GalNAc2 N-glycans, different genetic combinations were tested, e.g. Transporter +Salvage + Epimerase (“T+S+E” or “TSE”); or Transporter + Salvage (“T+S” or “TS”) ; or Transporter^- Epimerization (“T+E” or “TE”) with genetic constructs of codon usage optimized (cuo) coding sequences spaced by different intergenic regions derived from Leishmania major (J, AC, AJ, T, AF vs Y, Z, AJ, T, AF) and different site-specific integration loci (pfr and aTub). These different genetic constructs were integrated into StLMTB19915, a strain expressing an mAb with 2 exposed glycosites (Adalimumab K84N, D86N), >98% A2 N-glycans and devoid of O-glycosylation. The resulting strains (StCGP2801, 2803, 2805, 2807, 2847/2848) were not yet containing any GalNAc transferase, but their suitability to generate UDP-GalNAc as nucleotide activated sugar donor was tested by HPAEC-PAD on Chloroform/MetOH extracted cell pellets. The cells containing the salvage pathway enzymes (“T+S”) in StCGP2805 and one cell line StCGP2848, containing T+S+E, were grown in media supplemented with lOmM GalNAc.
[00273] Extracts from strains StCGP2805 and StCGP2848 clearly show detectable levels of UDP-GalNAc whereas in other extract samples, UDP-GalNAc is not or only detectable at minor amounts. Highest level of UDP-GalNAc was determined for the extract from StCGP2848. Interestingly, StCGP2847, another clone tested containing the same “T+S+E” construct (a second clone from the same transfection), but was not supplemented with GalNAc in the medium, did not show UDP-GalNAc. Also for StCGP2801 and StCGP2803 (both “T+S+E”) were not fed with GalNAc and also did not show any significant amounts of UDP-GalNAc, See FIG. 3B.
[00274] These results suggest that the salvage pathway is active in CGP when media is supplemented with GalNAc. This also means that no or only minor amount of GalNAc is present in the used Yeast extract media (YEH). Notably, Epimerization only (“T+E”) also did not show measurable levels of accumulated UDP-GalNAc, or if at all at very minor levels.
8.3 EXAMPLE 3
8.3.1 Testing Human GalNAc Transferases
[00275] The cell lines discussed in Example 2 containing different UDP-GalNAc biosynthesis pathways were further transfected with different human GalNAc transferase constructs (P4-GalNAcT3 and/or p4-GalNAcT4), and N-glycan profiles on the purified mAb were evaluated. First, the mAb was cleaved by IdeZ to generate F(ab’)2 and Fc subunits,
which were separated on SDS PAGE. Bands were cut from the gel and subjected to PNGaseF N-glycan release and labeling with PC (see method vi). Surprisingly, >80% A2GalNAc2 N- glycans on exposed (Fab) glycosites in one of the strains, StCGP2879 was found (see FIGS. 4A and 4B). In many of the strains, 50 to 80% A2GalNAc2 on Fab sites was detected. While on the Fab glycosites up to 80% A2GalNAc2 was observed, the conversion up to A2GalNAc2 seems to be much higher on the Fab glycosite compared to the native surface glycoproteins. The results of this study are illustrated in FIG. 5 and discussed below. The cell lines are described in Table 3.
[00276] Furthermore, on the Fc glycosite only minor amount of A2GalNAc2 (up to 10%) was observed. However, this was expected to be low since it was already seen before that the galactosylation is not very efficient on the sterically constraint N297 Fc glycosite.
8.3.2 Strains Containing Transporter, Salvage and Epimerization Pathways and (34- GalNAcT3
[00277] The targeted locus of the UDP-GalNAc pathway did not seem to make a difference comparing StCGP2853 [Pfr] with StCGP2855 [atub]. The intergenic region variants IrLmJ and IrLmAC seemed to be beneficial over IrLmY and IrLmZ.
8.3.3 Strains Containing Transporter and Salvage Pathways and |J4-GalNAcT3
[00278] The intergenic region variants IrLmY and IrLmZ seemed to be beneficial over IrLmJ and IrLmAC.
8.3.4 Strains Containing Transporter and Epimerization Pathways and |J4-GalNAcT3
[00279] The non-fed strain (StCGP2860) showed a good A2GalNAc2 amount (33% on Fab sites) despite no major UDP-GalNAc level having been observed in its parental strain (StCGP2807) by HPAEC-PAD.
[00280] Taken together, these results suggest that the epimerization pathway is active in CGP, albeit with lower efficiency than the salvage pathway (if media contains lOmM GalNAc supplement in salvage pathway strains) showing 45% A2GalNAc2 on exposed Fab sites (16% on cell surface) on StCGP2857. When both pathways are used in combination (like in parental strain StCGP2801 and 2803) the A2GalNAc2 levels found on Adalimumab Fab sites was higher with 67% and 80%, in strains StCGP2853 and StCGP2879, respectively.
8.3.5 Strains with UDP-GalNAc Biosynthesis and |J4-GalNAcT4
[00281] None of strains of the different UDP-GalNAc biosynthesis pathways containing only p4-GalNAcT4 had significant conversion to A2GalNAc2 (0.3-2.5%; not shown), indicating that P4-GalNAcT4 is not very active since the same parental strains were showing
conversion up to A2GalNAc2 upon transfection of P-GalNAcT3. The reason could be either because p4-GalNAcT4 is not well expressed in this genetic context or because this acceptor glycosites with A2 were not optimal for p4-GalNAcT4.
8.3.6 Strains Containing Transporter, Salvage and Epimerization Pathways, and P4- GalNAcT3 and p4-GalNAcT4
[00282] Targeting the [atub] locus seems to be slightly better than the [Pfir] locus comparing StCGP2877 with StCGP2879, based on cell surface A2GalNAc2 levels with 20% and 25%, respectively.
8.3.7 Strains containing transporter and salvage pathway, p4-GalNAcT3 and P4- GalNAcT4
[00283] The intergenic region variants IrLmJ and IrLmAC seem to be beneficial over IrLmY and IrLmZ.
8.4 EXAMPLE 4
8.4.1 Strain StCGP3169
[00284] To obtain a suitable parental cell line harboring the capacity to modify N-glycans to A2GalNAc2, StCGP3169 was generated using the following modifications, also described in FIG. 6
[00285] For the first cell line named StLMTB 18407 expressing different glycosyltransferases for conversion of the endogenous Man3 to A2 N-glycans by using functionally redundant enzymes for the first glycoengineering step (hsMGAT, drMGATl, hsMGAT2 and mMGAT2), wild type L. tarentolae (Stl0569) cells were transfected with an expression construct, called “G0-long_hyg[Pfr]”, formed by homologous recombination of 13 DNA fragments. These DNA fragments were designed with intergenic regions interspersing the coding sequences in the assembled synthetic polycistron. Homologous recombination in-between the fragments and between fragments and the Pfr locus on the genome was enabled by 200 bp to 500 bp homologous regions, respectively. StLMTB 18407 was analyzed with 1.7% Man3, 0.8% Al and 97.5% A2 N-glycans on its surface glycoproteins.
[00286] To produce a strain showing minimal amounts of Man3 and maximal amount of A2 on any polypeptide of interest, another genetic module, called “GO M3.2_pac[ssu-Poll]”, encoding several MGAT1 and MGAT2 copies (drMGATlb, SfGntl and rnMGAT2) spaced by intergenic regions, was integrated into the [ssuPolI] locus of StLMTB 18407 by multiple
homologous recombination of 10 fragments. The newly generated cell line StLMTB 19462 showed indeed complete, 100%, A2 on cell surface glycoproteins.
[00287] The next engineering step was integrating the UDP-GalNAc biosynthesis module, called “GalNAc synth (T+S+E)_ blefPfr]” into the Pfr locus, using 7 fragments. This resulting strain, StCGP3023, was further transfected to integrate the P4-GalNAcT3 enzyme by using genetic module “GalNAcT3_ bsd [ssuPolI]” by recombining 5 fragments and integrating into the ribosomal rDNA locus [ssu-PolI], benefitting from a high-level expression of the integrated construct by the RNA Poll polymerase. The strain called StCGP3053 showed 37% A2GalNAc2 on its cell surface glycoproteins.
[00288] Next, a OGNT triple deletion mutant, devoid of O-glycosylation was generated by the method of CRISPR/Cas9 based knock-outs for L. tarentolae (as described in the Assays above). The initial cell surface N-glycans of newly generated StCGP3169 had 29% A2GalNAc2.
[00289] Then we transfected StCGP3053 and StCGP3169 with Adalimumab (K84N/D86N) expression cassette to test for A2GalNAc2 levels on the exposed Fab glycosites. Both strains led to 82% A2GalNAc2 on the Fab sites (See FIGS. 7A and 7B). In order to expand the polypeptides of interest containing similar positioned glycosites, expression cassettes for mAb 5C9, a human IgG4 PAA mAb containing D86N Fab framework (FR) glycosite, and for 1 lk2, also a human IgG4 PAA mAb, containing D86N. Interestingly, while 5C9(D86N) showed 90% A2GalNAc2, 1 lk2 acceptor site D86N showed only 48% A2GalNAc2, along with 43% A2GalNAcl glycans (See FIGS. 8A and 8B). Pertuzumab, another human IgGl (like Adalimumab) was engineered with D86N and this Fab contained 60% A2GalNAc2 (data not shown). This could indicate that, despite similar expression levels of the antibodies secreted to the supernatant, the A2GalNAc2 efficiency varied due to different acceptor sequences (glycosite and/or surrounding framework regions), possibly due to the described peptide specificity of p4-GalNAcT3. However, another hypothesis could be the protein folding and structure surrounding the glycosite, posing some steric constraints for the transferase activity. On the other hand, it can’t be ruled out that slight expression levels of the UDP-GalNAc biosynthesis genes and of the transferases could also lead to this variability.
8.4.2 Strain StCGP3558
[00290] To generate another parental strain capable of generating A2GalNAc2 N-glycans, StCGP3558 was constructed as follows and described in FIG. 6.
[00291] StLMTB 19462 was engineered with a triple OGNT deletion, to yield
StLMTB20097. StLMTB20097 was created by RNP mediated replacement of all three OGNTs with the selection marker for geneticin resistance. Comparison of the N-glycan profiles released from L. tarentolae surface proteins of the parental cell line Stl9462 and the triple OGNT knock-out cell line St20097 demonstrated that the efficiency of N-glycan conversion to A2 was not affected by OGNT knock-outs introduced by the RNP transfection method (see, e.g., FIG. 12C in WO 2021/140143).
[00292] Then, a combined genetic module (named “GalNAc synth (T+S+E)_GalNAcT3_ bsd(C) [ssuPolI]) containing both, the UDP-GalNAc biosynthesis pathway and the P4- GalNAcT3 enzyme was introduced by multiple homologous recombination of 10 fragments into the ssu-PolI locus. The resulting strain StCGP3558 was then also tested for its capacity to generate A2GalNAc2 N-glycans on different polypeptides of interest:
[00293] Adalimumab (K84N/D86N) had 73% A2GalNAc2, and 1 lk2 D86N 40% A2GalNAc2 on the Fab glycosites. This is comparable to the other strain performance. Interestingly, both strains, StCGP3169 and StCGP3558, had -70% A2GalNAc2 levels on Fab site of Adalimumab even without supplementing GalNAc to the medium.
8.5 EXAMPLE 5 - Evaluation of Different GalNAc Transferases
[00294] First, different parental strain were generated, similar to StCGP3558, except that the genetic information of the human P-GalNAcT3 was exchanged to alternative GalNAc transferases (see Table 8). N-glycan profiles of cell surfaces glycoproteins showed around 50% A2GalNAc2 content when C. elegans GalNAcT (“CeGalNAcT”) was encoded, which suggests a better activity than the human transferase, p4-GalNAcT3 (40% A2GalNAc2). When both enzymes were combined in one parental strain, also 50% A2GalNAc2 were reached, however with additionally 10% of incomplete N-glycan, A2GalNAcl. Interestingly, when those cell lines were transfected with two different mAb constructs, either Adalimumab (K84N/D86N) or 1 lk2 (S84N/D86N), the conversion efficiency of CeGalNAcT as well as the other GalNAc transferases (St/Hh, derived from Salmo trutta and Hucho hucho) on the engineered Fab glycosites were lower than by the human p4-GalNAcT3 (See FIGS. 9A, 9B, and 9C). However, the GalNAc transferase derived from Parasteatoda tepidariorum (PtGalNAcT) reached also 67% A2GalNAc2 on Fab of Adali(K84N/D86N), shown in FIG. 9B. This varying efficiencies can either be explained by differences in their localization/retention in the secretory pathway, or differences in expression levels influenced for example by the coding sequences themselves or mRNA stability, or by the specific
I l l
activity on those peptide acceptor sequences such as primary sequences or steric constraints by the protein domains.
8.6 EXAMPLE 6 - Evaluation of uncharacterized UDP-GalNAc Transporter homologs
[00295] In eukaryotes, nucleotide sugars are synthesized in the cytoplasm or nucleus, whereas most glycosylation occurs inside the ER or Golgi compartments. Therefore, newly synthesized nucleotide sugars must be transported into the ER and Golgi lumen. Negative charge prevents these donors from simply diffusing into these compartments. To overcome this hurdle, eukaryotic cells have a set of energy-independent nucleotide sugar antiporters that deliver nucleotide sugars into the lumen of these organelles, with the simultaneous exiting of nucleoside monophosphates. The Km of the transporters ranges from 1 to 10 pm. Using in vitro systems, the transporters have been shown to increase the concentration of the nucleotide sugars within the Golgi lumen by 10- to 50-fold. This is usually sufficient to reach or exceed the calculated Km of glycosyltransferases that use these donors.
[00296] Theoretically, glycosylation may be controlled in part by regulating the availability of nucleotide sugars within the Golgi, presumably by regulating the transporters. The subcompartmental location (cis, medial, trans) of the transporters in the Golgi is not known nor are the physical relationships of the transporters to the various glycosyltransferases they service. Many putative transporters were previously identified by homology in the genomes of mammals, Drosophila melanogaster, C. elegans, plants, and yeast, but the level of amino acid identity does not provide any information to the substrate specificity. The UDP-GlcNAc transporters from mammalian cells and yeast are 22% identical, whereas mammalian CMP-Sia, UDP-Gal, and UDP-GlcNAc transporters have 40%-50% identity (Essentials of Glycobiology, 4th edition PMID: 35536922 DOI: 10.1101/9781621824213)
[00297] While there is limited biochemical information on UDP-GalNAc transporters available, it however poses another opportunity to maximize the levels of A2GalNAc2 N- glycan biosynthesis in engineered Leishmania host cells by increasing the availability of UDP-GalNAc in the Golgi by testing previously uncharacterized UDP-GalNAc transporter homologs. A wide sequence homology search using CeC03H5.2 as query was performed. However, the sequence homology search using CeC03H5.2 alone was believed unlikely to differentiate between UDP-GlcNAc and UDP-GalNAc transporters, especially in view of the fact that the C. elegans transporter CeC03H5.2 is also multifunctional (Caffaro, C. E.,
Hirschberg, C. B. & Beminsone, P. M. Independent and simultaneous translocation of two substrates by a nucleotide sugar transporter. Proc National Acad Sci 103, 16176-16181 (2006)). Accordingly, we extended the homology search to a second transporter called UGTREL7 (Uniprot Q9NTN3, also known as SLC35D1). UGTREL7 is described as a UDP- GalNAc and UDP -glucuronic acid transporter according to Muraoka (Muraoka, M., Kawakita, M. & Ishida, N. Molecular characterization of human UDP-glucuronic acid/UDP- N-acetylgalactosamine transporter, a novel nucleotide sugar transporter with dual substrate specificity. FEBS Lett. 495, 87-93 (2001). The sequence homology search was performed using either CeC03H5.2 or UGTREL7 as representative sequence and their reciprocal best hits were clustered for 80% sequence identity. From this, a subset of sequences for CeC03H5.2 homologs (Table 10) and for UGTREL7 (Table 11) was chosen to test experimentally in glycoengineered Leishmania cells.
[00298] StCGP4334 containing a GalNAc synthesis module with Salvage and epimerization enzymes (“S+E”) and P4-GalNAcT3 of Homo sapiens (HsGalNAcT3), integrated into the ssu-PolI genomic locus, was transfected with the different transporter homologs to CeC03H5.2 (FIG. 10A) or with the transporter homologs to UGTREL7 (FIG. 10B) These cell lines were evaluated for their capacity to generate A2GalNAc2 N-glycans on the recombinant Adalimumab (K84N/D86N) expressed and secreted by these cell lines. The parental strain StCGP4334 without any designated UDP-GalNAc transporter already showed 39% A2GalNAc2 N-glycans on the glycosites K84N and D86N of Adalimumab Fab, which indicates that there is some availability of UDP-GalNAc within the secretory pathway, either by being transported by a different (native) Leishmania tarentolae nucleotide- sugar transporter, or due to some other mechanism. However, when a designated UDP-GalNAc transporter was introduced in StCGP4334, such as CeC03H5.2, an increase to 53% A2GalNAc2 was observed. When the homologs to CeC03H5.2 were compared, GnF, GnH and GnJ performed better (57%, 56% and 62%, respectively), while GnG and GnI behaved similar to CeC03H5.2 or slightly less (50% and 49%, respectively). With 62% A2GalNAc2 achieved by GnJ, and thereby leading to almost 10% more A2GalNAc2 glycans compared to CeC03H5.2, an improvement by replacing the UDP-GalNAc transporter was demonstrated. GnJ (A0A4Y9Z8V0 Uncharacterized protein from Dentipellis fragilis) is therefore a suitable UDP-GalNAc transporter for incorporating to Leishmania host cell lines producing polypeptides comprising a biantennary, GalNAc-terminated N-glycan, specifically A2GalNAc2.
[00299] Furthermore, UGTREL7 containing cell line showed 54% A2GalNAc2 N- glycans, which is a similar improvement as seen for CeC03H5.2 when compared to 39% of the parental cell line without any designated transporter. When assessing UGTREL7 homologs, the GnM, GnN and GnO generated even higher A2GalNAc2 % with up to 67% for GnN. Only GnL was achieving less (FIG.ll).
[00300] Next, a different strain composition was tested by introducing the UDP-GalNAc transporter or homolog into StCGP4106, with a GalNAc biosynthesis expression module that contains the P4GalNAcT of Parasteatoda tepidariorum (PtGalNAcT) transferase instead of the human GalNAcT3. The combined genetic module containing PtGalNAcT, the UDP- GalNAc biosynthesis pathway and the GalNAc transporter CeC03H5.2 or a UDP-GalNAc transporter homolog, either GnF, GnJ or GnM, ^GalNAc wtA(Transporter +5'+E PtGalNAcT ble ”) was introduced by multiple homologous recombination of 10 fragments into the ssu-PolI locus (FIG. 12). In StCGP5351 expressing the UPD-GalNAc transporter GnF and the P. tepidariorum GalNAc transferase (“PtGalNAcT”), the Adalimumab (K84N/D86N) had 77% A2GalNAc2 as compared to 53% with the CeC03H5.2 UDP- GalNAc transporter in StCGP4978. While GnF, GnJ and GnM expression increased the A2GalNAc2 glycans on Adalimumab (K84N/D86N), GnF was led to the highest increase, suggesting that for the PtGalNAcT expressing strain, transporter GnF might be preferred over CeC03H5.2 in this genetic context (FIG. 13).
[00301] Taken together, this study indicates that (1) incorporating a heterologous UDP- GalNAc transporter protein is beneficial for obtaining high proportions of A2GalNAc2 glycans in glycoengineered Leishmania cells; (2) appropriate transporters can be selected based on sequence homology to known UDP-GalNAc transporters from other organisms; and (3) specific combinations of heterologous GalNAc transferases and heterologous UDP- GalNAc transporter proteins can be advantageous to optimize UDP-GalNAc availability and/or obtain high proportions of A2GalNAc2 glycans in glycoengineered Leishmania cells.
8.7 EXAMPLE 7 Combining different GalNAc Transferases and UDP-GalNAc Transporters
[00302] The results from Example 6 prompted to combine different UDP-GalNAc transporter homologs with different GalNAc transferases to create potent entry cell lines for introducing different polypeptides and therapeutic modalities that contain one or more N- glycosylation consensus sites (including but not limited to Ab scaffolds like mAbs, Fabs, scFvs, VHH, nanobodies, etc.) comprising A2GalNAc2 N-glycans.
8.7.1 Strain StCGP5359
[00303] To engineer a parental strain combining different GalNAc transferases and UPD- GalNAc transporters to generate A2GalNAc2 N-glycans, StCGP5359 was constructed as follows and described in FIG. 14. StCGP3558 contains the GalNAc biosynthesis module with the UDP-GalNAc transporter CeC03H5.2 and the human GalNAcT3 transferase (“HsGalNAcT3”) as described in 6.4.2 and FIG. 6. A second combined module containing both, the UDP-GalNAc biosynthesis pathway and the GalNAc transferase enzyme was introduced by multiple homologous recombination of 10 fragments into the ssu-PolI locus. For StCGP5359 the UPD-GalNAc transporter GnJ (A0A4Y9Z8V0 Uncharacterized protein from Dentipellis fragilis) and the C. elegans GalNAc transferase (“CeGalNAcT”) were used as a second combined genetic module. To evaluate the potential of the parental strain StCGP5359, it was transfected with an expression cassette for a camelid VHH scaffold (“hVHH2-l 1-FHGT4”) to test for A2GalNAc2 levels on a C-terminal glycotag, which is a peptide stretch harboring a N-glycosylation consensus site N-X-S/T, optimized for high site occupancy and tag integrity. High amounts of 88% A2GalNAc2 were detected on purified the VHH protein and proved the high potency of the selected biosynthetic machinery engineered into Leishmania cells for A2GalNAc2 N-glycans. Importantly, when the strain was passaged over time without any selection pressure, the high levels of A2GalNAc2 on the VHH protein were maintained for 37 and 66 generations, respectively, indicating that the multiple genetic insertions are stable and that the phenotype like viability, growth, protein expression yields and engineered N-glycosylation remained unchanged (FIG. 15). StCGP5359 is therefore a suitable host cell line producing polypeptides comprising a biantennary, GalNAc-terminated N-glycan, specifically A2GalNAc2 which mediates protein degradation.
8.7.2 Strain StCGP5942
[00304] StCGP5942 was constructed as follows and is described in FIG. 14. A combined module containing both the UDP-GalNAc biosynthesis pathway with the UPD-GalNAc transporter CeC03H5.2 and a combination of human and P. tepidariorum GalNAc transferases (“HsGalNAcT3” and “PtGalNAcT”, respectively) was introduced in StCGP552 by multiple homologous recombination of 10 fragments into the ssu-PolI locus. Here despite not using any additional UDP-GalNAc transporter homolog, a significant amount of A2GalNAc2 was achieved by the combination of HsGalNAcT3 and PtGalNAcT only, which led to 90% A2GalNAc2 on the VHH protein in StCGP6631. Moreover, StCGP6631 was
passaged over time without any selection pressure, and the high levels of A2GalNAc2 on the VHH protein were stable for 35 and 63 generations (FIG. 16). This strongly indicates that the genetic insertions of StCGP6631 are stable and the phenotype like viability, growth, protein expression yield and engineered N-glycosylation is maintained, thereby proving the applicability of parental entry strain StCGP5942 as host cell line for expressing therapeutic protein scaffolds harboring one or more glycosylation sites. These Leishmania host cells are capable of producing polypeptides comprising a biantennary, GalNAc-terminated N-glycan, specifically A2GalNAc2, which mediates protein degradation.
[00305] Table 9 Genetic constructs used for generating StCGP2879, StCGP3169, StCGP3558, StCGP2801, StCGP2803, StCGP2805, StCGP2807, StCGP2847, StCGP5003, StCGP5006, StCGP5007, StCGP5010, StCGP5012, StCGP5013, StCGP5016, StCGP5017, StCGP5049, StCGP5019, StCGP5021, StCGP4978, StCGP5351, StCGP5352, StCGP5694, StCGP5359, StCGP6044, StCGP5942, and StCGP6631. Flowcharts of strain construction are shown in FIGS. 5, 6, 10A, 10B, 12, and 14.
[00308] Table 12: A multitude of parental (entry) strains harboring different combinations of GalNAc transferases and different UDP-GalNAc transporters were tested for their capability of expressing A2GalNAc2 N-glycans by transfecting test scaffolds Adalimumab (K84N/D86N) and/or hVHH2-ll-FHGT4. Strains were rated for % A2GalNAc2 by "+++” for >80%, “++” for 60-80%, “+” for 30-60%, and “+/-“ for 1-30% A2GalNAc2. Abbreviations are as follows: cuo = codon usage optimized, FL = full length, tr = N-terminally truncated variant; “GalNAc synth” contains CeC03H5.2, salvage, and epimerization biosynthesis pathway. If another transporter was used instead of CeC03H5.2, it is captured in the description e.g. “GalNAc synth(cuo, GnJ)” harbors GnJ instead of CeC03H5.2.
9. EQUIVALENTS
[00309] The viruses, nucleic acids, methods, host cells, and compositions disclosed herein are not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the viruses, nucleic acids, methods, host cells, and compositions in addition to those described will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
[00310] Various publications, patents and patent applications are cited herein, the disclosures of which are incorporated by reference in their entireties.
Claims
1. A Leishmania host cell comprising: a. a recombinant nucleic acid encoding a polypeptide of interest; and b. a recombinant nucleic acid encoding one or more recombinant N- acetylgalactosamine (GalNAc) transferases, or functionally active variants thereof.
2. The host cell of claim 1, wherein the GalNAc transferase is heterologous to the host cell.
3. The host cell of claim 1 or 2, wherein the GalNAc transferase is P4- GalNAcT3, or a functionally active variant thereof.
4. The host cell of claim 3, wherein the P4-GalNAcT3 is human p4-GalNAcT3, or a functionally active variant thereof.
5. The host cell of claim 1 or 2, wherein the GalNAc transferases are P4- GalNAcT3 and P4-GalNAcT4, or functionally active variants thereof.
6. The host cell of claim 5, wherein the p4-GalNAcT3 and p4-GalNAcT4 are human p4-GalNAcT3 and P4-GalNAcT4, or functionally active variants thereof.
7. The host cell of claim 1 or 2, wherein the host cell further comprises: a. a recombinant nucleic acid encoding recombinant UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc; and b. a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway.
8. The host cell of claim 1 or 2, wherein the host cell further comprises: a. a recombinant nucleic acid encoding a recombinant UDP-GalNAc biosynthetic pathway protein capable of converting UDP-GlcNAc to UDP- GalNAc; and b. a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway.
9. The host cell of claim 1 or 2, wherein the host cell further comprises: a. a recombinant nucleic acid encoding recombinant UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc; and b. a recombinant nucleic acid encoding a recombinant UDP-GalNAc biosynthetic pathway protein capable of converting UDP-GlcNAc to UDP- GalNAc; and
c. a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway.
10. A Leishmania host cell comprising: a. a recombinant nucleic acid encoding a polypeptide of interest; b. a recombinant nucleic acid encoding one or more recombinant N- acetylgalactosamine (GalNAc) transferases, or functionally active variants thereof; and c. a recombinant nucleic acid encoding a recombinant UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway.
11. The host cell of claim 10 further comprises one or more recombinant nucleic acids encoding heterologous UDP-GalNAc biosynthetic pathway proteins capable of generating UDP-GalNAc.
12. The host cell of claim 10 or 11 comprising: a. a recombinant nucleic acid encoding recombinant UDP-GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc; and/or b. a recombinant nucleic acid encoding a recombinant UDP-GalNAc biosynthetic pathway protein capable of converting UDP-GlcNAc to UDP- GalNAc.
13. The host cell of any one of claims 10-12, wherein the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein are co-localized in the secretory pathway.
14. The host cell of claim 13, wherein the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein each independently comprise: a. a signal peptide localizing the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein in the secretory pathway; and/or b. a retention sequence retaining the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein in the secretory pathway.
15. The host cell of claim 14, wherein the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein each independently comprise the same signal peptide and/or retention sequence.
16. The host cell of claim 14, wherein the one or more GalNAc transferases and the heterologous UDP-GalNAc transporter protein comprise different signal peptides and/or retention sequences.
17. The host cell of any one of claims 14-16, wherein the signal peptide of the one or more GalNAc transferases and/or the signal peptide of the heterologous UDP-GalNAc transporter protein are derived from a. Leishmania species.
18. The host cell of any one of claims 14-17, wherein the retention sequence of the one or more GalNAc transferases and/or the retention sequence of the heterologous UDP- GalNAc transporter protein are derived from a Leishmania species.
19. The host cell of claim 17 or 18, wherein the Leishmania species is Leishmania tarentolae.
20. The host cell of any one of claims 14-19, wherein the signal peptide of the one or more GalNAc transferases and/or the signal peptide of the heterologous UDP-GalNAc transporter protein are processed and removed.
21. The host cell of any one of claims 7-20, wherein recombinant UDP-GalNAc biosynthetic pathway proteins and/or recombinant UDP-GalNAc transporter protein are heterologous to the host cell.
22. The host cell of any one of claims 9-21, wherein one or more of the recombinant nucleic acids are integrated into the [ssuPolI] locus of the host cell.
23. The host cell of any one of claims 1, 2 or 7-22, wherein the one or more GalNAc transferases are derived from a mammalian source.
24. The host cell of claim 23, wherein the mammalian source is Homo sapiens.
25. The host cell of any one of claims 1-24, wherein the one or more GalNAc transferases, or a functionally active variants thereof, are capable of catalyzing the addition of a GalNAc to a N-acetyl glucosamine-terminated glycan.
26. The host cell of any one of claims 1, 2 o 7-25, wherein the one or more GalNAc transferases are selected from the group consisting of p4-GalNAcT3, p4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or functionally active variants thereof.
27. The host cell of any one of claims 1, 2 o 7-26, wherein the one or more GalNAc transferases is selected from the group consisting of p4-GalNAcT3, p4-GalNAcT4, CeP4GalNAcT, Ptp4GalNAcT, and Stp4GalNAcT, or variants that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto.
28. The host cell of claim 26, wherein the one or more GalNAc transferases comprise P4-GalNAcT3, or an N-terminally truncated variant thereof.
29. The host cell of claim 28, wherein the one or more GalNAc transferases comprise P4-GalNAcT3.
30. The host cell of claim 28, wherein the one or more GalNAc transferases comprise an N-terminally truncated variant of P4-GalNAcT3.
31. The host cell of claim 30, wherein the N-terminally truncated variant comprises an amino acid sequence of SEQ ID NO: 2.
32. The host cell of claim 27, wherein the one or more GalNAc transferases comprise a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to p4-GalNAcT3.
33. The host cell of any one of claims 26-32, wherein the one or more GalNAc transferases comprise P4-GalNAcT4, or an N-terminally truncated variant thereof.
34. The host cell of claim 33, wherein the one or more GalNAc transferases comprise P4-GalNAcT4.
35. The host cell of claim 33, wherein the one or more GalNAc transferases comprise an N-terminally truncated variant of P4-GalNAcT4.
36. The host cell of claim 35, wherein the N-terminally truncated variant is comprises an amino acid sequence of SEQ ID NO: 4.
37. The host cell of claim 27, wherein the one or more GalNAc transferases comprise a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to p4-GalNAcT4.
38. The host of claim 27, wherein the one or more GalNAc transferases comprise CeP4GalNAcT, or a variant that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto.
39. The host of claim 27, wherein the one or more GalNAc transferases comprise CeP4GalNAcT.
40. The host of claim 27, wherein the one or more GalNAc transferases comprise Ptp4GalNAcT, or a variant that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereto.
41. The host of claim 27, wherein the one or more GalNAc transferases comprise Ptp4GalNAcT.
42. The host cell of any one of claims 1-41, wherein the recombinant nucleic acid encoding one or more GalNAc transferases comprises a first open reading frame (ORF) encoding a first GalNAc transferase and a second ORF encoding a second GalNAc transferase.
43. The host cell of claim 42, wherein the first ORF encoding the first GalNAc transferase and the second ORF encoding the second GalNAc transferase are integrated into the host cell in the same genetic module.
44. The host cell of claim 42, wherein the first ORF encoding the first GalNAc transferase and the second ORF encoding the second GalNAc transferase are integrated into the host cell in separate genetic modules.
45. The host cell of any one of claims 42-44, wherein the first ORF encoding the first GalNAc transferase and the second ORF encoding the second GalNAc transferase are integrated into the [ssuPolI] locus of the host cell.
46. The host cell of any one of claims 42-45, wherein the first and the second GalNAc transferases are different GalNAc transferases.
47. The host cell of any one of claims 42-46, wherein the first and the second GalNAc transferases are selected as a combination of GalNAc transferases listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
48. The host cell of any one of claims 42-47, wherein the first and the second GalNAc transferases are human p4-GalNAcT3 and human p4-GalNAcT4, respectively; or human p4-GalNAcT3 and CeP4GalNAcT, respectively; or human p4-GalNAcT3 and Ptp4GalNAcT, respectively; or functionally active variants thereof.
49. The host cell of any one of claims 1-48, wherein the host cell comprises a recombinant nucleic acid encoding one or more additional recombinant glycosyltransferases.
50. The host cell of claim 49, wherein the additional recombinant glycosyltransferase is heterologous to the host cell.
51. The host cell of claim 49 or 50, wherein the additional recombinant glycosyltransferase comprises one or more N-acetyl glucosamine transferases.
52. The host cell of claim 51, wherein the N-acetyl glucosamine transferase is selected from the group consisting of MGAT1 and MGAT2, or functionally active variants thereof.
53. The host cell of claim 51, herein the additional recombinant glycosyltransferase comprises MGAT1 and MGAT2.
54. The host cell of any one of claims 1-53, wherein the host cell is capable of producing polypepetides comprising a biantennary, GalNAc-terminated N-glycan.
55. The host cell of any one of claims 1-54, wherein the host cell is capable of producing polypeptides comprising an N-glycan of the following structure:
wherein the black square represents an N-acetyl galactosamine (GalNAc), the white square represents an N-acetylglucosamine (GlcNAc) residue and the black circle represents a mannose (Man) residue, and wherein X represents an amino acid residue of the polypeptide of interest.
56. The host cell of claim 54 or 55, wherein the host cell attaches the N-glycan to an N-glycosylation site of the polypeptide.
57. The host cell of claim 55, wherein the amino acid residue is Asn.
58. The host cell of claim 56, wherein the N-glycosylation site comprises a consensus sequence of N-X-S/T or N-X-C, wherein X is any amino acid except proline.
59. The host cell of any one of claims 1-58, wherein one or more endogenous enzymes from the glycan biosynthesis pathway have been deleted, mutated and/or functionally inactivated.
60. The host cell of claim 59, wherein the host cell does not have endogenous N- glycan elongation.
61. The host cell of any one of claims 1-60, wherein the host cell has been genetically engineered such that the formation of an O-linked GlcNAc on a polypeptide in the host cell is reduced or eliminated.
62. The host cell of claim 61, wherein the formation of O-linked GlcNAc in the Leishmania cell prior to genetic engineering is catalyzed by at least one N-acetylglucosamine (GlcNAc)-transferase.
63. The host cell of claim 62, wherein the gene encoding the at least one GlcNAc- transferase is functionally inactivated, downregulated, deleted, or mutated.
64. The host cell of any one of claims 61-63, wherein the formation of the O- linked GlcNAc is reduced by at least 5%, 7%, 10%, 12%, 15%, 18%, 20%, 25%, 30%, 35%,
40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% from the formation of the O-linked GlcNAc in a reference Leishmania cell.
65. The host cell of any one of claims 62-64, the at least one GlcNAc-transferase is selected from the group consisting of OGNT1, OGNT2 and OGNTL, and homologous GlcNAc-transferases thereof.
66. The host cell of any one of claims 61-65, wherein the host cell is a OGNT1, OGNT2 and OGNTL triple knockout.
67. The host cell of any one of claims 1-6 or 23-66, wherein the host cell further comprises a recombinant nucleic acid encoding heterologous UDP-GalNAc biosynthetic pathway proteins capable of generating UDP-GalNAc.
68. The host cell of claim 67, wherein the heterologous UDP-GalNAc biosynthetic pathway proteins are capable of converting GalNAc to UDP-GalNAc.
69. The host cell of any one of claims 7-68, wherein the heterologous UDP- GalNAc biosynthetic pathway proteins capable of converting GalNAc to UDP-GalNAc are derived from a mammalian source.
70. The host cell of claim 69, wherein the mammalian source is Homo sapiens.
71. The host cell of any one of claims 7-70, wherein the heterologous UDP- GalNAc biosynthetic pathway proteins comprise UDP-N-acetyl hexosamine pyrophosphorylase (UAP1), or a functionally active variant thereof.
72. The host cell of any one of claims 7-71, wherein the heterologous UDP- GalNAc biosynthetic pathway proteins comprise UDP-N-acetyl hexosamine pyrophosphorylase (UAP1), or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
73. The host cell of any one of claims 7-72, wherein the heterologous UDP- GalNAc biosynthetic pathway proteins comprise UDP-N-acetyl hexosamine pyrophosphorylase (UAP1).
74. The host cell of any one of claims 7-73, wherein the heterologous UDP- GalNAc biosynthetic pathway proteins comprise N-acetyl galactosamine kinase (GALK2), or a functionally active variant thereof.
75. The host cell of any one of claims 7-74, wherein the heterologous UDP- GalNAc biosynthetic pathway proteins comprise N-acetyl galactosamine kinase (GALK2), or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
76. The host cell of any one of claims 7-75, wherein the heterologous UDP-
GalNAc biosynthetic pathway proteins comprise N-acetyl galactosamine kinase (GALK2).
77. The host cell of any one of claims 67-76, wherein the heterologous UDP- GalNAc biosynthetic pathway proteins are capable of converting UDP-GlcNAc to UDP- GalNAc.
78. The host cell of any one of claims 8-77, wherein the heterologous UDP- GalNAc biosynthetic pathway proteins capable of converting UDP-GlcNAc to UDP-GalNAc are derived from a mammalian source.
79. The host cell of claim 78, wherein the mammalian source is Homo sapiens.
80. The host cell of any one of claims 8-79, wherein the heterologous UDP- GalNAc biosynthetic pathway proteins comprise hGalE, or a functionally active variant thereof.
81. The host cell of any one of claims 8-80, wherein the heterologous UDP- GalNAc biosynthetic pathway protein comprise hGalE, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
82. The host cell of any one of claims 8-81, wherein the heterologous UDP- GalNAc biosynthetic pathway proteins comprise hGalE.
83. The host cell of any one of claims 8-77, wherein the heterologous UDP- GalNAc biosynthetic pathway proteins capable of converting UDP-GlcNAc to UDP-GalNAc are derived from a bacterial source.
84. The host cell of claim 83, wherein the bacterial source is Campylobacter jejuni.
85. The host cell of any one of claims 8-77, 83, or 84, wherein the heterologous UDP-GalNAc biosynthetic pathway proteins comprise CjGne, or a functionally active variant thereof.
86. The host cell of any one of claims 8-77 or 83-85, wherein the heterologous UDP-GalNAc biosynthetic pathway proteins comprise CjGne, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
87. The host cell of any one of claims 8-77 or 83-86, wherein the heterologous UDP-GalNAc biosynthetic pathway proteins comprise CjGne.
88. The host cell of any one of claims 1-5 or 23-87, wherein the host cell further comprises a recombinant nucleic acid encoding a heterologous UDP-GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway.
89. The host cell of any one of claims 7-88, wherein the heterologous UDP-
GalNAc transporter protein capable of transporting UDP-GalNAc to the secretory pathway is derived from a nematode source, a mammalian source, a brachiopod source, a chordate source, choanoflagellate source, a gyrista source, a fungi source, a mollusk source, or a placozoan source.
90. The host cell of claim 89, wherein the nematode source is C. elegans,' the mammalian source is Homo sapiens,' the brachiopod source is Lingula unguis,' the chordate source is Parambassis ranga, Geotrypetes seraphini, or Scophthalmus maximus,' the choanoflagellate source is Salpingoeca rosetta, the gyrista source is Fragilariopsis cylindrus,' the fungi source is Dentipellis fragilis,' the mollusk source is Octopus bimaculoides; and/or the placozoan source is trichoplax sp. H2.
91. The host cell of any one of claims 7-90, wherein the heterologous UDP- GalNAc transporter protein is CeC03H5.2, or a functionally active variant thereof.
92. The host cell of any one of claims 7-91, wherein the heterologous UDP- GalNAc transporter protein is CeC03H5.2, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
93. The host cell of any one of claims 7-92, wherein the heterologous UDP- GalNAc transporter protein is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to CeC03H5.2.
94. The host cell of any one of claims 7-92, wherein the heterologous UDP- GalNAc transporter protein is CeC03H5.2.
95. The host cell of any one of claims 7-93, wherein the heterologous UDP- GalNAc transporter protein is GnF, GnG, GnH, GnI, or GnJ.
96. The host cell of any one of claims 7-90, wherein the heterologous UDP- GalNAc transporter protein is UGTREL7, or a functionally active variant thereof.
97. The host cell of any one of claims 7-90 or 96, wherein the heterologous UDP- GalNAc transporter protein is UGTREL7, or a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
98. The host cell of any one of claims 7-90, 96, or 97, wherein the heterologous UDP-GalNAc transporter protein is a variant that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to UGTREL7.
99. The host cell of any one of claims 7-90, 96, or 97, wherein the heterologous UDP-GalNAc transporter protein is UGTREL7.
100. The host cell of any one of claims 7-90, or 96-98, wherein the heterologous UDP-GalNAc transporter protein is GnL, GnM, GnN, or GnO.
101. The host cell of any one of claims 7-100, wherein the recombinant nucleic acid encoding a heterologous UDP-GalNAc transporter comprises a first ORF encoding a first heterologous UDP-GalNAc transporter and a second ORF encoding a second heterologous UDP-GalNAc transporter.
102. The host cell of claim 101, wherein the first ORF encoding the first heterologous UDP-GalNAc transporter and the second ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module.
103. The host cell of claim 101, wherein the first ORF encoding the first heterologous UDP-GalNAc transporter and the second ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in separate genetic modules.
104. The host cell of any one of claims 101-103, wherein the first ORF encoding the first heterologous UDP-GalNAc transporter and the second ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the [ssuPolI] locus of the host cell.
105. The host cell of any one of claims 101-104, wherein the first and the second heterologous UDP-GalNAc transporter are selected as a combination of heterologous UDP- GalNAc transporters listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
106. The host cell of any one of claims 101-105, wherein the first and the second heterologous UDP-GalNAc transporter proteins are the same UDP-GalNAc transporter protein.
107. The host cell of claim 106, wherein the first and the second heterologous UDP-GalNAc transporter proteins are each CeC03H5.2.
108. The host cell of any one of claims 101-105, wherein the first and the second heterologous UDP-GalNAc transporter proteins are different UDP-GalNAc transporter proteins.
109. The host cell of claim 108, wherein the first and the second heterologous UDP-GalNAc transporter proteins are CeC03H5.2 and GnJ, respectively.
110. The host cell of any one of claims 7-109, wherein:
a. the recombinant nucleic acid encoding one or more GalNAc transferases comprises a first ORF encoding a first GalNAc transferase and a second ORF encoding a second GalNAc transferase; and b. the recombinant nucleic acid encoding a heterologous UDP-GalNAc transporter comprises a third ORF encoding a first heterologous UDP-GalNAc transporter and a fourth ORF encoding a second heterologous UDP-GalNAc transporter.
111. The host cell of claim 110, wherein: a. the first open reading frame (ORF) encoding the first GalNAc transferase and and the third ORF encoding the first heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module; and/or b. the second open reading frame (ORF) encoding the second GalNAc transferase and and the fourth ORF encoding the second heterologous UDP- GalNAc transporter are integrated into the host cell in the same genetic module.
112. The host cell of claim 110 or 111, wherein: a. the first ORF encoding the first GalNAc transferase and the second ORF encoding the second GalNAc transferase are integrated into the host cell in separate genetic modules; and/or b. the third ORF encoding the first heterologous UDP-GalNAc transporter and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in separate genetic modules.
113. The host cell of claim 110 or 111, wherein the first ORF encoding the first GalNAc transferase, the second ORF encoding the second GalNAc transferase, the third ORF encoding the first heterologous UDP-GalNAc transporter, and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the host cell in the same genetic module.
114. The host cell of any one of claims 110-113, wherein the first ORF encoding the first GalNAc transferase, the second ORF encoding the second GalNAc transferase, the third ORF encoding the first heterologous UDP-GalNAc transporter, and the fourth ORF encoding the second heterologous UDP-GalNAc transporter are integrated into the [ssuPolI] locus of the host cell.
115. The host cell of any one of claims 110-114, wherein the first and the second
GalNAc transferases are different GalNAc transferases.
116. The host cell of any one of claims 110-115, wherein the first and the second heterologous UDP-GalNAc transporter proteins are the same UDP-GalNAc transporter protein.
117. The host cell of any one of claims 110-115, wherein the first and the second heterologous UDP-GalNAc transporter proteins are different UDP-GalNAc transporter proteins.
118. The host cell of any one of claims 110-117, wherein the first GalNAc transferase, the second GalNAc transferase, the first heterologous UDP-GalNAc transporter protein, and the second heterologous UDP-GalNAc transporter protein are selected as a combination of GalNAc transferases and heterologous UDP-GalNAc transporter proteins listed in Table 12, or variants that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous thereof.
119. The host cell of any one of claims 110-118, wherein the first and the second GalNAc transferases are human p4-GalNAcT3 and CeP4GalNAcT, respectively; and the first and the second heterologous UDP-GalNAc transporter proteins are CeC03H5.2, and GnJ, respectively.
120. The host cell of any one of claims 110-118, wherein the first and the second GalNAc transferases are human p4-GalNAcT3 and Ptp4GalNAcT, respectively; and the first and the second heterologous UDP-GalNAc transporter proteins are each CeC03H5.2.
121. The host cell of any one of claims 1-120, wherein the one or more GalNAc transferases and the polypeptide of interest are co-localized in the secretory pathway.
122. The host cell of any one of claims 49-121, wherein the one or more GalNAc transferases and the additional recombinant glycosyltransferase are co-localized in the secretory pathway.
123. The host cell of any one of claims 1-122, wherein the one or more GalNAc transferases each independently comprise a signal peptide localizing the one or more GalNAc transferases in the secretory pathway.
124. The host cell of any one of claims 1-123, wherein the one or more GalNAc transferases each independently comprise a retention sequence retaining the one or more GalNAc transferases in the secretory pathway.
125. The host cell of any one of claims 49-123, wherein the additional recombinant glycosyltransferase comprises a signal peptide localizing the additional recombinant glycosyltransferase in the secretory pathway.
126. The host cell of any one of claims 49-125, wherein the additional recombinant glycosyltransferase comprises a retention sequence retaining the additional recombinant glycosyltransferase in the secretory pathway.
127. The host cell of any one of claims 123-126, wherein the signal peptide is added to an N-terminally truncated variant of the GalNAc transferase and/or the additional recombinant glycosyltransferase.
128. The host cell of any one of claims 124-127, wherein the retention sequence is added to an N-terminally truncated variant of the GalNAc transferase and/or the additional recombinant glycosyltransferase.
129. The host cell of any one of claims 1-128, wherein the polypeptide of interest comprises a signal peptide localizing the polypeptide of interest to the secretory pathway and/or a retention sequence retaining the polypeptide of interest in the secretory pathway.
130. The host cell of any one of claims 123-129, wherein the signal peptide and/or retention sequence is derived from a Leishmania species.
131. The host cell of claim 130, wherein the signal peptide and/or retention sequence is derived from Leishmania tarentolae.
132. The host cell of claim 130, wherein the signal peptide is an invertase signal peptide from derived from Leishmania tarentolae.
133. The host cell of any one of claim 123-131, wherein the signal peptide is processed and removed.
134. The host cell of any one of claims 1-133, wherein the host cell is a Leishmania tarentolae host cell.
135. The host cell of any one of claims 1-134, wherein culturing the Leishmania host cell produces a composition of the polypeptide of interest, wherein said composition of the polypeptide of interest comprises an N-glycan of the following structure:
wherein the black square represents an N-acetyl galactosamine (GalNAc), the white square represents an N-acetylglucosamine (GlcNAc) residue and the black circle represents a mannose (Man) residue, and wherein X represents an amino acid residue of the polypeptide of interest.
136. The host cell of any one of claims 1-135, wherein the host cell is stable to passaging and/or continuous fermentation for 100 or more generations.
137. The host cell of any one of claims 1-136, wherein the host cell is any one of the strains listed in Table 3 or Table 9.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263410955P | 2022-09-28 | 2022-09-28 | |
US202263410936P | 2022-09-28 | 2022-09-28 | |
US63/410,955 | 2022-09-28 | ||
US63/410,936 | 2022-09-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024068768A1 WO2024068768A1 (en) | 2024-04-04 |
WO2024068768A9 true WO2024068768A9 (en) | 2024-06-13 |
Family
ID=88236448
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/076767 WO2024068768A1 (en) | 2022-09-28 | 2023-09-27 | Glycoengineering using leishmania cells |
PCT/EP2023/076745 WO2024068753A1 (en) | 2022-09-28 | 2023-09-27 | Glycan-mediated protein degradation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/076745 WO2024068753A1 (en) | 2022-09-28 | 2023-09-27 | Glycan-mediated protein degradation |
Country Status (1)
Country | Link |
---|---|
WO (2) | WO2024068768A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200022486A (en) | 2017-06-30 | 2020-03-03 | 림마테크 바이오로직스 아게 | Engineered and fully-functional custom glycoproteins |
CN113301925A (en) * | 2018-12-19 | 2021-08-24 | 小利兰·斯坦福大学理事会 | Bifunctional molecules for lysosomal targeting and related compositions and methods |
US20230287327A1 (en) | 2020-01-07 | 2023-09-14 | Limmatech Biologics Ag | Glycoengineering using leishmania cells |
US20230048847A1 (en) | 2020-01-07 | 2023-02-16 | Limmatech Biologics Ag | Engineered leishmania cells |
CA3192770A1 (en) | 2020-09-14 | 2022-03-17 | Limmatech Biologics Ag | Fab sialylation of antibodies |
-
2023
- 2023-09-27 WO PCT/EP2023/076767 patent/WO2024068768A1/en unknown
- 2023-09-27 WO PCT/EP2023/076745 patent/WO2024068753A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2024068768A1 (en) | 2024-04-04 |
WO2024068753A1 (en) | 2024-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7437162B2 (en) | Engineered and fully functionally customized glycoproteins | |
US20230287327A1 (en) | Glycoengineering using leishmania cells | |
US20230048847A1 (en) | Engineered leishmania cells | |
US20220056109A1 (en) | Glycoproteins with anti-inflammatory properties | |
Du et al. | A bacterial expression platform for production of therapeutic proteins containing human-like O-linked glycans | |
Zhong et al. | Biological insights into therapeutic protein modifications throughout trafficking and their biopharmaceutical applications | |
EP2971030B1 (en) | Oligosaccharide compositions, glycoproteins and methods to produce the same in prokaryotes | |
US11236136B2 (en) | Methods of producing glycosylated proteins | |
JP2012506710A (en) | A novel tool for the production of glycosylated proteins in host cells | |
WO2024068768A9 (en) | Glycoengineering using leishmania cells | |
US20240287568A1 (en) | Engineered and Fully-Functional Customized Glycoproteins | |
WO2017191208A1 (en) | Means and methods for generating complex glycans derived from fungal engineered hosts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23782494 Country of ref document: EP Kind code of ref document: A1 |